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Summary  
 
Genetic and genomic approaches have revolutionised the way we address disease 
aetiology, potential treatment and methods to understand fundamental biology. Many 
different approaches can be applied to attempt to resolve the mechanisms through which 
sequence variation disrupts downstream biological processes, which I discuss and apply in 
this thesis. Specifically, I use tractable haematopoietic cellular systems focusing mainly on 
neutrophils but also extending these analyses to monocytes and naïve CD4+ cells. First, I 
introduce the fundamental principles of human genetic variation and associated challenges in 
resolving functional mechanisms. I then discuss how immune functions are dysregulated in 
classical autoimmune diseases and emerging evidence for the role of these cells in complex 
disorders not previously considered immune-mediated. I then integrate molecular 
phenotypes from resting monocytes, neutrophils and CD4+ T cells with disease-risk loci. 
Molecular data have the advantage of enabling measurement in larger cohorts and have 
therefore been used in quantitative trait loci studies to identify variants influencing processes 
such as gene expression, histone modification or splicing. Using these data, I map molecular 
mechanisms acting at risk loci associated with a range of complex disorders. 
 
Following this, I highlight recent efforts in applying systematic genome-wide association 
approaches to cellular and functional traits, many of which can represent intermediate 
processes disrupted by complex disease. I then apply such approaches to novel neutrophil 
functional phenotypes to ascertain whether such population-based approaches can be used 
to gain insight into neutrophil biology. Finally, I discuss studies of haematological blood cell 
count traits and immunophenotyping and apply a targeted recall-by-genotype study to dissect 
the relationship between these traits, specifically neutrophil count and surface receptor 
expression.  
 
In summary, I demonstrate how describing biological mechanisms of genetic variants 
requires the integration of multiple and complementary datasets and offers insight into 
fundamental biology, disease risk and therapeutic utility.  
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Chapter 1  
 
 
 
Introduction  
 
 
 
 
 
 
 
 
1 
1 Introduction  
 
1.1 Human genetic variation  
Genetic variation describes differences in DNA sequences across individuals that are 
inherited from maternal and paternal chromosomes. Variation also arises through factors 
such as errors in DNA replication, incomplete DNA repair, or through the controlled 
development of the highly variable immune receptor genes (MHC, T cell receptor) (Barnes 
and Lindahl, 2004, Shiina et al., 2009).  
 
In studying population-level variation, we identify associations between the frequency of 
genetic variants and physiological differences. On a cellular level, we study how every cell in 
the human body contains the same DNA molecule yet different tissues carry out highly 
specialised functions. On a molecular level, sequence variation can affect gene expression 
and epigenetic functionality. Human genetics now encompasses the study of multiple layers 
of biological processes, which can represent intermediate steps through which variants 
ultimately affect organismal phenotypes.  
 
The most common type of genetic variation, and the focus of this thesis, is known as a single 
nucleotide polymorphism (SNP) where the type of nucleotide at one position varies across 
individuals. In humans, although there are four possible nucleotide combinations (A, T, G, C), 
in general only two of the possible four nucleotides are ever seen in a population, and one 
individual carries two copies (alleles) on each diploid chromosome (Casci, 2010, McDaniell 
et al., 2010). Variants are classified by the occurrence of the least frequent (minor) allele 
within a population. Common variants occur with minor allele frequency (MAF) ≥ 5% and rare 
variants are often defined as occurring with a MAF of less than 1%. A second class of 
variation is structural variation including insertions-deletions (indels), block substitutions, 
inversions and copy number variants (Frazer et al., 2009).  
 
SNPs are not inherited independently but are correlated, resulting in the systematic 
association and correlation of alleles at nearby loci (Slatkin, 2008). This structure is known 
as linkage disequilibrium (LD) and is variable across populations of different ancestries. 
The International HapMap Project defined LD regions in 269 individuals of four different 
populations including Yoruba in Ibadan, Nigeria (YRI), Utah with northern and western 
European ancestry (CEU), Han Chinese in Beijing (CHB) and Japanese in Tokyo (JPT) 
(International HapMap Consortium, 2005). Alleles of SNPs within the same LD block are 
inherited more frequently together in the same haplotype. A set of highly correlated loci 
(high LD) is known as a haplotype block, the boundaries of which are associated with 
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recombination hot spots. Within haplotype blocks, recombination is infrequent. In humans, 
haplotypes range in size from a few kb to over 100 kb (Wall and Pritchard, 2003, Daly et 
al., 2001). Despite the observation of a few large blocks, most European population 
haplotypes are smaller, between 5-20 kb (Wall and Pritchard, 2003). This discovery had 
wider implications for genetic association studies described in detail in Section 1.2.  
 
1.2 Identification of trait-associated genetic variants using genome-
wide association studies 
Identification of LD patterns, the establishment of public databases containing millions of 
curated SNPs and emerging microarray technologies together transformed genetic studies 
(International HapMap Consortium, 2005, Sachidanandam et al., 2001). At the beginning of 
the GWAS era, genotyping arrays could be designed based on known LD structure to 
contain probes assaying approximately 500,000 “tag” SNPs, which captured the majority of 
common European variation without directly genotyping every variant (Barrett and Cardon, 
2006). Later came the development of imputation methods, where high-quality haplotypes 
from reference populations were and still are used to estimate variant alleles that have not 
been directly genotyped (Huang et al., 2015). Using reference haplotypes such as those 
available from the UK10K, 1000 Genomes projects or both combined now enables 
association tests of tens of millions of variants (UK10K. Consortium et al., 2015, 1000 
Genomes Project Consortium et al., 2015, Huang et al., 2015). With the falling costs of 
whole-genome sequencing, we are also moving to using next-generation sequencing 
technologies to sequence all sites, which vastly improves the accuracy of rare or private 
variant detection (Bomba et al., 2017).  
 
Collectively these approaches are called genome-wide association studies (GWAS). For the 
analysis of diseases, GWAS identify discordant variant allele frequencies between cases and 
controls, where the association of a higher allele frequency with a disease suggests this is a 
risk factor. GWAS can also be applied to quantitative traits commonly using linear regression 
to test for association of the variant with increasing or decreasing trait values. In most 
studies, variants with additive effects are evaluated, where there is a linear and uniform 
increase in the trait value/disease risk with each copy of the effect allele (Bush and Moore, 
2012).  
 
For each variant, an independent statistical test is applied meaning that for a genome-wide 
approach, multiple tests are implemented. This greatly increases the probability of detecting 
false positive associations. When using a p value threshold of 0.05, there is a 5% probability 
of rejecting the null hypothesis by chance, which equates to a high number of observations if 
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performing millions of tests. Therefore, it is advisable to use a more stringent p value 
threshold. Based on the International Hapmap Consortium estimation of the number of 
common (MAF ≥ 5%) independent variants across the genome in a European population, a 
significance p-value threshold of 5 x 10-08 was suggested to control for multiple testing in 
GWAS (International HapMap Consortium). Alternatively, for a specific cohort, the Bonferroni 
correction can be used, where the threshold of 0.05 is divided by the number of independent 
tests. Alternative methods are discussed in Chapter 2 and implemented in Chapter 4. 
 
GWAS have transformed the study of complex traits and diseases by enabling the unbiased 
screening for significant genetic variants on a genome-wide scale. Hundreds of risk/trait-
associated loci have now been identified. As of the 10th October 2017, the NHGRI-EB GWAS 
catalog contains 52,491 unique variant-trait associations (MacArthur et al., 2017). This high 
number reflects the genetic architecture of complex traits in that they are multifactorial and 
explained by many variants influencing genes and pathways that are biologically relevant to 
the trait (polygenic) (Visscher et al., 2017). However, the overall phenotypic-variation 
explained by the identified loci is low, suggesting we have not been able to identify all genetic 
factors that constitute pre-calculated heritability estimates (Visscher et al., 2017). This is 
referred to as the “missing heritability” problem, which is an important challenge in the field 
but not the focus of this thesis (Manolio et al., 2009). 
 
Recently, an “omnigenic” model has been suggested in order to interpret the observation that 
trait heritability is spread across the whole genome, rather than clustered in key genes 
(Mumbach et al., 2017). This model posits that variants in highly relevant “core genes” 
directly affect the trait, but all genes (and variants within them) are highly interconnected 
through extensive networks, although a full knowledge of such connections is currently 
lacking (Mumbach et al., 2017). These multiple small effects cumulatively effect disease risk. 
The authors, however, acknowledge that GWAS provide important biological insights, such 
as identifying core genes and implicate pathways in which lead variants are enriched 
(Mumbach et al., 2017). Arguably, investigating cellular contexts of identified genes is still of 
value, particularly as the authors posit that these complex networks are also cell-type specific 
(Mumbach et al., 2017).  
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1.3 Challenges in gaining functional insight from GWAS  
Despite the successes of GWAS in identifying many trait-associated variants, there remain 
some key challenges. This main focus of this thesis is in the functional interpretation of the 
frequency and effect size spectrum of loci that is currently detectable by GWAS. This 
includes mainly common variants with modest effect sizes or in some cases low-frequency 
variants with intermediate effects (McCarthy et al., 2008). Mechanistic interpretation 
represents a major bottleneck in the GWAS to function process. Biological hypotheses are 
more straightforward when genetic variants are located within coding regions, particularly if 
the gene function is known and relates to a relevant phenotype and the variation results in a 
change in amino acid sequence (non-synonymous) (Vasquez et al., 2016). 
 
However, with the advent of GWAS, somewhat surprisingly, it became apparent that more 
than 90% of trait-associated SNPs were located in non-coding regions of the genome rather 
than within genic exons (Maurano et al., 2012, Vasquez et al., 2016). This complicates 
biological interpretation and linking of downstream consequences to the effect on the overall 
phenotypic trait.  
 
In addition, whilst LD enabled early successes of GWAS by allowing the assessment of tag 
SNPs, it complicates a definitive identification of the causal SNP(s). Causal SNPs are those 
that underlie the true trait association and of all variants in the locus demonstrate the best 
model fit to the phenotype (Battle and Montgomery, 2014). Distinguishing the true causal 
variants from highly correlated proxy SNPs (those with an r2 > 0.8) is extremely complex as 
these will likely fit the phenotype equally as well as the true causal variant (Battle and 
Montgomery, 2014). Larger sample sizes, high-density genotyping, imputation with a high-
quality reference panel or whole-genome sequencing all increase the number of variants 
identified and therefore the likelihood of identifying the causal variant (Battle and 
Montgomery, 2014). However, even the various statistical approaches for fine-mapping 
causal variants are limited in cases of high correlation between variants (Chun et al., 2017). 
Ultimately, functional experiments are required to fully resolve such loci. 
 
There are multiple approaches that attempt to address each of these challenges. This thesis 
will focus on those that aim to assign function to genetic loci, which can also aid identification 
of causal variants in some cases. I discuss the type of data and approaches in detail below. 
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1.4 Assigning function to genetic loci 
 
1.4.1 Understanding the non-coding regulatory genome  
Describing the biology of non-coding SNPs requires an understanding of the function of the 
regulatory genome. While we are unable to predict this function from DNA sequence, through 
the efforts of large-scale consortia such as ENCODE, ROADMAP and BLUEPRINT, we 
know now that much of the non-coding genome performs a regulatory function (Encode 
Project Consortium, 2012, Roadmap Epigenomics Consortium et al., 2015, Adams et al., 
2012). There are multiple different layers of (epi)genomic function. The data made available 
through such consortia can be used to investigate the context of non-coding genetic 
variation. Below, I summarise our current knowledge of key concepts of epigenomics 
function and gene regulation. 
 
1.4.1.1 Transcription initiation at promoters 
Transcription is a highly regulated process where RNA polymerase (RNAP) enzymes 
generate an RNA molecule that is complementary to the sequence of DNA. Transcription is 
initiated at core promoters, which are DNA segments of between 50 and 100 bp (Roy and 
Singer, 2015). Here, the core transcription machinery including RNAP and general 
transcription factors (GTFs) assembles. There are various RNAP enzymes, RNA polymerase 
II (Pol II) transcribes protein-coding genes as well as the non-coding RNAs, small-nucleolar 
(sn)RNA and micro(mi)RNA (Guiro and Murphy, 2017). Studies utilising cell-free systems 
identified six GTFs, TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH (Roeder, 1996, Roy and 
Singer, 2015). GTFs recognise specific elements of the core promoter through sequence-
specific DNA binding. Classification of mammalian promoters based on canonical elements 
is complex as many do not contain such sequences, which include the TATA box, Initiator 
(Inr) element, the TFIIB recognition element (BRE) and downstream promoter element (DPE) 
(Roy and Singer, 2015). For example, only 5-7% of eukaryotic promoters contain a TATA 
box, and as such there are many cases of non-canonical core promoters (Roy and Singer, 
2015). These can contain unmethylated CpG islands or ATG deserts (low occurrence of ATG 
trinucleotides). Particular chromatin modifications can also mark mammalian promoters, 
which I discuss in detail below.  
 
Initiation is an important regulated step in transcription. Recently, the association of 
rs34481144 with severe risk of influenza in humans was shown to involve the disruption of 
promoter activity as a result of the change in one nucleotide from G (protective) to A (risk) 
(Allen et al., 2017). rs34481144 resides with the 5’ UTR of the interferon induced 
transmembrane protein 3 gene, IFITM3. Through a series of elegant experiments, the risk 
allele was shown to be associated with lower IFITM3 gene expression, lower promoter 
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activity and lower promoter binding of the innate immune interferon, IRF3 and disruption of a 
CpG methylation site in CD8+ T cells, where reduced methylation increased binding of the 
insulator factor CTCF. Carriers of the risk allele had lower numbers of CD8+ T cells in the 
airways during influenza infection, suggesting how reduced IFITM3 expression (due to 
reduced promoter activity and demethylation) could increase susceptibility to severe infection 
and providing evidence for a role of IFITM3 in the cellular response to infection (Allen et al., 
2017). Therefore, sequence-specificity is important to the recruitment of factors required for 
promoter activity and can be affected by SNPs. This example also highlights a potential role 
for DNA methylation in regulating gene expression. 
 
1.4.1.2 Regulation of transcription by enhancers and other regulatory elements 
Transcription is also regulated by the activity of distal regulatory sequences located upstream 
or downstream of the promoter (Heinz et al., 2015). These cognate regulatory elements are 
known as enhancers that activate transcription (Roy and Singer, 2015). Enhancers were 
originally identified using plasmid-based assays as sequences of no more than 100 bp that 
could drive gene expression (Banerji et al., 1981, Banerji et al., 1983, Krijger and de Laat, 
2016). Enhancer-gene interaction can be promiscuous but also selective and may not 
necessarily be between the nearest gene (Javierre et al., 2016, Mumbach et al., 2017, 
Krijger and de Laat, 2016). STARR-seq, a massively parallel reporter assay that enables the 
assessment of all genome-wide candidate enhancers through the ability of these sequences 
to drive transcription, was used to show that there were two different clusters of enhancer 
sequences that separately activated housekeeping genes and developmental genes (Zabidi 
et al., 2015).  
 
Silencers have similar properties to enhancers but instead act to inhibit transcription. 
Insulators are boundary elements that inhibit the spreading of transcription and chromatin 
interactions between neighbouring genomic regions (Gaszner and Felsenfeld, 2006, Ali et 
al., 2016). CTCF is a key factor in mediating insulation (Ali et al., 2016). Therefore, the 
spatial and temporal control of gene expression by distal regulators represents another layer 
of regulation and functionality of the non-coding genome (Ong and Corces, 2011).  
 
The enrichment of SNPs in enhancer regions is now well established and commonly used as 
a method to assign functionality to non-coding SNPs (Farh et al., 2015, Huang et al., 2017b, 
Musunuru et al., 2010, Chen et al., 2016a). Multiple examples of SNPs modifying enhancer 
activity are discussed throughout this thesis and my investigation into disease risk loci in 
Chapter 2 adds further examples to the many already demonstrated.  
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1.4.1.3 Transcription factors 
Transcription factors regulate gene expression through the sequence-directed binding to 
DNA at either promoters or regulatory elements such as enhancers. Multiple transcription 
factors bound at enhancers interact with components such as the Mediator complex or the 
general TF, TFIID to help recruit RNA polymerase II (Kagey et al., 2010). Looping out of 
intervening DNA enables interaction between enhancers and promoters. Other factors, such 
as the cohesin complex can act as scaffold proteins to ensure the stability of these 
interactions (Kagey et al., 2010, Schmidt et al., 2010). A study that assayed the binding of 
over 100 transcription factors in colorectal cancer (CRC) LoVo cells found that TFs were 
bound in clusters across the genome; 75% of the TF peaks were localised in 0.8% of the 
genome, consistent with previous observations that TF act combinatorially (Yan et al., 2013). 
Almost all clusters were formed around cohesin, demonstrating the importance of the 
cohesin complex in enabling complex TF binding (Yan et al., 2013).  
 
The initial selection of enhancers during the differentiation of specific cell lineages is 
controlled by pioneer transcription factors such as the haematopoietic-specific master 
regulator, PU.1 (Heinz et al., 2015). Pioneer factors can bind to their cognate motifs prior to 
any transcriptional activity or chromatin modification and at sites of DNase I inaccessibility 
(Heinz et al., 2010, Pham et al., 2013). Although PU.1 is an important factor for multiple 
haematopoietic cell types, PU.1 binding was shown to be cell-type specific (Pham et al., 
2013, Heinz et al., 2010). Cooperative binding of PU.1 with other collaborative transcription 
factors together establish the cell-type specific transcriptional signatures that support 
lineage-specific differentiation (Heinz et al., 2015, Pham et al., 2013, Adams and Workman, 
1995). For example, PU.1 is required for the generation of the general myeloid progenitor 
and the common lymphoid progenitor but different co-factors are associated with PU.1 at 
cognate binding sites between macrophages and B cells (Heinz et al., 2010). For example, 
C/EBP and AP-1 motifs were highly enriched within macrophage-specific distal PU.1 sites 
whilst E2A, EBF, Oct and NF-κB motifs were enriched in B cell specific PU.1 sites. These 
additional TFs both had roles in macrophage and B cell differentiation respectively (Heinz et 
al., 2010). In a PU.1 deficient myeloid progenitor cell line, the absence of PU.1 resulted in a 
reduced genome-wide C/EBPβ binding pattern. No corresponding PU.1 motifs were found in 
the C/EBPβ binding sites that remained. Restoration of PU.1 expression in this cell line using 
a fusion protein, increased PU.1 binding and the number of induced C/EBPβ-bound sites, 
75% of which were now co-bound by both TFs and enriched for the PU.1 motif (Heinz et al., 
2010). The importance of combinatorial TF binding was confirmed by evaluating the effects 
of naturally occurring motif mutations in PU.1 and C/EBPa between two different mouse 
strains (Heinz et al., 2013). Loss of binding of one TF as a result of motif disruption led to the 
corresponding loss of the second TF and vice versa (Heinz et al., 2013). It is suggested that 
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co-binding of these TFs enables competition with nucleosomes to maintain open chromatin 
and establish the required cell-type specific binding (Heinz et al., 2010).  
 
Some enhancers require additional co-factors to become fully activated, particularly in 
response to external or internal signals. Cell type-specific responses to the same stimuli can 
be achieved through the collaboration between pioneer factors, which first select enhancer 
sites in the respective cell types and open chromatin (Mullen et al., 2011, Heinz et al., 2015). 
Following this, a second tier of signal-dependent TFs can bind to these previously 
established enhancers ensuring that a specific subset of regulatory elements is activated in 
different cell types (Mullen et al., 2011, Heinz et al., 2010, Ghisletti et al., 2010). Multiple 
studies have provided evidence for a relatively small number of TFs that interact and bind 
with pioneer factors to determine cell type specific differentiation and signalling responses by 
directing the genes to which signalling TFs bind. For example, Mullen et al. (2011) used 
ChIP-seq to show that TGFβ signalling is mediated by Smad2/3, but only 1% of Smad3 
binding sites were occupied in more than one cell type between embryonic stem cells, pro-B 
cells and myotubes (Mullen et al., 2011). Further, they showed that cell-type specific 
signalling responses were the result of Smad2/3 co-occupying distinct sites with cell-type 
specific master/pioneer TFs; Oct4 in ES cells, PU.1 in pro-B cells and Myod1 in myotubes 
(Mullen et al., 2011). Similar cooperative interactions were shown in vivo where 61% of NF-
κB binding sites in strain-specific mice were already bound by PU.1 and CEBPa before Toll-
like receptor 4 (TLR4) stimulation (Heinz et al., 2013).  
 
In summary, cooperative binding of a relatively small and defined group of TFs establishes 
cell-type specificity of gene expression, lineage differentiation and response to external and 
internal stimuli. Given the importance of TF in these processes, it is often investigated 
whether a SNP disrupts TF binding motifs, many examples of which are discussed 
throughout this thesis.  
 
1.4.1.4 Transcription elongation and RNA processing 
Transcriptional regulation is not restricted to initiation. For many mammalian genes, high 
levels of transcription initiation were observed, but this was not correlated with a high level of 
gene expression (Guenther et al., 2007). This is due to post-initiation regulation where 
negative elongation factors can cause Pol II promoter-proximal pausing. Pol II can be 
released by factors such as the Positive transcription elongation factor (P-TEFb) (Rahl et al., 
2010, Zhou et al., 2012). This mechanism is thought to enable fine-tuning in transcription to 
produce the optimal level of cellular gene transcription as some genes will progress to 
productive elongation but not all (Zhou et al., 2012). Regulation at this stage also influences 
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processes that can be coupled to transcription such as 5’ mRNA capping, splicing and 3’ 
cleavage and polyadenylation (Zhou et al., 2012).  
 
Splicing is the removal of introns within genes to produce a mature processed RNA. 
Alternative splicing is widespread, occurring with up to 94% multiexonic human genes (Chen 
et al., 2014). The process can generate multiple transcripts from a single gene as a result of 
exon skipping, alternative 3’ acceptors, alternative 5’ donor sites or intron retention (Figure 
1.1) (Chen et al., 2014, Nilsen and Graveley, 2010). Splicing can be tissue and 
developmental-stage specific and is important in disease, with 15% of disease-causing 
mutations being located in splice sites (Chen et al., 2014). Mutations in splicing factor genes 
occur at high frequency in haematological cancers (Chen et al., 2014). Extensive transcript 
diversity as a result of alternative splicing was recently shown in haematopoietic progenitor 
and precursor cell populations, where 7,881 novel splice junctions were discovered as well 
as 2,301 alternative splicing events (Chen et al., 2014). In many cases transcript changes 
were not associated with detectable changes in gene expression, showing that increasing 
cell-type commitment during lineage differentiation involves the use of alternative transcript 
isoforms. Therefore, a full understanding of development diversity requires an assessment of 
all transcriptome effects not just those at the gene level (Chen et al., 2014).  
 
Two methods to quantify splicing events are summarised in Figure 1.1. Both of these 
methods were used in the BLUEPRINT consortium and as such as used in the analysis of 
variant function throughout this thesis. Accurate splicing quantification requires RNA-seq 
data. This is a technique that uses next-generation sequencing to quantify genome-wide 
gene expression profiles, where high gene expression is represented by an increased 
number of reads mapping to the corresponding gene location in the reference genome 
(Marioni et al., 2008). Reads across splicing junctions can also be counted, as is employed in 
the splicing annotation method, referred to as percent splice in (Figure 1.1) (Chen et al., 
2016a). Alternatively, the relative expression levels of all known and annotated transcripts, 
as defined by GENCODE for example, can be estimated using RNA-seq reads across the 
gene body (Figure 1.1) (Chen et al., 2016a). 
 
Splicing and donor-acceptor sites are highly sequence specific and therefore could be 
disrupted by genetic variants (Figure 1.1). In addition, branch points, exonic and intronic 
splicing enhancers/silencers and mRNA secondary structures can also be influenced by 
SNPs and result in splicing changes (Hiller et al., 2006). For example, the multiple sclerosis 
risk SNP, rs17612638 (G) abrogates an exonic splicing silencer, which normally functions to 
repress the use of a 5’ splice site of exon 4 of the PTPRC gene (Lynch and Weiss, 2001). 
This gene encodes a receptor of the protein tyrosine phosphatase family, also known as 
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CD45, which expressed all nucleated haematopoietic cells (Lynch and Weiss, 2001, Nakano 
et al., 1990). The immune-related function of this gene suggests that disruption of the tightly 
regulated exon 4 and resultant alternative transcripts may underlie the observed MS risk 
(Lynch and Weiss, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Alternative splicing mechanisms produces multiple distinct transcripts  
Schematic summarises the different molecular changes involved in alternative splicing and the 
different possible RNA transcripts. The cognate vertebrate splicing donor site contained in the 5’ intron 
sequence (GT) is also shown along with the 3’ splicing acceptor site (AG). The polypyrimidine tract 
(py-py-py) is a region high in C and T/U pyrimidines. Upstream of this tract is the branch point, which 
includes an A nucleotide and is important in the splicing molecular mechanism. RNA-seq can be used 
to quantify the reads (shown in red) across the splicing junctions. The examples above show split 
reads across two introns and reads within an exon, which both support exon inclusion. Splicing can 
also be assessed by quantifying the expression of the known alternative transcripts (right) by counting 
reads expressed in fragments per kilobase of transcript per million fragments sequenced (FPKM). 
Adapted from (Chen et al., 2014, Nilsen and Graveley, 2010). The percent splice-in method portrayed 
above is similar to that described by Geuvadis consortium and the information in the figure above was 
adapted from the (Geuvadis, 2010) webpage listed in the references.  
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1.4.1.5 Chromatin structure 
The regulatory processes described above do not navigate a simple linear DNA sequence, 
but a complex three-dimensional structure known as chromatin. For DNA to fit into an 
approximate 10 µm-diameter nucleus it is highly condensed in a nucleoprotein complex 
(Nieto Moreno et al., 2015). 147 bp of DNA is wrapped 1.7 turns around the histone protein 
octamer, which is known as a nucleosome (Figure 1.2) (Luger et al., 1997). Octamers 
comprise two H3-H4 and two H2A-H2B dimers and histone H1 (Figure 1.2) (Luger et al., 
1997). Nucleosomes are repeating units (Figure 1.3) and this structure allows further 
supercoiling and condensation into functional structural domains (Lavelle, 2014). Chromatin 
remodellers disassemble local compacted nucleosomes to allow access for Pol II and other 
cofactors, which is essential for active gene expression. This is a state generally referred to 
as “open chromatin”, whereas “closed chromatin” generally refers to genes and regulatory 
elements that are inaccessible due to the compact structure (Figure 1.3) (Bannister and 
Kouzarides, 2011). Further compaction beyond this leads to the formation of constitutively 
closed heterochromatin containing repressed genes.  
 
Chemical modification of the core histone proteins or protruding amino-terminal tails is also 
an important regulatory mechanism and confers function to chromatin. Histone modifications 
are chemical groups that are added to specific residues in the histone protein sequence by 
chromatin modifying proteins (Figure 1.2). Possible modifications include histone 
phosphorylation, acetylation, methylation and ubiquitylation. The charges associated with 
certain modifications, such as the negatively charged phosphorylation, can affect the 
interactions between histones and, it has been suggested, with the negatively charged DNA 
phosphate backbone changing the local compaction of DNA (Bannister and Kouzarides, 
2011). In addition, these groups can act as molecular “flags” for the binding of histone 
chaperones, other functional cofactors or additional chromatin remodellers. These proteins 
contain domains which can recognise modifications, for example, CHD1 binds to H3K4me3 
through the chromodomain and the heterochromatin protein, HP1, binds to methylated lysine 
9 on histone H3 (Flanagan et al., 2005, Bannister et al., 2001). Proteins containing 
bromodomains bind to acetyl-lysine modifications and subsequently initiate transcription, 
therefore targeting these domains offers an attractive potential for specific therapeutics in 
inflammation, viral infection and in regulating oncogene expression (Filippakopoulos and 
Knapp, 2014).  
 
Histone modifications are dynamic, can be altered in response to intracellular and 
extracellular stimuli, and regulate multiple processes beyond chromatin structure and 
transcription including DNA repair, replication and recombination (Bannister and Kouzarides, 
2011). Chromatin structure within genic regions can also influence alternative splicing (as 
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discussed above) through kinetic coupling with transcription whereby nucleosomes act as 
obstacles, promoting Pol II pausing and influencing exon inclusion/exclusion (Kadener et al., 
2001, Schor et al., 2009, Bintu et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Histone structure and modifications  
Nucleosomes are protein structure units consisting of approximately 147 bp of DNA (dark blue) 
wrapped around the octameric protein structure containing two copies of each of the core histones 
H2A, H2B, H3 and H4 (yellow). Histone H1 is a linker histone that stabilises higher order structure of 
chromatin and protects the DNA from nuclease digestion. Most histone modifications (dark purple) 
occur on the N-terminal histone tails (green). Modifications considered in this thesis are shown below 
for the histone tail of the H3 core histone. The notation of, for example, H3K4me3 refers first to the 
histone H3, then to the lysine residue that is fourth in the sequence counting from the N-terminus and 
then to the chemical modification itself, here a tri-methylation of the lysine residue. Modifications also 
occur within the core globular protein structure. Adapted from (Fullgrabe et al., 2011).  
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Genome-wide profiling of histone-bound regions indicated that specific histone modifications 
are associated with specialised functional genomic regions including promoters or 
enhancers. As such, these approaches have transformed the way we now identify functional 
genomic regions (Barski et al., 2007, Hon et al., 2009). To identify these regions the 
technique, chromatin immunoprecipitation followed by next-generation sequencing (ChIP-
seq), uses antibodies specific to a histone modification (or transcription factor) to enrich 
crosslinked protein-DNA fragments for bound-regions, which are then sequenced (Barski et 
al., 2007, Schmidt et al., 2009). Bound genomic regions are identified by pile-ups of 
sequence reads (referred to as “peaks”), which provide a quantitative measurement of 
genome-wide protein binding (Figure 1.4).  
 
Insights from these genome-wide profiles include the observation that H3K4me3 
preferentially associates with promoters and marks regions of active transcription (Hon et al., 
2009). Chromatin signatures at promoters were found to be similar across cell types but in 
contrast, H3K4me1 associated with cell-type specific enhancers (Heintzman et al., 2009 
2009). However, many H3K4me1-associated enhancer regions were later found to be 
inactive when tested in reporter assays, leading to the discovery that active enhancers are 
marked by a combination of H3K4me1 and H3K27ac (Figure 1.2-1.3) (Creyghton et al., 
2010). Instead, H3K4me1 alone marks poised enhancers that may not necessarily be active 
but could reflect molecular ‘memory’ of previous activation (Heinz et al., 2015, Creyghton et 
al., 2010). For example, many inactive haematopoietic stem cell developmental genes were 
found to be regulated by distal enhancers enriched with H3K4me1 (Creyghton et al., 2010, 
Cui et al., 2009). H3K27ac, which is deposited by both p300 and CREB binding protein 
(CBP) can also mark active promoters, when not in conjunction with H3K4me1 (Creyghton et 
al., 2010).  
 
Clearly the context of chromatin functional state has important consequences for molecular 
function. For example, using STARR-seq, it was observed that although many sequences 
possessed the capacity to act as enhancers, many were endogenously repressed (Zabidi et 
al., 2015, Krijger and de Laat, 2016). The multiple layers of transcriptional regulation and 
chromatin context are summarised in Figure 1.3. Also shown is the high levels of 5-methyl 
cytosine (5mC) in closed chromatin, contributing to gene repression (Figure 1.3) (Jones, 
2012). Recent advances in genome-wide DNA methylation mapping techniques have 
highlighted the varied roles of this epigenetic mark depending on the genomic context and 
interpretation of the functional effect requires appreciation of multiple genomic factors 
(Jones, 2012). 
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Figure 1.3: Multiple layers of gene regulation  
This schematic summarises the many molecular processes that control transcription. The level of DNA 
compaction controls access of DNA-binding cofactors. In the bottom panel, DNA is highly compacted 
and hypermethylated at cytosine residues (5mC) preventing access to transcriptional cofactors and 
repressing gene expression. Histone remodelling proteins (purple) can open chromatin allowing 
access to other cofactors (top panel). This leads to activation of RNA polymerase II and transcription 
initiation at the core promoter. Enhancer-bound cofactors can also influence transcription of distal 
genes through long-range interactions as a result of DNA looping and clustering. DNMT = DNA 
methyltransferase. HAT = histone acetyltransferase. HDAC = histone deacetylase. HDM = histone 
demethylase. HMT = histone methyltransferase. TET = ten-eleven translocation. Adapted from (Greco 
and Condorelli, 2015). 
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1.4.1.6 Higher-order chromatin structure 
With the advent of chromatin conformation capture techniques came the ability to study the 
three-dimensional spatial genomic structure on a global scale, showing that regulatory loops 
are widespread and provide another mechanism for transcriptional regulation (Dekker et al., 
2002). Chromatin conformation capture (3C) and adaptations of this approach including 4C, 
5C, Hi-C, ChIA-PET and promoter-capture HiC (PcHiC), identify long-range interactions by 
formaldehyde cross-linking of genomic regions located close in physical space (de Wit and 
de Laat, 2012). Similar to ChIP-seq, these fragments are sequenced and mapped to the 
reference genome, thereby identifying fragments connecting distally located elements. 
Chromatin conformation techniques differ by the resolution of interactions detected. For 
example, genome-wide approaches such as HiC revealed chromatin loops on a larger scale 
(100kb to 5Mb) referred to as topologically associated domains (TADs) (Lieberman-Aiden et 
al., 2009, Dixon et al., 2012, Krijger and de Laat, 2016). TADs are more likely to be tissue-
invariant but sub-TADs (median size of ~185 kb) and regulatory loops that form within TADs 
are more tissue-specific and dynamic (Dixon et al., 2012, Phillips-Cremins et al., 2013, 
Krijger and de Laat, 2016). Stabilisation of TADs requires CTCF and cohesin whereas 
regulatory loops also require additional tissue-specific TFs (Krijger and de Laat, 2016, 
Phillips-Cremins et al., 2013, Kagey et al., 2010).  
 
The physical partitioning of the genome into these architectural domains correlates well with 
genomic function including actively transcribed or repressed genes (Symmons et al., 2014). 
A definitive causal relationship between promoter-enhancer chromatin looping and gene 
expression was demonstrated by inducing looping between the beta-globin gene and 
corresponding super enhancer (locus control region), which resulted in significantly 
upregulated beta-globin gene expression (Deng et al., 2014).  
 
Connections between distal enhancers and gene targets complicate assignment of genes to 
regulatory SNPs. HiC data can be used to identify target genes of distal regulatory SNPs. 
PcHiC is used predominantly in this thesis and achieves higher resolution in comparison to 
HiC by enriching fragments for genome-wide promoter-mediated interactions using an array 
with promoter-probes of all cellular genes (Mifsud et al., 2015). This approach was recently 
used to identify the interacting regions of 31,253 promoters in 17 primary human 
haematopoietic cells (Javierre et al., 2016). Interactions were found to be highly cell-type 
specific, recapitulating the haematopoietic tree and interacting regions were enriched in 
GWAS disease variants (Javierre et al., 2016). Using this data, the 6q23 locus, associated 
with RA and psoriasis, was found to interact with the promoter of the most proximal gene, 
TNFAIP3, but also with the promoter of IL20RA, located 680 kb upstream (McGovern et al., 
2016). The risk allele of the likely causal SNP in this locus, rs6927172, correlated with 
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increased gene expression of IL20RA, increased binding of both enhancer-associated 
histone marks and the TF, NFkB (McGovern et al., 2016). In this case, monoclonal therapy 
against IL-20 has been shown to be effective for both diseases (McGovern et al., 2016). On 
a genome-wide scale, an independent but similar capture approach, HiChIP, was used to 
map disease SNP target genes (Mumbach et al., 2017). Instead of focusing on promoter 
interactions, HiChIP is a protein-centric technique that was recently used with H3K27ac as a 
bait to assay interactions in T cell populations (Mumbach et al., 2017). Using H3K27ac 
interaction maps, 2,597 target genes were identified for 684 autoimmune disease variants 
(Mumbach et al., 2017, Trynka, 2017). Only 14% of the mapped target genes represented 
the closest gene to the GWAS variant. This demonstrates the utility of interaction data to 
identify target genes, which is important in the translation of GWAS to the clinic. 
Capture techniques can be used to identify SNP target genes, but long-range interactions 
could themselves be disrupted by these variants. Disruption of TF binding has long been 
suggested as the predominant mechanism underlying regulatory variation (Pai et al., 2015). 
However, only a minority, 10-20%, of GWAS SNPs were found to be located within TF 
binding motifs (of 823 variants assessed), suggesting other regulatory mechanisms may 
underlie genetic associations (Farh et al., 2015). Evidence of allele-specific interactions has 
been observed, using ChIA-PET of CTCF and Pol II in different human cell lines. For 
example, 50 loci showed allele-specific tandem loops (loops coordinated by two CTCF motifs 
positioned in a tandem manner) that contained phased SNPs within the gene body (Tang et 
al., 2015). 44% of these loci displayed allele-specific expression (Tang et al., 2015). The 
authors also showed that the asthma-associated SNP, rs12936231, disrupted a CTCF motif 
and CTCF binding further abrogating looping and chromatin topology, which they postulated 
could represent the primary molecular event underlying the locus (Tang et al., 2015). Similar 
observations have been made combining H3K27ac HiChIP interaction data from primary 
human cells with available genome phasing (Mumbach et al., 2017). The authors observed 
4.2% of loops exhibited allelic bias (FDR < 0.05) where risk alleles either disrupted or 
increased enhancer-gene interactions (Mumbach et al., 2017). Thorough examination of the 
allelic bias of chromatin interactions in a larger population-scale cohort is needed to establish 
this as a widespread disease-relevant regulatory mechanism.  
 
1.4.1.7 Non-coding RNA regulation  
90% of the genome is transcribed into non-coding RNAs including ribosomal, transfer-RNAs, 
long non-coding RNAs and microRNAs, compared to 2-3% transcribed to protein (Roy and 
Singer, 2015, Lee, 2012). miRNAs are short (19-24 nucleotides) and function to cleave or 
repress complementary mRNA post-transcriptionally where binding is mediated by the RNA-
induced silencing complex (RISC) (Hrdlickova et al., 2014). The translation of more than half 
of protein-coding genes is regulated by miRNAs (Hrdlickova et al., 2014). Many lncRNAs, 
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which consist of a heterogeneous group of RNAs more than 200 nucleotides, are thought to 
regulate expression of protein-coding genes (Harrow et al., 2012, Hrdlickova et al., 2014). 
lncRNAs exhibit cell-type specific expression and widespread regulatory functions through 
interaction with DNA, RNA or protein enabling the control of processes such as gene 
silencing, RNA maturation and transport, protein production and chromatin remodelling 
(Derrien et al., 2012, Hrdlickova et al., 2014).  
 
Non-coding RNAs have been implicated in a range of neurodegenerative, cardiovascular and 
autoimmune diseases as well as cancer (Hrdlickova et al., 2014). Disease SNPs have been 
shown to confer risk by disrupting the function of non-coding RNAs, for example, by altering 
RNA expression or by changing binding sites in target genes. rs57095329 is associated with 
systemic lupus erythematosus (SLE) and located in the promoter of microRNA, miR-146a 
(Luo et al., 2011, Hrdlickova et al., 2014). Increased SLE risk is associated with lower miR-
146a expression levels, observed in peripheral blood leukocytes (Luo et al., 2011). 
Upregulated type I interferon pathway activity is known to occur in SLE pathogenesis and 
miR-146a functions as a negative regulator of this activity, explaining how a decreased 
miRNA expression could increase disease risk (Luo et al., 2011, Tang et al., 2009). Non-
coding RNA function and target gene interaction is another important regulatory function to 
consider in genetic function studies. Figure 1.4 summarises how all of the described 
epigenomic data can be used to annotate function of trait-associated variants and in part aid 
the prediction of putative causal SNPs.  
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Figure 1.4: Annotating genetic variants with epigenomic function  
Schematic summarises initial steps in predicting molecular mechanisms of trait-associated SNPs. 
Imputation, targeting genotyping or use of whole-genome sequencing data identifies all variants in LD. 
Disease-associated SNPs are intersected with epigenomic regions such as chromatin modification or 
transcription factor binding (ChIP-seq binding peaks in green). Combined with high-resolution 
chromatin interaction data, putative target genes can be identified. Further techniques to identify 
function such as quantitative trait studies are discussed below. Figure based on (Krijger and de Laat, 
2016). 
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1.4.2 Quantitative trait loci studies with molecular phenotypes 
Annotating the genome with epigenomic data (Figure 1.4), while helping to highlight 
molecular function, is prone to chance overlaps. Alternatively, using epigenomic data as a 
quantitative trait in association mapping can identify, with statistical confidence, specific 
variants (and those in high LD) associated with disrupting a molecular function. If a genomic 
locus is associated with both a disease or complex trait and with a molecular phenotype such 
as gene expression, this is a strong indicator of possible causal mechanism (Nica and 
Dermitzakis, 2013). 
 
Variation in gene expression can arise from environmental factors, epigenetic effects, 
random biological noise and genetic effects. QTL mapping uncovers the genetic basis of 
variation in quantitative phenotypes in a similar approach to GWAS. Smaller cohorts can 
reduce power and therefore, rather than genome-wide, the number of variants tested in a 
QTL study is constrained within a genomic window surrounding each molecular feature. 
These QTLs are referred to as cis-QTLs, which are SNPs that act locally to the feature being 
investigated (Nica and Dermitzakis, 2013). The definition of “local” can vary between studies; 
a window of 1 Mb either side of the start and end of the feature was used in the Chen et al. 
(2016) study. This approach limits the burden of multiple testing if all genome-wide variants 
were assessed. Depending on the assay, the expression of all genes (~22,000) can be 
tested for cis-QTLs.  
 
Early studies showed heritability of gene expression, chromatin modifications and 
transcription factor binding and identified that eQTLs (SNPs associated with gene expression 
variation) were fairly widespread, with some observations of up to 30% of genes having an 
eQTL in lymphoblastoid cell lines (LCL) (Stranger et al., 2007, Price et al., 2011, Grundberg 
et al., Pickrell et al., 2010, Montgomery and Dermitzakis, 2011, McDaniell et al., 2010, Pai et 
al., 2015). With increasing sample sizes and denser genotypes or sequenced data, the 
number of discovered eQTLs has increased. For example, the latest G. TEx analysis of 
RNA-seq gene expression across 44 tissues with 449 donors identified 152,869 cis-eQTLs 
for 19,725 genes corresponding to 50.3% and 86.1% of all known lincRNA and protein-
coding genes respectively (G. TEx Consortium, 2017).  
 
Cis-eQTLs are enriched at gene start sites and variants upstream of the TSS are observed to 
have greater effect sizes than those in gene bodies, suggesting that SNPs regulating 
transcription have a larger impact than those that may regulate post-transcriptional 
processes (G. TEx Consortium, 2017). However, splice site QTLs or those that introduce a 
stop codon do have a high impact on downstream consequences (G. TEx Consortium, 
2017). Early eQTL studies demonstrated high cell-type specificity, Dimas et al. (2009) 
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identified that 69-80% of eQTLs across three cell types, LCLs, primary fibroblasts and 
umbilical T cells were cell type specific (N = 75) (Dimas et al., 2009). Similar tissue specificity 
has been later confirmed in primary cell types (Chen et al., 2016a). Cell-type specificity can 
also manifest as opposing direction of effects of the same QTLs in different contexts. For 
example, Raj et al. (2014) identified 7000 shared eQTLs between monocytes and T cells 
(Raj et al., 2014). The effect size for most eQTLs, defined as the most significant SNP per 
gene, was concordant across the two cell types but for 42 genes, the most significant SNP 
had opposing directions where the allele with increased expression in one cell and 
decreased in the other (Raj et al., 2014). QTL studies in stimulated cell types have shown 
that context specificity not only applies to different cell types but also to different active 
states. Specific QTLs were only detected in activated immune cells when stimulated by, for 
example, bacterial components (LPS) or inflammatory cytokines (IFN-g) (Fairfax et al., 2014, 
Naranbhai et al., 2015, Kim-Hellmuth et al., 2017, Alasoo et al., 2017).  
 
eQTLs are often used to integrate with GWAS SNPs to identify gene targets. Zhu et al (2016) 
used a Mendelian randomization method adapted for summary statistics to analyse complex 
trait and disease GWAS and blood eQTL data (N = 5311) and subsequently identified 126 
loci for which there was evidence of pleiotropy between gene expression and complex trait 
variance (Zhu et al., 2016). Here, pleiotropy describes genetic loci associated with two traits 
that may not be linked via a causal mechanism where the variant affects a phenotype 
through an endophenotype such as gene expression. Importantly, for approximately 60% of 
the colocalised cases, the regulated gene target, as identified by an eQTL, was not the 
nearest gene to the sentinel GWAS SNP (Zhu et al., 2016). Therefore, identifying gene 
targets based on proximity may lead to incorrect assignment.  
 
QTL studies also allow the integrated study of genetic effects on gene expression, chromatin 
and TF binding, which has provided many insights into the mechanism of gene regulation. 
55% of eQTLs in LCLs overlapped with DNase I hypersensitivity QTLs marking open 
chromatin, suggesting that a subset of eQTLs may influence gene expression through 
disruption of chromatin modification or transcription factor binding (Degner et al., 2012). 
Three studies measuring chromatin state, modification, TF binding and Pol II occupancy, 
provided initial evidence of high variability in enhancer function as well as suggesting that TF 
binding was the primary mechanism underlying modification of regulatory chromatin (Table 
1.1) (Kasowski et al., 2013, McVicker et al., 2013, Kilpinen et al., 2013). These observations 
were confirmed and expanded by two recent studies in LCLs that assayed genome-wide 
binding of histone modifications, PU.1 and Pol II binding (Grubert et al., 2015, Waszak et al., 
2015). Both studies showed extensive local correlation of molecular features in defined 
genomic windows (< 1Mb), which Waszak et al. (2015) referred to as variable chromatin 
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modules (VCMs). Interestingly, SNP-mediated changes in the local chromatin state were 
also correlated with those observed more distally in regions located up to 200 kb away 
(Denker and de Laat, 2015). This coordination was shown to result from physical interaction; 
Grubert et al. (2015) showed that 15% of proximal hQTLs were associated with changes at 
distal histone modifications that were connected by long-range chromatin interactions by 
using HiC and ChIA-PET data. Distal hQTLs were enriched within TADs and the majority of 
local-distal QTL pairs occurred between different enhancers (Grubert et al., 2015, Koch, 
2015). Both studies provided evidence that TF activity underpinned chromatin variation, 
which in turn correlated with gene expression, in 99% of cases positively (Waszak et al., 
2015). A single genetic variant could, therefore, propagate to multiple correlated features, 
perhaps explaining why a degree of chromatin variation cannot be correlated with proximal 
effects (Waszak et al., 2015). Single disease SNPs could therefore disrupt an entire 
coordinated molecular system, supporting the use of epigenomic data including chromatin 
interactions in identifying disease mechanisms and target genes and thus demonstrating the 
power of QTL studies to provide medically relevant insights as well as improve our 
understanding of genomic regulation (Koch, 2015, Denker and de Laat, 2015).  
 
Chen et al. (2016) extended these efforts by assaying gene expression, splicing, DNA 
methylation, H3K4me1 and H3K27ac QTLs across multiple primary human cell types; 
monocytes, CD4+ T cells and neutrophils (Chen et al., 2016a). Of the 20,403 genes 
assessed across the three cell types between 33.9-39.3% of genes had an eQTL. Here, an 
average of 9.89% of methylation probes, 25.7% of H3K4me1 peaks and 11.5% of H2K27ac 
peaks had at least one QTL. Confirming previous observations, there was a high degree of 
cell-type specificity to all marks (Dimas et al., 2009, Chen et al., 2016a). Particularly, hQTLs 
were highly cell specific, as expected for enhancer function. By considering lead SNPs and 
those in high LD (r2 ³ 0.8), ~43.4% of eQTLs were also hQTLs, confirming previous 
observations of high correlation between chromatin and gene expression. For 18.4% of the 
genes, a splicing QTL effect was identified, but these were largely independent of eQTLs, 
shown by a low concordance of lead QTLs for the respective traits (r2 < 0.1). There was also 
a high degree of colocalisation with autoimmune disease, which is discussed in detail in 
Chapter 2. The details of key QTL studies are summarised in Table 1.1.  
 
In summary, observations from QTL studies and genome-wide approaches discussed above 
both support the role of key TFs underpinning chromatin state effects and gene expression, 
at least for a subset of sites. For regulatory QTLs that cannot be explained by TF binding or 
correlated with gene expression effects, it remains to be shown whether these effects could 
be explained by disruption of long-range interactions or whether there is extensive 
redundancy between enhancers removing downstream consequences of genetic disruption.  
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Table 1.1: Summary of key blood quantitative trait loci studies 
Author Cell type Stimulated/Resting Molecular Trait Trait Assay Cohort 
(Dimas et al., 2009) LCL Resting Gene expression Microarray 75 
(Kasowski et al., 2010) LCL Resting NF-kB, Pol II ChIP-seq 10 
(Maranville et al., 2011) LCLs Glucocorticoids Gene expression Microarray 114 
(Degner et al., 2012) YRI LCL Resting Open chromatin DNase-seq 70 
(Barreiro et al., 2012) Dendritic cells M.tuberculosis Gene expression Microarray 65 
(Westra et al., 2013) Whole blood Resting Gene expression Microarray 5311 
(Battle et al., 2014) Whole blood Resting Gene expression RNA-seq 922 
(Lappalainen et al., 2013) LCL Resting Gene expression, miRNA RNA-seq 452-462 
(Kasowski et al., 2013) LCL Resting H3K27ac, H3K4me1, H3K4me3, H3K36me3 and 
H3K27me3, CTCF, SA1 
ChIP-seq 19 
(Kilpinen et al., 2013) LCL Resting H3K4me1, H3K4me3, H3K27ac, H3K27me3, TFIIB, 
Pu.1, MYC, Pol II 
ChIP-seq 8 + 2 trios 
(McVicker et al., 2013) YRI LCL Resting H3K4me1, H3K4me3, H3K27ac, H3K27me3, Pol II ChIP-seq 10 
(Ding et al., 2014) CEU LCL Resting CTCF ChIP-seq 51 
(Raj et al., 2014) CD4+ T cell, Monocytes Resting Gene expression Microarray 461 
(Fairfax et al., 2014) Monocytes LPS (2h), LPS (24h), 
IFNg (24h) 
Gene expression Microarray 262-414 
(Lee et al., 2014) Dendritic cells LPS (5hr), influenza 
(10hr), IFNb (6.5hr) 
Gene expression Microarray 534 
(Naranbhai et al., 2015) Neutrophils Resting Gene expression Microarray 101 
(Kumasaka et al., 2016) CEU LCL Resting Open chromatin ATAC-seq 24 
(Caliskan et al., 2015) PBMCs Rhinovirus Gene expression Microarray 98 
(Waszak et al., 2015) CEU LCL Resting PU.1, Pol II, H3K4me1, H3K4me3, H3K27ac ChIP-seq 47 
(Chen et al., 2016a) 
BLUEPRINT 
Monocytes, neutrophils, 
CD4+ T cells 
Resting H3K27ac, H3K4me1, gene, splicing, methylation ChIP-seq, RNA-
seq, 450K 
Up to 197 
(Joehanes et al., 2017) Whole blood Resting Gene and exon expression Microarray 5257 
(Kim-Hellmuth et al., 2017) Monocytes LPS, MDP, 5’-ppp-
dsRNA (90min, 1 h) 
Gene expression Microarray 134 
(Alasoo et al., 2017) 
(preprint) 
iPSC differentiated 
macrophages 
IFNg (18h), Salmonella 
(5h), IFNg + Salmonella 
Gene expression, chromatin accessibility/open 
chromatin 
RNA-seq, 
ATAC-seq 
86, 42 
(G. TEx Consortium, 2017) 44 Multiple tissues post mortem Gene expression RNA-seq 449 
Watt et al., 2018 (in 
preparation) 
Neutrophils Resting H3K4me3, H3K27me3, PU.1, CEBPB, CTCF ChIP-seq 22-110 
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1.5 Functional, cellular and immune phenotypes 
Beyond molecular phenotypes, heritable genetic variation has been observed in cellular and 
functional phenotypes. Examples include the levels of a broad range of blood cell types and 
surface receptor expression levels quantified using FACs-based immunophenotyping (Orru 
et al., 2013, Roederer et al., 2015) as well as cytokine production and circulating cytokine 
levels (Brodin et al., 2015, Ahola-Olli et al., 2017). These additional phenotypes allow 
comprehensive insights into immune functions and disease risk.  
 
The Human Functional Genomics Project (HFGP) has collated an array of deeply 
phenotyped individuals with information such as microbiome composition, immune 
responses against human pathogens and disease status (autoimmune, diabetes, Lyme’s 
disease, gout) (Netea et al., 2016, Li et al., 2016b). Li et al. (2016) demonstrated how host 
genetics plays a major role in the variation of immune cell cytokine responses from either 
whole blood, peripheral blood mononuclear cells (PBMCs) or macrophages stimulated ex 
vivo in a healthy population (Li et al., 2016b). Interestingly, the authors observed that the 
cytokine with the strongest inter-individual variation was IL6. Variants in this pathway have 
been previously associated with a multitude of diseases (Chapter 2). This further supports 
the functional importance of this cytokine in immune responses. In total, 17 novel genome-
wide significant QTLs were associated with the production of mostly monocyte- or T cell-
specific cytokines. cQTLs were enriched in regions under selective pressure, in ENCODE 
monocyte-specific enhancers, in infectious disease SNPs (for monocyte-derived cytokine 
QTLs) and in autoimmune disease SNPs (for T cell-derived cQTLs) (Li et al., 2016b). Similar 
autoimmune disease- and complex trait- loci enrichments were identified using 27 SNPs 
associated with circulating levels of 41 different cytokines from an independent GWAS in a 
large healthy cohort of up to 8,293 Finnish individuals (Ahola-Olli et al., 2017). Continuing on 
the efforts to measure protein-level traits, 38 variants were associated with immunoglobulin 
levels (IgA, IgG, IgM), which are effector molecules of the adaptive immune system (Jonsson 
et al., 2017). Similarly, these variants also had known roles in autoimmune diseases and 
haematopoietic malignancies. 
 
An exemplary study demonstrated how the combination of multiple pieces of genetic, 
molecular and functional evidence can resolve complex autoimmune disease risk loci, in this 
case, the TNFSF13B gene locus encoding the cytokine B cell activating factor (BAFF) (Steri 
et al., 2017). An indel variant was associated with multiple sclerosis and systemic lupus 
erythematosus in a Sardinian cohort, as well as with 18 different endophenotypes including B 
cell and monocyte counts (Steri et al., 2017). The variant produces an alternative 
polyadenylation site and a 3’ UTR truncated transcript, which resulted in both a gene 
expression and protein translation effect, the latter due to the presence of fewer miRNA 
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binding sites. Ultimately this culminated in an increased level of soluble BAFF. Elevated 
BAFF levels were observed prior to disease diagnosis in separate preclinical samples, which 
was clear evidence of the causal relationship between higher BAFF protein levels and 
autoimmune disease (Steri et al., 2017). This clearly shows the power of combining 
functional and molecular phenotypes with longitudinal and clinical datasets when evaluating 
causal relationships between functional and disease phenotypes.  
 
There are more and more studies recognising the importance of multiple phenotypes in 
facilitating functional interpretation of GWAS loci and in providing basic biological insights. 
Very recently, the Hi-HOST Phenome Project have generated a catalog cellular GWAS 
associations using 79 phenotypes in response to live pathogens in 528 LCLs and identified 
17 genome-wide significant loci (Wang et al., 2017a). The cellular phenotypes measured 
included readouts of endocytosis, endosomal trafficking, cell signalling, cell death, cytokine 
production as well as the molecular readouts of transcriptional regulation (Wang et al., 
2017a). In addition, the Enhancing GTEx (eGTEx) project was recently announced, wherein 
a bid to describe the effect of variation from “molecule to individual”, other intermediate 
measurements such as protein expression and telomere length will be assayed in the wide 
range of tissue types from this project in addition to gene expression and molecular 
phenotypes (eGTEx Project, 2017).  
 
In future, similar efforts will likely be extended to multiple primary cell types and greater 
sample sizes providing rich resources for functionally annotating genetic loci.  
 
1.6 Recall-by-genotype studies 
Recall-by-genotype (RbG) studies are genotyped-directed experimental phenotyping 
investigations representing downstream hypothesis-driven approaches to investigate 
functional mechanisms (Corbin et al., 2017). They have emerged as the primary choice for 
designing experiments to further investigate the function of observations first identified in 
large-scale genetic studies. They allow greater functional resolution with smaller sample 
sizes compared to hypothesis-free GWAS (Figure 1.7). 
 
RbG test a small number of predicted causal variants (between 1 and 10) selected from the 
integration of GWAS-associated variants, functional studies and statistical methods such as 
fine-mapping. Similar to GWAS, RbG studies have the advantage of utilising genetic variants 
that have arisen from the random allocation of alleles at conception, which cannot, in turn, be 
influenced by the traits of interest (Section 1.7.1). A further advantage of RbG studies are 
that they are designed to query causal relationships in selected stratified groups based on 
previously observed biological associations. This increases the precision of functional insight 
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in a cost-effective, efficient manner (Corbin et al., 2017). I demonstrate the implementation 
and utility of a RbG study in Chapter 4.  
 
1.7 Haematopoiesis as a paradigm for genetics 
Haematopoiesis is the production of all mature blood cell types including thrombocytes 
(platelets), erythrocytes (red blood cells), myeloid cells (monocytes, macrophages, 
neutrophils) and lymphocytes (B cells and T cells) (Figure 1.5). Self-renewing haematopoietic 
stem cells (HSC) in the bone marrow differentiate to lineage-committed progenitor cells, 
which further differentiate into mature cells (Orkin and Zon, 2008, Vasquez et al., 2016). 
Chromatin regulation is important in this differentiation process and mutations in factors 
mediating histone modification and chromatin architecture result in myeloid malignancies 
(Woods and Levine, 2015). Chromatin was recently shown to be highly dynamic during 
lineage specification with 17,035 enhancers established de novo mainly after commitment of 
the first lineage progenitor (Lara-Astiaso et al., 2014). TFs are key to the activity of these 
enhancers, full activation of which preceded lineage-specific gene expression programmes 
(Lara-Astiaso et al., 2014). Therefore, haematopoiesis represents a model system for the 
study of all stages of stem cell development as well as chromatin formation, transcription 
factory activity and the cell-type specificity of these processes.  
 
Mature haematopoietic cells perform vital biological roles including oxygen transport (red 
blood cells), blood clotting (platelets) and immune responses (myeloid and lymphoid cells). 
Sustained haematopoiesis occurs under homeostatic conditions as well as during infection, 
(Orkin and Zon, Amulic et al., 2012). Dysregulated blood cell function is a known factor in the 
aetiology of a wide variety of diseases. Understanding the biological context of disease-
dysregulated processes can highlight important haematopoietic pathways and novel genes in 
haematopoiesis and mature cell function. The role of these cells in disease and function is 
discussed in detail in Chapter 2 and 3 of this thesis.  
 
Haematopoiesis and mature blood cells are both relatively experimentally tractable. Whole 
blood is easily accessible from a high number of individuals and from this specific cell 
populations can be isolated with high purity and relative technical ease. The evolutionary 
conservation of haematopoiesis also facilitates study in model organisms. As a result, 
haematopoiesis is one of the best-characterised mammalian cellular differentiation systems. 
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Figure 1.5: Haematopoiesis and the involvement of essential transcription factors 
Differentiation of self-renewing haematopoietic stem cells to form all mature cells (red blood cell, 
platelet, mast cell, eosinophil, neutrophil, monocyte and macrophage, B and T lymphocytes, NK cells). 
The transcription factors required for each stage were discovered using conventional gene knockouts 
that resulted in a blockage of haematopoietic differentiation. LT-HSC: long-term haematopoietic stem 
cell, ST-HSC: short-term haematopoietic stem cell, CMP: common myeloid progenitor; CLP: common 
lymphoid progenitor, MEP: megakaryocyte/erythroid progenitor, GMP: granulocyte/macrophage 
progenitor. Additional TFs, not shown here, were predicted using a highly sensitive ChIP-seq protocol 
to be involved in 16 differentiation stages (Lara-Astiaso et al., 2014). Figure adapted from (Orkin and 
Zon, 2008).   
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Blood cell phenotypes such as full blood counts (FBC), are also readily measured by 
automated haematology analysers (Chami and Lettre, 2014, Astle et al., 2016). The 
deviation from normal size, physical characteristics or number of blood cells is diagnostic for 
human disease such as infection, anaemia, thrombotic diseases or haematological disorders 
(Table 1.2) (Vasquez et al., 2016, Soranzo et al., 2009). FBC is therefore routinely measured 
as part of clinical diagnosis and assessment of general health (Chami and Lettre, 2014). 
Table 1.2 summarises the full range of phenotypes that can be measured with recent 
analysers such as the Sysmex system (Astle et al., 2016, Vasquez et al., 2016, Sysmex 
Corporation). 
 
Blood cell traits vary across healthy individuals and part of this variation is due to genetic 
factors (Pilia et al., 2006, Evans et al., 1999, Garner et al., 2000, Chami and Lettre, 2014). 
Therefore, studying naturally occurring genetic variation of circulating mature blood cell 
counts is a common and successful strategy used to gain insight into the regulation of 
haematopoiesis (Table 1.2). This approach has yielded many insights, not only in identifying 
novel haematopoietic regulators but also for the wider field of human genetics. For example, 
blood GWAS has been successful in identifying novel regulators of haematopoiesis (Gieger 
et al., 2011, van der Harst et al., 2012, Bielczyk-Maczynska et al., 2014). Previously 
unknown genes identified from GWAS of RBCs and platelets displayed haematopoietic 
phenotypes in model organisms (Vasquez et al., 2016).  
 
Up until 2016, blood GWAS only explained a fraction of variation in the population (4-10%) 
and high-powered cohorts for studying myeloid and lymphoid parameters were lacking 
(Vasquez et al., 2016, Gieger et al., 2011, van der Harst et al., 2012). The recent large 
GWAS using data from the UK biobank cohort (N = 173,480) investigated a high number of 
traits, 36 in total (Table 1.2) (Astle et al., 2016). 2,706 independent variants were identified, 
representing a ten-fold increase in the number of known loci that included hundreds of rare 
variants with high effects sizes (Vasquez et al., 2016, Kim-Hellmuth and Lappalainen, 2016). 
Most of the sentinel variants were highly specific across red blood cell, white cell and platelet 
traits and enriched in corresponding cell-type specific enhancers. Coding variants were 
enriched with Mendelian disease mutations, a demonstration of how important clinical insight 
can be gleaned from large-scale GWAS. Plausible molecular mechanisms were identified 
through integration with the BLUEPRINT QTL data for 276 blood trait variants that 
colocalised with at least one molecular QTL (Astle et al., 2016). It was estimated that a 
higher proportion of variance in the blood indices was explained by the common autosomal 
genotypes from this study, for example between 5-21% of variance in white cell traits (Astle 
et al., 2016). The full UK Biobank cohort of 500,000 individuals could identify further 
significant variants explaining trait variance (Collins, 2012).  
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Table 1.2: Summary of the main haematological indices, measurement unit and related disorders  
Adapted from (Vasquez et al., 2016, Astle et al., 2016). Additional traits were also tested in the Astle et al. (2016) GWAS, that included for example the 
percentage of granulocytes that is made up by neutrophils. I list the main traits measuring mature blood cell counts here that are routinely measured and have 
been explored in previous studies. 
 Trait [Units] Description Determination Example Diseases/disorders 
RBC Red blood cell count [per pL] Count of RBCs per unit volume of blood Impedance (measured) 
Anaemia, polycythemia vera 
HGB Haemoglobin concentration [g/dl] Concentration of Hb per unit volume of blood Light absorbance (measured) 
HCT Hematocrit [%] Volume fraction of blood occupied by red cells Impedance (measured) 
MCV Mean corpuscular haemoglobin concentration [fL] Mean volume of RBCs (HCT/RBC)×10 (derived) 
RDW Red cell distribution width [fL] Coefficient of variation of red cell volume distribution 
CV of impedance measured red 
cell volume distribution 
(measured) 
MCH Mean corpuscular haemoglobin [pg] Average mass of Hb per red cell (HGB/RBC)×10 (derived) 
MCHC Mean corpuscular haemoglobin concentration [g/dL] 
Concentration of Hb per unit of volume 
occupied by red cells (HGB/HCT)×100 (derived) 
PLT Platelet count [per nL] Count of platelets per unit volume of blood Impedance (measured) 
Essential thrombocythemia, thrombotic 
Thrombocytopenic purpura 
MPV Mean platelet volume [fL] Mean volume of platelets (PCT/PLT)×10000 (derived) 
PDW Platelet distribution width [fL] Spread of the platelet volume distribution (PDV) 
Impedance: Coefficient of 
variation of PDV (measured) 
PCT Plateletcrit [%] Volume fraction of blood occupied by platelets Impedance (measured) 
WBC White blood cell count [per nL] Aggregate count of white cells per unit volume of blood Impedance (measured) 
Autoimmune/immunological, infection, 
inflammation, leukaemia 
NEU Neutrophil count [per nL] Count of neutrophils per unit volume of blood (NEUT%×WBC)/100% (derived) Myelodysplasia, bacterial infections 
LYM Lymphocyte count [per nL] Aggregate count of lymphoid cells per unit volume of blood (LYMPH%×WBC)/100% (derived) Lymphoma, viral infections 
MON Monocyte count [per nL] Count of monocytes per unit volume of blood (MONO%×WBC)/100% (derived) Myelomonocytic leukaemia, chronic infections (tuberculosis) 
EOS Eosinophil count [per nL] Count of eosinophils per unit volume of blood (EO%×WBC)/100% (derived) Allergies, asthma, parasitic infections 
BAS Basophil count [per nL] Count of basophils per unit volume of blood (BASO%×WBC)/100% (derived) Hyperthyroidism, myeloproliferation disorders 
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1.7.1 Genetics, correlation and causation 
Correlation between blood indices and increased risk of certain diseases such as obesity, 
stroke and cardiovascular diseases has been observed (del Zoppo, 1998, Poitou et al., 2011, 
Ensrud and Grimm, 1992, Hoffman et al., 2004, Boos and Lip, 2007). However, correlation 
does not necessarily show causation as epidemiological and observational relationships can 
be subject to confounding factors, measurement error, bias or reverse causation (where the 
disease state influences the endophenotype such as blood indices).  
 
Genetics, with the exception of somatic mutations, is pre-determined at birth where variants 
are segregated randomly and independently of other traits (Evans and Davey Smith, 2015). 
In this way, confounding and reverse causation are both reduced as genetics precedes any 
biological effect or outcome (Evans and Davey Smith, 2015). We can also measure genetic 
variants with high precision, reducing measurement error that can occur in observational 
studies. Approaches have therefore been developed that use genetic variants (instrumental 
variables) that are known to influence a biological intermediate (exposure), which itself 
affects disease risk. In this case, the studied variants should also be related to the risk of the 
disease. This approach can assess both the causality of biological intermediates and 
quantify the size of the causal effect and is referred to as Mendelian Randomization (Evans 
and Davey Smith, 2015). There are certain assumptions that must not be violated in these 
analyses, which in some cases can be challenging to definitively confirm. These are 
summarised in Figure 1.6.  
 
This approach was implemented by Astle et al. (2016) to test for causal relationships 
between blood indices and each of a group of six autoimmune, three cardiometabolic and 
five neuropsychiatric diseases. Positive correlations were found between eosinophil count 
and rheumatoid arthritis and asthma, with a weaker effect between neutrophil indices and 
asthma. Interestingly, there was a reduced likelihood for causality between red blood cell, 
white blood cell, granulocyte and neutrophil counts and risk of coronary heart disease (CHD), 
despite previously reported correlations (Wheeler et al., 2004, Astle et al., 2016).  
 
Overall, studying the process of haematopoiesis and mature cell function increases our 
understanding of basic biology. Concomitantly, it also offers the potential to use blood cell 
traits as disease biomarkers and tractable intermediate phenotypes in genetic studies and 
functional follow-ups.  
  
 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Mendelian randomization methodology and assumptions  
Schematic summarising a causal relationship between an exposure and an outcome/disease 
assessed by using genetic variants (Z) that are associated with the exposure and under causality are 
also associated with disease. Causal relationships are depicted with arrows. The three assumptions 
are also given. Adapted from (Evans and Davey Smith, 2015).  
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1.8 Aims of this thesis 
In this thesis, I use a combination of genetic and genomics approaches I have discussed to 
resolve functional consequences of genetic variation whilst also understanding the biology of 
haematopoietic cells. These are summarised in Figure 1.7. 
 
In Chapter 2, I discuss how these approaches have increased our understanding of 
autoimmune diseases. I apply the lessons learnt from these studies to diseases that are not 
traditionally classified as immune-mediated. I use epigenomic phenotypes to resolve 
mechanisms of risk loci and also explore potential insight into pathways or genes that could 
provide future therapeutic avenues for these diseases. I demonstrate that the combination of 
genomic and genetic approaches provides hypothesis-free identification of genes and 
pathways dysregulated in disease, representing an early step in identifying new therapeutic 
avenues. 
 
Following from this, I apply GWAS to novel neutrophil phenotypes with an overall aim of 
expanding the phenotype repertoire by providing additional functional datasets with which to 
annotate trait- or disease- associated loci. Finally, I implemented a recall-by-genotype study 
to perform an in-depth investigation into two genetic loci where there was previous evidence 
of an association with neutrophil count. Throughout my thesis, I demonstrate the application 
of varied but complementary approaches in gaining biological insight from genetic 
associations.  
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Figure 1.7 Approaches to investigate functional mechanisms of genetic variants  
Schematic summarises the type of experiments, number of individuals required, resolution of variants investigated and the chapters of this thesis where the 
techniques are used 
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Chapter 2  
 
 
 
Using immune molecular phenotypes to 
uncover biological mechanisms of 
disease-associated genetic loci  
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2 Using immune molecular phenotypes to uncover 
biological mechanisms of disease-associated genetic loci  
 
2.1 Introduction  
 
2.1.1 Lessons from genetic and genomic analyses of autoimmune diseases  
The study of autoimmune diseases (AID) has generated many important biological insights 
including demonstrating the central role for the function of multiple immune cell types (Farh 
et al., 2015, Glinos et al., 2017). Overall, there is a 4.5% prevalence of the 81 identified AID 
in the general population, which is higher for women (6.4%) than men (2.7%) (Hayter and 
Cook, 2012). The importance of genetic factors and shared environment is demonstrated by 
the familial clustering of autoimmune diseases (Gutierrez-Arcelus et al., 2016). Initial linkage 
studies identified some of these genomic risk regions that had large effect sizes by looking 
for markers that co-segregated with the disease phenotype. These included the MHC, 
encoding the major histocompatibility complex, with diseases such as Type 1 diabetes (T1D) 
(Rich et al., 1984) and systemic lupus erythematosus (SLE) (Gaffney et al., 1998) and the 
nucleotide-binding oligomerisation domain containing 2 (NOD2) gene with Crohn’s disease 
(Hugot et al., 2001, Gutierrez-Arcelus et al., 2016, de Lange and Barrett, 2015). Strong 
associations in the MHC region, which contains many immune-related genes, are now well 
established for a wide range of diseases, such as coeliac disease (CEL), rheumatoid arthritis 
(RA) and multiple sclerosis (MS) (Sollid et al., 1989, Nepom, 1998, Hollenbach and 
Oksenberg, 2015). These associations implicate a role for MHC-antigen presentation in 
triggering the immune response as a general phenomenon in autoimmune disease 
pathogenesis. Other important genes were also identified through candidate gene studies, 
which test for association with alleles of genes selected a priori (Gutierrez-Arcelus et al., 
2016). One example is the CTLA4 locus, which was associated with T1D and later with 
autoantibody-positive RA (Nistico et al., 1996, Plenge et al., 2005). CTLA4 encodes an 
immunoglobulin superfamily protein expressed on the surface of T helper cells that 
negatively regulates T cell activation (Nistico et al., 1996, Gutierrez-Arcelus et al., 2016).  
 
The advent of GWAS enabled systematic and unbiased genome-wide searches leading to 
the identification of hundreds of AID risk loci, many of which are shared between different 
immune disorders (Gutierrez-Arcelus et al., 2016). The majority of these signals are common 
(MAF > 5%) with small to moderate effect sizes (OR < 1.6) (Gutierrez-Arcelus et al., 2016). 
MS risk loci, excluding the MHC region, have odds ratios between 1.1 and 1.6, where an OR 
of 1 signifies no difference in odds of diseases between cases and controls for that allele 
(Gutierrez-Arcelus et al., 2016, ImmunoBase, 2017). Such observations supported the 
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common disease-common variant (CDCV) hypothesis, first proposed by Risch and 
Merikangas in 1996, which suggests that complex disease risk is a result of the accumulation 
of multiple, low-effect risk factors (Risch and Merikangas, 1996). However, larger sample 
sizes and higher-powered studies are required to detect rare variants, therefore future efforts 
may discover that variants with a MAF < 1% also play a role in common diseases (Bomba et 
al., 2017). 
 
Despite the large number of AID variants now discovered (more than 300 loci (Gutierrez-
Arcelus et al., 2016)), a limited degree of the estimated heritability is explained by non-HLA 
loci (Glinos et al., 2017). Heritability is the proportion of observable phenotypic variation that 
can be attributed to genetics, which can be estimated from twin or sibling studies (Selmi et 
al., 2012). A recent GWAS of systemic lupus erythematosus (SLE) including 15,991 controls 
and 7,219 cases, estimated the heritability explained by 43 identified risk alleles to be 15.3%, 
with a total estimated heritability of 66% (Bentham et al., 2015). This ‘missing heritability’ 
may be due to limitations in study power precluding detection of the full effect size and 
frequency spectrum of variants, particularly rare variants (Vasquez et al., 2016). The 
combination of multiple studies to increase sample sizes and application of improved 
imputation methods have been utilised by, for example, the International IBD Genetics 
Consortium (IIBDGC). These efforts enabled increased loci discovery allowing identification 
of novel pathways implicated in IBD risk such as cytokine signalling, innate defence and 
lymphocyte activation (de Lange and Barrett, 2015, Jostins et al., 2012). 
 
Investigation of the biological consequences of known variants has provided important 
paradigms in the functional interpretation of GWAS SNPs. Haematopoietic cell types have 
long been known to play key roles in immune responses to infection, homeostatic clearance 
of cell debris and in regulating the balance between reacting to non-self-antigen; not self-
antigen (Vasquez et al., 2016). Genomic data from haematopoietic cells are therefore ideally 
suited for mechanistic interpretation at AID risk loci. Early studies indicated that AID SNPs 
affect gene expression in whole blood and PBMCs, for example over half of coeliac GWAS 
variants were also eQTLs (Dubois et al., 2010, Glinos et al., 2017). These observations have 
been expanded to a wide-range of AIDs and multiple primary immune cell types and 
additional regulatory elements such as H3K27ac and TF binding (Farh et al., 2015, 
Tehranchi et al., 2016, Chen et al., 2016a). RNA splicing can also represent a gene 
expression-independent regulatory mechanism in genetic disease (Li et al., 2016c, Chen et 
al., 2016a). Li et al. (2016) showed that splicing (s)QTLs independent of eQTLs were 
enriched in gene bodies, in most cases within the target introns. In addition, the sQTLs were 
also enriched in AID even when compared to eQTLs (Li et al., 2016c).  
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Clinical insight can be gleaned from combining GWAS SNPs with immune molecular or 
functional phenotypes (Barrett et al., 2015). Selection of drug targets based genetic evidence 
provides promising therapeutic possibilities twice as often as those selected without such 
prior information (Nelson et al., 2015, Barrett et al., 2015). GWAS of genetic variants pre-
determined at birth simulates a randomised clinical trial, where randomisation ensures a 
balance of all confounders (Evans and Davey Smith, 2015). The advantage of GWAS is that 
drug administration is not required and individuals have been “exposed” across a lifetime 
rather than for the length of an RCT (Evans and Davey Smith, 2015, Finan et al., 2017). 
Integration of LPS-stimulated monocyte eQTL data and GWAS SNPs can aid therapeutic 
insight demonstrated recently where five IBD risk variants were to found increase gene 
expression of the integrin genes ITGA, ITGAL, ICAM and ITGB8 (de Lange et al., 2017). 
Integrins mediate leucocyte adhesion to inflamed endothelial tissues. Therefore, increased 
surface levels could contribute to the pro-inflammatory environment observed in IBD patients 
(de Lange et al., 2017, de Lange and Barrett, 2015). Targeting integrins, for example using 
monoclonal antibodies, has already shown promising therapeutic results in the context of IBD 
(de Lange et al., 2017). Clearly, discovering novel common associations and their associated 
mechanisms can still provide additional clinical insight.  
 
AID GWAS alone have also successfully identified genes and pathways that are current drug 
targets. For example, the IL6R pathway, which contains rheumatoid arthritis risk variants, is 
targeted by the humanised monoclonal antibody therapy, Tocilizumab (Okada et al., 2014, 
Law et al., 2014). The same RA GWAS also identified novel risk genes not currently targeted 
by RA therapies but were used for treating other diseases, offering the potential for the 
repurposing of licensed drugs (Okada et al., 2014). To further capitalise on the therapeutic 
potential of GWAS, a new genotyping array was designed to include genes encoding 
druggable proteins, targets with bioactivity and those with clinical indications of any licensed 
therapeutics (Finan et al., 2017). GWAS with such an array will enable direct association of 
variants with druggable genes (Finan et al., 2017). 
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2.1.2 Expanding the complex disease repertoire for which immune phenotypes 
can resolve mechanisms 
Inflammation has also been shown to be important in disorders not traditionally classified as 
immune-mediated such as Parkinson’s disease (Tufekci et al., 2012) and schizophrenia 
(Muller et al., 2015), suggesting functional and clinical insight could be gleaned from the 
application of similar approaches described above. Below, I discuss previous evidence for 
the role peripheral immune function in the pathogenesis of five diseases, which I focus on in 
this thesis.  
 
2.1.2.1 Advanced age-related macular degeneration (AMD) 
AMD is the leading cause of irreversible blindness later in life in the developed world. AMD 
affects the central part of the macular and is classified into early, intermediate or advanced 
based on severity (Pennington and DeAngelis, 2016). The hallmark of AMD is the 
accumulation of lipid-rich, protein-containing drusen deposits between the retinal pigment 
epithelium (RPE) and Bruch’s membrane (BM) in the retina (Figure 2.1). The RPE forms part 
of the blood-ocular barrier and performs many important functions including nutrient 
transport, cytokine release and phagocytosis of fragments released from photoreceptors 
(Tan et al., 2016). Towards the end stages of the disease, the RPE eventually disintegrates 
leading to loss of photoreceptors and vision (Figure 2.1). Ordinarily, the RPE and sub-retinal 
regions are devoid of blood vessels, but in the neovascular (“wet”) form of the disease, 
abnormal growth of blood vessels from the choroid spreads into these regions (Pennington 
and DeAngelis, 2016) (Figure 2.1). Most current therapies target this growth by inhibiting the 
angiogenesis-promoting vascular endothelial growth factor A (VEGFA) (Pennington and 
DeAngelis, 2016). However, disease progression continues for most patients, requiring 
further treatment. 
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Figure 2.1: Schematic of retinal structure and the effect of AMD pathology  
This schematic shows the outer layers of the central retina in normal conditions (left) and the different 
types of AMD classifications. Small drusen deposits accumulate in the retinal pigment epithelium 
(RPE) in early AMD, and as the disease progresses, the Bruch’s membrane (BM) becomes thicker 
and additional drusen deposits form. In the later stages of AMD, dry and wet, there is extensive 
accumulation of drusen deposits, loss of photoreceptors and damage to RPE integrity. The subretinal 
space refers to the space between the RPE and photoreceptors. In the wet form, choroidal 
neovascularisation (CNV) occurs. This figure was adapted from (Tan et al., 2016) under the CC 
license (http://creativecommons.org/licenses/by/4.0/). 
 
AMD is multifactorial with a substantial genetic component, although environmental factors 
such as smoking and age also contribute (Seddon et al., 2005). Genetic studies have 
revealed many associated loci and have provided evidence for the involvement of immune 
components. For example, almost 60% of AMD risk can be explained by variants located 
near the complement genes CFH, C2/CFB, C3, CFI and C9 (Tan et al., 2016). The risk to 
AMD also increases with rare alleles. For example, the highly penetrant missense mutation 
in the complement factor I gene (CFI), which functions to inactivate complement pathways, 
corresponds to an odds ratio of 22.20 (95% CI = 2.98-164.49) (van de Ven et al., 2013, Tan 
et al., 2016). The p.Gly119Arg mutant protein is expressed and secreted at lower levels (van 
de Ven et al., 2013).  
 
A recent large-scale GWAS from the International AMD Genomics Consortium (IAMDGC) 
that included 16,144 advanced AMD patients and 17,832 controls identified 52 independently 
associated variants in 34 loci (Fritsche et al., 2016). This study confirmed the involvement of 
inflammation and complement genes (VTN, CFH, C2/CFH, C3, CFI, C9) as well as lipid 
pathway genes (CETP, LIPC, APOE, ABCA1) (Fritsche et al., 2016). The complement 
pathway is an important part of innate immunity that functions to amplify immune responses 
ultimately resulting in the formation of a membrane attack complex (MAC) at the surface of 
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the pathogen causing cell lysis (Tan et al., 2016). Increased MAC in the retina and drusen 
has been observed in AMD patients (Tan et al., 2016, Hageman et al., 2001). Although the 
majority of the complement system is synthesised by the liver, there is also synthesis in the 
RPE and choroid (Tan et al., 2016, Luo et al., 2013). 
 
Despite initially being considered “immunologically privileged”, the RPE has been shown to 
contain specialised resident immunocompetent cells including microglia, dendritic cells and 
perivascular macrophages (Parmeggiani et al., 2012). Para-inflammatory (prolonged 
inflammation in response to damage)-associated modifications can result in damage to the 
blood-retinal barrier in AMD as well as microglial activation and recruitment of macrophages 
(Parmeggiani et al., 2012, Kauppinen et al., 2016). Indeed, immunocompetent cells such as 
lymphocytes and macrophages have been observed in AMD retinal tissues and isolated 
mouse bone marrow-derived M1 and M2b macrophages stimulated RPE cells to induce 
inflammatory cytokine expression and complement factors C3 and CFB (Parmeggiani et al., 
2012, Lopez et al., 1991, Luo et al., 2013).  
 
Systemic immune alterations such as increased serum complement components and pro-
inflammatory cytokines (IL-1a, IL-1b and IL-17) have been observed in AMD patients 
(Lechner et al., 2015). Higher numbers of circulating neutrophils were observed in 
neovascular AMD (nvAMD) patients (Lechner et al., 2015). Also, similarly in nvAMD patients, 
there was an increased inflammatory transcriptome signature in peripheral blood monocytes, 
and in an independent study monocytes expressed higher levels of chemokine receptors 
CCR1, CCR2 and CX3CR1, HLA-DR and phosphorylated STAT3 (Grunin et al., 2016, 
Grunin et al., 2012, Chen et al., 2016b). Recently, in a study of 161 nvAMD patients and 43 
controls, stimulated PBMCs, particularly monocytes, secreted higher levels of the IL8, CCL2 
and VEGF compared to controls (Lechner et al., 2017). The pro-inflammatory IL8 and CCL2 
promote the recruitment of neutrophils and monocytes and lymphocytes respectively 
(Lechner et al., 2017). Additional molecular mechanistic insight into monocyte-RPE 
interactions was shown using a coculture of human CD14+ blood monocytes and primary 
porcine RPE cells (Mathis et al., 2017). OTX2 is a key TF regulating retinal genes such as 
retinol dehydrogenase 5 (RDH5), which re-isomerises all-trans-retinal into 11-cis-retinal. It 
was shown that TNFa, secreted from activated monocytes, mediates the downregulation of 
OTX2 and RDH5 (Mathis et al., 2017).  
 
In summary, immune dysregulation in AMD could be the result of the combined action of 
resident and infiltrating immune cells as a result of a switch from clearance (of RPE-debris) 
and immunosuppressive environment to a proinflammatory milieu (Nussenblatt and Ferris, 
2007). Genetic variants could disrupt this balance, thereby influencing risk. Definitive 
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assessment of the causality of peripheral immune factors and disease pathogenesis is 
required, but the observations of systemic immune activation in AMD patients suggests that 
using the more accessible peripheral immune cells to identify functional mechanisms may 
provide further insight into the pathogenic process. Some success, for example, in an early 
pilot phase I/II randomized study of suppression of systemic immune activity, was observed 
for wet AMD (Nussenblatt et al., 2010). However, other attempts, including the use of 
eculizumab to inhibit complement have been less successful (Yehoshua et al., 2014). 
Elucidating the exact mechanisms of peripheral immune involvement may help these efforts.  
 
2.1.2.2 Coronary artery disease (CAD) 
Coronary artery disease (CAD) is the most common type of heart disease (Khera and 
Kathiresan, 2017). Familial history and therefore, a genetic component, has been implicated 
as an important risk factor (Framingham Heart Study (Watkins and Farrall, 2006), PROCAM 
study (Assmann et al., 2002), INTERHEART study (Yusuf et al., 2004)). Common CAD is 
multifactorial and polygenic (Won et al., 2015). Low-density lipoprotein (LDL) cholesterol 
levels, lipoprotein(a) and BMI have also been demonstrated to be causal risk factors and are 
themselves under genetic control (Watkins and Farrall, 2006, Do et al., 2013, Clarke et al., 
2009, Voight et al., 2012, Khera and Kathiresan, 2017). The INTERHEART study showed 
that adjustment for the known classical risk factors only marginally reduced the risk (OR from 
1.55 to 1.45), suggesting there are other genetic factors involved (Yusuf et al., 2004, Watkins 
and Farrall, 2006). 
 
There is a well-established causal association of the inflammatory IL6 cytokine pathway with 
CAD risk (Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium et al., 2012, 
Il R. Genetics Consortium Emerging Risk Factors Collaboration et al., 2012). The missense 
SNP, rs2228145, increases the soluble form of the IL6 receptor by improving the efficiency of 
membrane-bound receptor proteolytic cleavage while also increasing the unique transcript 
encoding the soluble receptor (Ferreira et al., 2013). Reduced IL6R membrane expression 
on monocytes and CD4+ T cells results in impaired signalling and IL6 response and reduces 
CAD risk (also that of RA), clearly demonstrating the pathogenic role of inflammation in 
disease progression (Ferreira et al., 2013).  
 
Monocytes play a key role in pathological plaque deposition in the coronary arteries, known 
as atherosclerosis (Ghattas et al., 2013). After recruitment to atherosclerotic lesions, 
monocytes mature into macrophages (Meeuwsen et al., 2017). Phagocytosis of oxidised LDL 
stimulates macrophage to form foam cells, which are a constituent of atherosclerotic plaques 
(Meeuwsen et al., 2017). Recruitment of other immune cells such as neutrophils, mast cells 
and lymphocytes also contributes to plaque destabilisation eventually leading to plaque 
rupture (Meeuwsen et al., 2017). 
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Supporting the importance of leukocyte function, the recent UK Biobank CAD GWAS with 
4,831 cases and 115,455 controls identified 15 novel associations including the ARHGEF26 
locus, which is involved in transendothelial migration of leukocytes and encodes the rho 
guanine nucleotide exchange factor 26 (Klarin et al., 2017). The novel ARHGEF26 locus was 
not associated with established risk factors, but previous mouse work did demonstrate a role 
in atherosclerosis (Klarin et al., 2017). Endogenous siRNA-mediated ARHGEF26 knock-
down decreased leukocyte adhesion to endothelial cells and transendothelial migration 
(Klarin et al., 2017). Overexpression of the exogenous mutant (Leu29) not only rescued the 
phenotype but was increased compared to wild-type, which is consistent with a gain of 
function ARHGEF26 effect associated with rs12493885 (Val29Leu) and increased CAD risk 
(Klarin et al., 2017). These observations are evidence that dysregulation of leukocyte 
function is associated with risk of CAD and disease prognosis.  
 
Understanding the contribution of immune processes to CAD risk has important clinical 
implications. Currently, clinical management of CAD-associated events has improved leading 
to more than a 50% decrease in age-adjusted mortality rate in the United States (Khera and 
Kathiresan, 2017). Despite this, CAD is still the biggest cause of death worldwide, and there 
is a 12% mortality rate within six months of the first coronary event (Meeuwsen et al., 2017). 
Many available therapies target lipid and thrombosis reduction, but some inflammation-
modulating processes are being investigated (Fernandez-Ruiz, 2016). Promising results 
were reported from a recent clinical trial targeting inflammation called the Canakinumab 
Antiinflammatory Thrombosis Outcome Study (CANTOS) (Ridker et al., 2017, Harrington, 
2017, Couzin-Frankel, 2017). The trial included more than 10,000 heart attack patients with 
elevated levels of C-reactive protein (CRP). The drug tested, canakinumab, is a human 
monoclonal antibody that targets the inflammatory cytokine interleukin-1b and is already 
used in the treatment of systemic juvenile idiopathic arthritis (Harrington, 2017). For patients 
receiving canakinumab as four infusions each year over 3.5 years, the risk of a second 
cardiovascular event decreased from 4.5% to 3.86% and the likelihood of angioplasty or 
cardiac bypass surgery decreased by 30% (Couzin-Frankel, 2017). However, an increased 
number of deaths from infection among patients who received more doses was observed 
(Harrington, 2017). While promising and offering a proof of concept for inflammation playing 
a key role in disease pathogenesis, further research is needed to provide more targeted 
immune therapeutics which may reduce the risk of mortality related to infection (Harrington, 
2017, Couzin-Frankel, 2017). Providing detailed descriptions of the pathways and cell types 
which may be involved in CAD risk could, therefore, represent an early step in improving 
therapeutic options for CAD patients.  
 
 43 
2.1.2.3 Alzheimer’s disease (AD) 
Alzheimer’s disease is the most common form of neurodegenerative dementia characterised 
by accumulation in the brain of amyloid β (Aβ) plaques and hyper-phosphorylated tau protein 
aggregates (Pimenova et al., 2017). This chapter focuses on late-onset Alzheimer’s disease 
(LOAD), which constitutes 99% of AD cases. LOAD is multifactorial with a strong but highly 
complex genetic component (Pimenova et al., 2017, Gatz et al., 2006).  
 
Involvement of immune components was highlighted in a large-scale meta-analysis of 74,046 
individuals (Lambert et al., 2013). For example, a significant intronic SNP was identified in 
complement factor 1 (CR1). CR1 is expressed on blood cells and specialised brain-resident 
immune cells known as microglia (Pimenova et al., 2017, Wyss-Coray and Rogers). Other 
immune loci identified include ZCWPW1/PILRA/PILRB, which are monocyte and neutrophil 
immune infiltration receptors, the HLA-DRB1/HLA-DRB5 locus of the MHCII region, CD33 
and the MS4A gene family, which are both expressed on microglia and myeloid cells 
(Pimenova et al., 2017, Lambert et al., 2013). 
 
Brain-resident microglia are active immune cells, but there may also be a role for systemic 
immune responses in disease pathogenesis (Heneka et al., 2015, Czirr and Wyss-Coray, 
2012). There are multiple lines of evidence that show that systemic inflammation 
detrimentally affects brain function and contributes to AD progression (Heneka et al., 2015). 
Prolonged LPS challenge in amyloid precursor protein (APP) transgenic mice, which contain 
a mutant APP associated with familiar forms of human AD, has been shown to result in 
cognitive impairment through increased amyloid deposition (Lee et al., 2008, Czirr and Wyss-
Coray, 2012). Increased cognitive decline was observed in AD patients with infection, which 
correlated with infection TNF levels (Heneka et al., 2015). However, the functionality of 
peripheral immune cells in AD pathogenesis and their interaction with the brain are not yet 
clear. There is some evidence that the integrity of the blood-brain barrier (BBB) can be 
compromised in AD, which could allow infiltration of peripheral monocytes (Zenaro et al., 
2017, Heneka et al., 2015). Compelling evidence from both mouse models and from human 
brain tissue showed that neutrophils could migrate to the central nervous system, which was 
dependent on the LFA-1 integrin, in turn, triggered by the Aβ42 peptide (Zenaro et al., 2015). 
Depletion of neutrophils resulted in memory improvements in mice. This study suggests 
that neutrophils could contribute to inflammatory conditions in AD and also damage the 
BBB (Zenaro et al., 2015).  
 
Integration with genomics data from the Immune Variation project with AD risk loci 
demonstrated enrichment among monocyte eQTLs, but not T cells, suggesting using 
monocyte data may help dissect mechanism underlying genetic susceptibility (Raj et al., 
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2014). Further demonstration of the importance of myeloid cells came from a recent 
association analysis of age of onset of Alzheimer’s disease-defined survival that identified 
protective rs1057233 (G) associated with reduced SPI1 expression in human myeloid cells 
(Huang et al., 2017c). SPI1 encodes the myeloid master transcription factor, PU.1, which is 
critical for myeloid lineage differentiation and function (Huang et al., 2017c). PU.1 levels 
correlated with mouse microglial phagocytic activity and reduced SPI1 expression 
corresponded to reduced AD risk (Huang et al., 2017c). Global enrichment of AD heritability 
in myeloid and B-lymphoid H3K4me1-designated enhancers and in the PU.1 cistrome (i.e. 
genome-wide binding regions as assayed by ChIP-seq) was also demonstrated (Huang et 
al., 2017c). Circulating blood monocytes are easily accessed in high numbers compared to 
brain-derived tissue and share transcriptional patterns with brain-resident microglia (Raj et 
al., 2014). Therefore, although there is evidence for a role of peripheral immune cells in AD, 
these cells are also useful as highly related proxies for specialised brain cells (Raj et al., 
2014, Proitsi et al., 2014). 
 
Taken together these observations provide evidence for the role of immune cells in AD 
pathogenesis, suggesting that integrative genomic approaches using immune data may 
provide insight into pathogenic mechanisms. 
 
2.1.2.4 Lung function and chronic pulmonary obstructive disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disease and is the 
third leading cause of global mortality (Wain et al., 2015). The ratio of two lung 
measurements, FEV1/FVC, is used to evaluate airflow obstruction and diagnose COPD. 
FEV1 measures how much air is exhaled in one second after maximal inhalation. FVC 
measures the volume of air exhaled after a maximal inhalation and then a six-second 
maximal forced exhalation (Weiss, 2010). 
 
Smoking and indoor pollution are major risk factors for disease pathogenesis, but there is 
also a strong genetic component underlying smoking behaviour and disease risk (Wain et al., 
2015, Hukkinen et al., 2011).  Evaluation of these lung ratios as quantitative traits has 
allowed the identification of genetic determinants of lung function in large populations, 
enabling greater power to detect associations. Ten loci were found to be associated with 
extremes of the lung ratio FEV1 in never smokers, and one was located in the MHC region, 
HLA-DQB1/HLA-DQA2 (Wain et al., 2015). This important immune locus potentially 
implicates an immunological role in extremes of lung function and as this locus was also 
associated with COPD also highlights immune factors in this disorder. 
A hallmark of COPD is chronic inflammation but whether this and the role of immune cells 
are causal independent risk factors for COPD remains to be definitively demonstrated 
(Brusselle et al., 2011). Cigarette smoke activates innate immune cells, which then stimulate 
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an adaptive immune response (Brusselle et al., 2011). Viral and bacterial infections 
exacerbate COPD and potentiate the inflammatory environment in the lung (Brusselle et al., 
2011). Dysregulation of peripheral immune cells could contribute to the pathogenesis of the 
disease, either due to the extrapulmonary effects or through infiltration into the lung 
(Brusselle et al., 2011). Neutrophil infiltration has been linked to tissue destruction and 
disease progression in COPD patients (Huang et al., 2017a). Understanding potential 
immune-mediated molecular disruptions associated with the disease can help the design of 
treatments with the aim to reduce serious symptoms and complications (Brusselle et al., 
2011).  
 
2.1.3 Identification of disease-relevant cell types using enrichment approaches 
Disease-relevant cell types are not always known and have traditionally been identified 
through immunology studies, patient observations and mouse models (Glinos et al., 2017). 
For example, inflammatory cells were identified in the brain lesions of patients and 
autoreactive T cells responding to myelin antigens were identified in the mouse model for 
multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) (Fletcher et al., 
2010). 
 
With the advent of high-throughput genetic association studies and increased availability of 
cell-type specific epigenome data from consortia such as the Encode Project Consortium 
(2012), Roadmap Epigenomics Consortium et al. (2015) and IHEC (Stunnenberg et al., 
2016), novel statistical enrichment approaches were developed to assess genomic evidence 
for the relevance of cell types in complex disease and annotate the putative function of non-
coding GWAS variants. These approaches evaluate the statistical significance of a quantified 
overlap between GWAS SNPs and regulatory annotations. Annotations can take of the form 
of ChIP-seq binding/signal regions, open chromatin regions or chromatin regulatory states all 
denoted with the genomic start and end positions of the mapped genomic region (referred to 
as a peak). An assessment of the significance of enrichment is required given that a large 
degree of the genome can be bound by these regulatory features, leading to spurious 
functional assignment occurring by chance if only a simple overlap is applied (Iotchkova et 
al., 2016).  
 
Earlier functional enrichment approaches, for example as implemented by Maurano et al. 
(2012) demonstrated an enrichment (40%) of significant GWAS variants from 207 diseases 
and 447 quantitative traits in open chromatin (DHS sites) assayed in 349 tissues, compared 
to frequency and genomic-location matched SNPs from 1000 Genomes Project (Maurano et 
al., 2012). This high enrichment highlighted that underlying regulatory function of non-coding 
SNPs, demarcated by open chromatin, could underpin many complex trait associations. In 
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addition, the authors demonstrated the ability of functional enrichment studies in the de novo 
identification of relevant cell types by comparing the enrichment of progressively more 
significant trait-associated variants in cell-type specific DHS sites to the proportion of all 
SNPs from the summary statistics that also overlapped the same DHSs. Higher enrichment 
for Crohn’s disease variants was observed in Th17, and Th1 T cell open chromatin than 
other immune cell types and multiple sclerosis variants were enriched in B and T cell open 
chromatin (Maurano et al., 2012). The basis of predicting disease relevant cell types lies in 
the known cell specificity of regulatory element activity. Therefore, preferential enrichment in 
regulatory data from certain cell types suggests these variants are more likely functional in 
those cell types. This approach enables efficient identification of relevant cell types without 
complex patient, animal or in vitro studies by leveraging known disease risk loci and 
experimentally derived epigenomic data.  
 
However, the above method did not account for linkage disequilibrium (LD) between 
significant variants (Iotchkova et al., 2016). Chance overlaps are also more likely to occur in 
regions of highly correlated variants, where high LD between variants can lead to overlaps 
that are not truly functional (Alasoo et al., 2017). This can inflate enrichment values and 
generate false positives. Later methods accounting for variant correlation made other 
interesting observations, that enrichment of disease SNPs in cell specific H3K4me3 regions 
associated with active transcription was not driven by gene proximity, and could, therefore, 
highlight potentially causal variants (Trynka et al., 2013). Enrichment of trait-associated 
SNPs in cell type-specific DHSs was confirmed by an independent method, fgwas, and also 
observed depletion in repressed chromatin (Pickrell, 2014). Predicted causal SNPs of a 
variety of autoimmune diseases were shown to be enriched in cell type specific H3K27ac 
enhancer regions and genetic heritability is also highly enriched in regulatory regions (Farh et 
al., 2015, Finucane et al., 2015). Collectively, these enrichments suggest that a high 
proportion of disease risk is mediated by regulatory changes that could ultimately generate 
variation in gene expression (Chun et al., 2017).  
 
Evidence of enrichment below the genome-wide significance threshold (p values £ 5 x 10-08) 
has been observed (Maurano et al., 2012), suggesting that appropriately evaluating 
enrichment at genome-wide suggestive thresholds (commonly p value £ 1 x 10-05) could 
provide biologically relevant observations particularly when limited power precludes 
discovery of all true associations (Maurano et al., 2012). To address the potential 
confounding issues and to provide a robust assessment of enrichment at all GWAS 
significance thresholds, a novel method was developed within the Soranzo team by 
Valentina Iotchkova, known as GARFIELD (GWAS Analysis of Regulatory or Functional 
Information Enrichment with LD correction) (Iotchkova et al., 2016) (described in detail in 
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Materials and Methods). GARFIELD annotates independent variants, accounting for LD as 
well as for genomic location and minor allele frequency. The odds ratio is calculated for 
multiple GWAS thresholds, allowing for assessment of informative enrichment at suggestive 
thresholds, which can highlight novel findings given limited study power. The method 
confirmed enrichment of Crohn’s disease variants in blood DHS (Iotchkova et al., 2016) and 
demonstrated highly significant enrichment of blood cell indices in corresponding cell-type 
specific enhancers (Astle et al., 2016).  
 
Recently, the application of the GARFIELD method has been extended to assess the 
enrichment of GWAS SNPs in molecular QTLs where QTLs were used as regulatory 
annotations. This approach demonstrated enrichment of neutrophil, monocyte and T cell 
molecular features in autoimmune diseases including IBD, RA, T1D and MS (Chen et al., 
2016a). An independent study of naïve and stimulated iPSC-derived macrophage eQTL and 
chromatin accessibility QTLs also used GARFIELD to reveal enrichment in autoimmune 
diseases, Alzheimer’s disease and schizophrenia (Alasoo et al., 2017). 
 
2.1.4 Colocalisation methods evaluate shared genetics across different traits 
Enrichment methods do not assess whether variation in regulatory function and disease risk 
or trait variance can be attributed to a single shared variant or whether these are driven by 
independent effects in the same locus, known as pleiotropy (Chun et al., 2017). Therefore, 
once enrichment approaches have highlighted relevant cell types, robust approaches are 
required to identify loci where there is evidence for shared genetic control of multiple traits. 
This can be achieved by using Bayesian colocalisation methods (described in detail in 
Materials and Methods) (Pickrell et al., 2016, Guo et al., 2015). 
 
Robust evaluations are particularly important given that eQTLs are widely present across the 
genome, and the majority of expressed genes are likely to be associated with at least one 
cis-eQTL (Pai et al., 2015). Guo et al. (2015) developed and implemented a Bayesian 
colocalisation method (coloc) using ten immune disease-associated variants (595 in total 
from 154 regions) and eQTLs from resting and stimulated monocytes and naïve B cells (Guo 
et al., 2015). They identified 125 eQTLs that overlapped with disease SNPs, but only six 
genes had evidence for colocalisation (two traits share the same causal variant). A higher 
proportion, 21% across all AID loci tested colocalised with LCLs, CD4+ T cells and CD14+ 
monocytes eQTLs (FDR < 5%), identified using an independent method (Chun et al., 2017). 
For some diseases, this proportion was higher, for example 60% for ulcerative colitis loci 
colocalised with at least one eQTL (Chun et al., 2017). Overall, across all diseases, 75% of 
the disease-eQTL pairs were identified as pleiotropic where independent genetic variants 
within the locus were associated with each trait (Chun et al., 2017). Therefore, the previous 
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usage of colocalisation methods has demonstrated the need for appropriate evaluation of 
shared trait and QTL loci, demonstrating that simple overlap approaches are prone to false 
positives.  
 
2.1.5 Aims of this chapter 
We previously demonstrated the enrichment of molecular phenotypes in AID variants and 
described many disease loci where there is evidence of shared molecular mechanisms 
(Chen et al., 2016a). It is therefore well established that while GWAS provide unbiased 
systematic identification of disease-associated loci, functional insight must be gleaned 
through the combination of intermediate phenotypes QTLs. Detailed “omic” data collected 
from healthy individuals can be used as a powerful tool in understanding disease 
mechanisms, as these cohorts enable association of variants with intermediate phenotypes 
which themselves have not been affected by disease status. This limits the confounding 
factors and possible reverse causation whereby a dysregulated disease state could cause 
molecular changes rather than those changes being risk factors for the disease. The 
combination of genomics and functional experiments have also demonstrated how the 
disruption in the function of peripheral immune cells can contribute to the pathogenesis of a 
wide-range of diseases.  
 
To expand this analysis, I used the same molecular QTLs from the BLUEPRINT project, but 
applied them to a collection of four non-autoimmune disorders and one prototypic AID, SLE 
(Chen et al., 2016a). I used the GARFIELD method to evaluate significant enrichment of 
GWAS variants in immune molecular QTLs. Following this, I implemented statistical 
colocalisation methods using gene expression, histone and splicing-associated QTLs in 
neutrophils, monocytes and T cells with GWAS SNPs. I then further evaluated whether there 
is evidence that immune phenotypes can, at least in part, aid the development of mechanistic 
hypotheses underpinning genetic risk at disease loci. I also thoroughly investigated biological 
mechanisms to provide functional hypotheses that will aid the design of further experimental 
dissection of disease loci. I demonstrated that this approach required the integration of 
multiple data sources and analytical approaches in order to provide in-depth molecular 
insight into a specific disease locus.  
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2.2 Materials and methods  
Quantitative trait loci (QTL) data: Molecular phenotypes from the BLUEPRINT study were 
used to assign function to disease loci (Chen et al., 2016a). The study design, summarised in 
Figure 2.2, included generation of a mean read depth of ~7X-whole-genome sequences, 
transcriptomes (RNA-seq), histone ChIP-seq data (H3K4me1, H3K27ac) and DNA 
methylation probes (450K array) in population sample of up to 197 healthy individuals. These 
data were collected in three cell types, CD66b+CD16+ neutrophils, CD14+CD16- monocytes 
and CD4+CD45RA+ T cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Summary of the BLUEPRINT Epigenome variation project  
Overview of the study design and molecular traits investigated in BLUEPRINT. Figure reproduced 
from (Chen et al., 2016a) under the CC license (http://creativecommons.org/licenses/by/4.0/). 
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For investigating genetic functional mechanisms in this chapter, I focused on gene 
expression, splicing events (exon skipping or alternative acceptors or donors, Figure 2.2), 
H3K27ac and H3K4me1 QTLs from all three cell types. I also evaluated disease variant 
enrichment in methylation QTLs. Full analysis methods are detailed in Chen et al. (2016) but 
briefly, phenotype values of histone signal from ChIP-seq and expression from RNA-seq data 
were corrected for sequencing centre batch effects. For ChIP-seq data, phenotypes were 
normalised by the total number of million reads per individual (RPM) and normalised by 
taking log2. Gene expression was normalised in DESEQ and expressed in units proportional 
to log2FPKM, corrected for gene length and sequencing depth. These phenotype values 
were used for the whole cohort for visualisation and further testing described in this chapter. 
For QTL association, unknown sources of non-genetic covariation were removed by 
correcting for the first ten PEER factors (Chen et al., 2016a). Each feature was tested for 
association with variants within the feature and 1Mb upstream and downstream of the start 
and end position. The p value of association was corrected for increased false positives due 
to testing multiple variants by calculating the qvalue. This method controls for the false 
discovery rate, which is the proportion of false positives generated by testing multiple 
hypotheses (Bass JDSwcfAJ, 2015). Variants with a qvalue less than 5% were designated 
significantly associated with the phenotype. For visualising modified histone regions with 
more resolution, as in Figure 2.10 and 2.17, aligned reads expressed in log2RPM were used 
for gene expression and histone signals and calculated across 50 bp non-overlapping sliding 
windows across the genome.  
 
Disease GWAS datasets: To perform colocalisation methods, I collected summary statistics 
from GWAS with European cohorts of relatively high sample sizes and power. All GWAS 
were annotated with the genome build hg19. Z-score was calculated using the supplied 
effect size estimate divided by the standard error. Advanced age-related macular 
degeneration summary statistics including beta and standard error estimates were provided 
by kind permission of the International AMD Genomic Consortium (Fritsche et al., 2016). The 
study consisted of 12,023,830 variants, 16,144 cases and 17,832 controls. Alzheimer’s 
disease summary statistics were obtained from the International Genomics of Alzheimer’s 
Project (IGAP) stage 1 meta-analysis from 2013 (Lambert et al., 2013). Stage 1 of the study 
consisted of 7,055,881 SNPs, 17,008 cases and 37,154 controls. Coronary artery disease 
(CAD) summary statistics were obtained from the CARDIoGRAMplusC4D consortium 
website from 2015 study (Nikpay et al., 2015). The study consisted of 9,455,778 variants, 
60,801 CAD cases and 123,504 controls and the additive model associations were used in 
this chapter. Summary statistics for systemic lupus erythematosus were obtained from the 
immunobase website and accessed in October 2016 (ImmunoBase, 2017). The new SLE 
GWAS consisted of 7,219 cases and 15,991 European controls (Bentham et al., 2015). The 
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summary statistics of extremes of the lung ratio, FEV1, from never smokers were obtained 
from the UKBiLEVE project as part of the UK Biobank access (Wain et al., 2015). The initial 
study included 50,008 individuals, which were further stratified into never or heavy smokers 
and further into range of FEV1, for example, 9745 never smokers with low FEV1, 9827 never 
smokers with average FEV1 and 4902 never smokers with high FEV1 (Wain et al., 2015). 
Type 2 diabetes summary statistics (Morris et al., 2012) were also used to compare 
enrichments of other traits, these were accessed from the DIAGRAM consortium website 
(Stage 1 GWAS) in 2016. Further details of the GWAS summary statistics and website links 
are detailed in the Supplementary Information. 
 
GWAS enrichment (GARFIELD): GARFIELD (Iotchkova et al., 2016), was implemented to 
assess significant enrichment of GWAS SNPs with molecular QTLs. In this thesis, the 
version of the method utilises genome-wide summary statistics to calculate odds ratios for 
association between an overlap (SNP-QTL annotation) and disease status (significant p-
value for the disease/complex trait), as was used in the Astle et al. (2016) and Chen et al. 
(2016) studies. The QTL summary statistics are formatted into annotations by selecting all 
significant QTLs (qvalue < 5%) for each QTL type and each cell type. Where there are 
duplicated QTLs, due to association with multiple features, the lowest p value is used. The 
method greedily prunes input GWAS disease/trait-associated variants, retaining the most 
significant variant and removing variants with LD r2 ³ 0.1. LD tags are pre-calculated using 
1Mb windows and the combined UK10K and 1000 genomes Phase 3 panel (Europeans). 
The process is repeated until no significant variants remain. Independent variants are then 
overlapped with the annotations of interest by matching genomic positions. SNPs in high LD 
with the independent variant are also annotated as overlaps (r2 ³ 0.8). Odds ratios are 
calculated at various GWAS thresholds (1 x 10-08, 1 x 10-07, 1 x 10-06, 1 x 10-05, 1 x 10-04, 1 x 
10-03, 1 x 10-02, 1 x 10-01, 1). The significance of the odds ratio at each GWAS threshold is 
calculated using a generalized linear model in a logistic regression approach that controls for 
LD (number of variant proxies), minor allele frequency and local gene density (variant 
distance to the TSS) input as categorical variables. The method corrects for multiple 
annotations tested by applying the Bonferroni correction using the effective number of 
annotations, which is calculated based on the correlation between annotation-SNP overlap 
matrices. In this thesis, there was an increased representation of rare variants in the 
specially designed respiratory array used in the FEV1 UKBiLeve summary statistics and rare 
variants were also included in the AMD and CAD studies. In the BLUEPRINT molecular data, 
the analysis focused on common variants (MAF ³ 1%). Therefore, variants with a MAF < 1% 
were filtered from these summary statistics before evaluating enrichment.  
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Generation of regions for colocalisation input: I performed a locus pre-selection step to test 
for colocalisation as assessing all regions across the whole genome would constitute a high 
computational burden given the vast number of QTL associations. I generated a list of 
regions where significant disease SNPs and index molecular QTLs overlapped, based on the 
hypothesis that genomic regions associated with molecular feature(s) and a complex trait 
were more likely to share underlying genetic causes. Specifically, starting from the 
BLUEPRINT QTL summary statistics, significant QTLs (qvalue £ 5%) were selected. For 
each disease-QTL combination, overlaps were annotated if any lead QTL per feature (gene, 
splicing, methylation probe, H3K27ac or H3K4me1 peak) and proxy variants in high LD (r2 ³ 
0.8), were also significant in the GWAS summary statistics (p value £ 5 x 10-08). If the overlap 
occurred with lead QTL proxies, the corresponding lead QTL information was retained. For 
each lead QTL, all features associated with the unique lead QTLs that overlapped were 
identified. These were referred to as feature-QTL pairs and represent different regions tested 
for colocalisation (Figure 2.3). For each pair, the genomic region assessed in colocalisation 
was defined by the BLUEPRINT QTL testing region (SNPs within the feature and 1 Mb 
upstream and downstream). Only variants that overlap between the QTL and disease study 
are evaluated in colocalisation.  
 
Colocalisation of disease and molecular trait-associated loci: To perform colocalisation, I 
implemented the method, gwas-pw (Pickrell et al., 2016). This is a Bayesian method that 
assesses whether the overlap observed between a GWAS SNP and molecular trait QTL is 
due to a sharing of the genetic effect, i.e. the same genetic variant is associated with both 
the GWAS trait and the molecular trait. The method estimates a probability that the 
association evidence in a given genomic region falls into one of four models. Model 1 and 2 
indicate that the locus contains a single variant associated with the first trait or the second 
trait only, i.e. there is one association. Model 3 indicates colocalisation where a single variant 
is associated with both traits. Finally, model 4 indicates that two independent associations 
exist, where the variant is associated with the first trait and a second, independent variant is 
associated with the second trait (Figure 2.4).  
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Figure 2.3: Summary of molecular QTL and disease locus colocalisation approach 
This schematic summarises the selection of overlapped QTL-SNP regions and assignment of the 
disease SNP after colocalisation on individually tested regions. Variants tested for association in each 
set of summary statistics are represented by a coloured dot and the schematics represent manhattan 
plots with the higher the variant, the more significantly associated with the specified trait. Molecular 
features, such as genes or histone binding regions are represented by coloured blocks. For each 
identified GWAS-feature pair, lead QTLs and proxies associated with molecular features (above the 
curved orange line) are selected and an overlap is called if any of these SNPs are significantly 
associated with the GWAS trait (p value £ 5 x 10-08) (above the straight orange line). For each overlap, 
all features significantly associated (qvalue £ 5%) with this lead QTL are assessed for colocalisation 
(above as the blue and green features). All SNPs within the feature and the cis-genomic region, 
defined as 1Mb upstream and downstream, are input to colocalisation if shared with the GWAS study. 
Where many features colocalised with one disease locus, the lead disease SNP in the test window 
(light blue) is used to assign the previously reported locus. The bottom panel represents a scenario 
where an overlap may have been detected between a molecular feature SNP and a significant GWAS 
SNP, but colocalisation was not detected with the disease GWAS signal.  
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(1) 
 
 
(2) 
 
 
(3) 
 
 
(4) 
Full details are listed in the Pickrell et al. (2016) publication but I briefly summarised the main 
points and equations from the method below. Here, we assume that the BLUEPRINT and 
disease cohorts are independent and there is no overlap or correlation. First, the method 
calculates a Bayes factor, which corresponds to the association evidence for three 
alternative models (below). Bayes factors for each SNP are approximated from Wakefield 
[2008]. Equation 1, below, gives the Wakefield approximate Bayes factor for model 1 where 
the SNP is associated with trait 1.  
 
 !"#$% 	= 	(1 − +%exp	 /0%12 +%3 
 #$(%) = 	!"#$% 
 #$(1) = 	!"#$1 
 #$(6) = 	!"#$%!"#$1	, 
 
 
where 0% is the Z score estimate (the maximum likelihood estimate of beta divided by 
standard error, (8%	) of each SNP with the trait of interest and +% = 	 9:;:<	9:	. Bayes factors are 
averaged over computations with varying !. Therefore, in this method, the Z score for a 
SNP in the region for each trait is used to evaluate evidence for colocalisation. The three 
approximate Bayes factors above relate to three models; where the SNP is associated with 
the first trait (equation 2), second where the SNP is associated with the second trait 
(equation 3) and the third where a SNP is associated with two traits (equation 4).  
 
Next support for an association is evaluated in a given genomic region, +, for all SNPs in the 
region. The regional Bayes factor (>#$?) is evaluated for each model against the null model 
of no association in the region. The >#$? evaluates the integral sum of the posterior 
probability (PP) for all SNPs in the region where the PP is the product of the Bayes factor 
and the prior probability of the variant being causal in the locus. In the model, all SNPs have 
equal prior probability of being causal. The method assumes one casual variant and if this is 
missing, the power to detect a shared genetic effect is reduced (model 3).  
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>#$?(%) = 	@AB(%)#$B(%)CBD%  
 
>#$?(1) = 	@AB(1)#$B(1)CBD%  
 
>#$?(6) = 	@AB(6)#$B(6)CBD%  
 
>#$?(E) = 	@@AB(%)CFD% AF(1)#$B(%)#$F(1)G[I	 ≠ K]CBD% , 
 
 
where AB(%)is the prior probability that SNP I is the causal one under model 1, AB(1), is the prior 
probability that SNP I is causal under model 2 and AB(6) is the prior probability that SNP I is 
causal under model 3. >#$?(E)assumes there are two causal SNPs that independently 
influence the two traits. M refers to the number of SNPs. The SNP priors are set as follows AB(%) = 	AB(1) = 	 AB(6) = 	 %C. 
 
Next, the prior probability of the regional models is calculated by the method to maximise the 
log-likelihood function of all SNPs in a region, over all four models. In our case, this is 
calculated per locus, which is pre-defined as a region with an overlapping molecular QTL and 
GWAS SNP (Figure 2.3) not genome-wide, given the tendency for QTL testing regions (2 Mb 
regions) to overlap. Finally, a posterior probability for each model per locus is calculated by 
multiplying the corresponding model prior probability by the >#$?. For each locus, four 
posterior probabilities are generated for model 1, 2, 3 and 4. The PP for model 3 is used to 
evaluate whether there is evidence for a shared genetic effect. 
 
There are some limitations in this method. It is difficult to distinguish between model 3 and 4 
if there is high LD between the lead variants of each of the two traits (r2  ³ 0.8). The model 
does not provide an estimation and direction of causality between the molecular trait and 
disease.  
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The threshold for calling a region colocalised was PP ³ 0.99 for model 3, as this gives high 
confidence that there is statistical evidence for an underlying shared genetic signal between 
two traits. Only regions where there were equal or more than 20 SNPs shared between the 
disease and molecular datasets were considered as colocalised loci. Locus zoom plots were 
generated using custom scripts and used to provide visual evidence for colocalisation. The p-
value supplied in the GWAS datasets was used in plotting as well as the raw p-value for the 
molecular QTLs (not 5% qvalue). Only SNPs that were shared between the disease and 
molecular QTLs were plotted in the locus zoom plot (as these were the input into gwas-pw). 
Final results excluded the MHC region, which was defined as the region on chr6 between the 
positions 20000000 and 40000000 based on previous investigations of the region (Trowsdale 
and Knight, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Schematic of the four models evaluated by colocalisation methods 
describing the relationship between two trait associations within a locus  
In this analysis, the genomic region above represents a molecular QTL testing region overlapping a 
GWAS SNP. Model 1 and 2 are single association models, model 3 represents a colocalised region 
where two traits have shared genetic signals and model 4 is where two independent variants are 
associated with different traits. Figure reproduced from Pickrell et al, 2016 (Pickrell et al., 2016). 
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Assigning a unique disease locus: Multiple molecular features colocalised with some disease 
loci. In order to evaluate all possible molecular consequences of each disease loci, a lead 
disease SNP was assigned to each feature-QTL pair, each assessed independently for 
colocalisation. Molecular features sharing the same disease SNP were aggregated. The SNP 
with the lowest p-value in the testing region (+/- 1Mb) was selected from the GWAS 
summary statistics. The assigned SNP was compared to the reported disease lead SNP. In 
most cases, there was an exact match between the assigned and reported disease SNP. 
However, for SLE and AD, summary statistics from the full meta-analysis were not publicly 
available, instead for both summary statistics from the stage 1 GWAS were available. 
Reported lead SNPs in the study were based on meta-analysis. In these cases, LD (r2 
1000G) between the assigned and reported disease SNP was used to assign the published 
locus. For SLE, three regions significant in stage 1, which colocalised with features were 
removed from the final results as no corresponding region could be identified in the published 
meta-analysis. The FEV1 GWAS contained a complex region of extended LD that was 
classified as the KANSL1 inversion locus, defined by one conditionally significant genetic 
signal. The extended LD made it difficult to assign a lead disease SNP in my analyses. I 
found that features colocalised with FEV1 disease SNPs rs111907488, rs62060763 and 
rs2532349 were all located in this region, therefore I combined all of these features into the 
KANSL1 locus defined by the study reported lead SNP, rs2532349. Importantly, this method 
assigns the most significant lead SNP per locus, but the colocalisation could occur between 
secondary or further independent signals in either GWAS or BLUEPRINT associations. 
However, the lead SNP is assigned for ease of comparison to previous findings. In depth 
investigation of each locus is required to assess whether colocalisation occurs with the 
primary signal. 
 
Conditional SNP analysis within phenotype: To gain a better understanding of molecular 
signals and whether these were shared between cell types, I used GCTA conditional analysis 
to estimate conditionally independent signals based on association statistics and LD between 
the variants in the locus. GCTA version 1.25.2 with the --cojo-cond option was implemented 
using QTL summary statistics from the BLUEPRINT study (Chen et al., 2016a, Yang et al., 
2011, Yang et al., 2012). Summary statistics for each feature were input into GCTA. For LD 
estimation, genotype information from the BLUEPRINT cohort was used in plink hard call 
format using the --bfile option. Iterative conditional analysis was performed if any SNPs were 
associated with the phenotype after conditioning on the lead SNP. To evaluate this the q 
value, which represents the p value corrected for the number of SNPs tested in the region, 
was calculated using the qvalue R package version 1.43.0 (Bass JDSwcfAJ, 2015). GCTA 
was then implemented on output summary statistics conditioning on the SNP with the lowest 
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qvalue from the previous conditional analysis. In most cases, the conditional analysis was 
confirmed by using a simple linear regression model with individual genotype data in R.  
 
Linear regression analysis: For specific loci, as part of an in-depth investigation, various 
linear regression models were implemented using the lm() function in R. Phenotypes as 
described above were extracted from the full matrices from the Chen et al. (2016) study for 
features of interest. Units were log2RPM for the histone signal or normalised expression 
values, which are proportional to log2FPKM. SNP genotypes were input for every individual 
where 0 denotes homozygous reference, 1 heterozygous and 2 homozygous alternative, the 
latter was the defined effect allele for the Chen et al (2016) BLUEPRINT study. Genotypes 
were input as numeric to test for a trend across the 0,1,2 genotypes rather than as a factor 
where the difference between each genotype level is evaluated. Genotypes and phenotype 
values were matched using the unique study ID. To evaluate the causal relationships at the 
AMD TNFRSF10A locus, I used phenotype values for 158 individuals for which all phenotype 
data was available (gene, H3K27ac, H3K4me1). I implemented a two-stage approach to test 
for causality, first removing the effects of particular phenotypes by including these as 
covariates in a linear model. I used the Shapiro Wilko test to confirm normality of residuals 
after correction and used these residuals to test for remaining association with the locus lead 
SNP genotype. 
 
R2 and goodness of fit: The model fit was evaluated using the R2 generated from the lm() 
function. Briefly R2 or the coefficient of determination measures the proportion of N	that is 
explained by O, the predictor variable, where a value of 1 demonstrates that O explains all of 
the variation in N.	To evaluate whether fitting of additional covariates improved the model fit, 
the anova() function in R was used to perform a Chi-squared test to compare nested linear 
model 1 and linear model 2, related by the inclusion of additional covariates into model 2 
(see Section 2.3.5.2). The chi-squared test evaluates whether the reduction in the residual 
sum of squares is statistically significant or not. 
 
Linkage disequilibrium calculation: LD between variants was assessed using the 1000 
genomes panel via the HaploReg resource and denoted as 1000G (Ward and Kellis, 2012). 
Alternatively, where indicated, LD was calculated from the Astle et al. (2016) cohort using 
PLINK v2 with the flags --ld and --bfile for the input imputed hard call files generated as part 
of the main GWAS analysis (Astle et al., 2016).  
 
HL60 differentiation model: Additional functional data was required in some cases to further 
assign mechanism to disease loci. There are known limitations with access to primary human 
neutrophils and technical difficulties associated with using genomics approaches in these 
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cells. The cell line, HL60, are commonly used as a model for neutrophils but resemble an 
early population of promyelocytes (Birnie, 1988). To address this and provide an additional 
high-quality granulocytic dataset, I implemented a well-established method for differentiating 
the HL60 cell line into a more mature neutrophil-like state and functional phenotype, with the 
addition of all-trans retinoic acid (ATRA) or dimethyl sulfoxide (DMSO) (Breitman et al., 1980, 
Chang et al., 2006). HL60 cells were grown at 370C in RPMI medium supplemented with 
10% FBS and penicillin and streptomycin. Cells were passaged at a cell density of less than 
1 x 106 cells per mL media. HL60 cells were seeded at a density of 10 x 106 cells/mL and 
incubated with either 1 µM ATRA or 1% DMSO for 96 hours. Cells without addition or either 
ATRA or DMSO were grown for 96hours without media change as a control. Every 24 hours, 
cells were counted for viability using a C-chip counting chamber and 1:1 dilution of Tryphan 
blue. After 96 hours, cells were harvested and fixed with 1% formaldehyde. To assess the 
success of differentiation, cell viability as well as the surface expression of neutrophil marker 
CD11b were measured. For flow cytometry measurements, 1 x 106 cells were harvested, 
spun at 1200 rpm for 5 minutes and pellets were resuspended in 100 µL FACS buffer (2% 
BSA, 0.001% EDTA in D-PBS). Cells were washed and incubated with 5 µL of Fc receptor 
blocking solution (Human TruStain FcX, BioLegend 422301) for 10 minutes on ice and 
afterwards washed with FACs buffer (1200 rpm for 5 minutes). 2 µL of the relevant antibody 
or isotype control was added for 30 minutes at 40C (Table 2.1). The stained cells were then 
washed three times. Unstained and isotype controls were also prepared. Samples were 
analysed using a BD LSR Fortessa Cell Analyser. In addition, gene expression of candidate 
genes known to vary in the differentiation process was also evaluated. RNA was extracted 
using a QIAGEN RNeasy mini kit and treated for DNase using TurboDNase (Life 
Technologies). Oligo(dT) primers and Superscript II (Invitrogen) were added for 2 hours at 
420C for reverse transcription. HL60 genomic DNA was used as a control for the RT-PCR 
standard curve. CT values were calculated and compared to two reference genes, actin and 
C/EBPb.  
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Figure 2.5: CD11b surface expression is increased on HL60 differentiation with DMSO 
or ATRA  
Dot plots and histograms of the fluorescent signal of either CD11b (top panel) or CD16 (bottom panel) 
measured using flow cytometry. CD11b surface expression is increased on differentiated HL60 cells 
(DMSO and ATRA) compared to dividing HL60 (undifferentiated). CD16 expression is largely 
unchanged upon differentiation as has been previously observed (Jacob et al., 2002). Reduced 
proliferation and known gene expression changes (Lee et al., 2002) were also demonstrated 
(Supplementary Figures 2.1-2.2).  
 61 
Chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq): ChIP 
experiments were adapted from a previously published protocol (Schmidt et al., 2009), with 
some modifications. 20 x 106 cells were used for TF immunoprecipitation (IP) and 5 x 106 
cells for histone modifications. Cell pellets were fixed by incubation with 1% formaldehyde for 
10 minutes at RT, followed by five minutes with 2.5M glycine. Cells were pelleted and 
washed with PBS, flash frozen in dry ice and stored at -80°C. Cells were sonicated for eight 
cycles with 30 seconds on and 45 seconds off at 4°C using a Diagenode PicoRuptor 
biorupter. Sonication efficiency (150-500bp fragments) was verified using an Agilent DNA 
bioanalyser. 2.5µg of each antibody was bound to Protein A Dynabeads (Invitrogen) in a 4-
hour incubation. Sonicated lysate was added to the antibody-bead mix and incubated 
overnight at 4°C. The bound-beads were then washed with cold RIPA buffer ten times. 
Crosslinks were reversed with incubation at 65°C for five hours to elute DNA. Samples were 
then incubated with 2µl RNase at 37°C for 30 minutes followed by incubation with Proteinase 
K at 55°C for one hour. Ampure beads (Beckman Coulter, A63881) were added to the DNA 
in a 1:1.8 ratio and samples were washed twice in cold 70% ethanol. DNA was then eluted in 
50 µl elution buffer. Samples were stored at -20°C prior to Illumina library preparation, which 
was carried out according to the Illumina TruSeq ChIP sample kit protocol. An additional step 
of enriching fragments through PCR prior to gel purification was added to avoid amplification 
of contaminants. RNA index sequences were ligated to ChIP-enriched DNA fragments (200-
500bp in size) for multiplexed libraries. Libraries were submitted for single-end sequencing 
with a read length of 50bp using a HiSeq2000. For analysis of sequencing data, reads were 
first aligned to the human reference genome (hg19 CRCh37) using BWA version 0.6.1 with 
default parameters (Sanger pipelines). ChIP-seq data analysis was performed using an in-
house pipeline developed by Louella Vasquez that implemented standard analysis 
procedures, described here. Duplicate reads were removed (Picard MarkDuplicates v1.103) 
and reads with a zero-mapping source were removed. Peaks were called using MACs 
v2.0.10.20131216 (Zhang et al., 2008) with default parameters using the estimated fragment 
size evaluated by PhantomPeakQualTools vr18. Narrow flags were used for all factors apart 
from H3K4me1 for which the broad flag was used. For the background control, sonicated 
input DNA was used from the respective ATRA or DMSO treatments. Encode quality control 
metrics (Phantom Quality Tools) were used to evaluate the success of IP as well as visual 
inspection in the UCSC genome browser. Significant peaks were selected if 1% FDR or less.  
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Antibody Supplier Source/Clone 
Anti-PU.1 Santa Cruz, sc22805 Rabbit polyclonal 
Anti-CEBPb Santa Cruz 150 X Rabbit polyclonal 
Anti-trimethyl histone H3(lys4) Diagenode C15410003 Rabbit polyclonal 
Anti-H3K27acetyl Abcam ab4729 Rabbit polyclonal 
Anti-monomethyl histone H3(lys4) Diagenode C15410194 Rabbit polyclonal 
PE Mouse Anti-Human CD11b BD Pharmingen 557321 ICRF44 
PE Mouse IgG1, K isotype control BD Pharmingen 556650 MOPC-21 
Pacific Blue Anti-Human CD11b BD 558123 ICRF44 
Pacific Blue Mouse IgG1, isotype control BD 558120 MOPC21 
APC CY7 Anti-Human CD16 BD 557758 3G8 
 
 
 
 
 
 
 
Table 2.1: Antibodies used in ChIP-seq and flow cytometry experiments  
Antibodies against specific proteins studied, the supplier and reference as well as source or clone for 
flow cytometry experiments.  
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2.3 Results  
2.3.1 Functional enrichment in five diseases 
First, I aimed to assess the enrichment of non-autoimmune disease SNPs in immune 
molecular QTLs. I used the GARFIELD method (Materials and Methods) to evaluate 
significant enrichment by calculating the odds ratio (OR) for enrichment of GWAS variants in 
molecular features such as gene expression, RNA splicing, histone marked regions and 
lastly DNA methylation from three cell types (Chen et al., 2016a). Higher OR estimates 
indicated increased odds that an overlap occurs with a significant GWAS variant as opposed 
to an overlap with a non-significant GWAS variant.  
 
I identified significant enrichment of AD, CAD, FEV1, AMD and SLE variants associated at 
the GWAS p value threshold of 1 x 10-05 in a number of molecular feature types, ranging from 
four significant features for AD to all features with significant enrichment for SLE. This is in 
contrast to the complete lack of significant enrichment of immune QTLs with Type 2 diabetes 
(T2D) SNPs. I included T2D-associated SNPs as a negative control as despite recent links to 
inflammation, it is currently considered that a disordered metabolic state in Type 2 diabetic 
patients then leads to immune dysregulation (Hameed et al., 2015). This is supported by low 
enrichment of T2D variants in immune molecular features, as observed previously in two 
independent studies, and further confirmed here in my analysis (Figure 2.6) (Chen et al., 
2016a, Alasoo et al., 2017).   
 
The highest and some of the most significant enrichments were observed with neutrophil, 
monocyte and T cell splicing QTLs and FEV1-associated variants, with a mean OR of 12.520 
across all three cell types and p values ranging from 6.404 x 10-18 for T cell splicing QTLs to 
2.264 x 10-24 for neutrophil splicing QTLs. Significant enrichment in splicing QTLs was also 
observed for other traits. AMD-associated variants showed the highest enrichment in splicing 
QTLs from all three cell types (mean OR = 4.541), with the highest OR also in neutrophils. 
SLE-associated variants also showed the highest enrichment in neutrophil splicing regions 
(OR = 5.247, p value = 8.505 x 10-13).  
 
However, there were large OR confidence limits for the FEV1 splicing enrichment, which 
indicated a higher error in this measurement. This could be due to a lower number of variants 
overlapping these annotations when in comparison to some (but not all) of the disease 
GWAS. For FEV1, 24 variants were annotated as overlapping monocyte splicing QTLs at the 
GWAS p value threshold of 1 x 10-05, 24 overlapping T cell splicing QTLs and 24 with 
neutrophil splicing QTLs, but for AMD-GWAS, 39, 36 and 40 variants overlapped monocyte, 
neutrophil and T cell splicing QTLs respectively at the same GWAS 1 x 10-05 p value 
threshold.  
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SLE-associated variants were significantly enriched across all molecular QTL types, whereas 
other trait variants demonstrated more variable enrichment patterns. The high and significant 
enrichment across the majority of QTL and cell types was previously observed for other 
autoimmune diseases including Crohn’s disease, rheumatoid arthritis and multiple sclerosis 
(Chen et al., 2016a). The ubiquitous effect may reflect extensive cross-talk between different 
immune cell populations or that increased power in both GWAS and QTL studies are 
required to fully resolve finer immune cell population signatures.  
 
Interestingly, CAD was the only trait for which there appears a possible cell-type specific 
pattern of enrichment with a consistent significant enrichment for monocyte gene, H3K27ac, 
H3K4me1 and methylation QTLs, which was in agreement with the established role for 
monocytes in CAD aetiology (discussed above). The mean OR for the significantly enriched 
monocyte features, as calculated from the GARFIELD output data was 2.737. Significant 
neutrophil annotations showed a slightly lower average OR of 2.310, and the equivalent p 
values of enrichment were less significant than the equivalent p value for monocyte 
annotations apart from for neutrophil splicing, which was not significant in monocytes. For T 
cells, only gene, H3K27ac and methylation QTLs showed significant enrichment with CAD 
variants.  
 
In summary, this approach has demonstrated significant enrichment of non-autoimmune 
disease variants in molecular QTLs, where greater enrichment was observed in all cases for 
at least five molecular QTL types than the negative case of T2D. For example, all five 
disease-associated variants showed significant enrichment in monocyte and neutrophil 
eQTLs. These significant enrichments suggest that these GWAS variants may result in 
functional changes in immune cells that could underpin mechanisms at some genetic risk 
loci. Therefore, using these molecular data to further study disease loci could aid the 
generation of biological hypotheses of downstream consequences at these loci.  
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Figure 2.6: Enrichment of molecular QTLs in six diseases  
Histogram plot summarises the enrichment of molecular QTLs in a range of diseases. Higher 
enrichment represents a greater overlap of disease SNPs and molecular QTLs and is indicated by an 
increased odds ratio (OR) on the y-axis calculated by GARFIELD. Represented here is overlap of 
disease variants at the suggestive GWAS p value threshold, 1 x 10-05. The significance of the overlap 
is depicted by the colour scale of the plots (purple is more significant), and is corrected for the number 
of effective annotations (Methods) and for 5 diseases (where significant enrichment was expected, 
which excludes Type 2 diabetes). Annotations are enriched with OR ³ 1. The OR confidence limits are 
reflected by the error bars, with arrows to designate values beyond the maximum OR shown in the 
figure. Type 2 diabetes was included as a non-immune negative control and as such no significant 
enrichment was observed for these SNPs. G refers to gene features i.e. eQTLs, K27 to H3K27ac 
hQTLs, K41 to H3K4me1 hQTLs, M to methylation QTLs and S to splicing QTLs (percent-splice in as 
defined in the main BLUEPRINT paper and detailed in Methods).  
 
 
2.3.2 Colocalisation of molecular traits with five diseases 
Formal statistical testing is required to evaluate whether the molecular trait and disease 
associations can be attributed to the same underlying causal genetic variant. I therefore 
implemented the colocalisation method, gwas-pw, which uses prior information regarding the 
effect sizes (expressed as a Z-score) of two traits within one locus (detailed in the Materials 
and Methods). I assessed colocalisation between each of the five complex diseases/traits 
described above; AD, SLE, CAD, AMD and FEV1 with four molecular traits, gene expression, 
H3K72ac & H3K4me1 modifications and RNA splicing from three cell types monocytes, 
neutrophils and naïve CD4+ T cells (Chen et al., 2016a). The overall aim of this approach 
was to identify to what extent immune molecular features could explain mechanisms at 
unique disease loci reported from each GWAS.  
 
Across all five diseases, I identified that 46% (55/120) of previously reported disease loci 
colocalised with at least one molecular feature using a high posterior probability of 
colocalisation (PP ≥ 0.99) (Table 2.2). The highest percentage of colocalised loci was 
observed with systemic lupus erythematosus (SLE) variants (54%), which is expected as 
SLE is a paradigmatic autoimmune disease displaying strong immune cell involvement (Dai 
et al., 2014, Farh et al., 2015). SLE was included in this chapter to provide a positive control, 
as strong enrichment of SLE variants in lymphoid and monocyte enhancers (high H3K27ac) 
has been previously demonstrated using ROADMAP data (Farh et al., 2015). Neutrophil data 
was not assessed in this previous study, despite recent observations of the importance of 
this cell type to SLE pathogenesis (Weidenbusch et al., 2017). Using the BLUEPRINT 
neutrophil data, therefore, provided the opportunity to gain novel insight into neutrophil-
mediated risk at SLE loci.  
 
The lowest percentage of colocalised loci was observed with coronary artery disease (40%). 
However, of the 43 common GWAS loci excluding the MHC region that were assessed, there 
were still 17 CAD loci that colocalised with at least one molecular feature. Therefore, this 
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type of analytical approach affords the potential to form molecular hypotheses of up to one-
third of the known loci within clearly defined cell type populations facilitating downstream 
experimentation.  
 
 
 
Disease 
Disease 
variants 
(+MHC) 
Disease 
loci 
(+MHC) 
All coloc 
(%) 
Gene 
coloc 
PSI 
coloc 
H3K4me1 
coloc 
H3K27ac 
coloc 
AMD 41 (45) * 32 (33) 16 (50) 9 4 10 12 
CAD 43 (44) 43 (44) 17 (40) 7 3 12 15 
SLE 24 (25) * 24 (25) 13 (54) 6 2 6 9 
AD 14 (15) 14 (15) 6 (43) 2 3 4 4 
FEV1 7 (9) * 7 (9) 3 (43) 3 1 2 2 
All 129 (138) 120 (126) 55 (46) 27 13 34 42 
 
 
 
Table 2.2: Number of colocalised disease loci per feature type  
Number of colocalised unique disease loci per feature type, per disease. The percentage of all 
features colocalised per disease is the ratio of colocalised loci over total common loci that were 
defined in the GWAS excluding the MHC region. For the AMD statistics, 7 variants and 1 locus with a 
MAF < 1% were also excluded and not counted in the table above. Each disease locus that 
colocalised with at least one feature across three cell types is counted as one colocalisation. For AMD, 
the percentage was calculated with respect to the disease loci (32) not the number of independent 
variants (41), where at some loci there were multiple independent genetic signals. Where some form 
of conditional analysis was performed and identified further signals this is designated by *.  
 
 
Nearly half of the disease loci (27/55, 49%) colocalised with at least one eQTL in at least one 
cell type across all diseases. Of these 27 loci, eight loci colocalised with at least one eQTL in 
monocytes and no other gene effects in neutrophils or T cells (AD MS4A6A, AMD TBC1D23, 
AMD CETP, AMD TNFRSF10A, CAD REST, CAD PPAP2B, FEV1 TSEN54, SLE BANK1) 
(Figure 2.8). Two loci, CAD NT5C2 and FEV1 RP11-186N15.3, colocalised with eQTL effects 
in neutrophils only i.e. no other colocalised eQTL was detected in either monocytes or T cells 
and similarly only two loci colocalised with T cell specific eQTLs (AMD HIGD1AP14 and SLE 
BLK). Where gene effects were not unique to one cell type, in the majority of cases at least 
one colocalised gene was shared between two or three cell types (80%, 12/15). 
 
In total, there were 13 disease loci that colocalised with at least one percent-splice-in (PSI) 
effect, which could include exon skipping or alternative donor or acceptor usages. A subset 
of loci colocalised with eQTLs and splicing effects in the same gene such as AD MS4A6A, 
AMD PILRB, CAD NT5C2 and SLE IRF7, which highlighted cases where a disruption of 
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alternative splicing could lead to a change in the overall level of gene expression. 
Alternatively, five loci colocalised with a splicing QTL but not an eQTL across all cell types. 
These included AD CR1, AMD NPLOC4, CAD MIA3 and CAD IL6R, which all colocalised 
with exon skipping events in the corresponding genes as well as the SLE FCGR2A locus, 
which colocalised with exon skipping events in the FCGR2A gene in neutrophils and the 
FCGR3A gene in monocytes. Genetic control of splicing has previously been shown to be 
relevant to disease risk and also often independent of both gene expression and histone 
activity (Li et al., 2016c). Therefore, investigating splicing events as well as gene expression 
can highlight additional molecular mechanisms (Odhams et al., 2017, Li et al., 2016c, Chen 
et al., 2016a). 
 
Next, I evaluated whether there existed any specific cell type patterns across the five 
diseases. In addition to assessing the number of disease loci that colocalised with at least 
one feature, I counted all colocalised gene and splicing QTL effects including where there 
were multiple features for one disease locus (Figure 2.7). For example, in this analysis, the 
AMD TNFRSF10A locus colocalised with eQTLs in monocytes for three genes: TNFRSF10A; 
CHMP7 and RP11-1149O23.3, which were counted as three monocyte-specific features. I 
also limited my analysis to genes and splicing effects to avoid over-inflating the feature 
counts. In the BLUEPRINT cohort, overlapping histone modification signal peaks from 
multiple individuals were merged to create a unified peak list facilitating the identification of 
QTLs across all individuals (example in Figure 2.10) (Chen et al., 2016a). This could 
generate broad regions that could contain the signal of multiple correlated peaks. Elucidation 
of the exact putative enhancer region for the corresponding colocalised gene therefore 
required further molecular dissection (as discussed later in this chapter) (Figure 2.10-12, 
2.17). To avoid over-estimating the importance of cell type by counting multiple correlated 
histone regions I assessed the gene and splicing effects for possible cell-type specific 
patterns.  
 
18 monocyte features colocalised across all disease loci in total. Nine neutrophil- and nine T 
cell-derived features also colocalised across all loci (Figure 2.7). There was a higher degree 
of shared colocalised genes and/or splicing junctions between monocytes and neutrophils 
(seven) than between monocytes and T cells (three) or between neutrophils and T cells 
(one). This could be expected given that monocytes and neutrophils are derived from the 
common myeloid progenitor cells whereas CD4+ T cells differentiate from the common 
lymphoid progenitor and deviate more in function (Figure 1.5 (Orkin and Zon, 2008)). 
Interestingly, there were also seven gene or splicing effects that occurred in all three cell 
types, suggesting these loci may have more ubiquitous effects (AD EPHA1-AS1, AMD 
PILRB and MEPCE at the same locus, AMD RP11-644F5.10, CAD NT5C2, CAD GGCX and 
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SLE IRF7). Indeed, I observed that the AD EPHA1-AS1 (EPHA1 antisense RNA 1) locus 
lead SNP was also a significant eQTL for this gene across multiple tissues assayed in the 
(G. TEx Consortium, 2015) including adipose, lung, spleen and whole blood. I observed the 
same broad tissue effect for the AMD PILRB locus, where the lead SNP was also a 
significant eQTL across more than 15 different tissues including coronary artery, brain, 
adipose and pancreas. Finally, the CAD GGCX locus, was also an eQTL in over ten tissues 
including aorta artery, stomach, pancreas and adipose. In summary, this approach 
demonstrated that across all five diseases, the most commonly colocalised features were 
monocyte-derived. 
 
The majority of disease loci also colocalised with either H3K27ac, H3K4me1 QTLs or both 
(89%, 49/55). Across all three cell types, 42% (20/55) of loci that colocalised with gene or 
splicing QTLs also colocalised with a histone QTL from the corresponding cell type in at least 
one cell type (i.e. where a monocyte eQTL colocalised with either a monocyte H3K27ac or 
H3K4me1 QTL). In these cases, colocalised histone-bound regions may demarcate putative 
regulatory regions for the respective colocalised genes (Section 2.3.5 onwards for detailed 
examples). In addition, 43% (23/55) of disease loci colocalised with a histone QTL but not a 
gene or splicing QTL. These could represent poised enhancers indicating that the regulated 
genes are active in other cell types or that these regulatory QTLs affect processes beyond 
gene expression and splicing (Pai et al., 2015).  
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Figure 2.7: Colocalised gene and splicing QTLs per cell type and cell type combination 
across all diseases  
All gene or splicing QTL features are counted for each cell type combination, for example the CAD 
GGCX locus colocalised with GGCX eQTLs across all three cell types so was counted as a shared 
MNT signal, but in the same locus, VAMP8 eQTL colocalised in T cells only, so this was counted as a 
T cell (T) specific signal. The highest number of genes and splicing QTL features were in monocytes, 
demonstrating the potential importance of these cells across all diseases.  
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2.3.3 Colocalisation of molecular traits reveals potential molecular 
mechanisms at disease risk loci  
I observed a high proportion of disease loci colocalised with molecular features but to form 
detailed mechanistic hypotheses for specific disease loci, integration of all colocalised 
features across cell types is required. Below, I discuss specific insights into the potential 
function of genetic risk loci.  
 
Colocalisation with eQTLs offers the most intuitive interpretation of the molecular 
consequences at disease risk loci by identifying genes with altered expression levels. Figure 
2.8 summarises the multiple molecular features I identified as colocalised with each disease 
locus. Figure 2.8 also describes the status of the previously predicted gene for the GWAS 
locus. There were several instances, 18 in total, where the colocalised gene matched 
previous target predictions for that locus, including AD MS4A6A, AMD SRPK2, RDH5, 
CETP, CNN2, PILRB/A, TNFRSF10A, CAD NT5C2, LIPA, REST, GGCX, PPAP2B, FEV1 
TSEN54 and SLE BANK1, IRF7, BLK, ITGAM, UBE2L3.  
 
All colocalised genes matching previous predictions at SLE loci had direct immune roles, 
which is expected for this prototypic autoimmune disease, but also in this case likely due 
to the use of publicly available eQTL data in the initial assignment of GWAS locus by the 
authors (Bentham et al., 2015). From my analysis, I identified colocalised eQTL genes, 
BANK1 and BLK, which act in related B cell signalling pathways and are both regulated by 
type 1 interferons (Delgado-Vega et al., 2010). Here, these gene effects were T cell-
mediated; a decrease in T cell BLK expression correlated with an increased disease risk, 
which was also observed in the original GWAS study. I also identified the gene ITGAM, 
where a neutrophil eQTL colocalised at this locus and decreased gene expression 
corresponded to decreased disease risk (rs9673398, EA = G, eQTL beta = -0.4896, SLE 
OR = 0.81). ITGAM encodes integrin alpha M chain, which forms the leukocyte-specific 
Mac-1 receptor shown to be important for neutrophil and monocyte-endothelial adherence 
and phagocytosis (Rebhan et al., 1998). I also identified other well-known immune genes 
such as UBE2L3, which encodes a ubiquitin conjugating enzyme E2 L3 involved in 
targeting proteins for degradation (Rebhan et al., 1998). Variants within the gene have 
also been associated with risk of Crohn’s disease, coeliac disease and rheumatoid arthritis 
(Fransen et al., 2010, Zhernakova et al., 2011). Here gene expression was positively 
correlated with SLE risk, confirming observations from the original GWAS (Bentham et al., 
2015) Interestingly, the eQTL was more significant in neutrophils (eQTL lead, rs2298429, 
p value = 1.188 x 10-30) than monocytes (eQTL lead rs5749485, p value = 2.901 x 10-04) 
and the effect greater in magnitude (neutrophil, EA = G, beta = 1.267, SE = 0.110, 
monocyte, EA = C, beta = 0.448, SE = 0.124). Neutrophil eQTLs were not assessed as 
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part of locus assignment from the Bentham et al. (2015) SLE GWAS, instead stimulated 
monocytes, B cells, CD14+ monocytes, NK cells and CD4+ T cells were included (Bentham 
et al., 2015). This suggests that neutrophils may be the effector cell for this disease risk 
locus, demonstrating the importance of assessing multiple cell types, particularly in this 
context as neutrophils have been shown to be important in the aetiology of lupus 
(Weidenbusch et al., 2017).  
 
I also identified colocalised genes with immunological roles for the other traits I investigated. 
AD risk variants have been identified with within the MS4A cluster containing multiple genes 
encoding accessory proteins that amplify receptor function and regulate immune cell 
activation and survival (Proitsi et al., 2014). Significantly increased blood MS4A6A transcript 
levels have been associated with common coding SNPs in a cohort of approximately 300 AD 
patients, suggesting higher protein levels could contribute to the pathogenic pro-inflammatory 
AD phenotype (Proitsi et al., 2014). The authors found that MS4A6A was the only gene 
significantly differentially expressed, with higher expression in the patient cohort compared to 
the normal elderly controls. The MS4A6A expression effect was associated with SNP 
genotype but this effect was only significant in the patient group. By contrast, I identified that 
the AD MS4A6A locus colocalised with multiple genes in this locus including MS4A6A, 
MS4A4A and MS4A4E in monocytes and a further monocyte splicing QTL for MS4A6A. I 
observed the same positive correlation between gene expression and disease risk, where 
higher expression of MS4A6A, MS4A4A and MS4A4E corresponded to increased AD risk. 
My analysis identified MS4A effects in healthy individuals, which suggested in contrast to 
previous observations that the expression effect could contribute to the risk of AD, rather 
than reflect an expression effect that is perturbed in the disease state. There is evidence that 
the effect I identified and the previous effect could represent the same genetic signal, the LD 
between tested variants was moderate (r2 0.54-0.61). Higher expression of these genes 
could, therefore, aid prediction of risk and also provide potential targets to investigate for 
therapeutic lowering of the expression levels.  
 
For CAD, I confirmed the well-known IL6R locus, discussed in Section 2.1, colocalised with 
an exon skipping event in the IL6R gene generating higher levels of the transcript encoding 
soluble IL6R, thus providing clear validation of my analytical approach. Other CAD loci also 
highlighted the importance of immune activity, for example, I identified that the CAD PPAP2B 
colocalised with monocyte expression of this gene (rs56186267 EA = A, p value = 3.098 x 
10-10, beta = 0.885, SE = 0.141) as well as a H3K27ac marked region (p value = 1.884 x 10-
07, beta = 0.780, SE = 0.150) towards the 3’ end of this gene. The PPAP2B intronic SNP, 
rs72664324, which is in high LD with the lead BLUEPRINT SNP (r2 = 1, 1000G) has 
previously been identified as disrupting the binding of a C/EBPb transcription factor (TF) 
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within a macrophage LDL-induced dynamic open chromatin region (Reschen et al., 2015). 
Monocytes recruited in vivo to atherosclerotic plaques differentiate into macrophages, which 
are in turn stimulated to form foam cells by uptake of environmental lipids (Reschen et al., 
2015). PPAP2B encodes the enzyme, LPP3, which deactivates pro-inflammatory mediators, 
such as those released from foam cells. Increased gene expression confers a protective 
CAD effect. Similarly, in the colocalised monocyte effects I identified, increased PPAP2B 
gene expression as well as increased signal of the H3K27ac modification (and therefore 
enhancer activity) corresponds to a decrease in CAD risk. Evidence also suggested that this 
was a monocyte-specific effect as PPAP2B expression was not tested in T cells due to low 
expression and in neutrophils, the association was not significant after correcting for multiple 
testing (rs72664324/rs56186267, p value = 1.975 x 10-01). The classical CD14+CD16- 
monocytes studied in the BLUEPRINT is known to differentiate into macrophages in inflamed 
tissues (Ohradanova-Repic et al., 2016). Therefore, the identified monocyte colocalisation at 
this locus suggests that enhancer activity and PPAP2B gene effects may be present in 
monocytes before stimulation and differentiation to macrophages, which in turn further 
supported the relevance of these tissues to CAD risk mechanisms. 
 
A subset of AMD loci also colocalised with immune-related genes including the TNFRSF10A 
gene encoding the TRAIL 1 receptor and the PILRB/A genes encoding the paired 
immunoglobulin-like type 2 receptor beta and receptor alpha that regulate immune responses 
(www.genecards.org), (Rebhan et al., 1998). Similarly, I identified evidence for a possible 
immunological role for the AMD CNN2 locus, for which colocalised genes were disparate 
across all three cell types in this study (Figure 2.8). The locus colocalised with the eQTL for 
CNN2 in monocytes, for CTB-31O20.2 in neutrophils and for ABCA7 in T cells, a gene 
located approximately 1 kb downstream of CNN2 on chr19. The transporter encoded by 
ABCA7 is involved in pathogen-mediated phagocytosis, a process which requires actin 
skeleton reorganisation (Humphries et al., 2015). CNN2 encodes calponin 2, a protein 
involved in the structural organisation of actin filaments, suggesting these two genes may 
have coordinated functions (Humphries et al., 2015). Genes in the ABCA7 locus, including 
CNN2, have been shown to be involved late-onset Alzheimer’s disease aetiology (Humphries 
et al., 2015), although in this chapter the locus was evaluated in the context of AMD, this 
suggests a role for this cluster in age-related disorders. Therefore, although divergent 
colocalised genes across cell types may suggest differential functions in each tissue, a 
thorough assessment at each locus is required to evaluate whether the combined activity of 
genes may highlight important disease-relevant pathways.  
 
In addition to immune function, I provided further support for the importance of lipid pathways 
in CAD and AMD. Important loci included the CAD LIPA locus that colocalised with monocyte 
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and T cell expression of the LIPA gene and the AMD CETP locus colocalised with monocyte 
expression of the CETP gene, which encodes cholesteryl ester transfer protein. LIPA 
encodes lysosomal acid lipase A and the association of the intronic SNP, rs1412444 with 
increased LIPA gene expression levels in blood cell types and increased CAD risk is 
relatively well established (Zeller et al., 2010, G. TEx Consortium, 2015, Wild et al., 2011). I 
confirmed this direction of effect in monocytes but observed that in T cells, the effect was 
less significant and a decreased in LIPA expression corresponded to increased CAD risk 
(rs1412444 monocyte p value=2.044 x 10-49, T cell p value= 4.588 x 10-06). In neutrophils, 
rs1412444 was not significantly associated with LIPA expression (p value = 7.031 x 10-02), 
suggesting that within the limits of the power of this cohort, the LIPA monocyte expression 
effect was most functionally relevant to CAD risk. Further supporting this is the colocalisation 
of this locus with a H3K27ac peak (10:90993615:91006217) and a H3K4me1 peak 
(10:90987967:91024823), which both directly overlap rs1412444. Together the activity of 
these histones could function as a putative enhancer for the LIPA gene as an increase in 
H3K27ac and H3K4me1 signal corresponds to an increased in LIPA expression and 
increased CAD risk.  
 
I also identified colocalised genes with more general functions. The FEV1 TSEN54 locus 
colocalised with a monocyte eQTL for the TSEN54 gene encoding a subunit of the tRNA 
splicing endonuclease complex (Figure 2.8). Despite a more general function, the 
colocalisation with monocyte expression appeared to reflect a relatively selective cell-type 
effect within this dataset. TSEN54 was not tested in neutrophils due to low expression 
(median log2FPKM = 2.719, BLUEPRINT cohort). TSEN54 gene expression was high in T 
cells and monocytes (median log2FPKM T cells = 9.433, median log2FPKM monocytes = 
7.067) but the lead T cell eQTL (rs7225469 EA = C, beta = -1.197, SE = 0.176, p value = 
9.348 x 10-12) was not highly correlated with the lead FEV1 variant, rs7218675 (r2 = 0.26 
1000G). These, therefore, may represent independent effects, providing both a hypothesis 
and a cellular model where decreased TSEN54 expression in monocytes corresponds to an 
increase in FEV1 ratio. The cell-type specific observation is an improvement on the initial 
observation that the GWAS locus was a significant TSEN54 eQTL in the heterogeneous mix 
of whole blood (Wain et al., 2015).  
 
I also identified a monocyte and T cell gene target, RDH5, that colocalised with the AMD 
locus where the encoded protein has a specialised role seemingly localised to the disease 
tissue (retina). RDH5 encodes the 11 cis-retinol dehydrogenase enzyme, which catalyses the 
final step in the synthesis of the mammalian pigment chromophore, 11 cis-retinaldehyde 
(Liden et al., 2001). Multiple lines of evidence link RDH5 disruption to impaired eye function; 
for example, the rare night blindness disorder fundus albipunctatus is caused by RDH5 
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mutations and in AMD-like pathology and impaired dark adaptation is observed in the RDH5 
mouse model (MGI:1201412) (Blake et al., 2014, Fritsche et al., 2016). 
 
Here, a decrease in RDH5 expression in both monocytes (rs3138141 EA = A, p value = 
5.512 x 10-12, beta = -0.780, SE = 0.113) and T cells (rs3138141, p value= 1.931 x 10-10, beta 
= -0.760, SE = 0.119) corresponds to an increase in AMD risk (rs3138141, beta = 0.15). 
RDH5 expression is widely expressed beyond ocular tissues and the specialised retinal 
RPE-tissue (Wang et al., 1999). Interestingly, rs3138141 has shown to be a significant eQTL 
in over 10 different tissues from the (G. TEx Consortium, 2015) but I did not identify 
colocalisation of this locus in neutrophils. Instead a seemingly independent QTL was 
associated with neutrophil RDH5 expression but not with AMD risk (rs142106092, RDH5 
p=4.536 x 10-06, AMD p=0.147, rs3138141 r2 < 0.2 1000G). The functional significance of a 
specialised gene with a fairly ubiquitous effect remains unclear, but I did observe significant 
enrichment of AMD variants in monocyte eQTLs (Figure 2.6), providing evidence that among 
the ubiquitous expression, the monocyte-derived expression effect may be more likely to be 
disease-relevant. Certainly, there is a well-known role for Vitamin A, of which 11-cis-retinal is 
a derivative, in regulating the immune system and a further immune-link was demonstrated 
by reduced RPE RDH5 expression in an in vitro system as a result of TNFa secretion from 
activated pro-inflammatory CD14+ monocytes (Mora et al., 2008, Mathis et al., 2017). Further 
complicating mechanistic interpretation, this locus colocalised with a more significant gene 
expression effect in monocyte (p=9.234 x 10-34), T cell (p=6.880 x 10-18) and neutrophil 
(1.427 x 10-24) of a second gene, RP11-644F5.10, for which there is no current characterised 
function. In addition, RP11-644F5.10 and RDH5 are directly overlapping, and rs3138141 is 
located within both genes.  
 
The disease loci that colocalised with well-studied genes confirmed the validity of my 
analytical approach. I have also provided functional evidence for loci that may have 
previously been suggested without eQTL evidence and often based on genomic proximity to 
the lead SNP. Where eQTL data was used, utilising specific cell populations provides 
tractable and specific cellular models for functional follow up. Supplementary Figure 2.3 
shows the regional association plots for all features colocalised at the loci described here 
and Supplementary Table 2.2 lists all of the colocalised features for all marks (the most 
significant colocalised features per disease locus is summarised in Figure 2.8). 
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M N T Colocalised 
      Significant QTL 
      Non-significant QTL 
      Not tested 
  
  SNP Locus Mark Feature M N T 
AD rs10792832 PICALM gene PICALM 0.2112 0.006546 0.3747 
      H3K27ac 11:85865916:85876777 COLOC COLOC 0.655 
      H3K27ac 11:85843685:85857459 3.64E-13 0.03119 COLOC 
      H3K4me1 11:85823185:85935960 0.4717 COLOC 0.03785 
AD rs10948363 CD2AP gene CD2AP 5.25E-11 4.32E-08 0.1826 
      H3K4me1 6:47512736:47517132 NA NA COLOC 
AD rs11771145 EPHA1 gene EPHA1 4.46E-12 0.7691 9.76E-19 
      gene EPHA1-AS1 COLOC COLOC 1.98E-21 
      gene TAS2R41 COLOC COLOC 3.74E-07 
      gene TAS2R62P NA COLOC 0.004497 
      gene TAS2R60 COLOC COLOC 2.45E-07 
      H3K27ac 7:143133149:143136359 COLOC 0.6102 0.01081 
      H3K4me1 7:143052447:143144656 COLOC COLOC 1.48E-09 
      psi EPHA1-AS1 NA NA COLOC 
AD rs6656401 CR1 gene CR1 1.15E-05 0.09972 0.1309 
      psi CR1 COLOC COLOC 0.5953 
AD rs6733839 BIN1 gene BIN1 2.54E-23 NA 1.16E-32 
      H3K27ac 2:127805979:127846262 3.63E-11 2.41E-08 COLOC 
AD rs983392 MS4A6A gene MS4A6A COLOC 5.45E-46 0.0003864 
      gene MS4A4E COLOC NA NA 
      gene MS4A4A COLOC NA NA 
      H3K27ac 11:60072491:60079697 COLOC 0.8078 0.9906 
      H3K27ac 11:59932786:59958180 0.729 COLOC 0.1253 
      H3K4me1 11:59867337:59870007 3.81E-15 COLOC NA 
      H3K4me1 11:60097581:60108825 COLOC 0.07696 0.9938 
      psi MS4A6A COLOC NA NA 
AMD rs10033900 CFI gene CFI NA NA NA 
      gene HIGD1AP14 0.4939 NA COLOC 
AMD rs11080055 VTN gene VTN NA NA NA 
    TMEM97 gene TMEM97 3.69E-18 NA 8.01E-17 
      gene SARM1 0.6002 COLOC 0.04608 
      gene TMEM199 COLOC COLOC 0.4475 
      H3K27ac 17:27592619:27623928 0.448 0.8503 COLOC 
AMD rs1142 KMT2E gene KMT2E 0.2907 0.5427 0.9923 
    SRPK2 gene SRPK2 COLOC COLOC 0.004606 
      H3K27ac 7:104840590:104849222 COLOC 0.8071 0.05853 
      H3K27ac 7:104982791:105001752 0.1078 COLOC 0.9979 
      H3K4me1 7:104817678:105045953 COLOC 0.8201 0.9957 
AMD rs140647181 COL8A1 gene COL8A1 NA NA NA 
      gene TBC1D23 COLOC 0.07068 0.03012 
      H3K27ac 3:99927877:99930243 NA NA COLOC 
      psi TBC1D23 5.88E-13 COLOC 3.14E-08 
AMD rs142450006 MMP9 gene MMP9 0.04053 0.3637 NA 
      H3K4me1 20:43711858:43736607 0.07593 COLOC 0.007974 
AMD rs1626340 TGFBR1 gene TGFBR1 3.40E-12 2.55E-05 0.002198 
      H3K27ac 9:101863436:101906508 0.06671 COLOC 0.1084 
      H3K4me1 9:102394208:102401582 0.1536 0.2267 COLOC 
      H3K4me1 9:101924908:101933600 0.5274 COLOC 0.01866 
AMD rs201459901 C20orf85 gene C20orf85 NA NA NA 
      H3K27ac 20:55937467:55942133 COLOC 0.354 0.7897 
AMD rs3138141 RDH5 gene RDH5 COLOC 0.0126 COLOC 
    CD63 gene CD63 0.003242 0.7507 0.2168 
      gene RP11-644F5.10 COLOC COLOC COLOC 
      psi unknown_5611300 NA COLOC NA 
      psi unknown_5611300 NA COLOC NA 
AMD rs5817082 CETP gene CETP COLOC 0.003206 0.266 
      H3K27ac 16:56996497:57122386 COLOC 4.39E-15 1.60E-09 
      H3K4me1 16:56989796:57234898 COLOC 2.88E-06 0.07802 
AMD rs61985136 RAD51B gene RAD51B 0.2299 0.004451 0.9687 
      H3K27ac 14:68744958:68766276 0.6537 COLOC COLOC 
      H3K27ac 14:68807602:68809821 COLOC NA 0.5042 
      H3K4me1 14:68786646:68813506 COLOC 0.3942 0.307 
      H3K4me1 14:68705681:68768652 0.07207 COLOC 0.6581 
AMD rs62247658 
ADAMTS9-
AS2 gene ADAMTS9-AS2 NA NA NA 
      H3K27ac 3:64800574:64803236 NA COLOC NA 
      H3K4me1 3:64807275:64815846 COLOC 1.39E-12 0.01343 
AMD rs6565597 NPLOC4 gene NPLOC4 2.60E-07 1.66E-08 4.21E-10 
    TSPAN10 gene TSPAN10 NA NA 1.86E-07 
      H3K27ac 17:79578768:79583302 0.01192 0.1444 COLOC 
      H3K27ac 17:79585940:79590489 COLOC COLOC 0.3615 
      H3K4me1 17:79594768:79608902 COLOC 0.3306 COLOC 
      psi NPLOC4 COLOC NA COLOC 
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AMD rs67538026 CNN2 gene CNN2 COLOC 5.11E-11 3.75E-10 
      gene ABCA7 2.12E-14 1.17E-14 COLOC 
      gene CTB-31O20.2 0.6581 COLOC 0.6218 
      H3K27ac 19:1024681:1033920 COLOC 0.3879 COLOC 
AMD rs72802342 CTRB2 gene CTRB2 NA NA NA 
    CTRB1 gene CTRB1 NA NA NA 
      H3K27ac 16:75298651:75302321 NA COLOC 0.1213 
      H3K4me1 16:75230954:75238400 0.8262 COLOC 9.42E-13 
      H3K4me1 16:75294112:75310094 COLOC 6.33E-18 0.5055 
AMD rs7803454 PILRB gene PILRB COLOC 2.27E-27 COLOC 
    PILRA gene PILRA 0.06639 0.6898 COLOC 
      gene AC005071.2 0.4077 COLOC NA 
      gene RP11-758P17.2 0.1541 0.004381 COLOC 
      gene ZCWPW1 0.07687 0.06617 COLOC 
      gene MEPCE COLOC COLOC COLOC 
      gene STAG3 COLOC COLOC 2.57E-07 
      H3K4me1 7:99906073:99912427 COLOC COLOC NA 
      psi unknown_9993580 COLOC COLOC COLOC 
      psi PILRB 1.36E-09 3.44E-06 COLOC 
      psi PILRB COLOC COLOC NA 
AMD rs79037040 TNFRSF10A gene TNFRSF10A COLOC 7.28E-19 1.60E-24 
      gene RP11-1149O23.3 COLOC NA 0.4856 
      gene CHMP7 COLOC 2.58E-23 0.0002873 
      H3K27ac 8:23048166:23092260 COLOC 4.48E-23 0.005492 
      H3K4me1 8:22998146:23133613 COLOC 1.66E-20 0.6454 
CAD chr2:203828796:I WDR12 gene WDR12 0.3616 0.002469 0.02933 
      gene AC073410.1 0.9984 NA COLOC 
      gene NBEAL1 COLOC 0.006781 0.0001839 
      gene ALS2CR8 COLOC 0.2959 1.84E-06 
      gene ICA1L COLOC NA 4.46E-18 
      H3K27ac 2:204364327:204367436 5.41E-06 COLOC 0.5396 
      H3K4me1 2:204391511:204403180 COLOC 0.5698 0.7331 
CAD rs11065979 SH2B3 gene SH2B3 0.104 0.0001661 0.1831 
      H3K27ac 12:112386996:112391985 0.986 NA COLOC 
CAD rs11191416 NT5C2 gene NT5C2 0.1322 COLOC 2.76E-20 
    CYP17A1 gene CYP17A1 NA NA NA 
    CNNM2 gene CNNM2 0.02526 0.9728 0.2835 
      gene RP11-332O19.2 0.2602 COLOC 0.06549 
      H3K27ac 10:104811999:104815290 0.3237 0.1027 COLOC 
      psi NT5C2 COLOC NA COLOC 
CAD rs1412444 LIPA gene LIPA COLOC 1.53E-17 COLOC 
      H3K27ac 10:90248309:90252291 0.9914 0.001553 COLOC 
      H3K27ac 10:90993615:91006217 COLOC COLOC 0.7929 
      H3K4me1 10:90987967:91024823 COLOC COLOC 0.0884 
CAD rs17087335 REST  gene REST COLOC 1.32E-07 0.04083 
    NOA1 gene NOA1 0.0001337 1.88E-13 0.0007168 
      H3K27ac 4:57823529:57826313 COLOC COLOC 0.9597 
      H3K4me1 4:57820927:57828891 COLOC COLOC 0.9247 
CAD rs1870634 CXCL12 gene CXCL12 NA NA NA 
      H3K27ac 10:44339141:44344636 COLOC 0.9953 0.9881 
      H3K27ac 10:44499917:44501820 NA COLOC NA 
      H3K27ac 10:44468665:44477554 8.00E-09 9.89E-09 COLOC 
CAD rs2487928 KIAA1462 gene KIAA1462 NA NA NA 
      H3K27ac 10:30314435:30318729 0.1174 0.9031 COLOC 
      H3K4me1 10:30286485:30293313 0.3683 0.3357 COLOC 
CAD rs28451064 KCNE2  gene KCNE2 NA NA NA 
    (gene desert) H3K27ac 21:35594186:35597126 COLOC 0.9563 NA 
      H3K27ac 21:35444064:35452944 4.87E-06 COLOC 0.0001358 
      H3K27ac 21:35389093:35398453 0.8855 0.004742 COLOC 
      H3K4me1 21:35592772:35599590 COLOC 0.05872 0.7575 
CAD rs4468572 ADAMTS7 gene ADAMTS7 NA NA NA 
      H3K27ac 15:79049034:79056595 0.9945 1.98E-14 COLOC 
      H3K4me1 15:79121511:79127959 COLOC COLOC 0.8847 
      H3K4me1 15:79029778:79035218 1.29E-11 3.43E-24 COLOC 
CAD rs56289821 LDLR gene LDLR 0.264 0.1346 0.747 
      H3K4me1 19:11105519:11214483 1.69E-05 COLOC 0.703 
CAD rs6689306 IL6R gene IL6R 0.8348 0.1819 1.67E-05 
      H3K27ac 1:154372031:154419908 0.001644 COLOC 0.0008632 
      H3K4me1 1:154342399:154479953 0.3354 COLOC 0.07064 
      psi IL6R 1.22E-34 6.48E-29 COLOC 
 
M N T Colocalised 
      Significant QTL 
      Non-significant QTL 
      Not tested 
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CAD rs67180937 MIA3 gene MIA3 4.60E-06 1.10E-11 0.00326 
      H3K4me1 1:222943024:222949002 0.2198 0.443 COLOC 
      psi MIA3 NA 0.3278 COLOC 
CAD rs7212798 BCAS3 gene BCAS3 2.03E-09 1.15E-17 0.9953 
      H3K27ac 17:58166053:58170841 0.0001232 2.56E-09 COLOC 
CAD rs7528419 SORT1 gene SORT1 0.9913 0.1588 NA 
      gene PSRC1 COLOC COLOC NA 
      H3K27ac 1:109109862:109115257 0.6716 0.9297 COLOC 
      H3K27ac 1:109812607:109818851 COLOC COLOC 0.7188 
      H3K4me1 1:109779241:109861456 COLOC COLOC 0.1123 
CAD rs7568458 VAMP8 gene VAMP8 0.0008599 0.02193 COLOC 
    GGCX gene GGCX COLOC COLOC COLOC 
    VAMP5 gene VAMP5 0.00644 0.0001995 7.15E-13 
      H3K27ac 2:85760296:85771243 0.5556 COLOC 0.8968 
      H3K4me1 2:85523177:85561159 1.74E-07 COLOC 0.3407 
CAD rs9349379 PHACTR1 gene PHACTR1 0.2713 3.73E-27 0.0001698 
      H3K27ac 6:12961893:12964068 COLOC NA NA 
      H3K4me1 6:12953822:12975623 0.0001088 COLOC 0.07909 
      H3K4me1 6:13023419:13036119 COLOC 0.0006436 0.105 
CAD rs9970807 PPAP2B gene PPAP2B COLOC 0.167 NA 
      H3K27ac 1:56969801:56978117 COLOC 6.49E-18 0.9961 
      H3K27ac 1:56931078:56933449 NA COLOC NA 
FEV1 rs7218675 TSEN54 gene TSEN54 COLOC NA 7.59E-09 
FEV1 rs78420228; CDC123 gene CDC123 0.0003258 2.66E-10 0.1907 
  rs67863175 gene RP11-186N15.3 NA COLOC NA 
      H3K27ac 10:12310277:12315701 COLOC 0.0004045 0.8191 
      H3K4me1 10:12273289:12320006 COLOC COLOC 0.2496 
SLE rs10028805 BANK1 gene BANK1 COLOC NA 0.6 
      H3K27ac 4:102711289:102714021 0.002441 COLOC 0.5958 
      H3K4me1 4:102752891:102758975 0.3542 COLOC 0.6823 
      H3K4me1 4:102739046:102740746 COLOC NA NA 
SLE rs10488631 IRF5 gene IRF5 1.92E-06 1.29E-12 0.5604 
      H3K27ac 7:128720370:128724585 COLOC 5.96E-09 0.9439 
      H3K27ac 7:128733525:128737997 0.182 0.5037 COLOC 
SLE rs10774625 SH2B3 gene SH2B3 0.104 0.0001661 0.1831 
      H3K27ac 12:112386996:112391985 0.986 NA COLOC 
SLE rs11644034 IRF8 gene IRF8 0.01812 NA 0.7138 
      H3K4me1 16:85911735:86006346 COLOC 0.3754 0.0008389 
SLE rs11889341 STAT4 gene STAT4 0.9677 0.4934 0.1968 
      H3K27ac 2:190816300:190818184 COLOC NA NA 
SLE rs12802200 IRF7 gene IRF7 COLOC 0.1174 COLOC 
      gene PHRF1 COLOC 0.08128 0.06116 
      gene LRRC56 COLOC NA 3.88E-16 
      gene C11orf35 COLOC 0.7022 0.003011 
      H3K27ac 11:600961:621989 COLOC COLOC COLOC 
      H3K4me1 11:601613:633623 COLOC 0.4968 COLOC 
      psi IRF7 0.209 COLOC 0.4256 
SLE rs1801274 FCGR2A gene FCGR2A 0.06609 0.0001976 NA 
      psi FCGR3A COLOC 0.444 NA 
      psi FCGR2A NA COLOC NA 
SLE rs2304256 TYK2 gene TYK2 9.48E-07 COLOC COLOC 
SLE rs2663052 WDFY4 gene WDFY4 5.47E-23 1.78E-23 0.08037 
      H3K27ac 10:49965615:49980674 0.4339 0.02857 COLOC 
SLE rs2732549 CD44 gene CD44 0.2831 0.00392 4.94E-07 
      H3K27ac 11:35087097:35089761 0.713 NA COLOC 
SLE rs2736340 BLK gene BLK 0.1084 NA COLOC 
      H3K27ac 8:11348864:11353299 0.0282 0.6601 COLOC 
      H3K4me1 8:11345910:11367069 5.45E-06 0.982 COLOC 
      H3K4me1 8:11336396:11344630 COLOC 0.9725 0.003204 
SLE rs34572943 ITGAM gene ITGAM 8.26E-05 COLOC 0.2477 
      gene C16orf58 COLOC 0.2932 0.1895 
      gene RP11-388M20.2 NA COLOC NA 
      gene RP11-347C12.10 0.1404 COLOC NA 
      H3K4me1 16:31355247:31421179 0.7632 9.40E-10 COLOC 
SLE rs7444 UBE2L3 gene UBE2L3 COLOC COLOC 0.909 
      H3K27ac 22:21938482:21985305 0.05233 COLOC 0.1385 
      H3K4me1 22:21917050:22033004 COLOC COLOC 0.2029 
      H3K4me1 22:22399916:22404237 NA 0.5305 COLOC 
 
Figure 2.8 Disease loci colocalised with multiple molecular features  
Summary of 54 disease loci colocalised with at least one feature. Where multiple features of the same 
type colocalised, the most significant feature per cell type is given. For each locus, the status of the 
previously reported locus is given. The most significant SNP per locus as denoted by the study is 
given. Colocalisation is the dark colour, non-colocalised significant QTLs, lighter colour, non-significant 
QTL by light grey and not tested, dark grey. The FEV1 KANSL1 inversion locus is excluded. 
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2.3.4 Therapeutic utility of colocalised gene targets 
I have discussed how genetic studies of human cohorts provide the design of a randomised 
clinical trial without complications of intervention or reverse causation as genotype is 
randomly determined at birth (Finan et al., 2017). However, case-control GWAS are still 
limited in the identification of the exact mechanistic targets. Here, I have leveraged the 
advantage of GWAS data to identify risk-associated regions together with molecular traits to 
precisely detect potential putative target genes. I next evaluated whether any of the genes I 
identified through expression or splicing effects for all colocalised loci (excluding the KANSL1 
inversion locus) were known drug targets for the disease of interest or with other disorders 
highlighting the potential for drug repurposing (Finan et al., 2017). I collated information from 
both DrugBank (DrugBank, 2017) and the Open Targets (Open Targets, 2017) platform and 
identified 11 genes, which are targets for compounds or drugs that are currently under 
investigation, approved or experimental (Table 2.3) (Law et al., 2014, Koscielny et al., 2017). 
These included three CAD risk genes; IL6R, GGCX, NT5C2, three AMD risk genes; RDH5, 
TNFRSF10A, CETP, SRPK2 and four SLE risk genes; BLK, TYK and the closely related and 
located FCGR3A/FCGR2A (Table 2.3). 
 
I also queried my colocalised genes with a recently updated curation of the “druggable 
genome” resource from the Finan et al. (2017) study. This resource is composed of three 
tiers of genes predicted to encode druggable proteins including recent first-in-class drugs, 
biotherapeutics, drugs in late-phase development at the time of publication, preclinical small 
molecules with potential to bind proteins as reported in ChEMBL, secreted or plasma 
membrane-bound proteins that represent ideal targets for monoclonal antibodies and 
proteins that have greater than 50% identity with approved drug targets (Finan et al., 2017). 
Using this resource, I identified a further six druggable genes including the AMD ABCA7 
(small molecular or biotherapeutic), CAD LIPA (small molecule), CAD VAMP8 
(biotherapeutic), AMD SRPK2 (small molecule), SLE ITGAM (biotherapeutic) and AD CR1 
(biotherapeutic).  
 
In total, there was evidence of potential therapeutic utility for 17 genes identified in my 
analysis. In conclusion, such colocalisation approaches using molecular QTLs provides an 
additional layer of genetic and functional evidence for the selection of pre-clinical drug 
targets while also highlighting potentially affected cell types for further testing (Glinos et al., 
2017, Okada et al., 2014). 
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Gene/Target Disease Drug Target Mechanism Status Treated Disease 
Accession 
/ChEMBL 
 
NT5C2- Cytosolic purine 5’-
nucleotidase (HGNC 
Acc:8022) 
CAD 
ATP, small molecule. Unknown - Nutraceutical DB00171 
Ribavirin, small molecule, guanosine 
nucleoside interferes with synthesis of 
viral mRNA, 
Inducer A Hepatitis C, viral haemorrhagic fevers DB00811 
 
IL6R- Interleukin-6 receptor 
subunit alpha (HGNC 
Acc:6019) 
CAD 
Tocilizumab, antagonist, inhibits IL6R 
alpha subunit Antibody A 
RA, SJIA, schizophrenia, 
temporal arteritis, AML, 
HIV, immune system 
disease 
DB06273 
Sarilumab, antagonist, inhibits IL6R alpha 
subunit Antibody PIV 
RA, ankylosing 
spondylitis, uveitis, 
immune system disease 
DB11767 
SA237, antagonist, IL6Ralpha/GP130 Antibody PIII Neuromyelitis optica, CHEMBL3833307 
 
GGCX- Vitamin K dependent 
gamma-carboxylase (HGNC 
Acc:4247) 
CAD 
Phylloquinone/Vitamin K1 small molecule Inducer A Haemorrhagic conditions DB01022 
Anisindione, small molecule 
anticoagulant Inhibitor A 
Venous thrombosis, 
embolism DB01125 
Menadione/Vitamin K3, small molecule Cofactor A Nutraceutical DB00170 
Coagulation factor VIIa Recombination 
human promoting hemostasis Unknown A 
Haemorrhagic 
complications DB00036 
Drotrecogin alfa, recombinant activated 
human protein C Unknown A, I, W Sepsis (withdrawn) DB00055 
Coagulation Factor IX (Recombinant) Unknown A Factor IX deficiency DB00100 
Glutamic Acid Unknown A Nutraceutical DB00142 
Coagulation Factor IX Human, serine 
protease Unknown A Factor IX deficiency DB13152 
 
TYK2- Non-receptor tyrosine-
protein kinase (HGNC 
Acc:12440) SLE 
Tofacitinib, small molecule antagonist, 
inhibits janus kinases Inhibitor A, I 
RA, immune system 
disease, UC, psoriasis, 
CD, 
DB08895 
2-(1,1-DIMETHYLETHYL)9-FLUORO-
3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-
F]ISOQUINOLIN-7-ONE, small molecule 
Unknown E - DB04716 
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Cerdulatinib, small molecule antagonist, 
tyrosine kinase inhibitor Inhibitor PI 
Non-hodgkins lymphoma, 
chronic lymphocytic 
leukemia 
CHEMBL3545284 
Peficitinib, small molecule antagonist, 
tyrosine kinase inhibitor Inhibitor PIII 
RA, psoriasis, liver 
disease CHEMBL3137308 
 
FCGR3A- Fc fragment of IgG, 
low affinity IIIa, 
receptor/CD16a (HGNC 
Acc:3619) 
 
FCGR2A- Fc fragment of IgG, 
low affinity IIa, receptor/CD32 
(HGNC Acc:3616) 
SLE 
Cetuximab, antibody binds EGFr, HER1, 
c-ErbB-1 and competitively inhibits 
binding of EGF 
Unknown A 
EGFR-expressing 
metastatic colorectal 
carcinoma 
DB00002 
Etanercept, protein binds to TNF Unknown A, I RA, psoriasis DB00005 
Immune Globulin Human, antibody mix 
binds and kills bacteria and viral particles Antagonist A, I Immunodeficiencies DB00028 
Adalimumab, human monoclonal binds 
and blocks TNF-alpha reducing 
inflammation 
Unknown A RA, CD, psoriatic arthritis, ankylosing spondylitis DB00051 
Abciximab, antibody binds to glycoprotein 
IIb/IIIa receptor and inhibits platelet 
aggregation 
Unknown A Coronary intervention DB00054 
Gemtuzumab oxogamicin, antibody binds 
and kills CD33 leukemic cells Unknown A, I, W AML DB00056 
Trastuzumba, antibody binds human 
epidermal GF receptor inhibits 
proliferation of tumour cells 
Unknown A, I HER2 Breast cancer DB00072 
Rituximab, antibody binds CD20 and kills 
B cells Unknown A 
CD20+non-hodgkins 
lymphoma, chronic 
lymphocytic leukaemia, 
RA 
DB00073 
Basiliximab, immunosuppressive binds 
IL-2R alpha Unknown A, I 
Prevent kidney transplant 
rejection DB00074 
Muromonab, binds to and kills CD3+ cells Unknown A, I Prevent organ rejection DB00075 
 
BLK- B lymphoid tyrosine 
kinase (HGNC Acc:1057) 
SLE 
Dasatinib, small molecule antagonist, 
SRC inhibitor Inhibitor 
A 
 
Neoplasm, leukaemia, 
lymphoma CHEMBL1421 
Ilorasertib, small molecule antagonist, 
SRC kinase inhibitor Inhibitor 
PII 
 Neoplasms CHEMBL1980297 
ENMD-981693, small molecule 
antagonist, SRC inhibitor Inhibitor PII 
Pancreatic carcinoma, 
breast cancer CHEMBL52885 
XL-228, small molecular, SRC inhibitor Inhibitor PI Lymphoma, leukemia CHEMBL3545085 
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TNFRSF10A- Tumor necrosis 
factor receptor superfamily, 
member 10a (HGNC 
Acc:11904) 
AMD 
Dulanermin, protein, TNFRSF10A/B 
agonist Agonist PII 
Non-Hodgkins  
lymphoma, lung/colorectal 
carcinoma, 
CHEMBL2107846 
Mapatumumab, TNFRSF10A agonist Agonist PII 
Non-Hodgkins  
lymphoma,myeloma, 
various carcinoma 
CHEMBL2108621 
 
CETP 
Cholesteryl ester transfer 
protein, plasma (HGNC 
Acc:1869) 
AMD 
Evacetrapib, small molecule Inhibitor PIII CVD, lipid, hypercholesterolemia CHEMBL2017179 
Anacetrapib, small molecule Inhibitor PIII CHD, CVD, lipid, hypercholesterolemia CHEMBL1800807 
Dalcetrapib, small molecule Inhibitor PIII Acute coronary syndrome, CHD, CVD CHEMBL313006 
 
SRPK2- SRSF protein kinase 
2 
AMD 
Adenine, small molecule Unknown A Nutraceutical DB00173 
Purvalanol, small molecule Unknown E - DB02733 
Phosphoaminophosphonic acid-
adenylate ester, small molecule inhibits 
ATPase 
Unknown E - DB04395 
 
RDH5- 11-cis retinol 
dehydrogenase (HGNC 
Acc:9940) 
AMD 
NADH, small molecule - - Nutraceutical, possible PD, AD, CVD DB00157 
Vitamin A, small molecule. Unknown A Nutraceutical DB00162 
 
 
 
 
Table 2.3: Colocalised genes that are also known drug targets  
Table summarises colocalised genes from expression and/or splicing effects that are known drug targets using DrugBank version 5.0.9, accessed August 2017 and 
Open Targets Platform, accessed October 2017 (Koscielny et al., 2017). The gene name was used to search the platforms for known targets. The drug, status, 
mechanism of action on target, diseases for which the drug is used, accession number (DrugBank, 2017, Law et al., 2014) or CHEMBL reference (Bento et al., 
2014) are listed. Nutraceutical is a food source that provides health benefit. Drug status is listed as A = approved, W = withdrawn, I = investigational, E = 
experimental or maximum clinical trial either completed, ongoing or terminated (PI/II/III). The diseases for which the drug is currently used or investigated are also 
given or some example diseases where multiple conditions have been investigated. Disease abbreviations: PD = Parkinson’s disease, AD = Alzheimer’s disease, 
CVD = cardiovascular disease, RA = rheumatoid arthritis, SJIA = systemic juvenile idiopathic arthritis, CD = Crohn’s disease. SRC inhibitor = src family kinase 
inhibitor, CD = Corhn’s disease, UC = ulcerative colitis, AML = acute myeloid leukemia.   
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2.3.5 Complex regulatory mechanisms highlighted through integration of 
multiple molecular evidence 
The combination of gene expression, splicing and histone QTLs enables not only a deeper 
description of disease risk mechanisms but is also a valuable tool in understanding how 
genes are regulated under homeostatic conditions. Above I summarised broad themes from 
my analysis, but a definitive description of the regulatory mechanism at each locus requires 
in-depth analysis and integration of multiple data sources. Here, I discuss approaches to 
distinguish likely putative regulatory mechanisms from multiple colocalised phenotypes 
involving complex histone activity, transcription factor binding and non-coding RNA function, 
demonstrating the importance of in-depth investigation at every disease locus.  
 
2.3.5.1 Cell-type specific regulatory activity at the CAD SORT1 locus 
Not all loci colocalised with genes that matched previous predictions. One clear example was 
the CAD SORT1 locus, where I identified colocalisation with monocyte and neutrophil 
PSRC1 gene expression as well as H3K27ac and H3K4me1 signal in these cell types 
(Figure 2.9). SORT1, a gene which encodes the multi-ligand sortilin receptor protein, has 
been previously identified as the liver target gene of the causal SNP, rs12740374 (Musunuru 
et al., 2010). There was also a significant PSRC1 expression effect in human liver, but the 
largest observed effect was with the expression of SORT1 (Musunuru et al., 2010). 
Increased hepatic Sort1 expression in mice was also shown to modulate hepatic very-low 
density lipoprotein (VLDL) secretion resulting in reduced secretion of LDL-C therefore 
lowering LDL levels, which is known to decrease CAD risk (Musunuru et al., 2010). These 
effects were recently reproduced in iPSC-differentiated hepatocyte-like cells (HLCs) from 68 
lines (Warren et al., 2017). Intracellular metabolites were extracted from these HLCs, and it 
was demonstrated that in minor allele-carrying individuals (rs12740374, T), there was a 
significant decrease in lipid metabolites such as triacylglycerol, diacylglycerol and 
aminoadipic acid, which has been associated with CAD (Warren et al., 2017). There is, 
therefore, clear evidence that in liver cells, SORT1 hepatic expression and Sortilin protein 
levels were significantly associated with rs12740374 genotype and that this protein has a 
causal role in lipid regulation conferring protection (minor allele, T) to CAD risk. How sortilin 
exactly modifies lipid phenotypes is not yet clear and will require further experimental 
investigation (Kjolby et al., 2015).  
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Figure 2.9: Regional association plot of the CAD SORT1 locus  
Locus zoom plots show association strength in -log10(p value) for variants that were shared between 
studies testing CAD (grey), monocyte gene expression (blue), monocyte H3K27ac (green) and 
monocyte H3K4me1, (purple). The respective lead SNPs for each feature are highlighted in orange. 
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In my analysis with the BLUEPRINT cohort, I identified that increased PSRC1 expression 
(rs12740374 EA = T, monocyte p value = 4.364 x 10-21, beta = 1.016 SE = 0.108, neutrophil 
p value = 2.572 x 10-10, beta = 0.723, SE = 0.114) corresponds to a decreased risk of CAD 
(rs12740374 EA = T, p value = 4.63 x 10-23, beta = -0.114, SE = 0.011). The predicted causal 
SNP, rs12740374 is located upstream of the PSRC1 gene in the 3’UTR of the CELSR2 gene 
(Figure 2.10). Compared to SORT1, very little is known regarding the function of PSRC1, 
which encodes a proline/serine-rich coiled coil protein 1 (Kjolby et al., 2015). 
 
In monocytes and neutrophils, I identified that SORT1 was expressed, but was not 
significantly associated with an eQTL. Both PSRC1 and SORT1 expression were low in T 
cells and below the threshold for association testing. The locus also colocalised with 
monocyte and neutrophil H3K4me1 and H3K27ac QTLs for peaks located just upstream of 
the PSRC1 gene (Figure 2.10). The difference in modification level between individuals of 
discordant genotype was greater for H3K4me1 than H3K27ac (Figure 2.10) and the 
association more significant in both monocytes and neutrophils (Figure 2.9). Combined with 
the upstream location relative to the gene of these histone modifications, I postulated that 
this region acted as an enhancer for both PSRC1 and SORT1. Genetic disruption of 
H3K4me1 could, in turn, alter downstream PSRC1 gene expression in monocytes and 
neutrophils. 
 
I investigated whether differences in regulatory function may explain the difference in the 
primary gene targets between haematopoietic and hepatic cell types, i.e. why the strongest 
effect was PSRC1 in monocytes and neutrophils but as previously established, SORT1 in 
liver (Musunuru et al., 2010). First, I used ENCODE ChIP-seq data from the hepatocyte cell 
line HepG2 to show that there was equivalent histone signal in the region overlapping 
rs12740374 as well as proximal to the SORT1 promoter compared to both monocytes and 
neutrophils (Figure 2.10). Therefore, differences in enhancer activity seemed not explain the 
observation that PSRC1 was significantly associated with rs12740374 and not SORT1. 
Instead, additional regulatory factors may generate cell-type genetic regulation of gene 
expression.  
 
Binding of the liver-enriched transcription factor (TF), C/EBPa, to the motif containing the 
rs12740374 SNP was previously demonstrated in cultured human hepatocellular carcinoma 
cells (Hep3B) (Musunuru et al., 2010). Further, the major allele of rs12740374, G, disrupts a 
nucleotide of the C/EBP motif, GTTGCTCAAT, where TT and AA are the consensus 
nucleotides (Musunuru et al., 2010). The liver-enriched TF, C/EBPa, bound to the minor 
allele and directly affected SORT1 expression levels in Hep3B cells (Musunuru et al., 2010). 
In addition to regulating many metabolic liver genes, C/EBPa is essential for granulopoiesis, 
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regulating important genes such as the granulocyte-stimulating factor receptor (G-CSFR), 
but its expression decreases as maturation advances (Bardoel et al., 2014, Jakobsen et al., 
2013). I hypothesised that binding of C/EBPa may be divergent between hepatocyte and 
haematopoietic cells as differential TF binding at regulatory regions is important for 
generating cell-type specific gene expression (Hardison and Taylor, 2012, Heinz et al., 
2015). First, I used ChIP-seq data from the Soranzo team of C/EBPa in the monocytic cell 
line, U937 (unpublished data) to investigate regions of binding. I used two repeats of C/EBPa 
U937 ChIP-seq data and demonstrated that there was no equivalent C/EBPa binding directly 
over rs12740374 in U937 cell lines (peaks are represented by blocks as designated by a 
ChIP-seq peak caller) (Figure 2.10).  
 
I further investigated whether different TFs may bind at the rs12740374 locus, instead of 
C/EBPa. C/EBPb is a member of the same basic region leucine zipper-family (bZIP) as 
C/EBPa and as well as playing an important role in regulating chromatin dynamics and 
regrowth in liver, it is known to have an important role in haematopoietic cell differentiation 
and function (Jakobsen et al., 2013, Grontved et al., 2013, Bardoel et al., 2014). C/EBPa and 
C/EBPb also bind to the same motif (Jakobsen et al., 2013). In addition, the TF, PU.1, is a 
crucial factor in promoting lymphomyeloid differentiation and acts as a pioneer factor binding 
to nucleosomes and preceding deposition of H3K4me1 (Heinz et al., 2010). Based on these 
observations, I postulated that this highly functional region could be bound by different 
combinations of lineage-specific master regulators in alternative cell types.  
 
In order to establish whether these factors were bound, I generated C/EBPb and PU.1 
binding data using ChIP-seq in a differentiated HL60 cell line (Materials and Methods). HL60 
is an immortalised cancer cell line established from a patient with acute myeloid leukaemia 
and is thought to resemble the granulocyte precursors, promyelocytes (Birnie, 1988). Using a 
well-established method, I differentiated HL60 to a more mature neutrophil-like stage by 
addition of all trans-retinoic acid (ATRA) or dimethyl sulfoxide (DMSO) (Materials and 
Methods). Using ChIP-seq, I then generated genome-wide binding data for transcription 
factors PU.1 and C/EBPb as well as the histone modifications, H3K27ac and H3K4me1. 
 
Figure 2.11 shows that the neutrophil H3K4me1 modification activity is recapitulated in 
differentiated HL60, confirming that enhancer activity is likely in this region. Further, there are 
strong binding peaks shown for C/EBPb and PU.1 in both differentiated HL60 models. This 
confirms that master haematopoietic regulators are bound in this region in myeloid cells.  
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Figure 2.10: Genomic context of the CAD SORT1 locus 
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Genome browser plot of the rs12740374 CAD locus with H3K4me1 and H3K27ac colocalised features 
shown for HepG2 (liver) cells, primary monocytes and neutrophils. Signal peaks are shown for 
representative individuals from the BLUEPRINT cohort and the x-axis for peaks is given in reads per 
million. The exact location of the predicted causal SNP, rs12740374, is highlighted in a red box which 
shows that the SNP intersects with histone marks as well as C/EBPb and PU.1 in monocytes and 
neutrophils. C/EBPa binding in the monocyte-like cell line, U937, shows no binding in this region, 
suggesting differential TF binding at this cis-regulatory element underpins cell-type specific regulation 
of gene targets. The lower panel shows a zoom in on the region around the SNP upstream of the 
monocyte and neutrophil colocalised eQTL gene, PSRC1. Gene expression, H3K27ac and H3K4me1 
signal is shown stratified by genotype. The signal is shown for the lead SNP for the H3K27ac, in this 
case, rs660240, which is in high LD with rs12740374. The genotype-associated difference in 
H3K4me1 signal is greater than the signal for H3K27ac, suggesting this is predominantly an enhancer 
effect due to changes in H3K4me1 activity. The directions of all features at this locus with respect to 
CAD risk are shown on the right-hand side.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 C/EBPb and PU.1 are bound directly over rs12740374 in differentiated 
HL60 cells  
Zoom in of the genomic region of rs12740374, which is located directly within C/EBPb and PU.1 peaks 
from differentiated HL60 cells. H3K4me1 peaks for monocyte neutrophil and differentiated HL60 are 
shown to confirm that, at this locus, this model cell line recapitulates primary human cells. 
Neighbouring SNPs, rs7528419 (CAD GWAS lead) and rs660240 (certain histone peak lead) are 
located just outside or on the edge of the peak, showing how using TF data can aid in identifying the 
putative causal variant at disease loci.  
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Having demonstrated clear binding signal, I wanted to establish whether rs12740374 disrupts 
the haematopoietic binding of C/EBPb and/or PU.1 as was previously shown for C/EBPa in 
Hep3B cells. In order to assess this, I accessed an unpublished dataset from the Soranzo 
team of C/EBPb and PU.1 binding in primary human neutrophils (22 and 93 individuals 
respectively) and monocytes (nine and ten individuals respectively) (Stephen Watt, 
manuscript in preparation). Figure 2.12 highlights that in C/EBPb and PU.1 are also bound 
directly over rs12740374 in monocytes. The binding of these TFs appeared lower in primary 
neutrophils than in monocytes and the differentiated HL60 model. This was likely due to the 
increased technical difficulties associated with applying these approaches in primary 
neutrophils, as we have observed within our team. This further demonstrates the importance 
of confirming TF binding using the more tractable, differentiated HL60 model.  
 
Despite this lower level of binding, the higher number of individuals discordant at the 
rs12740374 genotype in the primary neutrophil cohort enabled me to investigate whether 
binding was associated with SNP genotype. Figure 2.12 shows primary monocyte and 
neutrophil binding of C/EBPb and PU1 around the PSRC1 locus and also binding of specific 
peaks stratified by the genotype of this SNP. Both C/EBPb and PU.1 peaks directly 
overlapping rs12740374 are significantly associated with genotype as evaluated using linear 
regression (C/EBPb, p value = 7.351 x 10-04, PU.1 p value = 1.584 x 10-06). I confirmed that 
no other immediate surrounding peaks are significantly associated with rs12740374 (Figure 
2.12 and data not shown). This evidence suggested that in neutrophils, the major allele of 
rs12740374 may disrupt binding of PU.1 and C/EBPb as well as H3K4me1 activity, which 
could result in disruption of PSRC1 expression. I also demonstrated that binding of C/EBPb 
and PU.1 occurs over rs12740374 in monocytes by showing representative binding of an 
individual heterozygous for rs12740374 (Figure 2.12). Although there was a limited number 
of individuals for which monocyte data was available, the concordance of the other molecular 
effects between monocytes and neutrophils suggests that C/EBPb and PU.1 binding could 
also be disrupted in monocytes. However, more individuals would be required to fully validate 
this effect.  
 
Interestingly, using publicly available promoter-capture HiC (Schofield et al., 2016, Javierre 
et al., 2016) data, I observed that a significant neutrophil and monocyte chromatin interaction 
fragment links rs12740374 to the promoter of the SORT1 gene (Figure 2.10). Despite this 
physical connection, SORT1 expression is not significantly associated with this SNP in 
monocytes or neutrophils. Therefore, this demonstrates that at some loci, the combination of 
TF bound is an important driving factor over chromatin interactions and enhancer activity in 
generating cell-type specific gene regulatory mechanisms, although further functional 
experiments would be required to fully ascertain this potential hierarchical regulation.  
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Figure 2.12: Transcription factor binding at the CAD SORT1/PSRC1 locus in 
monocytes and neutrophils  
Genomic region of PSRC1 and predicted causal SNP, rs12740374 showing binding of C/EBPb and 
PU.1 in monocytes and neutrophils (upper panel). In the lower panel, boxplots show the binding signal 
in log2RPM of neutrophil TFs at three peaks in the locus stratified by rs12740374 genotype. The p 
value is shown for the association with genotype as calculated using linear regression on standardised 
inverse normalised binding values in log2RPM. The only peaks significantly associated with 
rs12740374 are the C/EBPb and PU.1 that are bound directly over the SNP. The consensus C/EBPb 
motif is also shown with the position of the nucleotide disrupted by rs12740374, where the minor allele 
T creates the binding site and the major allele, G disrupts the binding site.  
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2.3.5.2 In-depth dissection of the molecular mechanisms at the AMD TNFRSF10A 
disease locus 
I identified colocalisation between the TNFRSF10A advanced age-related macular 
degeneration locus and three monocyte eQTLs; TNFRSF10A, RP11-1149O23.3 and 
CHMP7. In addition, this locus colocalised with three histone peaks; H3K27ac 
(8:23048166:23092260), H3K27ac (8.23092704.23132254) and H3K4me1 
(8:22998146:23133613) (Figure 2.14). I discuss here approaches to resolve this complex 
locus and provide paradigms for future efforts to identify mechanisms that influence disease 
risk in a cell type-specific manner. 
 
TNRFSF10A encodes the TRAILR1 receptor that binds the tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) (Diehl et al., 2004). TRAIL can bind four possible 
receptors: TNFRSF10A, TNFRSF10B (TRAIL-R2), TNFRSF10C (TRAIL-R3) and 
TNFRSF10D (TRAIL-R4) (Diehl et al., 2004). TRAIL-R1 and TRAIL-R2 are functional 
proteins that include an intracellular tail containing the death domain (Figure 2.14) (Diehl et 
al., 2004). TRAIL-R3, a GPI-linked protein and TRAIL-R4, a truncated protein that misses the 
death domain in the cytoplasmic tail, are both decoy receptors that do not activate TRAIL-
mediated apoptosis and can antagonise TRAILR1-2 signalling (Diehl et al., 2004, Guicciardi 
and Gores, 2009). Functional TRAILRs activate apoptosis in tumour cells, and were originally 
not thought to induce cell death in non-transformed cells (Diehl et al., 2004, Liguori et al., 
2016). Recently, however, TRAIL susceptibility leading to caspase-8-dependent apoptosis 
was observed in primary mononuclear phagocytes, where the expression of functional 
TNFRSF10A/TRAILR1 was highest compared to the expression on neutrophils and T 
lymphocytes (Liguori et al., 2016). No caspase-8 activation was observed in neutrophils or 
lymphocytes (Liguori et al., 2016). Macrophages may be more resistant to death signals as 
they represent a more activated immune cell than monocytes (Liguori et al., 2016). TRAILR2 
seems to have a more important role in stimulating apoptosis than TRAILR1 (Guicciardi and 
Gores, 2009).  
 
Up-regulation of the TNFRSF10A/TRAILR1 receptor has been shown to be associated with 
anti-inflammatory signals such as stimulation by the cytokine IL-10 (Liguori et al., 2016). In 
TRAIL-/- mice, cytokine production from macrophages and dendritic cells was increased and 
these mice had increased susceptibility to certain immune disorders such as autoimmune 
arthritis and diabetes (Diehl et al., 2004, Falschlehner et al., 2009). In the MS mouse model, 
EAE, blocking TRAIL resulted in increased CNS inflammation (Falschlehner et al., 2009). 
Therefore, in normal immune cells, the TRAIL system seems to exert a regulatory and 
suppressive role in the functioning of the immune response.  
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Figure 2.13: TRAILR1/2 signalling pathways  
The different pathways stimulated by TRAIL binding to TRAILR1/2, which are often both expressed on 
the same cell. TRAILR1/2 do not require internalisation for stimulation of apoptosis in type 1 cells, but 
is essential in hepatocytes, as an example of type 2 cells. In addition to inducing cell death, TRAIL 
promotes activation of pro-survival mediators such as NF-kB and MAP kinases through a distinct 
pathway as shown above left. Activation of NF-kB cannot overcome TRAIL-mediated apoptosis in all 
cell types. Slight differences occur between TRAILR1 and TRAILR2 signalling at the TRAF2 level. 
TRAILR1 instead activates JNK/SAPK (stress-activated protein kinase) via a TRAF2-MKK4 (mitogen-
activated protein/ERK kinase 4)-dependent pathway. Caspases are apoptosis activators. Bid, the 
truncated Bid (tBid) and Bax are all apoptotic proteins. cFLIP is a caspase 8-like inhibitory protein. 
RIP1 is the receptor-interacting protein 1, which is a death domain-containing serine/threonine kinase 
crucial in the balance between death and survival signalling, binds to all death receptors and can 
stimulate either a death cascade or a survival signal, in this case NF-kB activation by RIP1 activates 
survival pathways. TRADD is the TNF receptor-associated protein with death domain and acts as an 
adaptor protein. This figure and associated details described here were adapted from (Guicciardi and 
Gores, 2009). 
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I identified that decreased histone modification signal corresponds to decreased expression 
of both TNFRSF10A and RP11-1149O23.3 genes, which in turn corresponds to an increased 
AMD risk (Table 2.4 and 2.5). Given the evidence that TNFRSF10A functions in monocytes 
to negatively regulate immune responses, a decrease in expression could result in an 
increased inflammatory state that over a prolonged period could add to increased risk of 
AMD.  
 
There were two H3K27ac peaks that colocalised with this disease locus: 
8:23048166:23092260 that directly overlapped the SNP and 8:23092704:23132254, located 
downstream. The peak directly overlapping the SNP was more significantly associated (p 
value = 3.941 x 10-45, beta = -1.200, SE = 0.085, Table 2.5) than the downstream peak (p 
value = 1.647 x 10-09, beta = -0.638, SE = 0.106). Therefore, based on location and strength 
of association, I postulated that the overlapping peak contained a putative regulatory 
element. Indeed, in previous molecular QTL studies, for example with DNase I 
hypersensitive (open chromatin) regions, it has been observed that most significant QTLs lie 
close to the DHS peak and proximal region (target window), specifically 56% of dsQTLs are 
located within the associated DHS and 67% are within a window of 1 kb around the feature 
(Degner et al., 2012). In addition, molecular strength of association is known to decay with 
increasing distance from the SNP (Waszak et al., 2015). I also excluded the colocalisation 
with the eQTL of the CHMP7 gene from further analysis as the p values of association was 
also much less significant than the others (CHMP7 beta = -0.473, SE = 0.099, value = 1.880 
x 10-06, H3K27ac beta = -0.638, SE = 0.1058, p value = 1.647 x 10-09). Figure 2.14 and Table 
2.4 and Table 2.5 summarise the association statistics of the four AMD-colocalised features 
that I investigated further; the two genes TNFRSF10A and RP11-1149O23.3 as well as the 
H3K4me1 peak (8:22998146:23133613) and the single H3K27ac peak 
(8:23048166:23092260). 
 
For all monocyte colocalised molecular features, the lead SNP was rs13255394, a common 
SNP (EAF = 0.575) located just downstream of the TNFRSF10A gene start site (Figure 2.17, 
Table 2.4). I next evaluated whether the lack of colocalisation with either neutrophil or T cell 
features represented a true cell-type specific disease effect, or whether neutrophil or T cells 
effects are missed due to a limitation in power.  
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Figure 2.14 Regional association plots for the TNFRSF10A locus  
Locus zoom plots show association strength in -log10 p value for variants that were shared between 
studies testing AMD (grey), monocyte gene expression (blue), monocyte H3K27ac, 
8:23048166:23092260 (green) and monocyte H3K4me1, 8:22998146:23133613) (purple). The index 
disease SNP defined for the locus by Fritsche et al is rs79037040, but was not tested as part of the 
Blueprint study. The index molecular SNP, rs13255394 is labelled in orange and shown with respect 
to the genomic location, within exon 1 of RP11-1149O23.
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Table 2.4: Summary statistics of lead SNPs with gene expression of TNFRSF10A and RP11-1149O23.3 expression, H3K27ac and 
H3K4me1 modification phenotypes in monocytes, neutrophils and T cells  
Association statistics for the cell-specific lead SNPs for BLUEPRINT traits (Chen et al., 2016a). In bold are highlighted the lead associations in that cell type. 
AMD beta values and standard error estimates can be obtained by application to the IAMDGC consortium. 
  
Trait SNP R2 EA/OA EAF AMD beta AMD P Cell type Beta (SE) P 
TNFRSF10A 
rs13255394 (M 
lead) - C/T 0.575 + 9.92 x 10
-09 
Monocyte -1.047 (0.085) 5.249 x 10-35 
T cell 0.299 (0.110) 6.493 x 10-03 
Neutrophil -0.376 (0.096) 1.356 x 10-04 
rs7820465 (T 
lead) 0.141 A/G 0.23 - 8.64 x 10
-05 
Monocyte 0.585 (0.117) 5.892 x 10-07 
T cell -1.164 (0.108) 3.279 x 10-27 
Neutrophil 0.536 (0.117) 4.999 x 10-06 
rs4872078 (N 
lead) 0.005 T/G 0.47 - 1.950 x 10
-02 
Monocyte 0.132 (0.098) 1.761 x 10-01 
T cell -0.813 (0.094) 4.833 x 10-18 
Neutrophil 0.841 (0.087) 6.145 x 10-22 
RP11-1149O23.3 rs13255394 (M lead) - C/T 0.575 + 9.92 x 10
-09 
Monocyte -1.171 (0.079) 3.477 x 10-50 
T cell -0.295 (0.109) 6.734 x 10-03 
Neutrophil Not tested Not tested 
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Table 2.5: Summary statistics of lead SNPs for H3K27ac with H3K4me1 modification phenotypes in monocytes, neutrophils and T 
cells  
Trait SNP R2 EA/OA EAF AMD beta AMD P Cell type Beta (SE) P 
H3K27ac 
rs13255394 (M 
lead) - C/T 0.575 + 9.92 x 10
-09 
Monocyte -1.200 (0.085) 3.941 x 10-45 
T cell -0.027 (0.120) 8.201 x 10-01 
Neutrophil -0.873 (0.096) 6.868 x 10-20 
rs13255997 (T 
lead) NT G/A 0.510 + 8.540 x 10
-03 
Monocyte -0.261 (0.105) 1.301 x 10-02 
T cell 0.508 (0.111) 4.669 x 10-06 
Neutrophil -0.088 (0.103) 3.944 x 10-01 
rs4872090 (N 
lead) 0.402 A/T 0.763 + 1.240 x 10
-03 
Monocyte -0.877 (0.117) 5.407 x 10-14 
T cell -0.239 (0.130) 6.472 x 10-02 
Neutrophil -1.107 (0.105) 4.599 x 10-26 
H3K4me1 
rs13255394 (M 
lead) - C/T 0.575 + 9.92 x 10
-09 
Monocyte -0.858 (0.097) 8.652 x 10-19 
T cell -0.054 (0.140) 6.984 x 10-01 
Neutrophil -0.603 (0.102) 2.944 x 10-09 
rs8192332 (T 
lead) NT T/C 0.288 + 6.930 x 10
-02 
Monocyte -0.107 (0.125) 3.936 x 10-01 
T cell 0.651 (0.172) 1.592 x 10-04 
Neutrophil -0.064 (0.125) 6.091 x 10-01 
rs4872090 (N 
lead) 0.402 A/T 0.763 + 1.240 x 10
-03 
Monocyte -0.546 (0.119) 3.833 x 10-06 
T cell -0.188 (0.151) 2.142 x 10-01 
Neutrophil -1.083 (0.108) 1.583 x 10-23 
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Figures 2.8 and 2.15 show there was a significant eQTL for TNFRSF10A in both T cells and 
neutrophils, but the lead SNPs associated with these signals are different and did not 
colocalise with AMD at this locus (summarised in Table 2.4). In T cells, the lead SNP was 
rs7820465 (EA = A, EAF = 0.23, beta = -1.164, SE = 0.108, p value = 3.279 x 10-27, number 
of individuals = 169). In neutrophils, the lead TNFRSF10A eQTL was rs4872078 (EA = T, 
EAF = 0.47, beta = 0.841, SE = 0.087, p value = 6.145 x 10-22, number of individuals = 196). 
Neither of these SNPs were significantly associated with AMD (rs7820465 p value = 8.64 x 
10-05, rs4872078 p value = 0.020).  
 
I performed conditional analysis using GCTA and the eQTL summary statistics in each cell 
type (Materials and Methods). I tested for association of remaining SNPs after conditioning 
on the corresponding lead SNP for each cell type (Table 2.4 and Figure 2.15). In order to 
evaluate if any residual significant signals remained, I corrected the p value for the number of 
variants tested in the cis-region using the qvalue R package (Bass JDSwcfAJ, 2015) 
(Materials and Methods). There were no significant associations after conditioning on the 
respective lead SNP in monocytes or neutrophils (qvalue < 5%), which was evidence that 
within the power limitations of the cohort, there was one independent genetic signal in this 
region driven by the respective lead SNPs. In T cells, after conditioning on the lead SNP, 
rs7820465, there remained a marginally significant signal driven by the neutrophil lead SNP, 
rs4872078 (conditional beta = -0.394, conditional SE = 0.098, conditional p value = 5.946 x 
10-05, conditional q value = 0.046). I performed an iterative second stage of conditional 
analysis, using the output summary statistics generated by conditioning on rs7820465. In this 
second stage, I conditioned on rs4872078 and found no significant associations remained. 
None of these cell type lead SNPs were highly correlated; I calculated the LD r2 estimates 
using the UKBB cohort of nearly 175,000 individuals and found an r2 of less than 0.2 for each 
pairwise comparison (Table 2.4). Therefore, the association evidence suggests that 
expression of TNFRSF10A is regulated by varying independent signals across cell types and 
only the monocyte signal colocalised with AMD risk.  
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Figure 2.15: Different genetic signals across cell types at the TNFRSF10A locus 
Regional association plots show the association signals for two colocalised features, TNFRSF10A 
gene expression and H3K27ac signal (8:23048166:23092260) in each cell type. The respective lead 
SNPs are highlighted in orange in each association plot. For the TNFRSF10A gene expression effect, 
there were three lead SNPs with evidence from LD and conditional analysis suggesting these 
represented three independent genetic signals explained by rs13255394 (monocytes), rs7820465 (T 
cells) and rs4872078 (neutrophils and secondary T cells). For the H3K27ac signal effect, evidence of 
variant LD and conditional analysis suggested that there were two genetic signals 
(rs13255394/rs4872090 monocytes and neutrophils) and a marginal signal in T cells (rs13255997). 
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I next investigated the histone modified region, which I postulated, was a regulatory control 
region for this locus. Monocyte H3K27ac signal across all individuals within the cohort 
showed greater correlation with monocyte TNFRSF10A signal than monocyte H3K4me1 
(Figure 2.16, H3K27ac and TNFRSF10A Pearson’s r = 0.567, p value = 1.254 x 10-16, 
H3K4me1 and TNFRSF10A Pearson’s r = 0.177, p value = 0.03). The higher correlation with 
H3K27ac than H3K4me1 could reflect the different roles of these histone marks. H3K4me1 is 
known to demarcate poised enhancers, that may not be active in the current cellular context 
(Creyghton et al., 2010). H3K27ac marks promoters but also active enhancers when 
modified in combination with H3K4me1, and therefore is required for active gene expression 
in specific cellular contexts (Creyghton et al., 2010, Heintzman et al., 2009). Using the 
Blueprint consortium cohort, we also observed a strong positive correlation between per-
allele effect sizes of eQTLs and hQTLs (H3K27ac and H3K4me1) (Chen et al., 2016a). It is 
highly possible that at this locus, genetic disruption of H3K27ac is functionally more directly 
linked to gene expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Correlation of molecular features at the TNFRSF10A locus  
Heatmap shows unsupervised hierarchical clustering based on Pearson correlations between the 
molecular features. The Pearson correlation estimate is plotted between monocyte gene expression 
values or monocyte histone signal across the 158 individuals for which all of the molecular feature 
data was available.   
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In T cells, the H3K27ac signal was both weaker and explained by a different SNP (H3K27ac 
rs13255997, EA = G, EAF= 0.51, beta = 0.508, SE = 0.111, p value = 4.669 x 10-06, Table 
2.5, Figure 2.15) than in monocytes and there were no variants that reached the significant 
threshold for the H3K4me1 peak. There was evidence of regional histone signal in T cells as 
shown by the H3K27ac median log2RPM of 6.333 in T cells and 4.746 in monocytes and 
H3K4me1 median log2RPM of 7.246 in T cells and 7.146 in monocytes. This suggests that 
histone activity is present in both cell types, but the genetic regulatory mechanisms are 
divergent.  
 
In neutrophils, both peaks were strongly associated with the lead neutrophil eQTL, 
rs4872090 (Table 2.5, Figure 2.15). The r2 between the neutrophil histone lead SNP, 
rs4872090 and the monocyte histone lead SNP, rs13255394 was 0.402, and these SNPs are 
in close proximity approximately 2.29 kb apart (Figure 2.17). Conditional analysis using 
GCTA on hQTL summary statistics demonstrated that no significant signal remained after 
conditioning on the respective lead SNPs in either monocytes or neutrophils (qvalue < 5%). 
Interestingly, this was evidence that the histone signals can be explained by the same 
genetic signal in monocytes and neutrophils, despite the observation that the TNFRSF10A 
expression was controlled by independent SNPs across all cell types. Only in monocytes 
was there evidence for coordinated gene expression, histone activity and disease risk, which 
were all regulated by same SNP, rs13255394. Given that there was evidence of histone 
activity in other cell types, similarly, to the CAD PSRC1 locus explained above, this suggests 
that there are additional regulatory features that coordinate in generating cell type-specific 
regulatory mechanisms.  
 
I evaluated whether the additional colocalised gene, RP11-1149O23.3, could represent such 
an additional regulatory mechanism. Figure 2.17 shows that the lead SNP, rs13255394, is 
located within exon 1 of the non-coding RNA gene, RP11-1149O23.3. The p value for 
association with this RNA was more significant (p value=3.477 x 10-50) and the effect size 
larger (beta= -1.171, SE = 0.079) than with TNFRSF10A expression (Table 2.4), suggesting 
this is an important functional effect at this locus. 
 
The lead SNP for this locus identified in the original GWAS discovery (Fritsche et al., 2016) 
was rs79037040 which is also located in exon 1 of RP11-1149O23.3, but closer to the TSS 
of both RP11-1149O23.3 and TNFRSF10A (Figure 2.17). Figure 2.17 shows the raw histone 
signal (in log2RPM) stratified by genotype (bottom panel), which enabled identification of the 
location of disrupted histone activity with a greater resolution (50bp across the genome). It 
was clear that the position of rs79037040 was directly in the centre of the monocyte and 
neutrophil H3K27ac peaks. This SNP is in high LD with rs13255394 (r2 = 0.837, 1000G) 
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suggesting that rs13255394 and rs79037040 likely explain the same genetic signal. 
rs79037040 was filtered from the first phase of BLUEPRINT cohort analysis due to stringent 
quality control thresholds. However, efforts within our group have been undertaken to 
reanalyse this cohort with improved imputation procedures generating a denser SNP panel, 
which included rs79037040. This analysis, referred to as phase 2, was performed by Kousik 
Kundu in the Soranzo team. I confirmed that in the phase 2 association testing, rs79037040 
was now the lead SNP for all of the colocalised molecular features described thus far (Table 
2.6). In addition, the colocalisation method used in this chapter, gwas-pw, calculates the 
posterior probability (PP) of all tested variants being causal for the two colocalised traits. 
Colocalisation with the new phase 2 summary statistics, calculated a PP for rs79037040 of 1 
for TNFRSF10A, RP11-1149O23.3, H3K27ac and H3K4me1 traits. Therefore, all evidence 
supports that rs79037040 is the single causal variant for AMD risk and all monocyte 
molecular features. 
 
 
 
 
 
 
Feature SNP (EA/OA) Beta SE P 
Mono TNFRSF10A rs79037040 (T/G) -1.200 0.079 1.540 x 10-51 
Mono RP11-114O23.3 rs79037040 (T/G) -1.290 0.073 8.497 x 10-70 
Mono H3K27ac 
(8:23048166:23092260) rs79037040 (T/G) -1.291 0.082 7.830 x 10
-56 
Mono H3K4me1 
(8:22998146:23133613) rs79037040 (T/G) -0.9856 0.095 2.057 x 10
-25 
AMD rs79037040 (T/G) 0.109 0.016 4.5 x 10-11 
 
 
 
 
 
Table 2.6: Association summary statistics of the lead SNP from Blueprint phase 2 
genetic analysis  
The AMD disease lead, rs79037040 (later merged into the ID rs13278062) was tested only as part of 
the latest Blueprint genetic analyses (phase 2). Beta, standard error (SE) and p value for association 
are listed here. The effect allele, T is associated with a decrease in gene expression and histone 
signal is also associated with an increase in AMD-risk. The effect allele (T) frequency is 0.556. 
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Figure 2.17: Epigenome characteristics of the TNFRSF10A locus  
Genome browser figure of the genomic region around the TNFRSF10A gene and the proximal 
regulatory RNA, RP11-1149O23.3 located upstream on the opposite strand (top panel). Peaks shown 
were generated from a representative individual from the BLUEPRINT cohort predicted to carry the 
allele associated with the highest signal (Chen et al., 2016a). Locations of the lead QTL variants and 
their genomic locations are shown. The lead monocyte QTLs, rs13255394 (phase 1) and rs79037040 
(phase 2) are located within exon 1 of the RP11-1149O23.3-002/003 transcript. Solid blocks represent 
the colocalised peak, the second H3K27ac and H3K4me1 peaks extend further downstream than is 
shown. The bottom panel shows the raw histone signal, in monocytes and neutrophils, in Log2RPM 
(reads per million) calculated in windows of 50 bp across the genome. The gene expression signal is 
plotted from the raw signal expressed in Log2RPM. Each genotype of the lead monocyte SNP, 
rs13255394 is plotted (red for homozygous reference, TT). The genome browser plot (top panel) was 
generated with custom tracks using the Washu Epigenome browser (Zhou et al., 2011). The raw 
signal plots were generated using Blueprint data by Kousik Kundu (Chen et al., 2016a).   
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Less is known about the function of the non-coding RNA, RP11-114O23.3 compared to the 
TNFRSF10A encoded receptor. However, previously a regulatory relationship between 
RP11-114O23.3 and TNFRSF10A, two genes located on opposite strands, has been 
suggested (Zheng et al., 2016). Using microarrays, it was demonstrated that the expression 
of RP11-114O23.3 (also known as LOC389641) is increased in pancreatic ductal 
adenocarcinoma (PDAC) tissues and correlated with patient prognosis and high expression 
levels reduced overall survival (Zheng et al., 2016). RP11-114O23.3 expression increased 
proliferation and decreased apoptosis of cancer cell lines (Zheng et al., 2016). The authors 
identified a 378bp region that contained a highly conserved sequence directly upstream of 5’ 
end of RP11-114O23.3 that is the reverse complement of the TNFRSF10A promoter. In the 
same study upregulation of TNFRSF10A expression was observed in PDAC patient tissue 
compared to non-tumorous tissues. Crucially, siRNA mediated knock-down of RP11-
114O23.3 in SW1990 cells, significantly decreased TNFRSF10A expression but knock-down 
of TNFRSF10A had no effect on the expression of RP11-114O23.3. This suggests that 
RP11-114O23.3 regulates expression of TNFRSF10A through complementary sequence-
mediated binding.  
 
These analyses were performed either in cancer cell lines or in PDAC patient tissue. It could 
be possible that this relationship is not observed in healthy primary immune cells. In addition, 
to the best of my knowledge, possible genetic regulation of the relationship between these 
genes has not been previously explored. I therefore sought to investigate the relationship 
between RP11-114O23.3 and TNFRSF10A in monocytes, neutrophils and T cells.  
   
First, similar to the high significant correlation observed between the TNFRSF10A and RP11-
114O23.3 expression in PDAC tissues (r2=0.606, p<0.001, N = 106 patients), I also identified 
high correlation between monocyte expression values of the two genes across all 
BLUEPRINT individuals tested for these monocyte features (r= 0.804, p value = 3.962 x 10-
45, Figure 2.18, N = 194). However, in T cells, the correlation between RP11-1149O23.3 and 
TNFRSF10A expression was lower and less significant than that observed with monocytes 
(r= 0.172, p value = 0.025, N = 169) (Figure 2.18). Expression of RP11-1149O23.3 was not 
significantly associated with the lead T cell TNFRSF10A eQTL, when evaluating local FDR 
(Figure 2.18). In neutrophils, RP11-1149O23.3 was not tested due to low expression, where 
the median log2FPKM was 2.672 (N = 196), compared to 5.852 in monocytes and 6.644 in T 
cells. Combined, this is evidence that the relationship between expression of the two genes 
and the genetic regulation of each gene was monocyte specific.  
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Figure 2.18: Genetic control of TNFRSF10A and RP11-1149O23.3 is not shared across 
monocytes, T cells and neutrophils  
Gene expression of the two genes, in log2FPKM, is stratified by genotype of the respective lead 
TNFRSF10A SNPs in each cell type. The beta and p values of association are shown for each case, 
as calculated by the BLUEPRINT study (Chen et al., 2016a). The correlation between the gene 
expression raw signals is shown for each cell type and is strongest in monocytes. Here the phase 2 
lead SNP was used, rs79037040, but similar correlation was observed for the phase 1 lead, 
rs13255394 (data not shown). 
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I next sought to confirm that the observed correlation in healthy cells was consistent with a 
hierarchical regulatory mechanism as demonstrated by previous siRNA experiments where 
knockdown of RP11-114O23.3 in cancer cells affected TNFRSF10A expression and not vice 
versa (Zheng et al., 2016). To test this, I implemented a linear regression approach to model 
the gene expression of each gene using expression of the alternative gene as a covariate in 
the model. In this conditional approach, variation due to one gene was removed by correcting 
for expression of all individuals in the BLUEPRINT cohort (Materials and Methods). Following 
this, I tested for association of any variation in expression remaining in the residuals with 
rs79037040 genotype. I performed the analysis using only the phase 2 lead SNP, given the 
evidence that rs79037040 was the single causal SNP for all monocyte molecular feature 
associations.  
 
I first tested the univariate associations with rs79037040 for both genes using the lm() R 
function and confirmed significant associations observed in the QTL testing method from the 
BLUEPRINT study (Table 2.7) (Chen et al., 2016a). I applied the two-stage models (above 
and Materials and Methods) to test if the significant association with the casual SNP remains 
after removing any variation in TNFRSF10A expression that is due to variation in RP11-
1149O23.3 expression levels. I identified the strength of the rs79037040 association with 
TNFRSF10A gene expression decreased and was no longer significant after removing the 
RNA effect. The p value increased from 2.334 x 10-40 to 0.076 (non-significant) and the effect 
size (beta) decreased by 10-fold (Table 2.7). This demonstrated that RP11-1149O23.3 
contributes a high degree to variation in TNFRSF10A expression. I also applied the reverse 
model: RP11-1149023.3 ~ TNFRSF10A expression followed by testing the residuals for 
association with rs79037040. The results demonstrated that the p value increased from 
8.349 x 10-66 to 1.124 x 10-08, remaining significant and beta decreased only by 3.5 times. 
This reduction suggested that there may also be a smaller effect of TNFRSF10A expression 
on that of RP11-1149023.3, but the dominant effect is regulation of RP11-1149023.3 on 
TNFRSF10A expression. 
 
I extended the causality analysis of the different monocyte features to assess whether this 
approach may indicate that H3K27ac regulation also exerted an effect on gene expression. I 
applied the following model: TNFRSF10A gene expression ~ RP11-1149O23.3 expression + 
H3K27ac signal and then tested the residuals for association with rs79037040 (Table 2.6). I 
used R2 estimates, adjusted for the number of covariates in the model, to evaluate whether 
the model fit improves with the addition of the histone modification effect. The adjusted R2 
slightly increased when adding H3K27ac signal as a covariate, from 0.643 to 0.669, and a 
significant difference was confirmed using the ANOVA significance test for nested models (p 
value = 2.883 x 10-04, N = 158). Additionally, the inclusion of the colocalised H3K4me1 peak 
 106 
(8:22998146:23133613) as a covariate in the model, decreased the R2 estimate to 0.667 and 
was not significant when compared to the TNFRSF10A ~ RP11-1149O23.3 + H3K27ac 
model (p value = 0.812, N = 158).  
 
All together, these results suggested that both the RNA and H3K27ac influence gene 
expression of TNFRSF10A, but H3K4me1 has limited effect and that RP11-1149O23.3 
contributes a high degree to the variation in TNFRSF10A expression.  
 
 
 
 
 
 
 
 
Table 2.7: Conditional causality analysis in the TNFRSF10A locus  
Association results (beta, SE, and p value) from a simple linear regression model using non-
transformed phenotype values (as this demonstrated good model fit and normally distributed 
residuals). Similar trends were also observed for inverse normalised phenotype values. The univariate 
approach tests for association of the respective gene expression with the genotype of rs79037040 
(lead monocyte SNP from Blueprint release 2 and lead AMD SNP). Conditional analysis then tests for 
association of the gene with genotype whilst conditioning on the expression of the alternative gene. 
The increase in p value and decrease in significance is greatest when testing for association between 
the SNP and TNFRSF10A expression whilst conditioning on RP11-114O23.3 expression, which 
suggests the RNA may be causal for variation in expression of TNFRSF10A. The further approach 
conditions on the gene expression and H3K27ac signal and then tests the resulting residuals for 
association with the SNP genotypes. For all models, data from 158 individuals was used.  
 
 
Feature SNP (EA/OA) (EAF) Beta SE 
TNFRSF10A 
(rs79037040) 
Univariate -0.303 (0.017) 2.334 x 10
-40 
Conditional 
(RP11-114O23.3 expression) 
-0.031 
(0.017) 0.076 
Conditional 
(RP11-114O23.3 expression + 
H3K27ac signal) 
-0.025 
(0.017) 0.140 
RP11-114O23.3 
(rs79037040) 
Univariate -1.001 (0.034) 8.349 x 10
-66 
Conditional (TNFRSF10A expression) -0.283 (0.047) 1.124 x 10
-08 
Conditional 
(TNFRSF10A expression + H3K27ac 
signal) 
-0.264 
(0.047) 6.235 x 10
-08 
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2.4 Discussion 
In this chapter, I applied enrichment and colocalisation methods to evaluate the utility of 
immune molecular phenotypes, specifically of monocytes, neutrophils and naïve CD4 T cells, 
to dissect mechanisms of disease risk for a variety of disorders. I demonstrated that a high 
number, 46%, of tested disease loci colocalised with at least one molecular feature in at least 
one cell type and highlighted many important gene targets, some of which already have 
therapeutic utility (Table 2.3). Following this, I performed an in-depth analysis of two example 
disease loci, CAD SORT1 and AMD TNFRSF10A and demonstrated how the integration of 
multiple data sources is required to generate plausible mechanistic hypotheses.  
 
I identified significant enrichment of GWAS variants in regions of the genome known to be 
associated with immune molecular traits, particularly of monocyte and neutrophil eQTLs in all 
of the range of five diseases I studied. The relative absence of strong cell-type specific 
patterns for most diseases was consistent with previous observations using similar analytical 
approaches for the same molecular data but with a wider range of classical autoimmune 
diseases (Chen et al., 2016a). Here, for disease loci associated with coeliac disease, 
Crohn’s disease, inflammatory bowel disease, ulcerative colitis, multiple sclerosis, 
rheumatoid arthritis or Type 1 diabetes, colocalisation of 54% with eQTLs, 55% with splicing 
QTLs, 62% with H3K27ac and 54% with H3K4me1 QTLs was observed (Chen et al., 2016a). 
However, this analysis included the MHC region for all diseases, which may affect the 
estimates given the complex genetic architecture of this region. Comparison of colocalisation 
estimates with other studies and/or diseases is challenging, given the different methods 
available and approaches to evaluate colocalised loci. Using iPSC-differentiated 
unstimulated and stimulated macrophages, the highest number of colocalised eQTLs or 
chromatin accessibility (ca)QTLs were observed with inflammatory bowel disease variants 
(11 and five loci respectively) (Alasoo et al., 2017). The recent G. TEx eQTL analysis 
identified a similar percentage to my study; 52% of trait-associated variants colocalised with 
an eQTL in one or more tissues (G. TEx Consortium, 2017). 
 
Many of the colocalised genes identified had well-established or suggested roles in immune 
function. This is in agreement with increasing insight into the pathogenic involvement of 
inflammation in wider range of disorders and with the early promise of therapeutically 
targeting these pathways (Section 2.1). Based on these observations, I concluded that 
functional insight can be gleaned from using peripheral immune cell types in these diseases, 
which were traditionally not considered prototypic immune-mediated diseases. I also 
provided support for the importance of lipid-pathway genes such as the CAD loci colocalised 
with LIPA and the AMD locus colocalised with CETP. Through the identification of well-
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known examples such as these I confirmed the validity of my analytical approach as well as 
providing further mechanistic evidence for disease loci.  
 
This study is not the first to integrate GWAS loci with molecular features, certainly for 
autoimmune diseases, this is fairly widespread and as discussed in Section 2.1 has 
generated important insight (Farh et al., 2015, Chun et al., 2017). Using peripheral whole 
blood as a tissue source enabled QTL identification in large cohorts of healthy individuals, 
such as a study from 2013 of 5,311 individuals with replication in 2775 individuals (Westra et 
al., 2013). These data have been used to dissect gene expression consequences of trait-
associated loci with for example inflammatory bowel disease and lung function (FEV1) (Wain 
et al., 2015, Huang et al., 2017b). In comparison, an advantage of cohorts such as 
BLUEPRINT is in facilitating identification of the specific cell-type source of the genetic effect. 
In addition, BLUEPRINT enables the study of neutrophil effects, which are historically 
understudied despite that the important role in inflammation, immune cross-talk and certain 
disease aetiology. I highlighted one particular SLE locus, UBE2L3, where the strongest 
colocalised eQTL was from neutrophils compared to previous observations of correlation of 
this locus with UBE2L3 expression across monocytes, CD4 T cells, B cells and NK cells at 
this locus in the original GWAS study (Bentham et al., 2015). Definitive confirmation of 
disease-relevant mechanisms requires functional validation, but if clear demarcation of cell 
types is possible for at least a proportion of loci, this is an important preliminary step in 
designing these experiments and selecting experimental cellular models. Blood is an 
experimentally tractable and easily accessible tissue source and function is conserved 
across organisms facilitating the use of animal models (Orkin and Zon, 2008, Vasquez et al., 
2016). Providing colocalisations within blood for diseases where human biosamples for other 
relevant tissues are challenging to obtain, such as brain or ocular tissue, is a clear advantage 
of these findings.  
 
However, using whole blood and purified cell cohorts to fully resolve functional genetic 
mechanisms can be thought of as complementary. For example, the smaller sample sizes of 
cohorts such as BLUEPRINT (N = 200) limits the identification of trans QTLs. These are 
variants that affect molecular features located more than 1Mb away, or even on different 
chromosomes. Highly powered studies are required to detect these effects due to the 
increase in the multiple testing burden when expanding the testing window beyond variants 
in cis. Trans eQTLs were identified and replicated for 103 independent loci using the large 
whole-blood cohort described above (Westra et al., 2013). Complex-trait associated variants 
showed a high number of trans eQTL effects. Interesting insights into CAD variants were 
also gleaned from both cis- and trans-eQTLs identified in another large microarray gene- and 
exon-based QTL dataset of whole blood from 5257 individuals (Joehanes et al., 2017). 
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19,000 independent lead cis-eQTLs were detected compared to just over 6000 trans-eQTLs. 
By overlapping blood eQTLs with CAD SNPs or those in LD r2 ³ 0.8, Joehanes et al. (2017) 
identified genes for 21 of the 58 GWAS loci (Joehanes et al., 2017). Those in agreement with 
the effects identified in this chapter were eQTLs for LIPA, NT5C2, VAMP8 and GGCX, REST 
and also the PSRC1 target at the SORT1 locus. In my study, only the GGCX and NT5C2 
genes showed evidence of either expression or splicing effects across all three of the cell 
types studied here, enabling some assessment of cell-type specificity of the other loci among 
the three subsets studied in BLUEPRINT. Joehanes et al. (2017) identified trans effects at 
some CAD loci. For example, the evidence suggested that the VAMP5-VAMP8-GGCX locus 
(rs7568458) affected the expression of 5 genes in trans; CASP5, DPEP3, CRISPLD2, 
SLC26A8 and PKN2 (Joehanes et al., 2017). The expression of CASP5 has been previously 
shown to be associated with blood pressure, suggesting trait-relevant effects may occur in 
trans (Joehanes et al., 2017). In total, Joehanes et al. (2017) identified more CAD SNPs 
overlapping with gene QTLs than my analysis (21 compared to 8 e/sQTLs here), which could 
be due to the increased study power but could also represent overlaps occurring by chance 
without formal assessment such as those applied in colocalisation methods (Joehanes et al., 
2017). Future studies with larger cohorts and defined cell populations will combine the 
advantages of these two study types and provide the opportunity for identifying further 
regulatory pathways that also influence disease risk. Of course, blood cell types will not be 
the disease-relevant tissue for all loci, which may be the explanation for why I did not detect 
colocalisations for all loci. Part of the future work of this thesis will involve fully integrating 
disease loci with eQTLs from the (G. TEx Consortium, 2015) to evaluate effects across a 
wider range of tissue types.  
 
A further advantage of the BLUEPRINT cohort is that the it enabled concomitant assessment 
of multiple regulatory features rather than being limited to gene expression effects. 
Consideration of the genetic effects on chromatin state enables resolution of regulatory 
mechanisms at disease loci. It has been demonstrated that transcriptional and local 
epigenetic states are highly coordinated and that genetically controlled changes in gene 
expression may occur through disruption of chromatin states (Grubert et al., 2015, Waszak et 
al., 2015). My analysis focused on the histone modifications, H3K27ac and H3K4me1 and 
also RNA splicing effects, which were either independent of or in addition eQTL effects 
depending on the locus. In describing detailed mechanisms, I showed two loci that differed in 
the strongest chromatin effect being either H3K27ac or H3K4me1. These observations 
support the use of multiple sources and types of molecular data in fully investigating 
regulatory function. 
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The SORT1 CAD locus colocalised with PSRC1 eQTL but not a SORT1 QTL effect in these 
haematopoietic cell types. That PSRC1 is regulated (and not SORT1) in blood has been 
observed in independent cohorts (Zeller et al., 2010, Joehanes et al., 2017). However, I 
demonstrated this effect was also present in neutrophils and absent in CD4+ T cells. I further 
provided a potential molecular mechanism underlying the differences between hepatocytes 
and myeloid cells. Principally, this difference seemed to be explained by the binding of 
important haematopoietic TFs, C/EBPb and PU.1, to a C/EBP motif disrupted by 
rs12740374. In liver, C/EBPa was found to be bound at this motif and SORT1 was the 
strongest genetically regulated expression effect (Musunuru et al., 2010). Interestingly, using 
ENCODE data, I found that the liver pioneer factors, FOXA2 and FOXA2, were bound at the 
rs12740374 locus in HepG2 cells (data not shown) (Odom et al., 2006, Iwafuchi-Doi et al., 
2016, Zaret et al., 2008). I postulated that the binding of different pioneer TFs in different 
cells may promote regulation of the expression of alternative genes. The importance of 
pioneer factors in directing cell-type specific binding and expression has previously been 
observed (Heinz et al., 2010, Heinz et al., 2013, Mullen et al., 2011). In this way, SNP-
mediated disruption of a TF motif can result in opposing molecular consequences in different 
cells while the sequence effect remains the same.  
 
The challenge remains of interpreting the role of PSRC1 in blood cells and whether this gene 
is causally related to CAD. Gain-of-function studies in mice and genetic findings in human 
cohorts have both supported an association of the 1p13 minor haplotype (rs12740374 T 
allele) with increased hepatic SORT1 expression and decreased LDL-C and VLDL 
(Musunuru et al., 2010). However, in a mechanism thought to be independent of lipoprotein 
metabolism, SORT1 mediates LDL uptake in macrophages stimulating their differentiation to 
foam cells and therefore promoting atherosclerosis (Mortensen et al., 2014, Westerterp and 
Tall, 2015). It is conceivable, therefore, that the differences in response to LDL between liver 
and myeloid cells manifest in differences in CAD risk. This is supported by the observation of 
Musunuru et al. (2010) that although PSRC1 expression in human liver was significantly 
associated with rs12740374, overexpression of Psrc1 in mouse liver was not associated with 
any significant changes in total cholesterol (Musunuru et al., 2010). In my analysis, increased 
PSRC1 expression was associated with a protective CAD effect. Given little is known 
regarding the function of PSRC1, further work is required to evaluate this effect in 
haematopoietic cells and whether this effect could also be causal to CAD or whether the 
hepatocyte SORT1 effect is the only causal contribution of this locus to disease risk. For 
example, using CRISPR-Cas9 to knock-out this gene in iPSCs and differentiation to 
macrophages followed by stimulation with oxidised LDL to promote foam cell formation could 
highlight whether PSRC1 is involved through regulating this process. These experimental 
approaches are well established (Hale et al., 2015, Reschen et al., 2015). Implementation of 
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Mendelian randomization approaches could also help to ascertain whether the blood PSRC1 
effect of this locus represents a disease causal mechanism or purely pleiotropy.  
 
It would also be interesting to further evaluate the mechanisms through which cell-type 
specific genetic regulation of gene expression is achieved and confirm that the binding of 
PU.1 and C/EBPb is linked to PSRC1 gene expression. This is important for the design of 
novel treatments for understanding the effect of a drug on multiple tissues. Specific siRNA 
knock-down of PU.1, C/EBPb and C/EBPa in haematopoietic and hepatic cell lines, coupled 
with an assessment of the effect on PSRC1 and SORT1 gene expression, would 
demonstrate whether the binding of both factors is required for downstream gene expression 
or whether one TF acts as the putative regulatory factor. These experiments could be 
performed in the cell line models discussed above; differentiated HL60, the monocyte-like 
cell line, U937 and the hepatic cell line, HepG2.  
 
I also investigated a monocyte-specific effect at the AMD TNFRSF10A locus and identified a 
putative regulatory element for the TNFRSF10A and RP11-1149O23.3 genes that 
colocalised with the AMD locus. Although colocalisation was identified between both 
H3K4me1 and H3K27ac peaks, the effect was more significant with H3K27ac (Figure 2.14, 
Figure 2.17). In addition, in a linear model of TNFRSF10A gene expression, inclusion of 
H3K27ac improved the model fit, but not inclusion of H3K4me1. I also demonstrated the 
importance of other regulatory mechanisms at this locus, by identifying the colocalisation of 
an eQTL for RP11-1149O23.3 and further that expression of this non-coding RNA explained 
a significant degree of variation in TNFRSF10A expression. This relationship is a “local trans” 
regulatory mechanism, where a genetic variant affects the expression of one gene, which in 
turn regulates a proximally located, but distinct gene. Clearly genomic regulation in this locus 
involved both an RNA and histone effect, but the exact linear relationship between these 
effects is difficult to ascertain without functional validation. Open chromatin is required for 
active gene expression of most genes in order to enable access of the RNA polymerase II 
machinery to the transcription start site (Venters and Pugh, 2009). It is conceivable that 
RP11-1149O23.3 could either require established open chromatin to be expressed or to bind 
this region or could recruit further chromatin remodellers. Using CRISPR to knock-out the 
RNA and independently the histone region could allow an assessment of the downstream 
effect on TNFRSF10A expression may aid dissection of these relationships. It is thought that 
disruption of chromatin is proceeded by the alteration of transcription factor binding 
(McVicker et al., 2013, Kilpinen et al., 2013). Experiments such as ChIP-seq could also be 
used to identify other bound co-factors. The lead AMD and molecular feature SNP, 
rs79037040, located within exon 1 of RP11-1149O23.3 has also been predicted to disrupt 
the motifs of TFs LXR and NERF1a (Kheradpour and Kellis, 2014). These TFs are both 
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highly expressed in monocytes (>6 and >11 log2FPKM respectively from RNA-seq gene 
expression from (Chen et al., 2016a). Disruption of TFs bound, and histone activity at the 
RNA promoter could lead to changes in RP11-1149O23.3 expression, which further 
propagate to corresponding changes in the expression of TNFRSF10A.  
 
Given that TNFRSF10A is a surface expressed receptor, I postulated that downstream 
alterations in receptor surface expression or function would ultimately impact AMD risk. 
Expression of the TNFRSF10A gene in the AMD-relevant tissue, peripheral retinal pigment 
epithelium/choroid/sclera (PRCS) (FPKM PRCS = 1.91), is low compared to AMD-drug 
target gene, VEGFA (FPKM PRCS = 56.38) (Li et al., 2014), which potentially further 
provides evidence that the disease-relevant effect of this locus could be exerted in 
monocytes. TNFRSF10A (TRAIL-R1), TNFRSF10B (TRAIL-R2) and the decoy receptor 
TNFRSF10D (TRAIL-R4) are all highly expressed on the surface of primary monocytes from 
healthy individuals, with the highest surface expression observed for TNFRSF10B (Deligezer 
and Dalay, 2007, Liguori et al., 2016). The disease SNP is not associated with monocyte 
expression of the other TNF receptors (rs79037040 TRAILR2 p value = 0.976, TRAILR3 p 
value = 0.144, TRAILR4 = 0.504). Interestingly, despite the significant TNFRSF10A eQTLs in 
neutrophils and T cells, this receptor has been shown to be lowly expressed on freshly 
isolated primary neutrophils and T cells (Kamohara et al., 2004, Liguori et al., 2016). Instead 
the decoy protein TNFRSF10C (TRAIL-R3) receptor is highly expressed on the surface of 
neutrophils and to a lesser extent on the surface of lymphocytes (Kamohara et al., 2004, 
Liguori et al., 2016). TNFRSF10C expression was associated with a strong eQTL in 
neutrophils (rs7009522, EA = A, beta = 1.098, p value = 2.519 x 10-23) but was not tested in 
T cells. Therefore, post-transcriptional processes could play an important role in reducing 
surface expression of TNFRSF10A in certain cell types, highlighting the importance of 
integrating multiple sources of functional information to interpret the mechanistic 
consequences at disease loci. Similar experiments to those described in Chapter 4 of this 
thesis, where surface receptor expression was measured using flow cytometry in a recall-by-
genotype design could establish possible differences in surface expression associated with 
genotype.  
 
Lower expression of TNFRSF10A in monocytes corresponded to an increase in AMD risk. It 
has been postulated that recruitment of blood cells such as macrophages to the damaged 
retinal tissue in AMD could contribute to a pathogenic pro-inflammatory environment 
(Nussenblatt and Ferris, 2007). TNFRSF10A is known to be immunosuppressive. The 
evidence presented here suggests that lower TNFRSF10A gene expression could result in a 
reduced inability to downregulate pro-inflammatory responses in monocytes or in 
macrophages if differentiated to monocytes. It would be interesting to study these effects in 
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monocyte-derived macrophages to observe if cells with reduced TNFRSF10A expression 
show a more inflammatory profile.  
 
Not all loci that colocalised with histone features also shared a gene effect, either expression 
or RNA splicing, an observation that was also made in the Chen et al. (2016a) study and in 
other independent cohorts. For example, a study identifying iPSC-differentiated macrophage 
gene expression and chromatin accessibility QTLs (open chromatin using ATAC-seq) also 
found that of the 23 caQTLs that colocalised with a GWAS variant, only two of these also 
colocalised with an eQTL (Alasoo et al., 2017). These regulatory QTLs might impact gene 
expression in different cells, contexts or affect post-transcriptional processes (Alasoo et al., 
2017, Fairfax et al., 2014, Pai et al., 2015).  
 
Colocalisation approaches provide a statistical assessment of regions of the genome that are 
associated with two traits, but there are still some limitations to this approach. First, the 
power of the method to detect true colocalisation when the lead variants of each trait are in 
high LD (r2 ≥ 0.8) is limited and the method assumes one causal variant at each locus. 
Definitive demonstration of causality between traits, specifically whether the shared 
molecular effect is causal to disease risk, is not possible (discussed in detail in Chapter 5). 
 
Further, the colocalisation method does not distinguish between multiple independent 
genetic signals, which have been observed at molecular loci and in some cases colocalised 
with disease variants over or in addition to primary signals (Dobbyn et al., 2017, Ke, 2012). I 
used the pre-defined association signals from the Chen et al. (2016) where multiple 
independent signals were not investigated. Visual inspection of some colocalised loci in this 
analysis suggested the colocalisation may not be between the primary molecular association. 
Supplementary Figure 2.3 shows the colocalisation of the SLE FCGR2A locus with a splicing 
QTL for FCGR3A (CD16) in monocytes and FCGR2A (CD32) in neutrophils. Both genes are 
expressed in neutrophils and monocytes (³ 8 log2FPKM), and both receptors are expressed 
on the surface of each cell type (Stenberg et al., 2013, Cooper et al., 2012, Ziegler-
Heitbrock, 2007, Devaraj et al., 2013). The disease lead SNP and the FCGR3A splicing lead 
QTL are highly correlated (rs6671847, rs4657041 1000G r2=0.89) but the lead splicing SNP 
for FCGR2A is not highly correlated with the disease SNP (rs12129787 1000G r2 < 0.2). To 
assess this, future work will implement conditional analysis to identify independent genetic 
signals.  
 
In conclusion, I demonstrated that applying colocalisation methods to GWAS and molecular 
QTL data can provide detailed mechanistic hypotheses at disease risk loci, which are 
invaluable for facilitating further experimental investigation.  
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Chapter 3  
 
 
 
Expanding genetic studies to cellular 
phenotypes: analytical exploration of 
neutrophil function phenotypes   
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Collaboration Note 
The neutrophil function experiments were performed by Kate Waller, Carly Kempster, Harriet 
McKinney and Joana Batista under the supervision of Kate Downes at the NHS Blood and 
Transplant Unit, Addenbrookes Hospital. The project was also coordinated by Willem 
Ouwehand, Department of Haematology and Nicole Soranzo, Wellcome Trust Sanger 
Institute.  
 
The discovery cohort genotyping data from the Cambridge BioResource was analysed and 
processed by Heather Elding at the Wellcome Trust Sanger Institute. The whole-genome 
sequence data was analysed as part of the BLUEPRINT consortium (Chen et al., 2016a). 
 
Analysis of these data was performed in close partnership and supervised by Klaudia Walter 
(Wellcome Trust Sanger Institute). Klaudia also analysed the genotype data for the Sanquin 
replication cohort and devised the custom scripts to calculate the parameters from the real-
time data. All the other analyses described here otherwise were performed by myself.  
 
Taco Kuijpers and Judy Geissler (Sanquin Research, The Netherlands) coordinated the 
Sanquin replication cohort, which was genotyped at the Wellcome Trust Sanger Institute. 
The replication experiments were performed by Anton Tool at Sanquin Research, The 
Netherlands. Anton and Taco also provided helpful discussions on the details of the 
neutrophil function assays and on the approaches to analyse the Cambridge discovery 
cohort data.  
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3 Expanding genetic studies to cellular phenotypes: 
analytical exploration of neutrophil function phenotypes  
 
3.1 Introduction 
 
3.1.1 Neutrophil Biology and central role in immune responses 
Neutrophils, or polymorphonuclear leukocytes (PMNs), are the most abundant type of white 
blood cell, constituting approximately 40-60% of total white blood cells (Wright et al., 2010). 
Neutrophils are characterised by two distinctive morphologies; the lobulated nucleus and 
presence of protease-containing granules (Kaplan, 2013) (Figure 3.1). The closely related 
eosinophils and basophils, together with neutrophils, form the granulocytic family of 
leukocytes (Amulic et al., 2012). Often the first responders in an immune response, 
neutrophils deploy antimicrobial functions such as phagocytosis to remove pathogens and 
cell debris, degranulation to release granular lytic enzymes and the respiratory burst to 
produce reactive oxygen species (ROS) (Kaplan, 2013, Amulic et al., 2012). In healthy 
homeostatic conditions, the release of mature neutrophils from the bone marrow must be 
highly controlled to prevent inadvertent activation and possible tissue damage. During 
infection when the demand is increased, high numbers of neutrophils are released (Amulic et 
al., 2012).  
 
Neutrophils are technically complex to study being refractory to techniques such as 
transfection and RNA knock-down. In addition, as terminally differentiated cells they cannot 
be grown in tissue culture (Amulic et al., 2012). Many insights have been gleaned from either 
in vitro assessment, cell-line models (as discussed in Chapter 2) or mouse models. There 
are certain differences between murine and human PMNs that can complicate findings. For 
example, there is a lower number of circulating neutrophils in mice compared to humans 
(Amulic et al., 2012). 
 
Neutrophils were traditionally thought of as short-lived cells (6-8 hours), incapable of further 
expansion (terminally-differentiated) and therefore were assumed to play a more passive role 
in responding to activating signals (Wright et al., 2010, Amulic et al., 2012). However, it is 
now known that activated neutrophils possess the ability to perform most regulatory or 
immune-related functions possessed by macrophages, particularly when neutrophils are 
primed and have longer life spans (Wright et al., 2010). When stimulated, neutrophils can 
synthesise pro-inflammatory mediators, present antigen through MHC class II receptors to T 
lymphocytes as well as mediate extensive immune cell cross-talk as summarised in Figure 
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3.1 (Wright et al., 2010). Below, I discuss in detail the neutrophil functional responses 
relevant to this chapter.  
 
Neutrophil activation occurs via two-stages. First, resting circulating neutrophils can be 
“primed” by bacterial compounds and host cytokines and chemokines such as TNF-α, GM-
CSF or IFN-g (Wright et al., 2010). Upon activation, primed neutrophil responses are much 
greater than those of non-primed activated neutrophils (Hallett and Lloyds, 1995). For 
example, the gram-negative bacterial outer cell membrane lipopolysaccharides (LPS) prime 
neutrophils by stimulating the assembly of the NADPH oxidase complex on the membrane. 
Subsequent stimulation by the bacterial chemoattractant N-formylmethionine-leucyl-
phenylalanine (fMLP) then activates the complex (El-Benna et al., 2008). Priming can occur 
over minutes where pre-formed receptors contained within intracellular granules are 
mobilized and transported to the plasma membrane. In some cases, over longer periods of 
transcription further inflammatory molecules can be induced de novo (Wright et al., 2010). 
Full neutrophil activation and mobilisation of all neutrophil killing activities requires integration 
of multiple environmental signals and is the result of a cascade of activating signalling 
processes (Amulic et al., 2012).  
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Figure 3.1: The central role of neutrophils in the immune response  
Neutrophils are one of the first immune cells to respond to infection and possess a variety of anti-
microbial functions. Through cytokine release neutrophils can activate many other cells of the immune 
system leading to a coordinated adaptive immune response as well as innate response. A relatively 
new functionality has been observed in the presentation of antigens through MHC class II molecules 
to elicit T cell activation and proliferation. Some of these functionalities have also been observed to 
become dysregulated in the pathology of autoimmune disorders. Adapted from (Wright et al., 2014). 
 
 
Neutrophil activation requires the recruitment of these cells to inflamed tissues, which is 
achieved through neutrophil recognition of stimulated endothelial cells. Signals derived from 
either bacterial (LPS and fMLP) or host mediators (TNF-α, IL-1β, Il-17) stimulate the 
surrounding endothelial cells to express selectin adhesion molecules and members of the 
integrin super-family, intercellular-adhesion molecules (ICAMs) (Figure 3.3) (Amulic et al., 
2012, Borregaard, 2010).  Tethering of neutrophils to activated endothelial cells is mediated 
through neutrophil surface molecules, P-selectin glycoprotein ligand-1 (PSGL-1) and L-
selectin, which interact with the endothelial-expressed P- and E-selectins (Figure 3.3) 
(McEver and Cummings, 1997, Amulic et al., 2012). Neutrophils then roll along the 
endothelial wall with concomitant activation of signalling kinases including Src family kinases 
(Syk), phosphoinositide 3-kinase (PI3K) and p38 mitogen-activated protein kinase (Mueller et 
al., 2010, Amulic et al., 2012). Firm adhesion and the arrest of rolling occurs through integrin 
contact mediated by the neutrophil-expressed LFA-1 and Mac-1 receptors. Combined with 
activation by cytokines and chemoattractants, sustained interactions generate changes in 
neutrophil morphology and a process known as cell spreading (Figure 3.3) (Sengupta et al., 
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2006). Cytoskeleton rearrangements enable neutrophils to move along chemotactic 
gradients. At this stage, the respiratory burst is initiated (Amulic et al., 2012). Firm adhesion 
allows neutrophils to cross the cell membrane once they reach an endothelial cell junction in 
a process known as transendothelial migration (Figure 3.3). Neutrophil adherence to the 
endothelial surface is referred to as adhesion and is a vital step in recruiting neutrophils to 
the site of inflammation ensuring effector functions are appropriately stimulated reducing the 
risk of spurious tissue damage.  
 
At the site of inflamed tissue, further host and bacterial inflammatory signals activate the later 
stages of neutrophil activation. Chemoattractants signalling through GPCRs, such as the 
fMLP receptor, activate the MAPK/ERK signalling cascade culminating in the assembly of the 
respiratory burst complexes (Zarbock and Ley, 2008, Selvatici et al., 2006). The NADPH 
oxidase complex is a multi-protein complex that catalyses the production of powerful 
oxidising agents known as ROS (Figure 3.4) (Segal et al., 2000). ROS are directly 
antimicrobial but can also modify host molecules and responses and also influence the 
activity of granule proteins (Amulic et al., 2012).  
 
Sustained activation by chemoattractants along a chemical gradient also stimulates 
degranulation, which is the release of antimicrobial contents from the specialised organelles 
known as granules (Table 3.1). Granules are formed throughout the differentiation process, 
and their contents vary based on the changing transcriptional programme during 
development (Amulic et al., 2012). Granules fuse with either the plasma membrane or 
phagosome, releasing the antimicrobial contents and permanently changing the composition 
of those membranes (Amulic et al., 2012). Granule deployment has important functional 
consequences. For example, the specific granules (Table 3.1) contain with flavocytochrome 
b558, which is a component of the NADPH and therefore, the fusion of these granules with 
the phagosomal or plasma membrane promotes the respiratory burst response (Amulic et al., 
2012, Uriarte et al., 2011). Antimicrobial proteins can be categorised into three groups: those 
that bind to microbial membranes, those that possess enzymatic activity and those that 
deprive microbes of nutrients (Amulic et al., 2012). Some examples are given in Table 3.1. 
 
Activated neutrophils can also release extracellular traps (NETs), which are web-like 
structures of granule proteins and decondensed chromatin. NETs enable the neutralisation of 
a wide range of pathogens (Papayannopoulos, 2017, Brinkmann et al., 2004). This particular 
function is not studied in this chapter, but the dysregulation of this process is known to 
contribute to the aetiology of inflammatory disorders (Papayannopoulos, 2017). 
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Table 3.1: Examples of granule proteins, which granule(s) they are contained within 
and the function  
This table describes the four different types of granules and examples of granule protein content. The 
four granules include azurophilic, specific, gelatinase and secretory. The list is not exhaustive and 
there are other proteins contained in neutrophil granules. Exocytosis of neutrophil granules is an 
important process in activation in response to a stimulus and the destruction of phagocytosed 
pathogens. This table was adapted from (Amulic et al., 2012, Wright et al., 2010, Nelson et al., 2008).  
  
Granule protein Granule Type Function 
Myeloperoxidase (MPO) Azurophillic/primary Can react with H2O2 to produce ROS including hypohalous acids 
Lysozyme Azurophillic/primary, Specific (secondary) Degrades bacterial cell wall 
Elastase, Cathepsin G Azurophillic/primary 
Cleaves bacterial virulence factors and outer 
membrane proteins, binds to bacterial 
membranes 
Defensin Azurophillic/primary Arginine-rich cationic peptides, antimicrobial often by disrupting bacterial membranes 
Laminin receptor Specific (secondary), Gelatinase (tertiary) 
Cell surface receptor, important for cell 
adhesion. Binds laminin, an extracellular 
matrix protein 
Bactericidal/permeability-
increasing protein (BPI) Azurophillic/primary 
Binds to LPS and increased bacterial 
permeability and bacterial phospholipid 
hydrolysis 
Azurocidin Azurophillic/primary Binds to bacterial membranes 
Lactoferrin Specific (secondary) 
Binds to and sequesters iron, which is a 
bacterial nutrient and inhibits bacterial growth. 
Binds to lipid A of LPS resulting in a release of 
LPS from the membrane and increased in 
permeability 
Cytochrome b558 
Specific (secondary), 
Gelatinase (tertiary), 
Secretory 
Component of phagocyte NADPH oxidase 
fMLP receptor 
Specific (secondary), 
Gelatinase (tertiary), 
Secretory 
Receptor for bacterial chemoattractant fMLP 
MAC-1 (CD11b/CD18) 
Specific (secondary), 
Gelatinase (tertiary), 
Secretory 
Complement receptor 
Gelatinase Specific (secondary) Gp91phox/p22phox, CD11b, MMP25, arginase-1, b2-microglobulin, CRISP3 
Complement receptor 1 
(CR1) Secretory Complement receptor 
LFA-1 (CD11a/CD18) Secretory Integrin important for adhesion 
Proteinase 3 (PR3) Azurophillic/primary Serine protease 
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3.1.2 Neutrophils and disease 
Fully functional neutrophil responses are important for appropriate immune responses, which 
is clearly shown by the inability to fight infections due to defects in neutrophil activation and 
function in patients with certain primary immunodeficiencies (Bouma et al., 2010, Record et 
al., 2015). Mutations found in chronic granulomatous disease patients result in a non-
functional NADPH oxidase and deficient ROS production (Gennery, 2017, Segal et al., 
2000). As a result, these patients are susceptible to severe infection and autoinflammation 
(Gennery, 2017, Segal et al., 2000, Amulic et al., 2012).  
 
In Chapter 2, I also highlight examples where neutrophil function has been linked to complex 
diseases. Indeed, dysregulated neutrophil function is a key factor in the pathogenesis of 
certain inflammatory diseases, highlighting the importance of regulating neutrophil activity to 
balance effective immune responses while limiting damage to the host (Gupta and Kaplan, 
2016). Apoptosis of activated neutrophils is important in the return to homeostatic conditions 
after an inflammatory response (Wright et al., 2010). Failure of neutrophil apoptosis or 
deficient clearance of neutrophil apoptotic particles can cause chronic inflammation as 
observed for example, in chronic obstructive pulmonary disease (COPD) and rheumatoid 
arthritis (RA) (Amulic et al., 2012, Wright et al., 2010). Neutrophil products, such as MPO and 
PR3 (Table 3.1) are also known targets of autoantibodies, referred to as antineutrophil 
cytoplasmic antibodies (ANCA) and have been detected for example in the systemic 
autoimmune disease, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) (Gupta and Kaplan, 2016). The interaction of ANCAs with antigens on primed 
neutrophils can activate neutrophil effector processes as described above (Kaplan, 2013). 
Observations of the presence of ANCAs, activated neutrophils in the synovial fluid and 
granulocyte-dependent cartilage damage in RA patients also support a role for neutrophil 
dysregulation in this disease (Emery et al., 1988, Mohr and Wessinghage, 1978, Kaplan, 
2013). Indeed, neutrophils from RA patients in remission showed lowered adhesion and 
chemotactic characteristics, suggesting that migration to the synovial fluid may contribute to 
disease severity (Dominical et al., 2011).  
 
Beyond autoimmune diseases, there is a well-known association between inflammation and 
cancer, and neutrophils are present in high numbers in tumours where their infiltration is 
linked a worse prognosis (Jensen et al., 2009, Amulic et al., 2012). I also discussed the 
potential role of neutrophils in Alzheimer’s disease in Chapter 2 and more widely the 
contribution of inflammation to other complex diseases including coronary artery disease and 
age-related macular degeneration.  
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3.1.3 Functional phenotypes  
The observed dysregulation of neutrophil function in multiple immune disorders makes the 
therapeutic targeting of these functions attractive. Understanding the mechanisms of 
neutrophil function and how these processes can lead to host tissues damage is an 
important step in enabling their therapeutic manipulation (Mayadas et al., 2014). Genetic 
studies of these cells afford the opportunity to discover new biological pathways involved in 
function, which could aid the identification of potential intervention targets.  
 
In Chapter 1, I described how this goal is helped by using molecular phenotypes to 
understand disease- and complex trait-associated loci. Such approaches have already been 
successfully applied to neutrophils, as I highlighted in Chapter 2 with the BLUEPRINT 
consortium (Chen et al., 2016a). Another recent study also demonstrated the value of 
studying stimulated neutrophils by assaying neutrophil gene expression measured using a 
microarray (Naranbhai et al., 2015). The authors identified that 30% of 9,147 genes tested 
had at least one significant cis-eQTL (Naranbhai et al., 2015). Interestingly, many of these 
genes were known to function in central processes in neutrophil biology including 
differentiation, trafficking, granule formation, cytokine secretion, respiratory burst, 
phagocytosis and migration (Naranbhai et al., 2015). Some differences were observed with 
stimulated neutrophils, for example, rs1981760 was an eQTL for NOD2 in unstimulated 
neutrophils but regulated the expression of the interferon b gene, IFNB, in neutrophils 
stimulated by the NOD2 ligand muramyl dipeptide (Naranbhai et al., 2015). Interferon b is 
involved in response to NOD2 activation, showing rs1981760 acts at multiple stages of the 
NOD2 pathway in resting and activated cells. The variant is associated with the risk of the 
bacterial disease, leprosy (EA = T) but is protective for Crohn’s disease (Naranbhai et al., 
2015).  
 
In efforts to gain further insight into immunology and its genetic control, there has been a 
recent expansion in the type of phenotypes studied using genetic approaches. For example, 
measuring the immune cell production of cytokines in the blood, which has been shown to be 
highly heritable (Brodin et al., 2015). Indeed, studying protein-level intermediates provides a 
comprehensive picture of functional variation, particularly as the previous integration of eQTL 
and protein (p)QTLs showed that some gene effects are buffered at the protein level (Battle 
et al., 2015). In Chapter 1, I discussed some examples of genetic studies using cellular 
phenotypes. 
 
Measuring functional phenotypes in stimulated conditions is particularly important for 
studying immune function. The observed variation in cytokine responses was higher when 
blood cells were stimulated by a range of physiological stimuli than when compared to the 
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resting state (Li et al., 2016a). Combining loci associated with protein-level and molecular 
phenotypes allows identification of more of the functional steps involved in the pathway from 
sequence variation to organismal traits. For example, rs11141235 was associated with IL6 
levels after Candida stimulation and through using gene expression data acquired in PBMCs 
similarly stimulated, the locus was associated with expression of the gene, GOLM1, 
encoding the Golgi membrane protein 1 (Li et al., 2016a). Using a patient cohort, the authors 
further demonstrated that the GOLM1 locus was associated with candidemia, suggesting 
susceptibility is the result of genetically modulated GOLM1 gene expression and altered IL6 
cytokine production (Li et al., 2016a). This genetic approach, therefore, highlights potential 
novel genes involved in cytokine responses and infection susceptibility. 
 
Cohorts of functional data, therefore, have demonstrated that it is possible to study natural 
variation in a wide range of intermediate traits. These allow the identification of variants 
independently of their effects (or lack of effects) on molecular phenotypes, but also provide 
additional datasets with which to further annotate variants and move closer to the full 
description of regulation from variant to disease. As yet, there have been no large-scale 
efforts aimed at studying neutrophil functional phenotypes, due in large part to the technical 
complexities associated with working with these cells. However, given the central role of 
these cells in the immune response, such an approach could be highly impactful in informing 
our knowledge of neutrophil function.  
 
3.1.4 Aims of this chapter: Investigating neutrophil functional responses   
In this chapter, I aimed to build on recent efforts to reproducibly measure immune functions 
and subsequently identify genetic variants associated with functional readouts in healthy 
individuals. Rather than using a heterogeneous mix of blood cell types, we aimed to 
specifically study neutrophil responses, given the importance of these cells and their limited 
inclusion in genetic studies to date. Further, in generating a complementary neutrophil 
functional genetic dataset to the already established BLUEPRINT epigenome, we hoped to 
provide additional information for annotating genetic loci of immune and disease interest 
(Chen et al., 2016a).  
 
I focused on three neutrophil functional responses that represented key stages in activation 
of these cells; adhesion, degranulation and respiratory burst (Figures 3.3-3.5). I summarise 
the study design in Figure 3.2 below. Experimental measurement of these responses was 
carried out by our collaborators Kate Downes and team at the NHS Blood and Transplant 
Department. Here, I implemented the analytical exploration of what represented the first 
application of these traits to larger healthy cohorts, having previously been used to study 
neutrophils from patients with rare disorders (Anton Tool and Taco Kuijpers, Sanquin 
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Research, the Netherlands). First, I selected parameters representing biologically meaningful 
estimates of functional response across the whole cohort. Next, I investigated the technical 
reproducibility of these assays and the effect of known covariates. I then explored possible 
biological relationships between these functional phenotypes and last assessed whether any 
observed variation in the responses can be explained by identified genetic variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Neutrophil function study design  
Approximately 200 healthy blood donors were recruited and primary neutrophils were isolated to a 
high purity (Materials and methods). Three assays were then performed per donor with a range of 
stimuli to activate neutrophils. DNA was extracted and either processed by whole genome sequencing 
(part of BLUEPRINT) or genotyped as part of a larger Cambridge BioResource cohort. 
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3.2 Materials and Methods  
3.2.1 Neutrophil function data collection and experimental assays 
Neutrophil adhesion, degranulation and respiratory burst were experimentally measured by 
our collaborators at the NHSBT at Addenbrooke’s hospital (Kate Downes and Team). Here, I 
discuss the technical details of these assays as they are relevant to my quality control 
analysis and data exploration. To briefly summarise, for each assay fluorescence emitted 
from different fluorophores was measured for each individual using a plate-reader (Tecan, 
Infinite F200 PRO), and this represented the strength of neutrophil response. 
 
Sample collection and cell isolation: All sample collection and neutrophil purification was 
performed at the NHSBT and details of this process are detailed in (Chen et al., 2016a). 
Briefly, neutrophils were purified from whole blood using a series of Percoll gradients. The 
resulting cells (neutrophils and eosinophils) were washed, and neutrophils were positively 
selected using CD16 microbeads (Miltenyi) according to the manufacturer’s instructions. An 
average purity of CD66+CD16+ neutrophils was 98% as assessed by multicolour flow 
cytometry. Donors were obtained as part of the NIHR Cambridge BioResource 
(http://www.cambridgebioresource.org.uk/). Peripheral blood samples were collected from 
healthy donors with informed consent (A Blueprint of blood cells, REC 12/EE/0040, East of 
England-Hertfordshire Research Ethics committee). After broad outlier exclusion (see 
below), the cohort consisted of 138 donors where genetic data was available. There were 82 
females and 56 males within the cohort. The age of donors ranged from 22 to 75 with 75% of 
the cohort falling between the ages of 55 and 75. For 87 donors (59%) whole genome 
sequence data was available as part of the Blueprint consortium cohort and for 102 donors 
(73%), genotype data from genotyping arrays was available (see below). The data were 
collected over a period of one year, with between one and four donors measured per day. In 
56% of cases, a single donor was measured per day, and in 7% of cases, four donors were 
measured on the same day. Other exclusions, for example, outliers of the specific assay 
responses, are explained below.  
 
Adhesion assay: The adhesion assay measures activated neutrophils adhering to a plate as 
a model system for circulating neutrophils attaching to endothelial cells, a process which is 
essential for neutrophils to access infected or damaged tissues (Figure 3.3). Neutrophils 
were first labelled with calcein-AM, supplied in 50 μg/vial. 12.5 μL of DMSO was added to 
one vial 50 μg vial of calcein-AM. Cells were resuspended in HEPES buffer at 5.0 x 106 per 
ml. 1 μL of the calcein-AM mix was added per ml of cell suspension. The suspension was 
incubated in a shaking water bath for 30 minutes at 37°C and after 15 minutes tubes were 
shaken by hand and replaced. 12 mL of PBS was then added and the suspension was 
centrifuged at 1500 rpm for five minutes, resuspended again in 12 mL of PBS and 
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centrifugation was repeated as before. Finally, cells were resuspended in HEPES buffer and 
the concentration determined. For the adhesion assay, a calcein-labelled cell concentration 
of 2 x 106 per mL was used, and 80 μL of cell suspension was added to each well of a 96-
well maxisorp plate (Fisher, DIS-971-090X). Eight different stimuli were used in this assay. 
Final concentrations used to stimulate the neutrophils on the plate were as follows: 1 μM 
PAF (Sigma, P4904), 10 ng/mL TNF (PeptroTech, 300-01A), 20 μg/mL Pam3Cys (EMC 
microcollections, L2000) 10mM DTT (Sigma, D0632) 10 μM fMLP (Sigma, F3506), 1 μg/mL 
PMA (Sigma, P8139), 20 ng/mL LPS (Sigma, L2880) and 50 ng/mL LBP (R&D Systems, 
970-LP-025). After addition of the stimulus, the plate was covered with a sealer and 
incubated in a 370C CO2 incubator for 30 minutes to allow activated neutrophils to adhere to 
the plastic surface of the plate. Neutrophil adherence to the plate is a known non-specific 
interaction mediated through the neutrophil integrin receptor, CD11b/CD18, that is blocked 
by antibodies against CD11b or CD18 (Anton Tool, personal communication). After 30 
minutes, non-adherent neutrophils were washed from the plate using 100 μL of PBS at room 
temperature (RT). 100 μL of 0.5% Triton X-100 (Sigma, T8787) was then added to each well 
that contained cells, and the plate was incubated at RT for ten minutes. For the 100% input 
control, 20 μL of 2.5% of Trion X-100 was added to separate wells containing 80 μL of cell 
suspension. After incubation with Triton X-100, the plate was loaded onto the plate reader 
and one final fluorescence measurements was recorded. In all three assays, an unstimulated 
condition with the addition of only HEPES buffer was also measured on the plate reader. 
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Fig 3.3: Neutrophil adhesion  
This schematic shows the biological process of adhesion and experimental measurement (lower 
panel). Neutrophils are recruited to inflamed tissues described in four-stage process. Initial contact is 
mediated through selectins (1), initial tethering mediated by the constitutively-expressed neutrophil 
molecules, PSGL-1 and L-selectin. P-selectin and E-selectin are expressed by endothelial cells under 
infection or inflammatory conditions. (2) neutrophils then roll along the endothelial wall leading to 
strong adherence mediated by integrins (3) (Zarbock and Ley, 2008). During the rolling process, other 
receptor interactions activate further signalling processes in neutrophils to initiate neutrophil 
extravasation, cytoskeletal rearrangement leading to the release of neutrophil cytotoxic granules and 
production of reactive oxygen species. The neutrophil crosses the endothelial cell wall in a process 
known as transendothelial migration (4). To assay this response, neutrophils are labelled with the 
fluorescent molecule, calcein-AM and activated with the stimuli in the plate well. Fluorescence of 
adherent neutrophils is measured by a plate reader. Figure adapted from (Amulic et al., 2012). 
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Respiratory burst assay: This assay measured the NADPH-oxidase activity of neutrophils 
known as the respiratory burst response. This is the production of reactive oxygen species 
(ROS) by an activated neutrophil (Figure 3.4). Hydrogen peroxide (H2O2) is produced by the 
neutrophil respiratory burst and reacts with the Amplex® Red reagent in the presence of 
horseradish peroxidase (HRP) (ThermoFisher Scientific, 2017). The 1:1 reaction of Amplex® 
Red and H2O2 produces the red fluorescent molecule, resorufin (Figure 3.4). Resorufin is 
excited by 571 nm and emits at 585nm enabling the measurement of the cellular production 
of H2O2 using a plate reader. For this assay, the responses are measured by the plate reader 
in real-time, rather than an end-point measurement. The fluorescence measured was 
produced not from labelled cells (as with adhesion) but from the production of fluorescent 
resorufin as a by-product of the stimulated functional response. 
 
Unlabelled cell concentration used for the respiratory burst assay was 1 x 106 cells per mL in 
HEPES medium. The neutrophil cell suspension was pipetted into a black opaque 96 well 
plate (Fisher, DIS-210-190W). 100 μL of the 2x reaction mix containing a final concentration 
of 25 μM Amplex® Red (10-acetyl-3,7-dihydroxyphenozazine, Molecular Probes, A-12212) 
and 0.5 unit/mL HRP (Sigma, P-8250) was added to the plate along with 50 μL of cell 
suspension. The plate was then incubated at 37°C on the plate reader for five minutes. 50 μL 
of each stimulus was then added to the relevant wells, and the reaction is then measured in 
the plate reader immediately after. There were four stimuli used in the respiratory burst assay 
and the final concentrations used in the assay are as follows: 4 mg/mL Zymosan (Sigma, 
Z4250), 1 mg/mL STZ (Sigma, P8139), 1 μg/mL PMA (sigma, P8139), 2.5 μM PAF (Sigma, 
P4904) and 25 μM fMLP (Sigma, F3506) where PAF and fMLP were added to the same well 
as one condition. The reaction was measured on the plate reader for 60 cycles (30 minutes). 
The range of different stimuli, both biological and small chemical molecules are described in 
Table 3.2 with a description of how these stimuli activate the respective neutrophil functions. 
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Fig 3.4: The neutrophil respiratory burst response  
This schematic summarises the molecular reaction and experimental measurement of the respiratory 
burst response. Reaction of hydrogen peroxide (H2O2) with the Amplex® Red reagent in the presence 
of horseradish peroxidase (HRP) produces the red fluorescent molecule, resorufin. Resorufin can be 
excited by 571 nm and emits at 585nm enabling the measurement using a plate reader. Adapted from 
(Kobayashi et al., 2005). 
 
 
Degranulation assay: This assay measured the release of granule contents that occurs when 
a neutrophil is activated (Figure 3.5). Table 3.1 lists the different neutrophil granules and their 
contents. Here, neutrophil degranulation was measured by using a complex of a DQTMGreen 
BSA (DQBSA) (Molecular probes, D12050). In this form fluorescence from the green-
fluorescent BODIPY® FL dye is quenched (ThermoFisher Scientific, 2017). Proteases 
released from the neutrophil digest the DQBSA molecule so that the fluorescence is no 
longer quenched and can be measured by the plate reader. The experimental process 
mirrors the recognition and internalisation of pathogens by neutrophils that activates a series 
of molecular processing leading to the release of neutrophil granular contents into the 
phagosome and also the surrounding cellular environment. The release of antimicrobial 
peptides and other immune-related molecules leads to the destruction of the pathogen and 
recruitment of further immune cell types.  
 
HEPES medium was added to the relevant wells in the plate (black opaque 96-well plate as 
above for respiratory burst assay). 50 μL of unlabelled cells at 5 x 106 cells per mL were 
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added to the wells containing HEPES. A final concentration of 10 μg/mL of DQBSA was 
added to wells containing cells. For the stimuli, a final concentration of 5 μg/mL Cytochalasin 
B (CytoB, Sigma, C6762) was used, and 10 μL of this solution was added to the relevant 
wells containing neutrophil cell suspension and DQBSA. The plate was then incubated for 
five minutes at 37°C in the plate reader. The plate was then removed and 10 μM fMLP added 
to the relevant wells, where neutrophils were stimulated with a combination of CytoB and 
fMLP. After activation, the released DQTM Green fluorophores released are excited at 505nm 
and emit at 515nm. The reaction was measured in the plate reader for 120 cycles (60 
minutes).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.5: Neutrophil degranulation  
This schematic shows the biological process and experimental measurement of degranulation, which 
is the release of granule contents. The response from purified neutrophils in solution is measured 
using a fluorescent marker. Released neutrophil proteolytic enzymes break up the DQBSA molecule 
so that DQ is no longer quenched and the fluorescence can be measured using a plate reader. 
Adapted from (Amulic et al., 2012). 
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3.2.2 Data interpretation and exploration  
Given the novelty of the traits, we carried out extensive exploration of the data to identify 
potential artefacts. These next sections describe the process used to evaluate the utility of 
these traits in a genetic context and was carried out with close collaboration and supervision 
by Klaudia Walter.  
 
Initial exploration of data over time: To assess the variability of the measures over time, I 
plotted each trait value by date of acquisition across the 12 months. As a first diagnosis, we 
assessed traits as calculated by and provided by the plate reader software. These were 
relative fluorescence units measured at cycle 20 and 40 for respiratory burst and 
degranulation respectively. For adhesion RFU measurement was an end-point value after a 
30 minutes incubation (see above). Figure 3.6 also shows the two replicates of the 100% 
input control used in the adhesion assay and measured for each donor. The 100% input 
control is the measured calcein fluorescence (in RFU) from labelled cells after addition of a 
high concentration of Triton-X100 (Materials and Methods), which should release calcein 
from the cells and reflect a high adhesion response. This value is used to normalise the 
adhesion response for all other stimuli by dividing the stimulated RFU by the 100% input 
control (four of the total eight stimuli are shown in Figure 3.6 and listed in Table 3.2). 
 
We observed a substantial shift in trait values and distribution between the first 68 samples 
and those acquired after this point (Figure 3.6). In particular, for the adhesion response, the 
HEPES values were inflated compared to the samples acquired later (Figure 3.6). This 
elevated HEPES response level could reflect possible bacterial contamination in the original 
HEPES batch, resulting in neutrophil activation. The HEPES buffer was used in all parts of 
the experimental process including stimulus dilution. Therefore, the decision was taken to 
remove the first 68 samples.  
 
Selection of real-time assay parameters: One major challenge for the respiratory burst and 
degranulation real-time assays was the selection of a comparable measurement that can be 
used as a phenotypic trait for subsequent genetic studies. We explored the raw response 
distributions to select parameters that would best capture the highest dynamic range in 
response across the cohort yielding the largest resolution (Figure 3.7). 
 
The shape of the response distributions often varied considerably between stimuli (Figure 
3.7). For example, the respiratory burst response stimulated by Zymosan, a yeast particle, 
shows a slower activation profile than with serum treated Zymosan (STZ). STZ is Zymosan 
opsonised with immunoglobulin (Ig) and complement receptors that together stimulate a 
faster and higher neutrophil response by activating the integrin receptor CD11b/CD18. 
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Addition of Cytochalasin (CytoB) with fMLP also elicits a higher response (Figure 3.7). fMLP 
stimulates the production of diacylglycerol (DG) by phospholipase C (PLC). DG activates 
protein kinase C (PKC), a kinase that has been suggested to be involved in both ROS 
production and degranulation (Sato et al., 2013). CytoB has been shown to increase the 
diacylglycerol-mediated response stimulated by fMLP in neutrophils and therefore augments 
the fMLP response (Honeycutt and Niedel, 1986).  
 
We combined the observed reaction distributions with prior knowledge regarding the 
biological relevance of reaction ranges (Anton Tool, personal communication) to calculate a 
range of parameters directly from the raw responses for both the respiratory burst and 
degranulation assays. For example, we were advised that the respiratory burst reaction 
stimulated by PAF combined with fMLP, is an extremely rapid reaction reaching saturation 
within minutes. Therefore, we calculated parameters for the PAF & fMLP response within the 
first ten cycles (five minutes) of the reaction to avoid missing the oxidative burst peak.  
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Fig 3.6: Exploratory data analysis: measurements by time  
These plots depict the raw data distributions for example RFU values as collected directly by the plate 
reader software. All donor values for each assay are plotted against the date of acquisition of that 
sample. The top panel shows an example measurement of the RFU at 20 cycles for all respiratory 
burst conditions and the second panel shows RFU at 40 cycles for all degranulation conditions. The 
third panel depicts some example stimuli for the end-point RFU reflecting the degree of neutrophil 
adhesion on the plate. The fourth panel shows the adhesion 100% input control against date of 
acquisition. In panels 1-3 it can be observed how the first 68 samples show a very different relative 
response distribution to the remaining samples.  
 
Figure 3.7 shows that for an individual’s response distribution and within each well, there 
were small fluctuations between successive cycles, particularly apparent for the HEPES 
degranulation response. These small changes were likely due to plate reader resolution but 
could potentially have introduced errors in calculating our maximum and mean gradients 
from the raw distribution. These gradients were used as a comparative measure of the 
response of each donor in the real-time assays. Mean and maximum gradients were 
calculated using two successive cycles forming a tangent against the curve for which the 
gradient was calculated. For mean slope traits within the defined interval, gradients were 
calculated for each of successive cycles, and the mean was calculated of all these values (all 
summarised in Table 3.2). To remove these cycle-to-cycle deviations within each individual 
distribution, we applied the LOESS curve-fitting function to smooth each distribution (Figure 
3.7). LOESS is a non-parametric, local regression method, where the fitted points and 
standard errors are calculated with respect to the whole reaction distribution. An estimated 
curve is fitted to the reaction distribution curve. This was implemented using the loess() R 
function. Parameters were then calculated for each replicate separately and then averaged 
across trait replicates. The function did not effectively fit the PAF fMLP respiratory burst 
response before cycle 10 (data not shown) due to the rapid reaction in the early cycle-stages 
resulting in steep response gradients. This rapid reaction also meant that in the early part of 
the reaction, the response distribution was already smooth and therefore, the raw data 
without LOESS fitting was used to calculate the parameters for this response. The 
unsmoothed and smoothed distributions are shown in grey and purple respectively in Figure 
3.7.  
 
For adhesion data, there was an extra normalisation step with division of RFU by the 100% 
input control from the stimuli RFU. Following this, I calculated the averaged across the two 
technical replicates as described for the other two assays. In total, there were 29 traits 
across all three assays in the final list of parameters (Table 3.2).  
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Fig 3.7: Raw data response distributions for respiratory burst and degranulation  
These plots show the raw RFU at each cycle for replicate 1 and replicate 2 for every stimulus starting 
from the first measurement at cycle 1 up to the final number of cycles (60 or 120). Measurements are 
recorded every 30 seconds (one cycle) plotted on the x-axis. Fluorescence units are measured 
cumulatively. HEPES buffer is used in each assay as a measure of unstimulated functional response. 
Each line represents the whole RFU response distribution for one donor. Above is shown the 
response distributions for all donors in the cohort excluding the first 68 samples. A) Cumulative 
fluorescence recorded by a plate reader for the degranulation assay for each stimulus used. For the 
second HEPES replicate there was one donor which recorded a very low HEPES response, near to 
zero. It was suggested that this could be due to a technical artefact, therefore for this donor, the value 
for replicate 1 was used in place. B-C) Fluorescence measurements as recorded by a plate reader for 
the respiratory burst assay for each stimulus used. The raw relative fluorescence values (RFU) from 
the plate reader are plotted in grey. The values were fitted using the LOESS smoothing function and 
are shown in purple on the same plot. For respiratory burst responses stimulated by PAF fMLP the 
plot is shown with raw data. The LOESS function did not fit the raw data well below 10 cycles and so 
was not used to calculated the trait values. The individual response showing a very different reaction 
distribution, rising very quickly outside of the other donor responses, in the PAF & fMLP reaction (C 
bottom panel), was removed (discussed below). 
C 
 138 
 
Table 3.2: Functional traits and number of individuals for each trait across all three assays and stimuli used  
Table describes the different stimuli and their mechanism of action in each assay. The final traits used for each assay is also listed and the number of individuals (N) 
after final outlier removal within each trait is listed. A full understanding of the signalling pathways involved is not yet established, presented here is a mix of 
published and unpublished observations from our collaborators (Anton Tool, Taco Kuijpers).  
Assay Stimulus Trait N 
Respiratory 
burst 
PMA: phorbol myristate acetate, induces NADPH oxidase by direct stimulation of protein kinase 
C (PKC) 
RFU at 10 cycles 130 
RFU at 15 cycles 130 
Time to RFU at 40000 cycles 130 
Mean Slope: 10 to 15 cycles 130 
Maximum Slope 130 
STZ: serum-treated Zymosan, which is opsonised with Ig and complement receptors, involves 
the neutrophil CD11b/CD18 and Fcg receptors 
RFU at 15 cycles 129 
RFU at 20 cycles 129 
Time to RFU at 30000 129 
Mean Slope: 10 to 20 cycles 129 
Maximum slope 129 
Zymosan: cell wall preparation from S.cerevisiae, induces NADPH oxidase via CD11b/CD18 
RFU at 60 cycles 130 
Difference in RFU: 60 and 1 cycles 130 
Maximum Slope 130 
PAF + fMLP: PAF amplifies the RB response. fMLP stimulates the fMLP receptor, which 
activates NADPH oxidase via p47phox 
RFU at 6 cycles 127 
Maximum Slope 128 
Degranulation 
fMLP: N-formyl peptide released by bacteria, bacterial degradation or mitochondrial protein. 
Stimulates release of gelatinase granules 
RFU at 20 cycles 135 
Mean Slope: 20 to 40 cycles 135 
Maximum Slope 135 
Cytochalasin B + fMLP: CytoB, a fungal mycotoxin, inhibits actin polymerisation in cells and 
amplifies azurophilic and specific granule-mediated degranulation. Generates an increased 
degranulation response compared to fMLP alone 
RFU at 20 cycles 135 
Mean Slope: 20 to 40 cycles 135 
Maximum Slope 137 
Adhesion 
PMA: activates partially by the stimulation of PKC Final RFU 131 
PAF: platelet activating factor, binds to the GPCR, PAF receptor Final RFU 131 
fMLP: activates adhesion through the fMLP receptor Final RFU 131 
DTT: dithiothreitol reducing agent. Breaks disulphide bridges and activates integrin receptors Final RFU 129 
TNF: tumour necrosis factor, activates adhesion via the TNF receptor Final RFU 132 
LBP + LPS: LPS is a bacterial molecule that binds TLR4, LBP is LPS binding protein, an acute 
phase protein that binds to bacterial LPS to stimulate an immune response Final RFU 131 
Pam3Cys: TLR1/2 agonist Final RFU 132 
Hepes: control buffer, may reflect pre-stimulated adhesion Final RFU 128 
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Removal of outliers and technical reproducibility: For each individual, two repeat 
measurements were acquired where cell suspension from the same donor was added to two 
wells of the plate (referred to as technical replicates). I used the R function, cor.test to 
calculate the Spearman correlation between technical replicates across all individuals, for 
each trait. Before outlier removal the correlation averaged across all traits was high 
(respiratory burst rho= 0.906, degranulation rho= 0.972, adhesion rho= 0.956), suggesting 
good technical reproducibility.  
 
I next used these technical replicates to remove outlier measurements or extreme 
measurements using two thresholds. First, outliers beyond a threshold of 5 x standard 
deviation (5SD) between technical replicates were excluded. Second, I calculated a 3SD 
mean distribution threshold, to assess potential outliers with very high or low trait values, 
which could reflect extreme responders or technical artefacts. To differentiate between true 
high and low responders and technical outliers, I kept measurements that were outside of the 
mean distribution thresholds but well replicated (inside the 3SD replicate thresholds).  
 
For the adhesion assay, outliers were first excluded using the above thresholds from the un-
normalised stimulated RFUs if outside the two thresholds and also from the for raw 100% 
input RFUs. Finally, outliers were also excluded after normalisation with the 100% input 
control if this generated additional outliers by normalising with very high or low input control 
values.  
 
We further investigated four donor measurements that generated very extreme responses 
that lay far beyond the 3SD mean distribution threshold in most adhesion conditions (data 
not shown). We identified that these four donors were measured on the same day, the 22nd 
April 2014 and were the only donors processed using a single batch of a reagent Buffer 3, 
which is used in the neutrophil purification process. We excluded these donors from further 
analysis. The extensive investigation into batch effects is discussed below.  
 
I also excluded donors for which there was no available genetic data and then inverse 
normalised the trait values across the whole cohort to generate a normalised trait distribution.  
 
Covariate investigation: The identification of the four adhesion outliers described above 
suggested that these functional data may be subject to variation introduced by experimental 
covariates. We were able to investigate known experimental covariates such as reagent 
batch as changes were recorded during data acquisition. I also investigated the effect of 
environmental factors such as age, gender and season. Batch effects, which are sub-groups 
of trait values that exhibit different behaviour that is not related to genotype, must be 
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removed to reduce noise, improve power and avoid systematic stratification that can cause 
bias in association testing (Leek et al., 2010). 
 
In order to investigate the effect of season, we assigned the trait values to the different 
seasons based on when they were experimentally measured. These included: Winter (Dec-
Feb), Spring (Mar-May), Summer (Jun-Aug) and Autumn (Sep-Nov). In addition, if multiple 
donors were processed on one day (in some cases up to 4), all samples were read on one 
plate-reader plate and positioned from left to right. The fluorescent signal from each well is 
also read by the plate reader from the left to right, but the reaction was started once the 
stimulus was added to the plate prior to placing in the plate reader. We annotated each 
measurement with plate position to investigate whether machine reading could be a source 
of co-variation.  
 
I stratified trait values by these potential covariates to visualise the potential effect and Figure 
3.8 shows these effects for the adhesion traits as an example. I used inverse-normalised trait 
values after removal of donor outliers and donors with missing genotypes, to allow better 
comparison between traits. Patterns for inverse normalised and raw data were similar (data 
not shown). I calculated the significance of the effect of the covariate by using the one-way 
ANOVA, using the aov R function, to test if the means of each group were significantly 
different (shown in Figure 3.8). Certain covariates, such as buffer 3 significantly affected all 
traits from all three assays, except adhesion PAF (p value = 0.091) and respiratory burst 
PMA Time to RFU 40000 (p value = 0.11) (Figure 3.8). As described above, buffer 3, was 
used in the purification of neutrophils from whole blood and also had multiple batches. 
 
I observed that some covariates, such as season, showed variable significance across the 
different traits. In the case of adhesion, season has a significant effect on the response 
stimulated by LBP and LPS (p value = 1.6 x 10-07), HEPES (p value = 7.6 x 10-07), TNF (p 
value = 8.6 x 10-03) and DTT (p value = 2.2 x 10-03) but not Pam3Cys (p value = 0.18), PAF (p 
value = 0.25), PMA (p value = 0.15) or fMLP (p value = 0.65). The LBP/LPS response, for 
example, was lower in winter than it was in spring. LPS is the major component of gram-
negative bacterial outer membranes, eliciting an anti-bacterial neutrophil response. In 
addition, the HEPES response, which may represent the pre-stimulated neutrophil adhesion 
response was also lower in winter. For the respiratory burst, season as a significant effect on 
PMA RFU.10 (p = 6.3 x 10-05), PMA RFU 15 (p = 8.2 x 10-03), STZ RFU 15 (p = 4.4x 10-06), 
STZ RFU 20 (p = 2.2 x 10-04), STZ Time to RFU 30000 (p = 6.9 x 10-04), PAF + fMLP (p = 6.5 
x 10-06), Zymosan RFU 60 (p = 1.0 x 10-11), Zymosan Diff RFU 1.60 (p value = 2.2 x 10-19) 
and Zymosan max slope (p = 8.2 x 10-17). For these traits, the pattern was similar to 
adhesion, highest levels in summer, followed by spring and lowest in winter. For the 
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degranulation response, season was a significant effect on all traits, with the peak response 
in spring and decreasing in winter (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Reagent batch effect has a substantial effect on adhesion data  
Inverse normalised trait values for neutrophil adhesion stimulated by a variety of stimuli (columns) 
are shown stratified by covariate levels (rows). HEPES, buffer1, buffer 3 and Percoll are all used in the 
purification of neutrophils. Triton (Tx) is used in the input control and in the main assay processing. 
Position explains the position of the donor cells in the well depending on the number of donors 
assayed. Season is the time of year at which the measurement was acquired.  
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To further evaluate the effect of each covariate on trait values, I calculated the R2 value, 
which determines the percentage of the variation in response that is explained by the model. 
It is calculated by dividing the variation explained by the model by the total variation. The 
higher the R2, the more trait variation is explained by the model. For each trait, I calculated 
the R2 value for a linear model where the trait was the response variable and each covariate 
was fitted independently as the predictor variable. Here, R2 is expressed as a percentage of 
trait variation where 0.1 is 10%. Figure 3.9 shows an example of R2 of covariation for 
adhesion responses and the remaining traits in Supplementary Figure 3.9.  
 
Reagent batch, particularly that of the neutrophil purification buffers 1 and 3 explain a high 
proportion of the total variation in each neutrophil trait value. The R2 averaged across all 
traits from all three assays was 0.385 and 0.306 for buffer 3 and buffer 1 respectively. These 
high values underline the considerable effect that reagent batch had on these functional 
readouts. Interestingly, for all traits, season (mean R2 = 0.163) demonstrated a greater R2 
than age (mean R2 = 0.029) and gender (mean R2 = 0.036) of the donor, suggesting that 
season contributes a reasonable degree of trait variation. In addition, age was not a 
significant covariate for any of the traits tested. The observation of the effect of reagent batch 
and to a certain extent, season, has important implications for the experimental design of 
future studies involving these cellular functional responses.  
 
Covariate correction: Various approaches for correcting for these covariates were explored, 
but were often complicated by limited sample size (Klaudia Walter, data not shown). We 
decided to implement a conservative approach in correcting for covariates given the small 
sample size of this study, the large observed reagent batch effects and the lack of a 
complete, genome-wide replication cohort. We included all of the covariates in the trait 
correction process, termed the “full model”. This approach should lead to the lowest number 
of false positive associations in the downstream genetic analysis, as opposed to correcting 
only for those covariates with a significant ANOVA p-value or high R2 value.  
 
I used linear regression to correct for the technical variation related to these factors. 
Covariates were input as fixed effects and regressed onto the inverse normalised trait values 
using the R lm() function. The model fit was assessed using QQ plots (data not shown) and 
visualisation of the residuals both against time and stratified by covariates to assess whether 
the previous patterns and waves of variation were still present in the data. We concluded that 
the residuals generated from the linear regression demonstrated that a considerable 
proportion of the variation in the response had been removed (Figure 3.10). The mean of the 
trait values of each covariate batch was now similar, and the varying distribution of values 
has been removed (Figure 3.10). 
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Figure 3.9: Reagent batch explains a high proportion of variation in neutrophil 
adhesion responses  
Barplot shows the R2 estimates calculated from fitting a linear model for each trait (coloured) 
independently with each covariate (y axis). This shows that reagent batch explains a high proportion of 
variance in the trait values.  
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Figure 3.10: Correction of known batch effects  
Boxplots show the residuals stratified by covariate levels. The residuals are shown from linear 
regression models with all of the listed covariates were applied to each trait to remove variation due to 
changes in these factors. season. This demonstrated that the means of each level were equalised 
even for Buffer 3 for which there were 17 batches.  
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Phenotype correlation: In order to investigate whether there was evidence of any similarity 
between phenotype traits, I used unsupervised clustering analysis by calculating Pearson 
correlations between all pairwise comparisons between residualised trait values. The R 
package, pheatmap, was used to plot the heatmap demonstrating clusters between particular 
traits.  
 
3.2.3 Genetic analysis and integration with epigenomic datasets  
Genetic data: This cohort consisted of a mix of individuals either from the Blueprint 
consortium or the Cambridge BioResource (CBR) 
(http://www.cambridgebioresource.org.uk/). If individuals were part of the Blueprint 
consortium, whole-genome sequence (WGS) data was available and was analysed as part of 
this project (Chen et al., 2016a). For CBR individuals, genotypes were available from the 
HumanOmniExpress-12v1 chip, the HumanCoreExome-12v1-0 and HumanCoreExome-
12v1-1 genotyping chips, imputed using the combined reference panel of UK10K and 1000G 
Phase 1. Individuals were analysed as part of the large cohort (more than 3000 individuals) 
by Heather Elding, following all of the standard genotype QC procedures (Anderson et al., 
2010). A logistic regression of SNPs with genotyping batch was performed to remove 
variants with discordant allele frequencies across batches. For this study, only variants that 
were shared between the WGS and genotyping datasets were used in downstream 
association analysis. All alignments and analyses in the Blueprint EpiVar project were carried 
out using GRCh37/hg19 and GENCODE v15 (Harrow et al., 2012). The analysis of the WGS 
data was performed as part of the Chen et al. (2016) study (Chen et al., 2016a).  
 
Genetic association: The residuals of each trait were standardised and used as phenotypic 
traits in downstream genetic association analyses. Single variant association tests were 
performed using SNPTEST v2.4.0, and tested the association for each variant with each trait 
using an additive model (-frequentist 1). For each residualised trait, !" and variant genotypes, #", a linear model !" 	= 	 &' 	+ &)#" was fitted for *	 = 	1,2,3, . . . . , 0, where 0 is the number of 
individuals in the cohort. Genotype dosages were used (-method expected) to account for 
genotype uncertainty and expressed as the probability of each SNP genotype (AA, AB, and 
BB) per individual with 1 being most certain and NA for missing. Default quantile 
normalisation was disabled using the option -use_raw_phenotypes as the input phenotypes 
values were standardised at the stage of preparing the sample file. Variants with a MAF of 
less than 1% were excluded given the lack of statistical power to detect rare variant 
associations in this particular cohort.  
 
Visualisation: Manhattan and QQplots were produced either using custom in-house scripts or 
using the QQMAN R package (Turner, 2014). Locus zoom plots were generated using the 
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online tool (Pruim et al., 2010). Promoter-capture HiC plots were visualised using the 
Capture HiC plotter (CHiCP) (https://www.chicp.org) (Schofield et al., 2016).  
 
Significance threshold: All variants meeting the standard-genome wide association threshold 
of 5 x 10-08 were identified. 5 x 10-08 is an appropriate testing thresholds for common variants 
in a European population, as tested here. In addition, neutrophil biological and genomic data 
were used to annotate these associations (see below) and therefore for suggestive 
associations that could be evaluated in a biological context, a threshold of 1 x 10-07 was 
applied.  
 
Investigation of biological mechanism: I assessed whether significant or suggestive variants 
overlapped with any epigenomic or similar biological data in order to make predictions of 
possible variant functionality. I used ChIP-seq data from undifferentiated and differentiated 
HL60 cells, data from primary neutrophils from the BLUEPRINT consortium and epigenomic 
data including CTCF, PU.1 C/EBPb, H3K27me3 (repressive) and H3K4me3 (active 
transcription) from primary neutrophils as part of an unpublished dataset (Stephen Watt, 
manuscript in preparation) (all described in Chapter 2). Further, I used binding data from 
undifferentiated HL60 cells including P300 (enhancer co-factor), C/EBPe (TF) and cohesin 
subunits SA1 and Rad21 (cis-regulatory module protein) that was collected within the 
Soranzo team by myself and Stephen Watt. I used the bedtools analysis suite (bedtools 
version 2.23.0) with the -intersect option to assess intersection of genetic variants and 
molecular features. Promoter-capture HiC data from primary neutrophils, which describes 
long-range interactions between genomic locations, was used to identify potential target 
genes of significant variants (Javierre et al., 2016). In addition, the potential effects on 
neutrophil gene expression of function-associated variants were assessed using RNA-seq 
data as part of the Blueprint consortium (Chen et al., 2016a). Rare or lower-in-frequency 
variants were not tested within the BLUEPRINT study, therefore to evaluate the function of 
rare/low-frequency variants, associations were tested using the RNA-seq gene expression 
data in FPKM. 
 
Replication cohort: To confirm neutrophil function effects identified in the Cambridge 
discovery cohort, together with our collaborators, we established a cohort of healthy 
individuals in the Netherlands at Sanquin Research, University of Amsterdam (Sanquin 
cohort). Samples were genotyped at the Wellcome Trust Sanger Institute using the Illumina 
Human CoreExome Beadchip (coreex24) array. All genetic analysis for this cohort was 
carried out by Klaudia Walter (WTSI), but is summarised briefly here. A standard quality 
control protocol was implemented that included identity (³ 0.9), duplicate (£ 0.98) and gender 
checks (males £ 0.005, females ³ 0.174), as well as a minimal call rate (³ 0.95) and no 
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excess autosomal heterozygosity (three standard deviations). 157 donors were genotyped in 
two batches (83 donors in the first and 74 donors in the second batch). In total eight donors 
failed the heterozygosity threshold and three donors failed the duplicate threshold. 
Additionally, a principal component analysis (PCA) was carried out together with HapMap3 
samples which identified 14 population outliers, of which eight samples had also failed the 
heterozygosity threshold. In total 17 samples were excluded from further analysis. Samples 
were imputed using the Haplotype Reference Consortium (r1.1) using the EAGLE2+PBWT 
pipeline. The samples were processed with ethical consent approved by the WTSI Human 
Materials and Data Management Committee, reference 16/042 and titled: “Genetic variation 
in neutrophil cellular function- Biobank sample donors of Sanquin Research”. 
 
Genotype validation: We identified a genome-wide significant association for a low-frequency 
locus (rs116811177/rs115109232, MAF = 2%, Figure 3.14). Given the low-frequency of 
these SNPs, we used Sanger sequencing with probes designed for rs116811177 and 
rs115109232 to confirm the heterozygous genotypes for the five individuals in the discovery 
cohort association (Figure 3.15). The genotyping assay was designed by Agena Bioscience 
using the MassARRAY® System with the iPLEX® chemistry.   
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3.3 Results  
3.3.1 Phenotype Correlation  
This study describes the first large-scale exploration of neutrophil adhesion, degranulation 
and respiratory burst from a predominantly healthy cohort, which enables a direct 
comparison of the relationship between these responses. In total, 29 traits were assessed 
across three assays and 12 different stimuli (Table 3.2). For adhesion, eight different stimuli 
were used and the final response measured as a single relative fluorescence unit (RFU). For 
respiratory burst and degranulation, four and two different stimuli were used respectively. 
Traits were calculated from the response distributions for all donors measured for either 120 
or 60 cycles for each individual (Table 3.2).  
 
I implemented unsupervised clustering analysis using the Pearson correlation between each 
pairwise residualised trait comparison to investigate similarities between the different 
neutrophil functions (Figure 3.11). Interestingly, two higher order clusters were observed, one 
between respiratory burst and degranulation responses and the other of adhesion 
responses. Mean correlations within these clusters revealed that the correlation between 
degranulation and adhesion responses was particularly low (mean r = 0.068, SD = 0.052). By 
contrast, the average correlation between respiratory burst traits and degranulation traits was 
0.148 (SD = 0.093). However, the correlation between adhesion traits and respiratory burst 
traits was higher than that between degranulation and adhesion (r = 0.144, SD = 0.100). The 
correlations within responses of the same assay were all above 0.48 with the highest 
between degranulation traits (r =0.732, SD = 0.187).  
 
There was a negative correlation between both time to particular RFU respiratory burst traits 
(PMA time to reach an RFU at 40000 cycles and STZ time to reach an RFU of 30000 cycles) 
and the rest of the respiratory burst responses. A high responder will reach a high maximum 
slope or RFU in a shorter time period due to the fast reaction response. These traits also 
clustered with the rest of the adhesion responses. The biological reason underlying the slight 
correlation of these time traits with adhesion responses is unclear.  
 
The adhesion HEPES response was clustered with the rest of the adhesion responses, 
which could suggest that this condition demonstrates a degree of pre-stimulated activity in 
this particular function, which has been observed primarily in the adhesion assay over 
respiratory burst and degranulation by our collaborators (personal communication, Anton 
Tool). 
 
The higher observed correlation and similarity between degranulation and respiratory burst 
responses may reflect activation of shared components of biological pathways or that certain 
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stimuli lead to a concomitant activation of multiple biological pathways culminating in the 
activation of multiple neutrophil functions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Correlation of neutrophil function phenotypes  
Heatmap shows the correlation between standardised residuals from all traits and stimuli used in 
genetic association analyses. The Pearson correlation between all traits was calculated and used in 
unsupervised clustering analysis to assess the relationship between neutrophil functional responses. 
Respiratory burst and degranulation responses correlated more closely than to adhesion response 
with the exception of the response to HEPES (which should represent unstimulated responses) and 
the time to a specific RFU response. 
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3.3.2 Genetic variants associated with inter-individual variation in neutrophil 
function 
I used the standardised residualised values for the 29 traits described above in independent 
single variant genome-wide association tests. Just over six million SNPs after filtering for 
variants below 1% MAF were tested for association with each trait. We estimated that this 
study was powered to detect common variants of moderate to high effect size and low-
frequency variants with standard beta estimates of approximately 3 SD (Supplementary 
Figure 3.2).  
 
I identified two SNPs reaching genome wide significance that were associated with 
respiratory burst of neutrophils stimulated with PAF and fMLP (p value < 5 x 10-08, Table 3.3, 
Figures 3.12-3.14). The two low-frequency SNPs, rs116811177 (EA = G, EAF = 0.02, beta = 
2.92, SE = 0.398, p value = 2.39 x 10-11) and rs115109232 (EA = A, EAF = 0.02, beta = 2.92, 
SE = 0.398, p value = 2.39 x 10-11), are perfectly correlated with r2 of 1 (1000G). There were 
five individuals in the heterozygote state that demonstrated an increase in the respiratory 
burst response (Figure 3.15). No other genetic variants reached genome-wide levels of 
significance with any of the other functional traits. There were six variants that were 
associated at the suggestive p value threshold (p value < 1 x 10-07, summarised in Table 
3.3). All of these SNPs were low frequency (MAF < 5%) except one that was associated with 
adhesion response stimulated by PMA (rs57784565, p value = 8.59 x 10-08, MAF = 7.6%). 
The remaining variants were all associated with respiratory burst of neutrophils stimulated 
with PAF and fMLP.  
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Figure 3.12: Association results for neutrophil function responses  
Manhattan plot showing all variants associated with all traits at a p value threshold of 1 x 10-03 or less. 
A) Respiratory burst-associated variants, with a genome wide significant locus signal on chromosome 
5. B) Degranulation-associated variants showed a lower number of variants associated at the 
threshold than respiratory burst but possible suggestive signals on chromosome 2 and 9. C) 
Adhesion-associated variants with a signal that just missed the significance threshold (approximately 
9.0 x 10-08) on chromosome 17. Responses for all the conditions and traits were combined into one 
Manhattan plot per assay. Variants associated with a p-value threshold of less than 1.0 x 10-07 are 
highlighted in orange.  
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Figure 3.13: QQ plot of the respiratory burst PAF and fMLP RFU at 6 cycles response 
Expected -log10(p value) calculated using a uniform distribution against the observed -log10(p value) 
from the function single variant association test. The deviation from the expected line demonstrates 
that genome-wide significant variants were more associated with the trait than expected by chance. 
The genomic control factor, lambda, was 0.99, suggesting there was no evidence for population 
stratification in this sample cohort.  
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Table 3.3: Function-associated variants across all assays  
Table summarising statistics and annotations of variants reaching a suggestive p value threshold of 1.0 x 10-07. Genome-wide significant variants, 
rs116811177 and rs115109232 are low-frequency and associated with respiratory burst. For each variant, association statistics including p-value, beta, 
standard error of beta (SE) and minor allele-frequency (MAF) (in this cohort) are listed. Variant effect predictor (VEP) was used to annotation variants 
(McLaren et al., 2016). A range of epigenomic data was used to annotate potential function to these variants (Materials and Methods). PcHiC data describes 
neutrophil-specific promoter-capture HiC data. If a variant intersects with either fragment end of a long-range interaction the corresponding gene of the other 
end is listed. Intersection with histone modified regions or transcription factor binding regions as assayed by ChIP-seq is also listed. The protein expression 
column refers to a study that compared proteins expressed on the plasma membrane (PM) or secretary vesicles of human neutrophils (Uriarte et al., 2008).  
 
rsID Trait chr:pos EA:OA P value Beta SE MAF Annotation PcHiC Protein Expression Epigenome 
rs116811177 
Respiratory 
burst PAF + 
fMLP RFU 6 
5:55597870 G:T 2.392 x 10-11 2.92 0.398 0.020 Upstream, RNU6ATAC2P MAP3K1 
Expressed 
SV neu  
rs115109232 
Respiratory 
burst PAF + 
fMLP RFU 6 
5:55599891 A:G 2.392 x 10-11 2.92 0.398 0.020 Intergenic MAP3K1 Expressed SV neu  
rs147669752 
Respiratory 
burst PAF + 
fMLP RFU 6 
5:89571908 G:A 6.649 x 10-08 2.82 0.491 0.016 
Intron 
RP11-
61G23.1 
LINC00461 
CTC-
467M3.1 
  
rs117183808 
Respiratory 
burst PAF + 
fMLP RFU 6 
11:80312077 T:G 8.856 x 10-08 2.97 0.523 0.012 Intergenic    
rs7623696 
Respiratory 
burst PAF + 
fMLP RFU 6 
3:28332261 T:A 8.956 x 10-08 2.12 0.373 0.03 Intronic CMC1   H3K4me1 
rs57784565 Adhesion PMA 17:3635489 A:G 8.596 x 10
-08 1.31 0.231 0.076 Intronic ITGAE ZZEF1 
Expressed 
PM neu H3K4me1 
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Figure 3.14: Genic location of the most significant signal associated with neutrophil 
respiratory burst  
Regional plot of association for variants associated with respiratory burst RFU 6 in the region (+/- 700 
kb) of the lead variants, rs116811177/rs115109232. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: rs116811177/rs115109232 increases respiratory burst response after 
neutrophils are stimulated with PAF and fMLP  
Residualised values of the respiratory burst response stimulated by PAF and fMLP at RFU 6 cycles 
are stratified by genotype of the two SNPs of the top genetic signal associated with this trait. Trait 
values of each individual are demonstrated as light blue dots.  
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3.3.3 Functional annotation of the PAF & fMLP respiratory burst 
rs116811177/rs115109232 locus 
Figure 3.14 shows that the rs116811177/rs115109232 SNPs are intergenic, complicating 
identification of functional mechanism. In order to identify potential target genes, I used a 
range of publicly available datasets including gene expression QTLs (eQTLs) and promoter 
capture HiC data to query long-range interactions (Ward and Kellis, 2012, Chen et al., 
2016a, Javierre et al., 2016).  
 
Recently, it was demonstrated that complex-trait associated variants are enriched in regions 
of the genome connected through long-range chromatin interactions (Javierre et al., 2016). 
Potential distal gene targets of non-coding variants were identified using specific chromatin 
interaction data (Javierre et al., 2016). Therefore, to identify possible gene targets, I 
intersected variant positions (Table 3.3) with the fragment locations of promoter-capture HiC 
data from primary human neutrophils (Javierre et al., 2016, Schofield et al., 2016). I identified 
that both of the top most significant variants, rs116811177 and rs115109232, overlap a 
fragment that connected these variants to the promoter (and gene body) of two protein-
coding genes; MAP3K1 and AC022431.2 as well as an interaction that connected these 
variants to the promoter of the MIER3 gene (Javierre et al., 2016) (Figure 3.16). The latter 
gene, AC022431.2, which has no known genic annotation, was lowly expressed in 
neutrophils (median FPKM < 3 (Chen et al., 2016a)). In contrast, MIER3 (the mesoderm 
induction early response protein 3) and MAP3K1 (mitogen-activated kinase kinase kinase 1) 
were both expressed in neutrophils with MAP3K1 being the most highly expressed (> 9 
median FPKM).   
 
Having identified possible gene targets, I next investigated whether the SNPs were 
associated with differential expression of these genes. I queried both publicly available gene 
expression data (HaploReg v4.1 (Ward and Kellis, 2012) and the primary human neutrophil 
RNA-seq data from the BLUEPRINT cohort (Chen et al., 2016a). I used data from 
unstimulated cells, rather than stimulated, as the PAF & fMLP respiratory burst response was 
known to be a fast reaction (minutes) rather than over several hours. Therefore, any gene 
expression effect associated with these SNPs would have to be present in unstimulated 
neutrophils. The low-frequency rs116811177/rs115109232 SNPs were not tested as part of 
the BLUEPRINT, therefore I retrieved the normalised FPKM gene expression values and the 
genotypes of individuals discordant at these SNPs in order to identify any evidence of gene 
expression effects. Within this cohort, nine individuals were heterozygous for rs116811177 or 
rs115109232. I also considered genes in the proximal region with a median neutrophil gene 
expression value greater than 3 FPKM and those with a known function. The included: 
IL31RA, IL6ST, ANKRD55, FLJ31104, MAP3K1, SETD9, MIER3, SLC38A9 (Figure 3.14). I 
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did not detect any significant differences in gene expression for any gene including MAP3K1, 
despite the significant long-range chromatin interactions (Figure 3.16).  
 
I did not observe any further epigenomic intersections with the rs116811177/rs115109232 
SNPs and other datasets such as histone modification peaks or transcription factor binding 
(H3K4me1, H3K27ac, H3K4me3, PU.1, C/EBPb, C/EBPe, cohesin) using the bedtools 
intersect function (Materials and Methods).  
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Figure 3.16: Functional annotation of the rs116811177/rs115109232 (MAP3K1) locus 
Top panel depicts long-range interactions of the rs116811177/rs115109232 locus with various genes 
(labelled). Significant neutrophil interactions are shown in purple, with the MAP3K1 promoter 
interaction in yellow with interaction score of 12 (> 5 is a significant interaction over background) 
(Cairns et al., 2016, Dryden et al., 2014). This figure was produced using the Capture HiC Plotter 
(CHiCP) accessed in July 2017 (Schofield et al., 2016). The bottom panel shows there is no evidence 
of differential MAP3K1 gene expression with respect to genotype of the rs116811177 SNP.  
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3.3.4 Replication of the rs116811177/rs115109232 locus in an independent 
cohort 
In order to investigate whether we could replicate the association at the 
rs116811177/rs115109232 locus, we established an independent cohort of healthy 
individuals from Sanquin Research, University of Amsterdam, the Netherlands (Materials and 
Methods). The DNA from healthy individuals was genotyped at the Wellcome Trust Sanger 
Institute and the final number of individuals in this cohort was 140 (Materials and Methods).  
 
We aimed to use this cohort to replicate the increase in respiratory burst response within 
donors that were either heterozygous or homozygous for the effect allele of the 
rs116811177/rs115109232 locus. We decided that individuals of all three genotypes would 
be recalled and tested on the same day, in part to mitigate against the observed source of 
co-variation that can be introduced in measuring function on different days. Within the 
Sanquin cohort, there was one individual homozygous for the increasing PAF/fMLP 
respiratory burst effect allele (GG) and five heterozygous individuals. The homozygous 
increasing (GG) individual was recalled on the same day as individuals of either the 
heterozygous (GT) and homozygous decreasing (TT) genotype. These experiments are 
technically complex to perform and therefore a maximum of six individuals could be recalled 
on one day. The experiments were performed at Sanquin Research by Anton Tool.  
 
Figure 3.17 shows the initial replication effort where the respiratory burst response was 
measured in nmol H2O2/min per million neutrophils, where the raw measured RFU was 
converted to nmol using a calibration curve of known concentrations of H2O2. A higher 
concentration of H2O2 corresponds to a higher RFU and therefore higher response that could 
be compared to the Cambridge discovery cohort. Figure 3.17 shows a higher PAF fMLP 
respiratory burst response in a homozygous increasing individual (rs116811177, GG) 
compared to an individual of TT genotype (non-carrier, Figure 3.17). No similar difference in 
response was observed for the other conditions tested (Figure 3.17). The high PAF and 
fMLP response associated with increasing copies of the G allele was consistent with the 
observations of the effect of this locus in the Cambridge discovery cohort (Figure 3.15).   
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Figure 3.17: The rs116811177/rs115109232 (MAP3K1) locus in an independent cohort 
Neutrophil function responses for different stimuli and donors (bars) as measured at Sanquin 
Research by Anton Tool. The different bars are coloured based on the genotype of the 
rs116811177/rs115109232 locus. Genotype groups refer to the predicted direction of PAF/fMLP 
respiratory burst effect from the original Cambridge cohort (Figure 3.15). A similar increase in PAF and 
fMLP response is seen in the homozygous-increasing individual compared to the non-carriers. The 
response is measured in nmol H2O2 per minute per million neutrophils by conversion using a 
calibration curve. Error bars on the plots demonstrate the difference between technical replicates. 
PMNs = polymorphonuclear neutrophils. Figure adapted from Anton Tool. 
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3.4 Discussion 
We demonstrated, through thorough exploration and visualisation, how functional 
phenotypes are highly complex in both acquisition and sensitivity to environmental and 
technical factors, although good agreement was observed between technical replicates. I 
observed that after applying linear regression, the residuals, which contain the remaining 
variation after removal of specified sources of co-variation, did not show clear batch 
stratification (Figure 3.10). Some neutrophil responses were affected by external factors such 
as season (Figure 3.9, Supplementary Figure 3.1).  
 
Previously the effect of annual seasonality on cytokine production from stimulated PBMCs 
and macrophages has been shown in the Human functional genomics project (Ter Horst et 
al., 2016). In this study, the authors also tested the effect of season on cytokine immune 
responses using a linear regression approach and demonstrated that the production of 
TNFa, IL-1β and IL-6 are highest in the summer. Conversely, the anti-inflammatory alpha-1-
antitrypsin (AAT) production was highest in the winter. AAT seasonality was inversely 
correlated with the incidence of joint-disorder gout in a cohort of 800 patients. AAT inhibits IL-
1β corresponding to lower cell infiltration into mouse joints, potentially explaining how the 
drop of AAT increases the inflammatory environment leading to exacerbation of gout (Ter 
Horst et al., 2016). There is, therefore, precedence for the effect of season on immune 
responses. I observed that in most cases, neutrophil functional responses were lowest in 
winter. The biological reasons and physiological implications for this are unclear and could 
reflect seasonality or differences in environmental temperatures in experimental processing. 
The decreased inflammatory response in winter was in agreement with that observed by Ter 
Horst et al. (2016). In future, it would be interesting to investigate any available clinical data 
in order to assess any physiological correlations with this observation. In this study, the effect 
of season was removed using linear regression prior to genetic association tests.  
 
Individual’s age and gender did not have a large significant effect on most neutrophil 
responses as shown by the small R2 values and non-significant p values from ANOVA 
testing (Figures 3.8-3.9). Previously, differences in neutrophil differential gene expression 
have been observed between males and females (Ecker et al., 2017). Genes with higher 
expression levels in females were enriched in immune response pathways but those 
increased in males were enriched in basic cellular processes, which the authors suggested 
could explain the higher incidence of autoimmune diseases in women. Therefore, gender 
(and age) effects could have an effect on some responses, but in comparison to 
experimental factors and season the R2 estimates are lower. Indeed, gender was found to be 
a significant covariate for adhesion stimulated with TNF (p value = 3.9 x 10-03), Pam3Cys (p 
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value = 0.029), LPS (p value = 6.6 x 10-04) and fMLP (p value = 0.020) but was not significant 
for any degranulation or respiratory burst traits. 
 
Encouragingly, after correction for sources of co-variation, the correlation of trait 
measurements seemed to recapitulate aspects of previously observed biological 
relationships between these functional responses. Degranulation and respiratory burst traits 
formed a separate cluster compared to adhesion responses, which perhaps suggests the 
former biological processes share biological pathways or could be co-regulated. 
Degranulation responses and adhesion responses showed the lowest correlation of all 
comparisons. In the degranulation assay, we stimulated neutrophils with the soluble stimulus, 
fMLP. When using soluble stimuli, we know that DQBSA is cleaved by the elastase and 
Cathepsin G proteases, which are released into the neutrophil supernatant (Anton Tool, 
personal communication). These two proteases are contained in the azurophilic granules, 
which are known to be released at later stages in the neutrophil activation process (Table 
3.1) (Amulic et al., 2012). Therefore, this may explain the low correlation with adhesion 
processes, which occur earlier in neutrophil activation.  
 
There is evidence for adhesion-stimulated degranulation (and ROS production) in an 
“outside-in” signalling process mediated by integrins. Integrin interaction with surface-bound 
anti-b2 and anti-b3 monoclonal antibodies alone, without inflammatory stimulus activation, 
induces neutrophil respiratory burst (Berton et al., 1992, Lowell et al., 1996, Berton and 
Lowell, 1999). Indeed, regulation of these processes is required to prevent aberrant 
inflammation. An initial inhibition of ROS production following neutrophil adherence to the 
extra-cellular matrix proteins such as fibronectin, fibrinogen and laminin, acts as a 
mechanism to prevent inappropriate tissue damage as these cells migrate towards inflamed 
tissues (Zhao et al., 2003, Al Laham et al., 2010). However, currently, the full pathways 
involved in these responses are not yet known so further experimental evidence is required 
to thoroughly interpret these correlations. 
 
We were able to sufficiently correct for known technical and biological sources of covariation. 
However, the experimental design of this study did not enable correction for unknown 
sources of covariation or day-to-day effects. Studies with higher sample sizes have 
demonstrated a vast number of factors that lead to variation in trait values, for example in the 
large GWAS (N ~ 174000) of mature blood cell counts co-variation sources included time of 
measurement, menopausal age or smoking status (Astle et al., 2016). However, the 
detection of these effects in our study is limited by the low sample numbers, low number of 
traits and low number of individuals measured in one day (owing to the technical complexity 
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of the assays). In most cases (56%), only one donor was measured per day, prohibiting 
approaches such as within-day standardisation to correct for day-to-day changes.  
 
These issues highlight the importance of extensive exploration of association signals using 
other sources of biological data. In the original Cambridge discovery cohort, we identified a 
single genetic locus of two highly correlated, low-frequency SNPs rs116811177 (EA = G, 
EAF = 0.02, beta = 2.92, SE = 0.398, p value = 2.39 x 10-11) and rs115109232 (EA = A, EAF 
= 0.02, beta = 2.92, SE = 0.398, p value = 2.39 x 10-11) reaching genome-wide significance 
associated with the fMLP/PAF respiratory burst response. There were five heterozygous 
donors for the rs116811177/rs115109232 (MAP3K1) locus predicted have an increased 
respiratory burst response. Four of these donors had genetic data available from whole-
genome sequencing (mean PAF + fMLP RFU 6 residualised trait value = 2.12) while the 
remaining donor had data available from a genotyping chip (PAF + fMLP RFU 6 residualised 
trait value = 0.93). We identified that two of these donors had been assayed on the same day 
(26th January 2015). I identified that there were no reagent batch changes between the 
previous days and when these two donors were measured and both donors were female. 
This suggests that the increased responses were not due to any known sources of 
covariation. Given this limitation in our study design, we designed the Sanquin replication 
study (described below) so that donors of different genotypes will be measured on the same 
day, removing the possibility of day-to-day variation in affecting these responses.  
 
Despite these limitations, there is evidence that the proposed target gene of this locus, 
MAP3K1, is important in the respiratory burst response. MAP3K1, also known as MEKK, is a 
signalling kinase that activates the ERK and JNK pathways to coordinate downstream 
cellular processes such as proliferation, differentiation and stress (Chadee et al., 2002). It 
has also been observed that MAP3K1 is activated in response to fMLP in primary 
neutrophils, which is the same chemoattractant stimulating the respiratory burst response to 
which the rs116811177/rs115109232 is associated (Avdi et al., 1996). This could indicate 
that, through an effect not mediated by gene expression, the variants influence MAP3K1 
functioning in the respiratory burst response. For example, the phosphorylation status of 
MAP3K1 could be altered as a function of genotype, which could be experimentally 
measured and is under discussion as future work in the replication cohort. Further 
annotations provided by the HaploReg resource (Ward and Kellis, 2012) also provided 
evidence that this region may be important in cellular signalling. The signalling compound, c-
FOS has been shown in HUVEC cells to be bound at the r116811177 variant site using 
ENCODE ChIP-seq approaches. The second variant at this locus, rs115109232, is predicted 
to disrupt a Myc transcription factor motif, which is another important signalling molecule.  
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Subsequent to this analysis, it was identified that the Buffer 3 used in neutrophil preparation 
contained citrate, likely to facilitate measurement of full blood count in the Sysmex analyser. 
Citrate acts to chelates extracellular calcium, which could reduce calcium influx and in turn 
diminish neutrophil functional responses. Subsequent experimental repeats of these assays 
with and without calcium in the buffer demonstrated a decrease in functional responses. This 
could result in a decrease in power to detect signals and places greater importance on fully 
replicating the genome-wide significant locus identified in the Cambridge discovery cohort.  
 
In conclusion, despite the small number of samples, this study showed that GWAS of 
neutrophil functional traits could provide a means for discovering novel regulatory regions 
controlling immune responses, in this particular case of the neutrophil fMLP-respiratory burst 
response. However, the use of such datasets to annotate disease-risk loci that could be 
explained by dysregulated neutrophil function would require greater sample sizes as we were 
limited in power in this present study to broadly annotate disease-risk loci.  
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Collaboration Note 
The recall organisation of individuals and collection of blood samples was performed by staff 
at the NHS Blood and Transplant Department, Addenbrooke’s Hospital, University of 
Cambridge.  
 
Experimental work and assay development was supervised by Kate Downes as part of 
Willem Ouwehand’s team at the Department of Haematology, University of Cambridge. 
Genotype QC and processing were performed by Heather Elding and the merging of the 
genotypes relevant for this study was performed by Klaudia Walter. All other analyses were 
performed by myself.  
 
The Sanquin cohort was coordinated in conjunction with Anton Tool, Taco Kuijpers and Judy 
Geissler. Replication and further experiments were performed by Evelien Sprenkeler and 
Anton Tool at Sanquin Research, The Netherlands. 
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4 Dissecting the functional relationship between neutrophil 
count and surface expression of cellular receptors  
 
4.1 Introduction 
In the previous chapter, I discussed how studying genetic regulation of cellular traits could be 
complementary to studying molecular phenotypes in discovering novel pathways or genes 
involved in immune responses. Heritable genetic variation of a broad range of blood cell 
frequencies has also been previously identified using quantitative FACS-based 
immunophenotyping (Orru et al., 2013). In this study, immune cell frequencies of 95 cell 
types were profiled and the genetic contribution of 272 immune traits in a cohort of 1,629 
Sardinian individuals was evaluated (Orru et al., 2013). The authors identified 23 
independent variants at 13 loci and found three loci were known autoimmune risk genes 
(HLA, IL2RA and SH2B3/ATXN2). Hierarchical gating using antibody-labelled cellular 
receptors enabled the assessment of cell types such as regulatory T (TREG) cells, which are 
mostly characterised by the surface expression of CD39. These cells play important roles in 
regulating immune responses and preventing autoimmunity and from this study, were 
observed to be the most heritable traits (mean 55%).  
 
In addition to investigating cell frequencies, studying the cellular surface expression levels of 
proteins adds a further layer of functional insight into immune responses (Roederer et al., 
2015). The heritability of 78,000 immunophenotype traits in 669 female twins was evaluated, 
and 11 genetic loci explaining up to 36% of the variation in 19 traits (from the top 151 
heritable traits genetically assessed) were identified (Roederer et al., 2015). In this study, 
associations with two different mechanisms are described; the homeostatic regulation of cell 
levels through proliferation or elimination of a certain cell type and the regulation of the 
expression of the protein, presumably through variants affecting promoter or enhancer 
activity (Roederer et al., 2015). The authors examined the same highly heritable TREG 
ENTPD1/CD39 locus, through a variant in LD with the first identified by Orru et al. (2013), 
and found the association was explained by the phenotype (i.e. expression level of CD39), 
rather the frequency of TREG cells (Roederer et al., 2015). Therefore, cell population 
frequencies and the surface expression of phenotypic receptors are both highly heritable and 
thus integrating multiple sources of functional data aids our understanding of biological 
systems. In both studies, significant loci were also known to be associated with disease risk.  
 
I discussed in Chapter 1 how using an automated haematology analyser enables the 
measurement of mature blood cell counts, albeit a lower range of cell types compared to a 
FACs-based approach but the method is amenable for large cohorts, in this case of 173,480 
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European-ancestry individuals (Table 1.2) (Astle et al., 2016). This GWAS exemplified how 
studying the variation of haematological traits provided insight into blood cell biology and also 
the general architecture of complex traits. An unprecedented 2,706 independent variants 
associated with variation in 36 indices were identified (Astle et al., 2016). The functional 
importance of both coding and regulatory variants was demonstrated. Enhancer variants 
explained 19%-46% of heritable variation, similar to that of transcribed regions (4-30%). 
Coding variants were enriched in Mendelian genes, and medically important observations 
were made in leukocyte subsets, which previously had been investigated in studies of limited 
power (Astle et al., 2016). The associations from this GWAS provide a rich resource where 
in-depth functional interrogation of this dataset offers the opportunity to further dissect 
haematopoietic cellular biology.  
 
From an in-depth investigation of genetic loci associated with neutrophil count from the Astle 
et al. (2016) blood GWAS, I observed many cases of significant variants located within or 
nearby to genes encoding cellular receptor proteins. Roederer et al. (2015) posit that the 
surface expression of proteins represents an independent mechanism compared to cell 
levels. The variants from the Astle et al. (2016) GWAS were associated with neutrophil count 
but located in genes encoding receptors not traditionally used to quantify cell phenotypes. In 
addition, these receptors were known to be involved in neutrophil biology. Therefore, I 
postulated that variation in receptor levels associated with these loci, could be functionally 
linked to cell count. Differences in the surface expression of the receptor protein could result 
in altered receptor signalling, which in turn influence the numbers of circulating cells. 
 
After applying prioritisation methods described in Materials and Methods, I investigated 
variants associated with neutrophil count located in genes encoding two receptors, the 
granulocyte colony-stimulating factor receptor (GCSFR) and the urokinase receptor 
(PLAUR).  
 
GCSFR is expressed on the surface of progenitor and mature neutrophil granulocytes, 
with higher surface receptor expression levels detected at later stages of development, on 
more mature neutrophils (Nicola and Metcalf, 1985, Panopoulos and Watowich, 2008). 
Differentiation from haematopoietic stem cells to granulocytes is highly dependent on G-
CSF and to a lesser extent, GM-CSF (Mehta et al., 2015). The main motivation for 
investigating a possible functional relationship between count and surface expression is 
that GCSFR is essential for granulopoiesis and the cognate ligand to the receptor, G-CSF, 
is the principal cytokine-regulator of neutrophils (Panopoulos and Watowich, 2008). 
Both G-CSF and GCSFR- deficient mice have chronic neutropenia, with significant 
reductions in the levels of peripheral neutrophils and granulocytic precursors in the bone 
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marrow (Lieschke et al., 1994, Liu et al., 1996). In normal conditions, G-CSF stimulates 
proliferation of all stages of granulopoiesis and increases neutrophil survival (Lord et al., 
1989, Liu et al., 1996). This increased proliferation and survival is important to meet the 
demand of infection but is also exploited in clinical administration of G-CSF to neutropenic 
patients with very low neutrophil numbers (Panopoulos and Watowich, 2008, Sung and 
Dror, 2007). Both effects are termed ‘emergency’ granulopoiesis. (Semerad et al., 2002). 
Resolving the mechanism whereby variants located in the CSF3R gene are associated 
with neutrophil count is therefore clinically relevant. 
 
In addition to stimulating neutrophil production, G-CSF also affects function (Betsuyaku et 
al., 1999). The ROS response to fMLP is increased in neutrophils primed with G-CSF 
(Betsuyaku et al., 1999). The residual neutrophils that remain in GCSFR-deficient mice 
show impaired functionality such as adhesion and migration in response to IL8 (Betsuyaku 
et al., 1999). GCSFR signalling is therefore required for particular functions of normal 
neutrophils. 
 
Acquired GCSFR mutations increase the risk of acute myeloid leukaemia (AML) in patients 
with severe chronic neutropenia (SCN), for example due to C-terminal truncations that impair 
internalisation, increase surface receptor levels and stimulate proliferation over differentiation 
(Touw, 2015, Liongue and Ward, 2014, Ward et al., 1999, Aarts et al., 2004). Hereditary 
autosomal GCSFR mutations have also been observed, for example, T617N results in 
chronic neutrophilia due to constitutive activation of GCSFR as a result of dimerisation of the 
transmembrane domain (Plo et al., 2009). Clearly, GCSFR plays a key role in controlling 
neutrophil numbers and differentiation.  
 
I investigated a second receptor to evaluate whether a functional relationship between 
surface expression and neutrophil count may be widespread. The plasminogen urokinase 
receptor (PLAUR/uPAR) receptor missense variant, rs4760, was highly associated with 
neutrophil count. PLAUR, associates with the plasma membrane via a GPI-anchor, and 
binds and activates the extracellular urokinase-type plasminogen activator (uPA/urokinase) 
(Smith and Marshall, 2010). Active uPA then generates the protease plasmin, which in turn 
cleaves extracellular matrix components. Through this process, uPAR regulates proteolysis, 
cell survival, growth and migration (Smith and Marshall, 2010). Expression of PLAUR is 
increased during inflammation and tissue remodelling and is correlated with poor prognosis 
in cancer making this receptor a potential therapeutic target (Smith and Marshall, 2010, Del 
Rosso et al., 2008). 
 
 169 
Neutrophils express uPA and its receptor, PLAUR/uPAR (Gyetko et al., 1995). PLAUR 
functionality plays an important role in leukocyte adhesion and migration. PLAUR expression 
is increased during differentiation and activation of leukocytes, suggesting this receptor plays 
an important role in immune function (May et al., 1998, Nusrat and Chapman, 1991, Smith 
and Marshall, 2010). Treatment with an anti-CD87 (PLAUR) antibody inhibited chemotaxis in 
PMNs but was unaffected by anti-uPA antibodies, implicating the receptor in neutrophil 
function and migration (Gyetko et al., 1995). During specific infection with the bacteria 
S.pneumoniae, PLAUR-deficient mice had diminished granulocyte accumulation in the lungs 
and reduced survival, clearly providing evidence of the importance of PLAUR in neutrophil 
inflammatory responses (Rijneveld et al., 2002). 
 
4.1.1 Aims of this chapter 
I performed flow cytometry experiments in a recall-by-genotype (RbG) study (Section 1.6) to 
test whether pre-selected significant neutrophil count variants could also affect the surface 
expression of these receptors, potentially reflecting a functional link between this and 
neutrophil count. I also integrated my findings with available data sources including 
neutrophil molecular traits from the BLUEPRINT consortium (Chen et al., 2016a). In 
comparison to the functional GWAS I carried out in Chapter 3, which was performed over a 
year, this study took place over only two weeks. Blood was collected by the same nurses, 
and the same machine and reagent batches were used. Increase control over covariates in 
this shorter study allowed greater control over technical variability such as that observed in 
Chapter 3. 
 
Using such a RbG study design, I collected a panel of 2 cell surface markers of specific gene 
candidates (see below) measured in up to 70 individuals divergent for alleles of the 
independent neutrophil-count associated variants (Figure 4.6 and Section 4.2.1). I measured 
the mean fluorescence intensity of selected receptors, PLAUR and GCSFR on the surface of 
neutrophils in whole blood from healthy donors. I then tested the association of SNPs located 
within the receptor gene (and +/- 500 kB) with the level of these receptors as measured 
using flow cytometry. I then further integrated molecular sources of information and other 
external datasets to explain my observations and provide functional hypotheses. 
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4.2 Materials and Methods 
4.2.1 Selection of receptor and genetic variant candidates for experimental 
follow up 
This hypothesis-driven investigation was the result of my efforts to thoroughly integrate 
genetic information from a neutrophil count trait GWAS (Astle et al., 2016) with epigenetic 
and transcriptional information from the BLUEPRINT consortium (Chen et al., 2016a).  
 
As of December 2015, there were 17,673 variants associated with neutrophil count, which 
were clustered into 134 high LD groups (Astle et al., 2016). For the selection of 
candidates, I focused on common variants to ensure sufficient donor stratification across 
genotype groups in a cohort of less than 100. Applying this filter reduced the number of 
variants to 17175 and LD groups to 124. Genes were assigned to each variant if a variant 
overlapped a gene(s) and also the nearest upstream and downstream gene was also 
assigned. This resulted in a total of 567 unique assigned genes. Although these genes 
were assigned solely on proximity, a number of the most significant gene ontology terms 
identified using g:profiler suggested relevance to neutrophil biology, such as phagosome 
(p value = 9.92 x 10-13), immune response (p value = 3.42 x 10-11) and cytokine-mediated 
signalling pathways (p value = 6.40 x 10-10) (Reimand et al., 2016). Of these 364 had a 
known function using the PANTER classification gene ontology system (Version 12.0) (Mi 
et al., 2017). 11.5% of genes with a known function were annotated with “receptor activity” 
(Figure 4.1). I found, for example, that of the variants located directly within a gene, 21% 
had known receptor function including CSF3R, SLC25A24, FCGR2B, SLC12A7, 
SLC22A4, HLA-A, HLA-C, SLC44A4, HLA-DRB1, PLAUR, LY75, ACKR2, MYO1G, 
ACVRL1 and VMP1. 
 
I speculated that there may be a relationship between receptor cellular surface expression 
and neutrophil count, likely underpinning the role of signalling and cell communication during 
differentiation of mature neutrophils. Therefore, I set to test the hypothesis that genetic 
variants affecting neutrophil count could exert their effect through a change in receptor 
expression on the cell surface. I established several additional criteria for the selection of 
downstream variants from variants annotated with a known receptor gene. There must be a 
known function of the receptor in neutrophil biology. The region of association must be 
resolved to one or a few SNPs so there is a higher chance of identifying a causal signal 
linked to the experimental measurement.  
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Figure 4.1: Molecular function of neutrophil count variant assigned genes  
Pie charts show the proportions of molecular function annotations of the 364 genes with functional hits 
in the PANTER version 12 classification system. Receptor activity (11.5%) is highlighted in orange. 
The second pie chart (below) shows the proportions of molecular function terms within the highlighted 
receptor activity annotation.  
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I used neutrophil promoter-capture HiC data to verify that the assigned gene was the likely 
gene targeted by the variant (Javierre et al., 2016). If the presence of long-range 
chromosome interactions suggested the variants could be interacting with other likely 
candidate genes, then these loci were excluded. Criteria for gene functionality included 
expression in neutrophils or a known role of the gene in neutrophil biology. There must be 
available an antibody against the candidate receptor that has been previously validated in 
neutrophils. The antibody must be available conjugated to the fluorophore, phycoerythrin 
(PE), which emits a bright and stable fluorescence. The experimental design of the recall 
study, with up to 13 donors per day, limited the number of candidates I could feasibly 
investigate to a maximum of three. 
 
I applied these criteria to annotated genes as described above and prioritised two receptor 
candidates for downstream analysis; the granulocyte colony stimulating factor 3 receptor 
(GCSFR) and the urokinase receptor (PLAUR/uPAR). The existing genetic evidence for 
these loci is discussed below.  
 
4.2.1.1 G-CSF receptor  
GCSFR is encoded by the CSF3R gene (Entrez Gene:1441, Ensembl:ENSG00000119535). 
I have described how GCSFR plays a key role in differentiation leading to the production of 
mature neutrophils. I postulated that variation in surface expression levels could impact on 
neutrophil count or vice versa.  
 
An overview of the neutrophil count association in the Astle et al. (2016) study in this region 
is shown in Figure 4.2. The variant rs3917932 had the strongest association with neutrophil 
count (EAF =0.42, beta = 0.048, SE = 3.63 x 10-03, p value = 2.06 x 10-39, N = 173,480, Table 
4.1) and is also associated with granulocyte count, myeloid count, white blood cell count, 
monocyte percentage, neutrophil percentage, lymphocyte percentage, granulocyte 
percentage of myeloid cells, neutrophil + eosinophil count and basophil + neutrophil count. 
Conditional analysis was performed at the locus as part of the Astle et al. (2016) study. The 
authors also found a second low-frequency variant, rs3917914 (EAF = 0.01, beta = 0.16, SE 
=1.69e-02, p value = 1.69 x 10-22) in the same locus by regressing out the common signal 
(Astle et al., 2016). rs3917914 is also associated with granulocyte count, myeloid count, 
white blood cell count, neutrophil + eosinophil count and basophil + neutrophil count.  
 
To the best of my knowledge, there is no previous study investigating whether genetic 
variation in the neutrophil receptor surface expression also influences neutrophil count in 
healthy individuals. The experimental process I designed in this chapter tests the surface 
expression of GCSFR on mature circulating neutrophils. The count measured in the Astle et 
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al. (2016) paper describes the numbers of mature circulating neutrophils in a unit of whole 
blood. Therefore, this allows me to test my hypothesis that the expression of surface 
receptors on mature neutrophils is related to the numbers of mature neutrophils in the 
circulation using genetics as an anchor for causality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Genetic variants associated with neutrophil count in and around the 
CSF3R gene  
Regional association plot of variants associated with neutrophil count around the CSF3R locus. 
Conditional analysis performed as part of the analysis in Astle et al. (2016) revealed two independent 
Intronic signals, rs3917932 (common) and rs3917914 (rare/low frequency). The chromosomal location 
(hg19) is shown on the x-axis, the left-hand y-axis is the -log10(p-value) of association with the trait.  
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4.2.1.2 PLAUR 
The second candidate under investigate was the PLAUR receptor, encoded by the PLAUR 
gene (Entrez Gene:5329, Ensembl:ENSG00000011422). One missense variant, rs4760, is 
located within an exon of the PLAUR gene and is significantly associated with neutrophil 
count (EAF=0.84, beta = 8.61 x 10-02, SE= 4.92 x 10-03, p value = 1.43 x 10-68) (Table 4.1). 
rs4760 is also associated with granulocyte count, myeloid count, white blood cell count, 
monocyte percentage, neutrophil percentage, lymphocyte percentage, granulocyte 
percentage of myeloid cells, neutrophil percentage of granulocytes, neutrophil + eosinophil 
count and basophil + neutrophil count (Astle et al., 2016). rs4760 is associated with 
neutrophil count approximately 40 orders of magnitude more strongly than remaining SNPs 
in the proximal region. These proximal SNPs are also located within the neighbouring gene, 
CADM4 (Figure 4.3). Therefore, it is highly likely that rs4760 is the causal SNP in this locus.  
 
The rs4760 missense variant causes a leucine to proline amino acid change at residue 317 
(L317P). rs4760 is predicted to be possibly damaging in the angiogenesis pathway by 
PolyPhen prediction from the Cancer Genome Anatomy Project Genetic Annotation (Savas 
et al., 2006). Residue 317 is located within a PLAUR protein isoform 1 domain predicted to 
be non-cytoplasmic using Phobius (Kall et al., 2007). The probability of that this domain is 
transmembrane decreased when I manually substituted the leucine 317 for a proline (0.4 to 
0.1 where 1 is maximum likelihood) (Kall et al., 2007). This may suggest that this residue 
could impact the transmembrane domain or non-cytoplasmic domain functionality.  
 
Therefore, rs4760 and the PLAUR receptor were included in this study given the role of the 
PLAUR receptor in neutrophil biology and particular disorders as well as the prediction that 
this variant could affect receptor stability. The inclusion of PLAUR and GCSFR also enables 
dissection of the effects of both intronic (CSF3R) and missense (PLAUR) SNPs.  
 
In comparing the two receptor candidates studied here, GCSFR plays a pivotal role in 
neutrophil differentiation. PLAUR has been implicated in macrophage differentiation and 
phorbol-ester mediated differentiation of the neutrophil model cell line, HL60 (Rao et al., 
1995, Nusrat and Chapman, 1991). Therefore, demonstrating a shared relationship between 
neutrophil count and PLAUR surface expression might indicate a possible role in neutrophil 
development. In the case of GCSFR, indication of a shared relationship could highlight the 
importance of receptor number on the surface in differentiation by directly linking receptor 
signalling to neutrophil count. 
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Figure 4.3: Genetic variants associated with neutrophil count in and around the 
PLAUR receptor gene  
Regional association plot of variants associated with neutrophil count from the Astle et al. (2016) 
study. The most significant SNP, rs4760 is a missense SNP located in an exon of the PLAUR gene. 
rs4760 is more than 40 orders of magnitude more significant than remaining SNPs in the locus and is 
therefore predicted to be causal for the neutrophil count association in this locus. 
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rsID Chr:pos (hg19) EA/OA EAF Effect (SE) Astle Neu count P Gene Type 
rs4760 19:44153100  G/A 0.16 
-8.61 x 10-2 
(4.92 x 10-03) 1.43 x 10
-68 PLAUR Missense L317P 
rs3917932 1:36943916  C/G 0.42 
4.80 x 10-02 
(3.63 x 10-03) 
 
2.06 x 10-39 CSF3R Intron 3 full transcript (First intron of CSF3R-204) 
rs3917914 1:36947888 A/G 0.01 1.60 x 10
-01 
(1.69 x 10-02) 9.54 x 10
-22 CSF3R Intron 1 of full transcript (and truncated CSF3R-008 
 
 
 
 
Table 4.1: Candidate variants selected for functional follow-up  
Neutrophil-count (number of neutrophils per nL per unit volume of blood) associated variants from the blood count GWAS (Astle et al., 2016). The effect size 
is expressed in SD of the trait. The conditionally independent variant(s) for the CSF3R (one common, one rare) and PLAUR (one common) loci are listed. 
CSF3R gene transcripts, as referred to in the table, are shown in Figure 4.10. EA = the effect allele, here defined as corresponding to the decreasing receptor 
expression allele for the CSF3R locus (see Table 4.5). SE = standard error. EAF = effect allele frequency. P = p value of neutrophil count. 
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4.2.4 Study samples 
Individuals were recalled from the NIHR Cambridge BioResource 
(http://www.cambridgebioresource.group.cam.ac.uk) as part of the UNICORN study 
organised at the NHSBT, Addenbrooke’s Hospital. All individuals were of blood group O. 
Peripheral blood samples were collected from healthy donors with informed consent (A 
Blueprint of blood cells, REC 12/EE/0040, East of England-Hertfordshire Research Ethics 
committee). The cohort used for functional interrogation of the relationship between receptor 
surface expression and neutrophil count comprised of 70 individuals of European descent. 
The mean age of the individuals was 61.27 years, and the range was from 25 to 79 years. 
The cohort consisted of 27 males and 43 females. After integrating with available genotype 
data, and exclusion of outliers, the final sample numbers used for association were 66 
(GCSFR) and 65 (PLAUR).  
 
4.2.5 Flow cytometry assessment of receptor surface expression  
Blood was collected from 70 individuals across seven days. The number of donors 
processed per day ranged from six to thirteen. Blood samples were experimentally 
processed in batches of three-four donors. In the experimental processing, antibody volumes 
(Table 4.2) were first pipetted into the bottom of each tube. 100 µl of blood from each donor 
was then added to each tube. For each individual, three separate tubes were prepared, two 
receptor tests and one unstained sample (no antibody) (Table 4.2). In tubes 1-2 (receptor 
tests), the sample was labelled with specific antibodies for CD16 (APC), CD66b (FITC), 
which were used to identify the double positive neutrophil population in the gating strategy 
(Figure 4.4). In tube 1 the antibody against CD86 (PLAUR-PE) was added and in tube 2 the 
antibody against CD193 (GCSFR-PE) was added. After adding blood, tubes were mixed by 
inverting three times. After 20 minutes of incubation in the dark at room temperature, the red 
blood cells were lysed by addition of 2 ml of lysing solution and vortexed for three seconds. 
Following a six-minute incubation in the dark at room temperature, samples were then 
centrifuged at 600 x g for six minutes at 4°C (accelerator 9 and break 9). The supernatant 
was discarded and the pellet was re-suspended gently in 500 µl of PBS. Samples were 
vortexed for three seconds and stored at 4°C until ready for flow cytometry analysis. The time 
of labelling, lysing, fixing was recorded and investigated as potential covariates (see below). 
The samples were measured using a Beckman Coulter GalliosTM Flow Cytometer system.  
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Table 4.2: Contents of each sample tube per donor  
Table summarises the experimental design where six tubes were made per donor, two tubes 
contained different combinations of antibodies, one was the unstained sample and three were 
compensation controls.  
 
Specific controls were prepared for each experiment. First, for every donor, an unstained 
sample was processed in parallel except without antibody addition (Figure 4.4, Table 4.2). 
Second, compensation beads for PE, FITC and APC were prepared once per week and 
measured on the GalliosTM every day. One drop of each compensation beads was added to 
each of three tubes (Table 4.2 and 4.4). Compensation beads provide two distinct 
polystyrene micro-particle populations; the positive population which binds to mouse k light 
chain immunoglobulins and the negative population of beads with no binding capacity. 
Compensation was required to adjust for any spectral overlap in the three colours, PE, FITC 
and APC used in these experiments. 1.25 µl of anti-APC, 5 µl of anti-FITC and 4 µl PE were 
added to tubes 4, 5 and 6 respectively. Tubes were incubated in the dark at RT for five 
minutes. 1 mL of PBS was then added to each tube and these were stored at 4°C until use. 
The FlowJo software auto-compensation procedure was used to adjust for the multicolour 
flow cytometry data (PE, FITC and APC were used all in one tube to detect GCSFR/CD87, 
CD66b and CD16 respectively).  
 
Third, control beads were run daily to verify the optical alignment of the lasers and 
functionality of the fluidics system. Flow-CheckTM Pro Fluorospheres, a suspension of 
fluorescent microspheres, were analysed on the GalliosTM machine. Prior to sample 
ascertainment, mean fluorescence values for each laser were measured to detect any 
deviations from the pre-selected ranges that may require re-alignment of the lasers. Laser 
voltage adjustment was required only on the second day of experiments and correct 
functionality was confirmed after adjustment using the Flow-CheckTM Pro Fluorospheres. 
Lastly, isotype controls against the functional receptors (GCSFR and CD87) (Table 4.3) were 
Tube Blood Vol (µl) Antibody 
Ab Vol 
(µl) 
Lysis 
Vol (ml) Other Tube Type 
Tube 1 100 
CD16 
CD66b 
PLAUR/CD87 
1.25 
5 
18 
2 - PLAUR test 
Tube 2 100 
CD16 
CD66b 
CSF3R/CD114 
1.25 
5 
9 
2 - GCSFR test 
Tube 3 100 - - 2 - Unstained 
Tube 4 0 CD16 APC 1.25 - One drop of 
each 
negative/positive 
compensation 
beads 
Compensation 
Control 
Tube 5 0 CD66b FITC 5 - 
Tube 6 0 PE test/CD193 4 - 
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run for one donor and confirmed the lack of a high level of non-specific background signal 
(data not shown).  
 
 
 
 
Protein Antibody Colour Source Volume (µl) 
CD16 Mouse anti-human, VEP13, mouse IgM APC Miltenyi, 130-091-246 1.25 
CD66b Mouse anti-human, G10F5, mouse IgM, k FITC BD Pharmigen, 555724 5 
CD87/PLAUR Mouse anti-human, VIM5, mouse IgG1, k PE BD Pharmigen, 555768 18 
CD114/CSF3R Mouse anti-human, LMM741 (RUO), mouse IgG1, k PE BD Pharmigen, 554538 9 
Isotype control 
for CD87 and 
CD114 
Mouse Isotype IgG1, k PE BD Pharmigen, 555749. Lot: 3046675 20 
Isotype control 
for CD66b 
Mouse IgM K, Clone G155-
228 PE BD Pharmigen, 555584 20 
 
 
Table 4.3: Antibodies used for each marker in flow cytometry assays  
Evidence of previous use in neutrophils for each clone type was assessed before final selection of the 
antibody (CD87 VIM5 (Elghetany et al., 2003), CD114 LMM741 (Piper et al., 2010)).  
 
 
 
 
Bead/Reagent Supplier Code 
Flow-Check Pro Fluorospheres Beckman Coulter A63493 
Anti-mouse Ig, k/negative control compensation 
particles set 
BD Bioscience (BDTM) 
CompBead 552843 
Set-up beads for green/yellow laser Life Technologies 
C16508 
LOT: 
1438512 
Set-up beads for blue laser Life Technologies 
C16509 
LOT: 
1438509 
Set-up beads for red laser Life Technologies C16507 
Lysing (and fixing) solution 10X Concentrate BD Biosciences, BD FACSTM 349202 
 
 
Table 4.4: Reagents and beads  
This table lists the beads used for the control experiments, the supplier and catalogue number along 
with the reference for the lysing solution used in the protocol to remove red blood cells. 
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Gating Strategy: Figure 4.4 shows the gating process used for all individuals to identify 
neutrophil populations. First, the fluorescence signal from the FL2 laser (PE) across time of 
measurement was assessed. This gate was used to remove potential machine technical 
factors such as debris in the fluidics system. The time gate was selected manually for each 
sample and judged to remove regions of lower density fluorescence measurements at the 
start of the reaction. A similar gating procedure was applied in a recent paper, also 
measuring median fluorescence intensity (MFI) of defined receptors on the surface of 
immune cells (Roederer et al., 2015). 
 
The granulocyte population of neutrophils was selected using a plot of forward scatter height 
(FS-H) and side-scatter height (SS-H) (Figure 4.4). This population contains both granular 
cells, neutrophils and eosinophils. Doublet cells were then removed and following this, the 
double positive CD16+CD66b+ neutrophil population was selected. CD66b was used as a 
marker of granulocytes and is expressed on the surface of both eosinophils and neutrophils 
(Yoon et al., 2007). CD16 is not expressed on the surface of naïve eosinophils, therefore 
allowing specific selection of neutrophil populations (CD66+CD16+) (Davoine et al., 2002). 
10,000 events/cells of the double-positive neutrophil population were collected for each 
sample. The median fluorescence intensity (MFI) of the receptors (PE, FL2 signal) was 
calculated from this population and used as an estimate of the surface protein expression. 
 
4.2.6 Phenotype processing and genetic association  
Phenotype processing: Receptors were treated separately as tube 1 (PLAUR) and tube 2 
(GCSFR) respectively. The receptor MFI level of the unstained population (per donor) was 
subtracted from the receptor MFI level of the double positive CD16+CD66b+ neutrophil 
population and referred to as the normalised MFI value. The data were analysed and MFI 
statistics calculated using the FlowJo analysis suite version 10.1r5. 
 
Outlier removal: the mean and standard deviation of the normalised MFI of a total of 67 
donors was calculated, and any MFI value outside of the mean +/- 3 standard deviations 
thresholds were excluded. Overall, there were 66 individuals with genotype data for GCSFR 
and 65 for PLAUR, shown in Figure 4.5. 
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Figure 4.4: Gating strategy  
Fluorescence plots used to measure neutrophil surface receptor MFI from whole blood. A)-D) 
Unstained E)-H) Stained. First the time gate removed technical artefacts. The granule population was 
selected using FS-H and SS-H (forward scatter height and side scatter height). Doublets are removed 
and finally the double-positive neutrophils are selected and MFI of either PLAUR or GCSFR was 
measured for this population using the PE signal.  
Unstained: 
Stained: 
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Figure 4.5: MFI by time including outlier exclusion thresholds  
Plot of normalised MFI levels (unstained subtracted) in order of acquisition (samples by date). The 
mean of the MFI of all individuals is shown by the solid line. The mean +/- 3 standard deviations (SD) 
is shown by the dashed line. Donors with MFI values falling outside of these thresholds were excluded 
from the downstream analysis.  
 
 
Covariate investigation and correction: Before association testing, I investigated potential 
sources of technical co-variation and stratification. Known covariates included age, sex, full 
blood count measures, date and experimental information that I recorded. These included 
time of bleed, labelling, and fixing and experimental processing batch. Given the compressed 
time-frame of this study, no reagent or antibody batch changes occurred. Up to 13 donors 
were processed per day prohibiting experimental processing of all samples together. 
Individuals were bled at 30-minute intervals; therefore, batches of three-to-five donors were 
processed (labelled and fixed) together. This minimised the time between bleed and 
processing. Groups of samples were designated into an experimental processing batch if 
there was an unforeseen change in the experimental protocol that could have introduced 
variation. For the time covariates, if there were too many levels (in some cases, there was 
only one donor with a specific time), bins of ten minutes were created. 
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Full blood count was measured using both a Sysmex XE-5000 and XN-1000 haematology 
analyser for each donor (collected at the time of blood collection by NHSBT collaborators). 
Results from both XE-5000 and XN-1000 were considered, and in the case of covariates, the 
most significant association was used to select the measurement for covariate selection. 
I used ANOVA to assess whether covariates had a significant effect on the mean values of 
inverse normalised (and unstained normalised) MFI across different levels. No significant 
covariates (p value < 0.05) were found for GCSFR MFI levels. However, given that the 
experimental processing covariate reflects known experimental variation, I took the approach 
of conservatively adjusting for this batch effect using a linear model with processing batch as 
a predictor variable and GCSFR as the response variable, which marginally improved the 
strength of association.  
 
I identified several significant covariates for PLAUR MFI values including date, experimental 
processing batch, sex, eosinophil count, time from bleed to labelling and time from bleed to 
fixing. Some of these covariates potentially measured the same effects, for example, the two 
time-period covariates and date and experimental processing batch. I corrected for each 
covariate in a linear model and used the residuals to test if the second covariate was still 
significant. In all cases the covariates were no longer significant in the second iteration of 
linear regression. Therefore, I corrected for the covariate with the lowest ANOVA p value.  
 
In summary, date, sex, time from bleed to labelling and eosinophil count were used as 
covariates in a linear regression model to correct for these effects on the PLAUR surface 
expression levels. After outlier removal, I inverse normalised the unstained subtracted MFI 
values and then used the lm() function in R to correct for the specified covariates. Covariates 
were input as factors (date, sex, experimental processing batch) or as numeric for covariates 
such as time from bleed to labelling and eosinophil count. The effect of these covariates on 
PLAUR and GCSFR MFI levels are shown in Supplementary Figures 4.1 and 4.2. The 
corrected residuals were then standardised and used as an input into the genetic association 
tests described below.  
 
I calculated the adjusted r2 parameter of the linear model for each covariate independently 
against PLAUR MFI. The following adjusted r2 values were obtained: Date (0.15), Sex (0.05), 
absolute eosinophil count (EO) (0.06) and time from bleed to labelling (0.20), indicating that 
date and time from bleed to labelling explained the most amount of variation in PLAUR MFI 
levels. The adjusted r2 value for the overall model, correcting for all four covariates was 0.39.  
 
Investigation of neutrophil size: I next investigated whether MFI was affected by neutrophil 
size where a larger neutrophil could express a greater number of receptors on the surface 
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and vice versa for a smaller neutrophil. Currently, it is not known whether there is significant 
variation in the size of neutrophils in a general population. Measurements using a DxH 800 
Coulter haematology analyser showed mean neutrophil volume was larger in sepsis patients 
and has been suggested as an additional clinical diagnostic measure for acute bacterial 
infection (Lee and Kim, 2013, Chaves et al., 2005). Neutrophil size may, however, be highly 
regulated in healthy populations to ensure the circulation of neutrophils through blood 
vessels of defined diameters.  
 
I used an independent cell size parameter, NE-FSC, measured by the Sysmex haematology 
analyser (see above). NE-FSC is the forward light intensity of the NEUT area and gives an 
indication of cell size. I also investigated NE-SSC, which is the side scattered light intensity 
and represents the internal complexity or granularity of neutrophils (Buoro et al., 2016, 
Sysmex Corporation, 2010-2012). I assessed the correlation of these two parameters with 
the surface expression of both receptors and found no strong or significant correlations of 
GCSFR or PLAUR MFI and neutrophil parameters (p value <0.05) (data not shown). The low 
non-significant correlations suggested, that within the power limitations of this study, there 
was no evidence of a relationship between cell size and receptor expression (represented by 
MFI). Therefore, I did not implement a further size-normalisation for the receptor MFI values 
in addition to the steps described above.  
 
Genotype processing: Individuals were genotyped as part of a large cohort by the NIHR 
Cambridge BioResource. Genotype processing was performed by Heather Elding, and 
standard genotype quality control procedures were followed as described in (Anderson et al., 
2010). Genotypes were imputed against the combined reference set of UK10K and 1000 
Genomes Phase 1. Imputed genotypes were used for the single variant genetic association 
tests described below. As described in Chapter 3, I am currently validating genotypes of all 
lead SNPs in this cohort with Sanger sequencing, particularly to confirm genotypes of the 
significant rare SNPs.  
 
Single-variant genetic association and conditional analysis: The variants were extracted from 
gen files containing all included genome-wide variants from the genotyped cohort of 80 
individuals. The region for the PLAUR locus was set from chr19:43650247 to 
chr19:44674699 (500 kb upstream and downstream of the gene start and end positions). The 
region for the CSF3R locus was set from chr1:36431644 to chr1:37448879 (500 kb upstream 
and downstream of the gene start and end positions). Phenotype values were inverse 
normalised after outlier removal and corrected for covariates as detailed above. 
Standardised residuals were formatted in gen .sample format and input into SNPTEST v2.5, 
a slightly newer version that enables analysis of fewer than 100 samples (66 for GCSFR and 
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65 for PLAUR). The same linear model was fitted for each variant as described in Chapter 2 
Materials and Methods using the same options except with the additional (-
use_lower_sample_limit). For conditional analysis, this was run separately by conditioning on 
(condition_ on additive model) rs3917924 and rs3917912 as the top common SNP and rare 
SNP respectively. The analysis was also run by conditioning on both SNPs.  
 
Variant pruning: PLINK v2 was used to generate a list of independent variants using the -- 
indep option. The variants tested (gene +/- 500kb) were pruned using a pairwise r2 threshold 
of 0.1 with a variant count window of 500. Pairs of variants in the current window with a 
squared correlation greater than the threshold are pruned until no such pairs in the window 
remain.  
 
Minor allele frequency calculation: QCTOOL v1.4 was used to calculate minor allele 
frequency using the –snp-stats function using the final sample sizes after outlier removal. 
 
Linkage disequilibrium calculation: The correlation between variants, r2, was used to indicate 
the linkage disequilibrium between variants. For this functional dataset, genotypes were 
available for 80 individuals. This data was used to calculate r2 for the 14 most significant 
variants using PLINK v2 --flag with input data in gen format (--data and --oxford-single-chr 1). 
To avoid duplicate IDs the flag --set-missing-var-ids @:# was used. In addition, the Astle et 
al. (2016) cohort was used to calculate the LD between variants reaching the significance 
threshold as detailed in Chapter 2 Materials and Methods.   
 
Locus zoom plot: the LocusZoom website was used to generate initial locus zoom plots and 
cis-gene locations (Pruim et al., 2010) using summary statistics. 500 kb flanking of the gene 
was plotted. Custom scripts were used to generate the regional association plots with 
highlighted SNPs for the same genomic region.  
 
Gene annotation: In order to annotate the genic location of variants, the same annotation as 
used in BLUEPRINT (Chen et al., 2016a), GENCODE version 15 (ENSEMBL release 70), 
genome version hg19, was used. Custom scripts were developed to calculate intronic 
regions from the GENCODE annotation to specifically locate which intron each transcript the 
variants were located in. Introns were annotated as all regions between each exon from the 
start and end of the GCSFR gene which falls on the negative strand. HAVANA and 
ENSEMBL annotated transcripts were treated separately. 
 
Transcript abundance and visualisation: Transcript abundance was previously assessed 
within the BLUEPRINT consortium (Chen et al., 2016a). Briefly, transcripts were quantified 
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with Cufflinks v2.2.1 using RNA-seq data, Gencode v15 annotation and without de novo 
transcript assembly. Transcripts were visualised using the R package, ggplot2 (Wickham, 
2009). sQTLseekeR was used for isoform splicing QTL mapping as part of the published 
BLUEPRINT study (Monlong et al., 2014). For evaluation of absolute transcript expression, 
rather than transcript ratios, the Cufflinks quantified expression in FPKM was used (Chen et 
al., 2016a). 
 
Epigenome intersection: bedtools intersect version 2-2.23.0 was used to intersect molecular 
data with variant positions. Bed files for variant locations were generated by subtracting 1 
from the position of the variant to act as the start position of the bed file.  
 
Replication cohort: An independent cohort of 140 healthy individuals was established at 
Sanquin Research as described in Chapter 2. Donors heterozygous for rs3917912, 
rs3917914 and heterozygous and homozygous individuals for rs3917924 and rs3917932 
were identified and used for planning replication experiments (Section 4.5, Future Work). 
These individuals, along with donors with non-effect haplotypes for all SNPs were/are being 
recalled at Sanquin Research and MFI of GCSFR on neutrophils is being measured by Anton 
Tool and Evelien Sprenkeler.  
 
Phasing haplotypes: haplotypes were estimated in the original cohort using genotypes of 
three SNPs, rs3917932 (neutrophil count lead), rs3917924 (GCSFR lead) and rs3917914 
(lead rare SNP), using SHAPEIT v2 and genotype data from 80 individuals (Delaneau et al., 
2011). Three-SNP haplotypes were also estimated in the Sanquin replication cohort (above) 
using genetic data of the same three SNPs. In both cases, the HapMap phase II b37 genetic 
map was used to provide recombination estimates, as recommended. rs3917932 is missing 
from HapMap phase II cohort, in this case, SHAPEIT internally determines the genetic 
position. Haplotypes were phased using rs3917914 instead of rs3917912 as all genotype 
probabilities for rs3917914 heterozygous donors were above the threshold of 0.9. One donor 
heterozygous for rs3917912 with genotype probabilities less than 0.9 (approximately 0.8), 
SHAPEIT would therefore incorrectly call this genotype homozygous. 
 
Genotype validation: I used Sanger sequencing with probes for the SNPs rs3917914 and 
rs3917912 to confirm that the heterozygous individuals carried at least one GCSFR-surface 
level-decreasing allele at this locus (as shown in Figure 4.8 for the discovery cohort 
association). The genotyping assay was designed by Agena Bioscience using the 
MassARRAY® System with the iPLEX® chemistry.   
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4.3 Results  
4.3.1 Measurement of surface expression level in a cohort of 70 individuals  
I investigated predicted target genes for neutrophil-count association variants and identified 
that 11.5% of genes with a known function were annotated with receptor activity. I 
hypothesised that given the role of receptors in cell signalling and the importance of these 
processes in differentiation that there might exist a relationship between significant 
neutrophil-count variants located within receptor genes and the neutrophil surface expression 
of these corresponding receptors. I predicted a possible functional role between these two 
traits for the G-CSF cytokine receptor based on the importance of the signalling pathways of 
this receptor in controlling neutrophil differentiation and mature neutrophil counts 
(Panopoulos and Watowich, 2008). I also investigated the PLAUR receptor missense variant 
given the role of this receptor in neutrophil function and as a comparison to GCSFR, a 
receptor with a well-established role in neutrophil development.  
 
Figure 4.6 summarises the study design to test these hypotheses. Briefly, peripheral blood 
mononuclear cells (PBMCs) were stained with antibodies against CD16, CD66b, CD114 
(GCSFR) and CD87 (PLAUR) and the surface expression of the latter two receptors was 
measured in a CD16+CD66b+ neutrophil population. The mean fluorescence intensity (MFI) 
of the population is used in this study to represent a quantitative measurement of receptor 
surface expression.  
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Figure 4.6: Project and experimental design  
Overview of study and experimental design. Peripheral blood samples from 70 individuals were 
collected and labelled using specific antibodies. Mean fluorescence intensities (MFI) were collected for 
two receptors for surface expression on the neutrophil population using flow cytometry. These values 
for each individual were then used as a quantitative trait in genetic association tests to assess whether 
variation in surface expression was genetically controlled.  
 
 
4.3.2 Two independent genetic signals are associated with GCSFR surface 
expression levels 
Single-variant association tests were performed using GCSFR residualised MFI receptor 
values across 66 individuals. 14698 variants within the gene and 500 kb upstream and 
downstream of the start and end gene positions were tested for association with the receptor 
levels. These variants were pruned using a pairwise r2 threshold of 0.1 to generate a list of 
independent variants in the region (159). To correct for multiple testing, a stringent 
Bonferroni correction was used to correct for the number of independent variants tested 
(0.05/159) resulting in a significance p-value threshold of 3.14 x 10-04 for GCSFR. In the 
CSF3R locus, 14 genetic variants reached significant levels of association with surface 
expression levels of G-CSF receptor (Figure 4.7 and Table 4.5). Four of these variants were 
low-frequency, the rest were common.  
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 rsID chr 1 Pos (hg19) EA/OA EAF P 
Beta, 
(SE) 
EAF 
NEU 
NEU 
effect 
(SE) 
UKBB P 
BP 
beta 
(SE) 
BP P R
2 
Astle Genic location 
Rare 
signal 
rs3917912 36947936 T/C 0.02 1.53 x 10-05 -2.48 (0.53) 0.01 
0.16 
(0.02) 6.04 x 10
-19 - - - Intron 1 (CSF3R-008) 
rs3917914 36947888 A/G 0.02 1.62 x 10-05 -2.37 (0.51) 0.01 
0.16 
(0.02) 9.54 x 10
-22 - - 0.99 Intron 1 (CSF3R-008) 
rs116668546 36952851 A/G 0.02 1.69 x 10-05 -2.32 (0.50) - - - - - 0.71 Upstream (-) 
rs3917922 36945713 T/C 0.02 1.70 x 10-05 -2.32 (0.50) 0.01 
0.16 
(0.02) 9.32 x 10
-21 - - 0.85 Intron 2 (CSF3R-008) 
 
Common 
signal 
rs3917924 36945653 G/A 0.56 1.92 x 10-05 -0.68 (0.15) 0.61 
0.03 
(0.004) 2.49 x 10
-20 1.10 5.51 x 10-35 - Intron 2 (CSF3R-008) 
rs3917931 36944054 C/T 0.56 1.93 x 10-05 -0.68 (0.15) 0.61 
0.03 
(0.004) 1.96 x 10
-20 1.12 9.98 x 10-36 1.00 Intron 3 (Intron 1 of CSF3R-204) 
rs3832027 36945307 AG/A 0.56 1.96 x 10-05 -0.68 (0.15) 0.61 
0.03 
(0.004) 2.34 x 10
-20 - - 1.00 Intron 2 (CSF3R-008) 
rs3917925 36945559 G/A 0.56 1.97 x 10-05 -0.68 (0.15) 0.61 
0.03 
(0.004) 2.42 x 10
-20 1.12 9.98 x 10-36 0.99 Intron 2 (CSF3-008) 
rs3917932 36943916 C/G 0.39 2.32 x 10-05 -0.71 (0.16) 0.42 
0.05 
(0.004) 2.06 x 10
-39 - - 0.47 Intron 3 (Intron 1 of CSF3R-204) 
rs199833813 36954487 AT/A 0.59 3.01 x 10-05 -0.67 (0.15) 0.65 
0.03 
(0.004) 4.41 x 10
-15 - - 0.78 Upstream (-) 
rs6667127 36957501 C/T 0.59 3.43 x 10-05 -0.67 (0.15) 0.65 
0.03 
(0.004) 4.69 x 10
-15 0.97 1.24 x 10-19 0.78 Upstream (-) 
rs955115 36858145 C/A 0.77 1.53e x 10
-
04 
-0.93 
(0.23) - - - 0.59 4.95 x 10
-06 0.11 Downstream (-) 
rs3917933 36943655 G/A 0.55 1.62e x 10
-
04 
-0.61 
(0.15) 0.61 
0.03 
(0.004) 1.3 x 10
-19 1.12 9.98 x 10-36 1.00 Intron 3 (Intron 1 of CSF3R-204) 
rs11295216 36947906 C/CG 0.53 2.86 x 10-04 -0.65 (0.17) - - - - - 0.49 
Intron 3 
(CSF3R-008) 
 
Table 4.5: 14 Significant variants associated with the G-CSF receptor surface levels  
Summary statistics from the GCSFR surface level and Astle et al. (2016) neutrophil count (NEU). Bold SNPs are the lead GCSFR MFI or NEU SNPs. EAF, effect 
allele frequency derived from MAF calculated using 66 donors. Standardised beta and standard error (SE) is given. EAF NEU was calculated for 173,480 individuals 
in Astle et al. (2016) and effect in SD of the trait. Location is relative to the most abundant transcript, CSF3R-204 or the second most abundant truncated transcript, 
CSF3R-008. EA = effect allele. OA= other allele. BP EA and BP direction relate to the significant blueprint exon effect (corrected for local SNPs as qvalue). Variants 
not tested in the study are shown by missing values (-). LD in r2 between the variant and lead variant per common and rare signal respectively was calculated using 
the Astle et al. (2016) cohort.
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Figure 4.7: G-CSF surface expression association results  
Regional association plot of the CSF3R locus. The top panel shows associations with the GCSFR 
surface expression levels. Variants reaching significance are highlighted in blue (common) or orange 
(rare) (Table 4.5). Lead common and rare SNPs are designated with the rsID. The regional 
association plot for the neutrophil count association is repeated from Figure 4.10 for comparison. 
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I carried out conditional analysis including the lead rare and common SNPs as covariates in 
an association model to test if these were independent signals. The beta and p value of 
rs3917912 remained similar to the univariate model and when regressing out the common, 
rs3917924 signal in the association model (univariate beta = -2.48 (SE = 0.53), conditional 
beta = -2.10 (SE = 0.48), Table 4.6). Similarly, when testing for association of rs3917924 with 
GCSFR MFI while conditioning on rs3917912, the common SNP remained significant (Table 
4.6). After conditioning on both rs3917912 and rs3917924, no SNPs remained significant. 
Theses analyses provided evidence that the GCSFR surface expression association signal 
consists of two independent signals of different frequencies. Within the cohort of 66, three 
individuals carried the heterozygous genotype (T/C) for the low-frequency SNP, rs3917912. 
For clarity, I will refer to the significant signals that are described by lead SNPs, rs3917924 
and rs3917912 as the common and rare signals respectively.  
 
 
 
 
 
 
 
 
 
 
Table 4.6: Conditional analysis demonstrated the CSF3R locus contains two 
independent signals  
Results of the two lead SNPs (common and rare) for association with GCSFR surface levels are 
given. The univariate beta and p values are from initial genetic association tests. Association tests 
were repeated but with conditioning on the respective top SNPs i.e. condition on rare and test for 
common association and vice versa. The conditional beta and p values are given and show that in 
both cases the remaining signal is still significant, confirming the common and rare signals are 
independent. The association analysis was also performed conditioning on both common and rare 
SNPs and no variants remained significantly associated using the before mentioned threshold (data 
not shown).  
 
  
 Model EA/OA EAF Beta (SE) P value 
rs3917912 
(rare) 
Univariate T/C 0.03 -2.48 (0.53) 1.53 x 10-05 
Conditional 
(rs3917924) T/C 0.03 -2.10 (0.48) 4.42 x 10
-05 
rs3917924 
(common) 
Univariate G/A 0.57 -0.68 (0.15) 1.92 x 10-05 
Conditional 
(rs3917912) G/A 0.57 -0.57 (0.13) 5.53 x 10
-05 
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4.3.3 The relationship between GCSFR MFI and neutrophil count 
The neutrophil count association signal in the CSF3R locus is described by two independent 
signals; a common signal with lead SNP rs3917932 (EA = C, EAF = 0.42, beta = 0.048, SE = 
3.63e-03, p value = 2.06 x 10-39) and a rare signal with lead SNP rs3917914 (EA = A, beta = 
0.16, SE = 1.62 x 10-02, p value = 9.54 x 10-22) (Table 4.1) (Astle et al., 2016).  
 
The lead common neutrophil count variant, rs3917932 is significant in the GCSFR data, with 
a slightly less significant p value but larger beta than the GCSFR lead SNP, rs3917924 
(Table 4.5). These two SNPs are practically indistinguishable in the GCSFR data. In the 
Astle et al. (2016) study of neutrophil count, rs3917932 is 20 orders of magnitude more 
significant than rs3917924 (2.49 x 10-39, 2.49 x 10-20 respectively). There was also a 
reasonable correlation between the two SNPs; using HaploReg v4.1 1000 Genomes the r2 
between rs3917932 and rs3917924 is 0.46 (Ward and Kellis, 2012). I confirmed that 
rs3917932 and rs3917924 were not independently associated with GCSFR MFI using 
conditional analysis (data not shown). Combined, this was evidence that the neutrophil count 
and GCSFR surface expression common signal can be explained by the same causal 
variant(s), where the Astle et al. (2016) study has greater power to distinguish the putative 
causal variant (rs3917932).  
 
Both rare SNPs, rs3917914 (neutrophil count lead) and rs3917912 (GCSFR surface 
expression lead) are significant in the GCSFR data (p value 1.62 x 10-05 and 1.53 x 10-05 
respectively). The p values are similar in the neutrophil count association also (9.54 x 10-22 
and 6.04 x 10-19 respectively) (Table 4.5). These variants were perfectly correlated with r2 of 
1 (1000G). Therefore, it is highly likely that the neutrophil count and GCSFR surface 
expression rare signal can be explained by the same causal variant(s).  
 
I observed an unexpected inverse relationship between the associations of both variants with 
GCSFR surface expression and neutrophil count. For both common and rare signals, the 
GCSFR MFI-increasing allele was associated with decreased neutrophil count (Figure 4.8). I 
had predicted, based on the role of GCSFR in stimulating neutrophil differentiation, that there 
would exist a positive relationship between surface expression and neutrophil count, where 
more receptor would result in increased stimulation and higher neutrophil numbers 
(Panopoulos and Watowich, 2008, Mehta et al., 2015). My results suggest a more complex 
relationship where rather than the total surface expression of the receptor, possible structural 
or functional changes could link receptor activity to neutrophil count. 
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Figure 4.8: Directions of effect of the two independent genetic signals associated with 
GCSFR surface expression and neutrophil count  
Trait residuals are stratified by genotype of the rare (left) and common (right) SNPs. The top panel 
shows the GCSFR MFI residuals and the bottom panel shows the Astle et al. (2016) neutrophil count 
residuals. GCSFR trait values for each individual in the study (N = 66) are shown but not for neutrophil 
count (bottom panel) as the number of individuals tested was too high. 
 
  
 194 
4.3.4 Evidence of high molecular functionality in the CSF3R genic locus 
I next investigated whether using molecular and epigenomic data could aid the interpretation 
of the functional consequences at this locus and explain the inverse effect. In this study, the 
most significant SNPs were located in the introns of the CSF3R gene. It is known that 
enhancers, which are regulatory elements that control transcription can be located within 
introns in addition to upstream and downstream of genes (Pennacchio et al., 2013). 
Therefore, I investigated and reanalysed several public genomic resources and unpublished 
data to further characterise the potential molecular and epigenomic characteristics of the 
CSF3R locus.  
 
I found that most GCSFR-associated variants intersected with 
ROADMAP/ENCODE/BLUEPRINT primary neutrophil chromatin regulatory state data 
(Supplementary Table 4.1) (Ward and Kellis, 2012, Chen et al., 2016a, Carrillo-de-Santa-Pau 
et al., 2017). The common and rare SNPs intersected with active TSS (H3K4me3) chromatin 
states (rs3917924, rs3917912/4) and rs3917932 intersected with an active enhancer state 
(H3K27ac, H3K4me1). Using a combination of TF ChIP-seq data from primary neutrophils as 
well as the HL60 differentiated and undifferentiated cell line models described in Chapter 2, I 
identified that the region also showed evidence of PU.1, C/EBPb, C/EBPe and the enhancer-
associated co-factor, P300 (Supplementary Table 4.1). Examples of binding of some factors 
in the CSF3R locus is shown in Figure 4.9 with representative signal peaks from one 
BLUEPRINT individual.  
 
The intersection with epigenomic data demonstrated that this was a complex genic region 
with high molecular functionality, also confirmed by the varied transcript architecture, with 18 
different annotated transcripts in GENCODE v15 (Figures 4.9-4.10). While informative for 
general regional functionality, intersections are prone to chance overlaps and it is difficult to 
identify a potentially causal SNP or mechanism based solely on the overlap of epigenomic 
functionality. This is particularly the case, if multiple variants overlap the same or different 
peaks. In comparison, molecular quantitative trait loci (QTLs) afford the opportunity to dissect 
individual variant associations with specific molecular marks with statistical confidence. I next 
investigated such evidence, described below. 
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Figure 4.9 Epigenetic and transcript architecture of the CSF3R locus  
Regional genome plot of the CSF3R locus. H3K4me1, H3K27ac and PU.1 peaks are shown for 
primary mature neutrophils. The lead neutrophil count and GCSFR SNPs are shown. All CSF3R 
transcripts are given with the key transcripts discussed in this thesis labelled. Red transcripts are 
those with an issue such as retained intron, green transcripts are processed transcripts and blue 
protein-coding as predicted by GENCODE v17, the earliest version available in the Washu browser 
(Zhou et al., 2011).  
 
 
4.3.5 Molecular QTL effects of the common GCSFR MFI association 
I accessed the Blueprint consortium human variation panel dataset (Chen et al., 2016a), 
which provides molecular QTLs and allele-specific events in CD16+ neutrophils (Chapter 2 
Materials and Methods). The different molecular traits and analytical approaches are 
summarised in Figure 2.2. In Chapter 2, I focused on investigating gene expression, histone 
modification and percent-splice in QTLs that were measured in up to 197 individuals. Here, I 
also assessed the transcript isoform ratio QTLs as well as allele-specific gene and histone 
effects. Allele-specific approaches evaluate differences in expression or modification signals 
that occur within an individual heterozygous at the locus of interest and as a result can 
increase the power to detect genetic effects (Chen et al., 2016a). Transcript isoform effects 
also indicate splicing events that result in a differential ratio between two transcripts 
(summarised in Figure 1.1). As part of the main study, expression levels were quantified 
across all known transcripts normalised by the length of the transcript. The ratio of the two 
isoforms that exhibited the highest expression change and showed symmetrical changes 
were then evaluated for significant QTLs (Chen et al., 2016a). The size of the isoform effect 
is quantified as the maximum difference (MD) in relative expression between SNP genotype 
groups where a 20% shift in the relative expression of one transcript across genotypes is 
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reflected by an MD of 0.2 (Chen et al., 2016a). I was also able to access additional 
expression quantifications that were not part of the main analysis including exon and splicing 
junction QTLs, which were variants associated with different levels of RNA-seq reads 
specifically at exons and splicing junctions.  
 
SNPs with MAF of less than 1% (allele count = 4), were not included in the blueprint study. In 
addition, the index neutrophil count SNP, rs3917932, was not included in the final variant set. 
Therefore, from this point, I investigated effects of the common GCSFR signal and evaluated 
evidence that the GCSFR index SNP (rs3917924) was associated with specific molecular 
QTLs or phenotypes. 
 
rs3917924 was significantly associated with the allele-specific expression of the whole 
CSF3R gene (EA = G, p value = 5.59 x 10-33, beta = 0.10) (Chen et al., 2016a). Aligning the 
effects showed that reduced GCSFR surface expression corresponds with a small increase 
in GCSFR allele-specific gene expression and increased neutrophil count. This suggests that 
the reduced surface expression effect is not due to a reduction in the expression of full-length 
gene.  
 
There were no other associations of rs3917924 in the QTLs assessed as part of the main 
BLUEPRINT Chen et al. (2016a) study. However, I identified highly significant exon and 
splicing junction associations with rs3917924 (EA = G, p value = 1.09 x 10-37, beta = 1.10, 
Table 4.5). Interestingly, the exon corresponding to this effect was the third exon located in a 
truncated transcript, CSF3R-019, not the transcript encoding the full-length receptor (Figure 
4.10). rs3917924 is also located within exon 3 of CSF3R-019 (36,945,681-36,945,588). I 
next investigated whether these effects could reflect regulation at the level of individual 
transcripts. 
 
4.3.6 Differential CSF3R transcript expression associated with rs3917924 
Figure 4.10 shows there are 18 CSF3R transcripts of varying lengths included in the 
GENCODE v15 annotation (used in the BLUEPRINT study (Chen et al., 2016a)). Figure 4.10 
also shows how each exon contributes to the GCSFR protein domain structure, where the 
canonical third exon contributes to the N-terminal start of the protein. CSF3R-019 is a 
truncated transcript with a different third exon compared to the longer protein-coding 
transcripts such as CSF3R-024.  
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Figure 4.10: GCSFR transcript and protein structure  
Upper panel: All possible CSF3R transcripts (GENCODE v15) shown with lead SNP positions. The 
CSF3R gene is located on the reverse strand (right to left). Lower panel: Protein domains of the 
GCSFR protein with respect to contributing exons (exons 3-17 of CSF3R-204, which is most 
abundantly expressed and generates a functional protein). Different protein domains include an Ig-like 
domain, a cytokine receptor homologous domain (CRH), three fibronectin type III domains (FNR), a 
transmembrane domain (TM) and a cytoplasmic domain (Seto et al., 1992). S, the signal peptide, is 
required for direction of membrane proteins to the cell surface. Figure adapted from (Seto et al., 
1992).   
 198 
I evaluated the relative abundance expression of these 18 transcripts using the transcript 
expression quantifications from the BLUEPRINT project (Figure 4.11). The CSF3R-204 
transcript is the most abundant in neutrophils, followed by the 3’ truncated transcripts, 
CSF3R-008 and CSF3R-020.  
 
ENSEMBL (GRCh37 release 75 2014) predicts that the CSF3R-204 transcript encodes a 
protein product of 836 amino acids. CSF3R-008 retains an intron and is not predicted to be 
protein-coding (Figure 4.10). CSF3R-020 is also not predicted to be protein-coding, instead a 
processed non-coding transcript. In neutrophils and monocytes, the protein-coding CSF3R-
204 transcript was the most abundant, and GCSFR is known to be expressed on the surface 
(higher in neutrophils). In contrast, no protein-coding transcripts are expressed in T cells and 
the highest expressed transcripts are the truncated CSF3R-020 and CSF3R-008 
(Supplementary Figure 4.3) Interestingly, the receptor is not expressed on the surface of 
lymphocytes, suggesting the switch to higher truncated abundance may reflect a regulatory 
mechanism generating cell-type specific protein abundance (Christopher et al., 2011).  
 
I next investigated whether there was evidence that transcript level was affected by genotype 
of the common signal, possibly explaining the significant differential exon expression. I 
observed a visible change in expression level of the second most abundant transcripts, 
CSF3R-008 and CSF3R-020 (Figure 4.11). The ratio of these two transcripts was tested as 
part of the Chen et al. (2016) study based on the criteria I explained above. A cautioned, 
conservative approach for evaluating the significance of associations was used in this study; 
despite not meeting the stringent significant threshold corrected for multiple testing, there 
was some evidence of an effect. rs3917924 just missed the significance level for a single test 
(p < 0.05) for association with the CSF3R-008/CSF3R-020 ratio (p value = 0.060, MD = 
0.033). Other highly correlated SNPs that I also identified as significantly associated with 
GCSFR MFI, perhaps showed evidence of a small effect (rs3917933 p = 0.045, rs3917931, p 
= 0.035).  
 
I aimed to further resolve the transcript based effects, rather than evaluating effects on 
transcript ratios, I investigated genetic effects on the absolute expression of each CSF3R 
transcript expressed in fragments per kilobase of transcript per million fragments sequenced 
(FPKM). Using a standard linear regression approach on inverse normalised FPKM, I 
identified significant associations with rs3917924 and the three truncated transcripts, 
CSF3R-020, CSF3R-008 and CSF3R-019 (Figure 4.12). The association with CSF3R-019 
(containing the exon identified as a significant QTL) was the most significant (p value = 6.002 
x 10-44, beta = 1.155, SE = 0.063). This association was significant in monocytes, but 
reduced compared to neutrophils (p value = 9.148 x 10-05, beta = 0.399, SE = 0.100, 
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Supplementary Figure 4.4). No significant association was found with the expression level of 
the protein-coding transcript, CSF3R-204 in neutrophils (p value = 0.319) or in monocytes 
(Supplementary Figure 4.4).  
 
In ENSEMBL, the CSF3R-019 transcript is predicted to generate a very short protein of 21 
amino acids in length. Further, in the human cell atlas database, CSF3R-019 is not predicted 
to contain a transmembrane region and may represent a secreted protein (predicted by 
SPOCTOPUS (www.proteinatlas.org) (Uhlen et al., 2015, Viklund et al., 2008). The relative 
abundance shows low expression of CSF3R-019 (Figure 4.11). However, the absolute FPKM 
ranged from 1.70 to 20.08 across individuals with a median expression of 9.37 FPKM. Other 
CSF3R transcripts had even lower expression, some with 9 FPKM in neutrophils (CSF3R-
001, CSF3R-003, CSF3R-004, CSF3R-009, CSF3R-010). The FPKM cut-off used for 
transcripts in the BLUEPRINT study was 0.1, suggesting that CSF3R-019 may be 
moderately expressed, but at much lower levels than the dominant CSF3R-204 transcript 
(Chen et al., 2016a).  
 
In summary, reduced (allele-specific) gene-expression corresponds to increased truncated 
CSF3R-019 expression levels, reduced surface GCSFR expression and increased neutrophil 
count. Whether there is a regulatory role at the transcript level for the three differential 
expressed transcripts or at the protein-level with respect to the predicted truncated protein 
from CSF3R-019 requires further functional investigation.  
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Figure 4.11: Relative abundance of all CSF3R transcripts, stratified by genotype of 
rs3917924, may suggest a marginal genetic splicing effect  
Relative CSF3R transcript abundances stratified by the genotype of the common index GCSFR SNP 
identified in the BLUEPRINT study (Chen et al., 2016a). This figure demonstrates that there may be a 
difference in abundance of some transcripts across genotypes. This figure is adapted from the original 
produced by Diego Garrido Martin using data analysed as part of the BLUEPRINT consortium (Chen 
et al., 2016a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Association of the common SNP, rs3917924, with CSF3R transcript 
expression levels  
Absolute expression of the transcripts is tested for association with the lead GCSFR surface 
expression level SNP, rs3917924. Transcripts where a significant association with rs3917924 was 
identified are shown stratified by genotype. Transcript expression is measured in FPKM (expected 
fragments per kilobase of transcript per million fragments sequenced) and was estimated as part of 
the BLUEPRINT consortium using transcripts defined by the Cufflinks tool, without de novo assembly 
(Chen et al., 2016a). Regression was performed using inverse normalised FPKM values. The boxplot 
colour matches that of the corresponding transcript in Figure 4.10 and Figure 4.11.   
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4.3.7 Investigation of the rs4760, the PLAUR missense SNP  
I also investigated the surface expression of a second receptor, PLAUR, which has a role in 
neutrophil function (Section 4.1). I tested all variants for association with PLAUR MFI that 
were within the length of the gene and 500 kb upstream and downstream (N = 16155) 
including the predicted neutrophil count causal missense SNP, rs4760. The threshold I used 
for evaluating significantly associated variants was 2.2 x 10-04, which was based on 
correcting for 218 pruned, independent variants in the region (pairwise r2 threshold of 0.1). 
 
No significant associations with the PLAUR receptor level were identified (Figure 4.13). The 
missense SNP, rs4760, did not meet the stringent significance threshold (p value = 0.01). 
This could be suggestive evidence of association using the p value threshold for a single test 
(p < 0.05), but confirmation may require further testing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: PLAUR surface expression association results 
Regional association plot with PLAUR receptor surface expression. Variants within the gene and 
500kb upstream and downstream of the index SNP are shown with the –log10(p-value) of the 
association with receptor level (y-axis). There are many genes in this region, with the plot centred 
around the PLAUR gene. No associations were found to be significant in this region after correction for 
multiple testing.  
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Given the complexity of the relationship between GCSFR surface expression levels and 
neutrophil count, I explored other possible functionality of rs4760 in additional unpublished 
neutrophil-relevant datasets. I observed a significant association between rs4760 with two 
additional Sysmex haematological analyser traits, NE-FSC (EA = G, p value = 8.6 x 10-15, 
beta = 0.075, SE = 0.010) and NE-SFL (EA = G, p value 2.9 x 10-17, beta = 0.077, SE = 
0.010) that had been analysed by Parsa Akbari using the INTERVAL cohort of approximately 
50,000 individuals (unpublished observations). NE-FSC is a forward scatter parameter that is 
used as an estimated of neutrophil size. NE-SFL is neutrophil side fluorescence, which 
increases with a higher amount of cellular DNA and RNA (Buoro et al., 2016, Sysmex 
Corporation, 2010-2012). These two associations could be related as it is possible that a 
larger cell could contain a higher amount of nucleic acid. None of the significant SNPs 
associated with GCSFR surface levels were found to be significantly associated with 
neutrophil cell size or other additional granularity traits. Interestingly, when I tested for an 
association of rs4760 and NE-FSC that was also measured using a Sysmex haematology 
analyser within this recall study (N = 65), the association was not significant (p value = 
0.508). The significant association in the larger cohort perhaps suggests that this recall study 
was limited in power to detect associations of rs4760 with NE-FSC and possibly also PLAUR 
MFI. Using the pwr R package, I estimated that with a cohort size of 100 and p value 
threshold of 2.2 x 10-04, the study would be powered to detect variants of similar frequency 
(rs4760 MAF = 0.16) with a beta > 1, confirming my functional cohort was not powered to 
detect small effect sizes of associations (Champely, 2012).  
 
The effects of these associations demonstrate rs4760 causes a decrease in neutrophil count 
(EA = G, p value = 1.428 x 10-68, beta = -8.615 x 10-02, SE = 4.923 x 10-03) and an increase in 
neutrophil cell size (EA = G, p value = 8.6 x 10-15, beta = 0.075, SE = 0.010). The association 
with receptor expression from this study demonstrates a decrease in PLAUR surface 
expression, although this misses the stringent significance threshold applied (p value = 0.01, 
beta = -0.59, SE = 0.233). Given that little is known about the role of neutrophil size in 
development or function of neutrophils, this inverse relationship would need further 
investigation. 
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4.4 Discussion 
In this chapter, I used a recall-by-genotype (RbG) design to test a hypothesis that significant 
neutrophil count variants located in protein receptor genes were also associated with the 
surface expression of those receptors. I demonstrated in Chapter 3 how performing a QTL or 
GWAS study using neutrophil functional phenotypes is technically challenging. RbG studies 
provide an alternative but highly efficient design to test specific hypotheses based on 
previous biological and genetic observations, thus requiring a smaller sample size.  
 
Using a cohort of 66 healthy individuals, I identified common and rare signals located in the 
CSF3R locus that are significantly associated with the level of GCSFR neutrophil surface 
expression. Both signals were also independently associated with neutrophil count from a 
large GWAS study in 173,480 individuals (Astle et al., 2016). I identified an inverse 
relationship between these two traits; a decrease in GCSFR at the surface corresponded to 
an increase in neutrophil count. I also observed other molecular effects, including an 
increase in expression of the truncated transcript, CSF3R-019.   
 
The opposing direction of effects is not initially intuitive as signalling through the G-CSF 
receptor is known to increase neutrophil numbers and promote neutrophil differentiation 
(Lord et al., 1989, Lord et al., 1991, Panopoulos and Watowich, 2008). Naively, a positive 
relationship between level of GCSFR surface expression and neutrophil numbers could be 
expected. In this scenario, more signalling through the receptor could lead to a higher 
number of neutrophils during both differentiation and in the increased release of mature 
neutrophils from the bone marrow. However, this prediction does not take into account other 
more complex possibilities. Upon activation, GCSFR is internalised into the cell, a process 
which is dependent on the C-terminal internalisation motif and functions to regulate signalling 
preventing over-activation (Kindwall-Keller et al., 2008). Increased surface expression of 
GCSFR could, therefore, be a result of reduced internalisation due to less activation, perhaps 
reflecting a difference in protein functionality due to genotype (not tested here). A similar 
recall-by-genotype study where neutrophils are stimulated by G-CSF overnight, followed by 
measurement of the phosphorylation of downstream signalling targets such as STAT3 could 
help in assessing whether GCSFR activation or functionality is altered due to genotype. 
STAT3 is necessary for the increased neutrophil numbers and maturation during emergency 
granulopoiesis in response to G-CSF (Zhang et al., 2010). Experiments testing neutrophil 
responses to stimuli (as described in Chapter 3), could also indicate if despite lower surface 
receptor levels, the receptor is more sensitive to stimulation in individuals carrying the 
receptor lowering allele. For example, G-CSF has been shown to prime fMLP-dependent 
ROS production (Yuo et al., 1990, Khwaja et al., 1992).  
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Alternatively, GCSFR surface expression could have important ramifications for neutrophil 
count at the progenitor stage rather than the mature circulating neutrophils as tested here. To 
investigate this further, CD34+ progenitor cells could be collected from donors and 
differentiated in vitro allowing assessment of GCSFR surface expression at earlier and later 
stages of neutrophil development.  
 
From this study, it is unclear whether the truncated transcript, CSF3R-019, also plays a 
regulatory role given the strong association of the common signal with increased expression 
of this transcript. CSF3R-019 is predicted to generate a short protein of 21 amino acids that 
is missing a transmembrane domain and eventually secreted (Uhlen et al., 2015, Viklund et 
al., 2008). Predicted proteins generated from other CSF3R transcripts are associated with 
GO terms such as receptor activity and integral plasma membrane component, but no such 
terms are associated with the CSF3R-019 transcript. There is precedence for soluble 
receptor protein forms regulating membrane-bound receptor activity, either in an antagonistic 
or agonistic manner (Xing et al., 2003). Soluble IL6R (sIL6R) is generated from proteolytic 
cleavage of the membrane-bound form or alternative splicing (Farahi et al., 2017). sIL6R 
forms a complex with the ligand, IL6 and activates gp130, in turn leading to increased 
expression and nuclear translocation of STAT3 (Hawkins et al., 2012, Farahi et al., 2017). 
The GCSFR Ig-like domain (Figure 4.10) is a close homologue of gp130, located in the N-
terminal region and is required for G-CSF binding (Layton et al., 2001, Yorke-Smith et al., 
2011). However, all previous experimental evidence for truncated CSF3R mRNA and soluble 
GCSFR (sGCSFR), have been for receptors that are larger than that predicted to be 
encoded by CSF3R-019, for example, 80 and 85 kDa (Iwasaki et al., 1999, Fukunaga et al., 
1990). In addition, CSF3R-019 is expressed to a much lower level than the dominant CSF3R 
transcripts. To test if CSF3R-019 produces a soluble protein, plasma from recalled 
individuals of different genotypes could be tested for the existence of different soluble forms 
or qPCR of neutrophil RNA would help assessment of possible transcripts.  
 
Understanding the functional mechanism of the relationship between receptor surface 
expression and neutrophil count also has the potential for clinical benefit. rs3917924 was 
previously associated with mobilisation potential and recovery of granulocytes in patients 
receiving a transplantation of autologous peripheral blood progenitor cells (PBPCT) 
(Bogunia-Kubik et al., 2012). Peripheral blood progenitor cells (PBPCs) are a source of 
hematopoietic stem cells that can be used in place of bone marrow for transplantation 
(Jansen et al., 2002). Mobilisation is the increase in steady-state concentrations of PBPCs by 
inducing migration of hematopoietic cells into the periphery, which can be supplemented with 
injection of G-CSF prior to cell collection. Mobilisation also indicates recovery after PBPCT, 
where recovery is evaluated by the number of granulocytes per µL (Jansen et al., 2002, 
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Bogunia-Kubik et al., 2012). rs3917924 was associated with higher mobilisation potential and 
a faster recovery of granulocytes in patients after transplant, but in this study corresponded 
to a lower GCSFR surface expression (Bogunia-Kubik et al., 2012). The authors state that 
this effect may be due to the alternative allele (A) resulting in an impaired interaction 
between G-CSF and its receptor leading to a lower response to G-CSF. This could, 
therefore, be explained by the evidence listed above, that a higher surface level of the 
receptor is reflective of a lower activity leading and a lower level of internalisation. 
 
I did not identify any significant associations with the PLAUR receptor, but the neutrophil 
count lead variant, rs4760 was associated with measures of neutrophil size and nucleic acid 
content in a larger study (N = 50,000, Parsa Akbari, unpublished). This association was also 
not significant in my cohort of 65 individuals, suggesting that to further evaluate the 
relationship between neutrophil count, size and PLAUR MFI, larger sample sizes would be 
required. The lead SNPs associated with GCSFR MFI were not associated with any 
additional neutrophil measures studied in this larger GWAS, suggesting that the relationship 
of receptor surface expression and neutrophil count may be specific to each type or 
functionality of receptor studied and certainly seems more complex than I initially predicted.  
 
Given the well-known examples of other soluble receptors regulating receptor function, I 
queried my variants in a GWAS of the human plasma proteome including nearly 3000 protein 
levels in a cohort of 3,301 individuals (Sun et al., 2017). In this, a soluble form of the PLAUR 
receptor was studied, but there was no equivalent soluble version of GCSFR included in the 
study. Plasma PLAUR levels were significantly associated, not with rs4760, but with an 
independent SNP, rs36229204 (EA = T, OA = C, EAF = 0.038, beta = -0.48, SE = 0.07, p 
value = 5.2 x 10-13) (Sun et al., 2017). The rare SNP, rs36229204 (CEU MAF = 0.038) was 
not significantly associated with neutrophil count (Astle et al., 2016) and not correlated with 
rs4760. This suggests these SNPs are two independent associations within the PLAUR locus 
with different functional consequences, indeed soluble PLAUR has been suggested to 
competitively inhibit PLAU protein binding to the membrane-anchored PLAUR receptor form 
(Sloand et al., 2008). Two independent genetic regulatory effects on different stages within 
the same receptor function pathway further demonstrates how complex these receptor 
functions and their relationship to neutrophils count are.  
 
In conclusion, genetic analyses can aid the development of functional hypotheses, but further 
experimental investigation is required. Examples have been discussed here, such as 
investigating the activity of the receptor as a function of genotype, or investigating the 
relationship between GCSFR receptor expression and the numbers of neutrophil progenitors. 
Below, I describe ongoing efforts to replicate the GCSFR receptor signal. 
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4.5 Future work: Replication of the GCSFR MFI effect 
Replication of the common and rare associations with GCSFR MFI is currently being 
explored using the Sanquin cohort described in Chapter 3. It was possible to recall only a 
maximum of 20 individuals from this cohort. I therefore designed the study to maximise the 
power to replicate the MFI effect. In order to select the donors predicted to have the maximal 
difference between GCSFR expression levels and to investigate the relationship between 
common and rare signals, I estimated the haplotypes using the genotypes of the three lead 
SNPs (rs3917914, rs3917924, rs3917932) using SHAPEIT (Materials and Methods). Both 
common index SNPs were phased to ascertain whether the effect alleles were located on the 
same haplotype, which would negate the need to select one of the common SNPs and 
potentially enable an assessment of the causality between the two common SNPs. One rare 
SNP was used in the haplotype analysis as there was no difference between heterozygous 
donors given the perfect correlation between rs3917914 and rs3917912. rs3917914 was 
selected as all of the genotype probabilities of the heterozygote donors were above 0.9, the 
threshold implemented in SHAPEIT.  
 
Figure 4.14 shows the GCSFR MFI stratified by haplotype in the original RbG study I 
performed. A similar decrease in surface GCSFR was associated with haplotypes that carry 
two copies of the common decreasing alleles (CGG/CGG) than with haplotypes that carry an 
additional rare decrease allele (CGA/GGG), where the decreasing alleles were in order of 
rs3917932 (C), rs3917924 (G) and rs3917914 (A). Interestingly, a bigger decrease in 
GCSFR MFI occurred in individuals with haplotypes that were homozygous for the 
rs3917932 decreasing alleles (CGG/CGG) than those that were homozygous for the 
rs3917924 decreasing alleles (CGG/GGG). This confirms the larger observed beta estimate 
for rs3917932 from the association with GCSFR MFI (rs3917932 beta = -0.71, SE = 0.16, 
rs3917924 beta = -0.68, SE = 0.15) and is evidence that rs3917932 is likely causal common 
SNP.  
 
I also estimated the haplotypes in the Sanquin cohort using the genotype data from the same 
SNPs (Table 4.7). Although missing from the original cohort, within the Sanquin cohort four 
individuals were also homozygous for both the common lead SNPs, CGG/CGA and 
heterozygous for the decreasing rare allele (A). Based on my association evidence, this 
haplotype combination would be associated with the lowest GCSFR MFI. I suggested 
recalling five individuals homozygous for the GAG/GAG haplotype (highest GCSFR MFI) and 
all CGG/CGA individuals (lowest GCSFR MFI) (Table 4.7). Comparison of individuals with 
these haplotypes should give the greatest power to replicate the receptor effect. This is 
currently ongoing. Experiments assessing STAT3 phosphorylation (described above) and 
measuring neutrophil function responses (Chapter 3) are also being considered.  
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Figure 4.14 GCSFR MFI stratified by haplotype  
GCSFR MFI residuals (original Cambridge cohort) stratified by haplotype of rs3917932 (decreasing 
allele = C), rs3917924 (decreasing allele = G), rs3917914 (decreasing allele = A). The lowest receptor 
expression was associated with individuals who are heterozygous for the rare variant and the 
neutrophil count lead variant, rs3917932 (CGA/GGG). CGA contains the lowering effect alleles for all 
three SNPs. There were no individuals homozygous for the rare lowering haplotype (CGA) in the 
cohort. The left panel shows the effects in individuals with homozygous haplotypes. The right panel 
shows MFI for all of the haplotypes estimated using 66 individuals.  
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Table 4.7: Haplotype frequencies of the Sanquin replication cohort  
Haplotype frequencies of the four main haplotypes for the Sanquin replication cohort are shown, along 
with all the haplotype combinations in 140 individuals. There are 9 unique haplotype genotype 
combinations and the frequencies matched those from UK10K (data not shown). The suggested 
number of individuals to be recalled is listed and based on haplotypes that will demonstrate the 
biggest difference in receptor levels as predicted from the discovery cohort. 
   
Haplotype (estimated 
frequency) 
Haplotype Genotypes No of Individuals 
recalled 
CGA (3%) 
CGG/CGA 4 
CGA/GGG 2 
CGA/GAG  
CGG (43%) 
CGG/CGG 4 
CGG/CGA - 
CGG/GAG  
CGG/GGG  
GGG (22%) 
CGG/GGG  
CGA/GGG - 
GGG/GAG  
GGG/GGG  
GAG (33%) 
CGG/GAG  
CGA/GAG  
GGG/GAG  
GAG/GAG 5 
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5 Conclusion and outlook 
 
5.1 The compromise between high-throughput and in-depth 
functional insights 
With recent technological advances and the falling cost of whole-genome sequencing, the 
main challenge we now face is not the generation of genetic data but in the interpretation of 
biological mechanisms linking GWAS loci to function. We must consider what are the best 
approaches in understanding the different steps involved in the pathway from sequence 
variation to organismal phenotypes such as disease susceptibility. Addressing these 
challenges will aid the translation of GWAS findings to the clinic and capitalise on the power 
of genetics to predict and identify drug targets. 
 
In this thesis, I have used a combination of approaches and phenotypic traits in an attempt to 
understand the cellular and functional consequences of genetic variation. These methods fall 
into two broad categories. First, large-scale annotation efforts such as those from the 
ENCODE and BLUEPRINT consortia provide broad functional insight into multiple loci across 
the genome. These data can be used to either annotate variants with epigenomic 
functionality or directly linking molecular phenotypes to variants in formal QTL association 
tests. Second, detailed bespoke investigations such as recall-by-genotype studies or 
targeted genome-editing provide in-depth insight but are generally lower-throughput and 
focus on a small number of loci. An important question as we endeavour to move from 
GWAS to function, is should our focus be on the application of GWAS in larger sample sizes 
(perhaps in millions of individuals) using existing traits or on increasing the phenotype 
complexity by continuing recent efforts to apply genetic approaches to functional and cellular 
traits? 
 
In Chapter 1, I provided further demonstration of the power of molecular QTLs in providing 
workable mechanistic hypotheses for disease- and complex trait-associated variants as well 
as suggesting a relevant and specific experimental cellular model. I also provided further 
support for how the identification of genes dysregulated by variants can highlight potential 
therapeutic targets for disease treatment and management. The use of such phenotypes to 
provide functional insight through colocalisation and enrichment methods, as employed here, 
is a vast improvement on early methods of gene target identification, which relied on 
proximity to the sentinel variant with no indication of causal cell types involved. Indeed, QTL 
discovery is now being extended to a wider range of cell types and cellular contexts and will 
vastly improve our ability to search for the molecular consequences of significant loci. 
However, it is important to note that large-scale annotation efforts in multiple cell types and 
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large cohorts require substantial financial, logistical and analytical investment, as I 
experienced through working as part of the BLUEPRINT and UK Biobank consortia (Chen et 
al., 2016a, Astle et al., 2016). In addition, for certain cell types, it is challenging to access 
human samples. In some cases, important cell populations are present in low numbers and 
therefore provide technical challenges in both isolation and the application of genomic 
approaches. Some advances have already been made in applying ChIP-seq to small 
populations, such as haematopoietic progenitors (Lara-Astiaso et al., 2014). Many protocols 
for the differentiation of induced pluripotent stem cells (iPSCs) to different cell populations 
are already available and advances in this area will also facilitate the study of a wider range 
of cell types, particularly when coupled to genome-engineering approaches such as 
CRISPR. Extensively characterised iPSC cell lines are available to research groups through 
The Human Induced Pluripotent Stem Cells Initiative (HipSci, http://www.hipsci.org).  
 
Even with the already vast amount of epigenome and QTL data available to the wider 
community, I have shown that to reach full mechanistic understanding still requires detailed, 
painstaking and often manual integration and annotation of important loci. Creating unified 
databases to summarise and visualise all available genetic, functional data and the multiple 
associations for each locus would greatly facilitate these efforts. Certainly, platforms such as 
HaploReg (Ward and Kellis, 2012), the Open Targets Platform (Koscielny et al., 2017) and 
DrugBank (Law et al., 2014) already improve the efficiency of this process, as I showed 
throughout my thesis. However, a unified browser of all available data from multiple cell 
types would greatly improve the formulation of functional hypotheses of individual genetic 
loci.  
 
In Chapters 2 and 3 of this thesis, I moved beyond molecular processes, first performing a 
GWAS on novel neutrophil function traits and second performing an in-depth functional 
investigation into neutrophil count and surface receptor expression, which in both cases 
provided functional insight into the biology of the important immune cell type, neutrophils. 
Recall-by-genotype studies leverage the power of previous GWAS, in this case of nearly 
174,000 individuals, to design follow up experiments that delve deeper into the functional 
processes.  
 
My implementation of functional phenotypes here was not the first example of the utilisation 
of these traits in genetics (Orru et al., 2013, Roederer et al., 2015, Steri et al., 2017, Li et al., 
2016b, Astle et al., 2016, Ahola-Olli et al., 2017). Indeed, for some cell types (particularly 
PBMCs and monocytes/macrophages) and assays (cytokine production), these 
measurements are as tractable as the genomic approaches used in molecular QTL studies. 
However, in Chapter 3, my work demonstrated that for some phenotypes and cell types, 
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measurement of function can be technically complex and subject to many sources of co-
variation. Specifically, I outlined the difficulties in working with neutrophil function, which may 
represent a particularly challenging cell to work with compared to other haematopoietic cell 
lineages and I discussed possible reasons for this in Chapter 3. However, I gleaned 
mechanistic insight from small cohorts (10s-100s) using other functional measurements on 
these cells, namely flow cytometry of the surface expression of receptor proteins. In studying 
a specific neutrophil count associated locus, the important neutrophil receptor, GCSFR, I 
identified that while there was no evidence of association of the same common variant with 
the standard molecular phenotypes (gene expression, histone modifications), the locus was 
significantly associated with surface receptor expression, allele-specific expression and the 
expression level of certain CSF3R transcripts. Clearly, additional insight can be obtained by 
combining multiple layers of molecular, cellular and functional information. 
 
Combining the lessons learnt from this thesis and from other similar studies, it is clear that 
many trait-associated variants affect not just one functional phenotype but many processes 
from the epigenome, to gene expression, post-transcriptional processes, protein levels, cell 
function, cell abundances and beyond. In reality, we cannot restrict our efforts to just one 
type of approach. Collating multiple phenotypes from unified large populations will enable 
phenome-wide association studies that identify multiple phenotypes affected by a single 
locus. Thus, molecular and functional networks could be constructed and provide insight into 
the complexity of interconnections in biological processes. Expanding sample sizes of these 
cohorts will increase power and enable detection of trans effects, which from our currently 
limited knowledge of these affects, seem to be even more subject to changes in cellular 
contexts (Delaneau et al., 2017). Providing dense, if not complete, genetic maps using high 
quality imputation or whole-genome sequencing combined with rich phenotype data will 
potentially lead to a full description of the genetic architecture of complex traits and perhaps 
eventually, prediction of an individual’s risk based on their genetics. Such initiatives are seen 
with the recent biobank studies from, for example, the UK Biobank (Collins, 2012), 
INTERVAL (Moore et al., 2014) and the Precision Medicine Initiative in the United States 
(Sankar and Parker, 2017).  
 
Below, I discuss two key challenges that we face in understanding functional genetic 
variation; that is the ever-increasing complexity of the regulatory epigenome and dissecting 
causal variants and causal relationships between different traits. To end, I highlight particular 
ongoing efforts to address these challenges and highlight a particular area in human disease 
that could also reveal interesting interactions with human disease; the microbiome.  
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5.2 The ever-increasing complexity of the epigenome and the 
regulatory code 
Despite the vast amount we have learnt from genome annotation methods and large-scale 
consortia, we are still unable to read the regulatory code. We cannot yet predict epigenomic 
function directly from sequence alone. What we do know is that the regulatory genome is 
more complex than originally predicted. For example, the genomic regulatory function is 
highly cell type and context- specific as well as controlled in the three-dimensional space in 
addition to the early two-dimensional models of regulation of protein binding to a linear DNA 
sequence. Transcription factors and other regulators bind DNA with multiple cofactors 
forming large functional clusters, as I set out in Chapter 1. Complex interactions between 
cofactors located at varying genomic distances could perhaps underlie the observations of 
distal SNPs affecting TF binding even when they are not located within or nearby to the 
binding site (Wang et al., 2017b). Context specificity and the complexity of multiple layers of 
regulation suggests that in order to answer these questions we would require genome-wide 
binding profiles of all possible TFs and cofactors in all possible cell types and contexts and 
connect local effects to all interactions in the 3D space. While this seems like a daunting 
task, observed high functional correlation in genomic domains such as TADs, sub-TADs or 
variable chromatin modules may reduce the dimensionality of the regulatory genome thereby 
allowing us to study only the key “seed” factors that explain the majority of variability in the 
genomic region (Grubert et al., 2015, Waszak et al., 2015). Indeed, in this thesis, I 
demonstrated that different variant target genes between myeloid and hepatic cells at the 
CAD SORT1 locus seemed to be due to the binding of lineage-specific pioneer factors, PU.1 
and FOXA1 respectively. It seems remarkable that a small number of factors may be able to 
control cell-type specific transcription, but the challenge is establishing which layer of 
functionality underpins the causality at a particular locus and whether causal TF binding, as 
has been suggested, is a general genome-wide phenomenon or applies to specific cases 
(Wei et al., 2017). 
 
Indeed, as we build our understanding of the regulatory genome, we find that the genome is 
even more complex and often challenges previously established functional paradigms. This, 
in turn, further complicates the interpretation of non-coding sequence variation. For example, 
I have described in this thesis how the histone modification, H3K4me1, is generally 
associated with poised or active enhancers and correlates with cell-type specific gene 
expression (Heintzman et al., 2009). Recently, however, a role for H3K4me1 bound at 
promoters was observed in inducible gene repression, rather than activation from a distal 
enhancer (Cheng et al., 2014). This repression seems to be mediated by the 
methyltransferase, MLL3/4 and appeared to restrict access to readers of the active promoter 
mark, H3K4me3 (Cheng et al., 2014). It was also recently shown that intragenic enhancers 
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can attenuate gene expression rather than activate it. By using CRISPR-cas9 knock-down, 
the authors showed that deleting an intragenic enhancer from the mouse ESC gene, Meis1, 
led to de-repression in the region and phenotypes consistent with ESC differentiation 
(Cinghu et al., 2017). Therefore, intragenic-enhancer repression appeared to have a 
physiological role. Interestingly, this effect was evident for genes that were not highly 
expressed but were expressed at medium-to-low levels, which may suggest that weaker 
intragenic enhancers could be repressive and stronger intragenic enhancers remain active 
(Cinghu et al., 2017).  
 
Both of these examples show the importance of considering the full genomic context when 
interpreting variant function. They also demonstrate a need to increase our efforts to study all 
aspects of genomic regulation to help us ascribe function to important genetic variants. 
 
5.3 Causal variants and causal relationships 
Identifying causal variant(s) is an important step in fully understand the mechanism of action 
of genetic loci. In Chapter 2, I briefly discussed how the colocalisation method provides a 
posterior probability estimate of each variant being causal that can be used to fine-map 
potential causal variant(s) based on association evidence (Section 2.3.5.2) (Pickrell et al., 
2016). Although not applied in this thesis, there are also other statistical methods available 
for fine-mapping causal variants (Spain and Barrett, 2015). In addition, I demonstrated how 
epigenomic information can facilitate fine-mapping, for example, if a particular variant 
disrupts a TF binding motif (CAD SORT1, Figure 2.10) or lies directly under a histone peak 
(AMD TNFRSF10A, Figure 2.17). However, for loci that contain many variants in LD that 
overlap the same epigenomic marks, we are still limited in detecting the causal variant. In 
this case, further experimental approaches could be employed to help dissect complex loci. 
For example, the combination of genome engineering and high-throughput production of 
induced human pluripotent stem cells (iPSCs) (Kilpinen et al., 2017) allows single nucleotide 
knock-out in a wide range of differentiated cell types. Coupling CRISPR-Cas9 approaches 
with tractable experimental read-outs, could help distinguish between closely correlated 
variants by experimentally comparing their effect sizes on an intermediate phenotype. In 
addition, using denser genetic information in GWAS also increases the chances of identifying 
the true causal variant. In Chapter 2, when I used the denser BLUEPRINT phase 2 cohort 
that included the predicted causal SNP, the associations at the AMD TNFRSF10A locus 
were more significant for all phenotypes of interest. 
 
Establishing causality between different traits is also a complex challenge in human genetics. 
I described this concept in Chapter 1, where establishing whether a particular trait is a causal 
risk factor for a disease requires more than just identifying a high correlation between the two 
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factors. Establishing causality between intermediate (including molecular) phenotypes and 
disease risk provide useful readouts for monitoring disease progression, for potential 
therapeutic targets and also for experimental use in querying functional relationships at 
genetic loci. A clear therapeutic success started with the observation that variants within the 
HMG-CoA reductase gene, HMGCR, are associated with lipid levels. Now, HMGCR is 
targeted by cholesterol-lowering statins (Kathiresan et al., 2009). Cholesterol and LDL levels 
are known risk factors for coronary artery disease (Khera and Kathiresan, 2017). 
 
In this thesis, I used a colocalisation method to provide a statistical assessment of regions of 
the genome that were associated with two different traits but this method does not provide a 
definitive demonstration of causality between traits. Mendelian randomization (MR) 
approaches have been successfully used to assess the causality between traits such as 
blood counts and complex diseases or LDL and CAD risk (Astle et al., 2016, Khera and 
Kathiresan, 2017, Holmes et al., 2017). MR application to molecular traits is complex. Often 
there is extensive QTL pleiotropy, where a variant affects multiple genes, which could all 
exert different effects on the outcome/disease. I also investigated examples where a genetic 
variant was associated with multiple molecular phenotypes such as TF binding, enhancer 
activity, and gene expression. In these cases, there may be multiple molecular routes 
through which a change in gene expression could affect an outcome. There also could be 
inter-relationships between the molecular function, which would essentially be described as 
reverse causation. In Figure 5.1, I highlight possible interactions and directionality between 
multiple epigenomic functions, partly based on my observations in Chapter 2. These complex 
molecular relationships can violate MR assumptions (Evans and Davey Smith, 2015).  
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Figure 5.1: Complex molecular regulatory mechanisms  
This schematic summarises possible complex regulatory mechanisms that could occur at one genetic 
locus. Block arrows represent the direction of regulatory effect and dashed arrows represent possible 
feedback mechanisms or relationships between functions. The generally accepted model is that 
pioneer factors first bind and then stimulate further chromatin modifications to form cis-regulatory 
elements, but for some TFs, open chromatin or certain functionality is required (hence the dashed 
arrow). There could also be feedback mechanisms between the level of gene expression and 
molecular regulators. 
 
 
In light of this, I would argue that currently, integrating QTLs with disease GWAS SNPs is 
state of the art in forming molecular hypotheses, but currently demonstrating a causal 
relationship must come from downstream experimental testing. Many common variants, 
however, have small effect sizes on diseases or complex traits, making it difficult to 
experimentally demonstrate an effect on disease as a result of manipulation of gene function. 
Mouse models can highlight the consequences of extreme cases of gene knock-out or 
overexpression, which can identify relevant phenotypes. However, if a target has effects on 
many pathways, such as TNFRSF10A, this could be difficult to ascertain. Intermediate 
phenotypes that have been shown to be causal risk factors for a particular disease can be 
used as tractable experimental readouts to establish causal mechanisms. For coronary 
artery disease, our knowledge of causal intermediate risk factors is quite advanced due to 
extensive MR analysis and experimental evidence. In particular, LDL levels can be measured 
in mouse models and the effect of variant knock-down or overexpression on these levels can 
and have been evaluated (Musunuru et al., 2010). Indeed, cellular responses are also 
tractable experimental measures. I have already discussed the example of measuring the 
propensity of macrophages to form foam cells after exposure to oxidised LDL (Reschen et 
al., 2015). 
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However, amenable intermediate risk factors have not yet been established for all diseases, 
particularly for diseases that involve tissues that are difficult to access such as age-related 
macular degeneration, Alzheimer’s disease or schizophrenia. If there is a causal role for 
peripheral blood cells in these diseases, it would be interesting the perform MR analysis 
using blood counts and these diseases to assess whether these are causal risk factors. 
Future work must involve efforts to identify tractable and causal disease intermediates. This, 
combined with experimental investigation would enable definitive assessment of the causality 
between peripheral immune function and for example AMD. 
 
While a definitive causal relationship between immune factors and some of the diseases 
studied here has yet to be determined, therapeutics targeting dysregulated immunological 
processes that reduce disease severity or progression or manage severe symptoms. 
Therefore, there is a potential benefit to the management of these disorders through 
identifying pathways that increase disease severity for example. 
 
5.4 Ongoing efforts and future goals in functional genomics 
The next few years promise to be an exciting era for human genetics both in studies of vastly 
increased sample sizes and in new efforts to understand cellular function. In one of the 
largest single genetic cohorts and most comprehensive resource, genetic data and detailed 
phenotypes of 500,000 individuals has been released by UK Biobank project. The increased 
power of this dataset will allow identification of many more rare variants and will transform 
our knowledge of the allelic architecture of complex traits (Vasquez et al., 2016). 
 
There are also exciting ongoing efforts in improving our understanding of human cellular 
biology. The Human Cell Atlas is an international collaboration aiming to use cutting-edge 
single-cell approaches to classify all human cells (Rozenblatt-Rosen et al., 2017). Although 
we have learnt much from genomic approaches applied to bulk tissue samples, the results 
provide an average picture across all possible cellular sub-types. Accurate molecular 
blueprints on a single cell basis for every type of cell in the human body will provide 
unprecedented insight into cellular interactions, different cellular states, transitions involved 
in differentiation, and potentially uncover previously unknown cell subtypes. Integration of 
these data with GWAS variants will allow us to gain a more detailed understanding of how 
genetic variation affects cellular phenotypes ultimately influencing disease risk (Rozenblatt-
Rosen et al., 2017).  
 
Another important factor in modulating immune responses that was not explored in this 
thesis is the gut microbiome. Changes in the composition of these bacteria and their 
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taxonomy have been implicated in multiple human diseases such as inflammatory bowel 
disease, multiple sclerosis, rheumatoid arthritis and asthma (Hall et al., 2017, Berer et al., 
2017). A role for host genetic variation in bacterial composition alternations was revealed 
through using microbiome analysis such as 16S rRNA or metagenomics sequencing as the 
phenotype in GWAS (Hall et al., 2017). Identified loci had a clear role in disease, for 
example, 48 IBD risk genes were also associated with altered gut microbiome composition 
(Hall et al., 2017). The interaction between the host and microbiome also affects the 
production of host cytokines. Up to 9.7% of the variation in cytokine production was 
explained by the gut microbiome (Netea et al., 2016). Clearly, the influence of the 
microbiome in immune responses and genetic disease is an important area to consider. 
Large cohorts including the Framingham 4000 cohort (Mahmood et al., 2014) and TEDDY (N 
= 10,000) (Group, 2007) will perform microbiome GWAS and enable further exploration of 
the host-microbiome inter-relationship. As ever, there is the challenge of assessing causality 
between these factors and disease outcome. 
 
I discussed how experimental approaches using causal risk factors as tractable readouts and 
MR approaches are currently employed to assess causality between different phenotypes. In 
future, longitudinal studies where susceptible individuals are tracked prior to disease onset 
would be invaluable in assessing the causality between immune function, microbiome 
composition or molecular changes with disease. This requires the establishment of detailed 
population-based biobanks that collate a wide-range of rich phenotype data including 
molecular, cellular and functional measurements as well as lifestyle factors (Leading Edge 
Voices, 2017). The INTERVAL study is such an example where the design is analogous to a 
randomised clinical trial. Here the aim is to link genetic determinants to the propensity of 
individuals to develop anaemia after repeat blood donations (Moore et al., 2014). Rich 
phenotypic data will be collected at several time points. 
 
For complex diseases with later-in-life onset, such as age-related macular degeneration or 
Alzheimer’s disease, realising the potential for causality assessments may take several 
generations of data collection and analysis. However, currently these resources will allow us 
to build our knowledge of pleiotropy, heritability and genetic architecture of many traits. 
Biobank resources may also help us understand why some individuals who carry the risk 
variants do not develop disease (Leading Edge Voices, 2017). Importantly, these biobanks 
also provide the opportunity of engaging the public in scientific endeavours as we move to 
collating data from larger and larger populations. Such large and potentially dynamic data 
resources bring with them consent and ethical challenges, which will need to be addressed 
(Caulfield and Murdoch, 2017).  
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In summary, although there remain challenges in interpreting the function of GWAS 
associations, a decade after the initial GWA studies, we have seen many examples of the 
power of genetics to uncover novel biological paradigms and potentially improve the success 
of therapeutic candidates in clinical trials. Indeed, GSK and Regeneron recently committed to 
sequence the first 50,000 UK Biobank samples, providing a denser variant set than the 
original array genotyping (GlaxoSmithKline plc., 2017). AstraZeneca announced efforts to 
build an integrated genomic database consisting of two million genomes as well as clinical 
trial and electronic health records data (AstraZeneca, 2016). It has even been estimated that 
by 2025, between 100 million and two billion human genomes would have been sequenced 
(Stephens et al., 2015). This wealth of genetic data may well enable us to completely resolve 
the genetic heritability and allelic architecture of complex traits and in doing so transforming 
our knowledge of basic science and the genetic risk of complex disease. 
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GWAS summary statistics contributions 
 
We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary 
results data for these analyses. The investigators within IGAP contributed to the design and 
implementation of IGAP and/or provided data but did not participate in analysis or writing of 
this report. IGAP was made possible by the generous participation of the control subjects, 
the patients, and their families. The iSelect chips was funded by the French National 
Foundation on Alzheimer's disease and related disorders. EADI was supported by the 
LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, 
Institut Pasteur de Lille, Universite de Lille 2 and the Lille University Hospital. GERAD was 
supported by the Medical Research Council (Grant no 503480), Alzheimer's Research UK 
(Grant no 503176), the Wellcome Trust (Grant no 082604/2/07/Z) and German Federal 
Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant 
no 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant 
R01 AG033193 and the NIA AG081220 and AGES contract N01AG12100, the NHLBI grant 
R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and 
Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 
AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC10196728. 
International Genomics of Alzheimer's Project (IGAP) is a large two-stage study based upon 
genome-wide association studies (GWAS) on individuals of European ancestry. In stage 1, 
IGAP used genotyped and imputed data on 7,055,881 single nucleotide polymorphisms 
(SNPs) to meta-analyse four previously-published GWAS datasets consisting of 17,008 
Alzheimer's disease cases and 37,154 controls (The European Alzheimer's disease Initiative 
EADI the Alzheimer Disease Genetics Consortium ADGC The Cohorts for Heart and Aging 
Research in Genomic Epidemiology consortium CHARGE The Genetic and Environmental 
Risk in AD consortium GERAD). In stage 2, 11,632 SNPs were genotyped and tested for 
association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. 
Finally, a meta-analysis was performed combining results from stages 1 & 2. The text above 
was reproduced at request from the International Genomics of Alzheimer's Project (IGAP). 
 
We thank the IAMDGC consortium for sharing the summary statistics and effect sizes of 
advanced age-related macular degeneration GWAS from Fritsche et al. (2016). The list of 
consortia members can be found in (Persad et al., 2017).  
 
Applications and queries can be made through the following contacts: goncalo@umich.edu, 
larsf@umich.edu  
 
Further information on AMD statistics: http://amdgenetics.org 
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CEBPA c-myc CEBPE cdk1 cdk2 PU.1 ccnd1 CEBPB c-jun Fos
ATRA 24h 0.15 0.04 3.25 1.31 1.28 1.13 0.68 4.56 1.12 12.15
DMSO 24h 0.62 0.05 0.54 2.40 0.94 0.62 0.49 1.31 1.15 11.24
control 96h 1.13 2.88 0.56 1.98 3.37 1.89 1.74 8.21 9.18 36.20
ATRA 96h 0.02 0.02 0.13 0.26 0.37 1.15 2.13 5.58 45.50 103.63
DMSO 96h 0.40 0.01 0.11 0.51 0.20 0.83 0.51 1.39 5.62 127.25
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Supplementary Figure 2.1: Proliferation of dividing and differentiated HL60 cells Cell 
count of HL60 cells shown for each 24-hour period after addition of either DMSO or ATRA at different 
concentrations shown. The control HL60 cells had no addition and continued to proliferate until 
reaching a maximum, likely due to limited nutrients as medium was not changed in this period. The 
reduced proliferation of ATRA and DMSO conditions is evidence of differentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.2: Changes in gene expression as a result of HL60 gene 
expression Barplot shows changes in expression of 10 genes known to be affected by HL60 
differentiation. Expression was measured by real-time qPCR and the change in expression is 
evaluated with respect to HL60 cells grown for 24 hours. Figure produced by Stephen Watt.   
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Supplementary Figures 2.3: Examples of disease loci and colocalised molecular 
features  
Regional association plots for particular colocalised loci mentioned in the main text of this 
chapter (left plot). The disease locus as defined by the GWAS study and the lead SNP in 
brackets is included, as well as the cell type and feature that is colocalised. The eQTL gene 
is also included in the legend. The correlation between p values of the two traits is also given 
(right plot). If a locus is colocalised, then the p values in the locus should be correlated. 
These also provide an initial indication of independent signals that may not be colocalised if 
the correlation is lower. 
 
A) Advanced age-related macular degeneration CNN2 locus 
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B) Coronary artery disease LIPA locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 251 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) Advanced age-related macular degeneration NPLOC4 locus 
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D) Coronary artery disease IL6R locus 
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E) Coronary artery disease VAMP5-VAMP8-GGCX locus 
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F) Coronary artery disease CYP17A1-CNNM2-NT5C2 locus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G) Systemic lupus erythematosus TYK locus 
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H) Coronary artery disease SORT1 locus 
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I) Extremes of FEV1 lung ratio TSEN54 locus  
 
 
 
 
 
 
 
 
J) Advanced age-related macular degeneration RDH5 locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 258 
K) Advanced age-related macular degeneration TNFRSF10A locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L) Systemic lupus erythematosus FCGR2A locus 
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Disease locus = CETP (rs5817082)
QTL coloc = Monocyte gene
Genomic location (Mb)
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QTL coloc = Monocyte K27AC
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Disease locus = BLK (rs2736332)
QTL coloc = T cell K4ME1
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
K4ME1
●
● ●●
●
●
●●
●● ●●
●
●●
●
●
●
●●● ● ● ●●
●●
● ●●●● ●●●●●
● ● ●
●
●
● ●●
●
●●● ●
●
●
●
●●
●●
●
●●
●●
●
●
●
●●
● ● ●●
●●
● ●
●
●
●●
●
●● ●
●
●●●
●
●
●
●
●
●●●●● ●●
●
● ●
●●
●
●● ●●● ●●●
●●
●
●
●● ●●
●●●●●●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●●●●
● ●
●
●●●
●
● ●●
●
● ● ●
●
●●
●
● ●●
●
●
●●
●
●
●
●●●●
● ●●
●
●
●
●●
●
●
●● ●
●
●●●
●●
●
●
●
● ●
●
●
● ●●● ●● ●● ●
●●
●●●● ●
●
●
●●● ●●
●●
●
● ●
●●
● ●●●●
●●
●●●
● ●
●
●●
●
●● ●●●
●
●
●
● ●● ●● ●●
●
●●
●
● ●●
● ●● ●●
●
●
●
●● ●
●
●
●●
●
●
● ●● ●
●●
● ● ●
●
●
●●●
●●
●
●●
●
●
●
●
●
● ●
●●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●●
●●●●● ● ● ●
●
●
●
●●
●●
●
● ●
●●
●
●●●
●●
●
●●●●
●●
●
●
●
●
●
●
●
● ●
●
●
● ●● ●
● ●
●
●●
●
●
●●●
●●● ●●
●
●● ●
●●
●
●
0 2 4 6 80
10
tcel K4ME1 8:11345910:11367069 SLE
QTL −log10PG
W
AS
 −
log
10
P
Q) Systemic lupus erythematosus BLK locus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 263 
●●
●
●
●●
●
●●●●●●●
●●
●
●
●●●
●●●●●●●●
●●●
●
●●●●●●
●●
●●
●
●●
●
●●●
●
●
●●
●
●●●
●
●●
●
●
●
●●
●
●●●●●●●●
●
●●●●●●●●●
●
●●●●
●●●●
●
●●●●●
●●●●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●●
●●
●●●
●●●
●
●
●
●
●
●●●●●●●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●●●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●●
●●
●
●●●●●
●●●●
●
●●
●●●
●
●●
●
●●
●
●
●
●
●●●●
●
●
●●●
●
●●
●●●●●●●●●
●
●●●●●●
●
●
●●●
●●●●
●
●●●●
●●●●●●
●●●●
●●
●
●●●●●●●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●●● 0
5
10
●
●●●●●●
●●
● ●
●●
●
●●●
●●●●
●
●
●
●
●●●
●
●●
● ●
●
●●●●●●
●
●
●●
●
●●
●
●
●●
●●●
●●
●●
●●●
●●●
●
●●
●
●
●
●
●●
●● ●
●
●
●●
●
●●●●●●●
●
●
●
●
●
●●
●●
●
●
●
●●
●●
●
●●
●
●
●
●
●●●●
●
●
●●●●
●
●
●
●●●●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●●●●●
●
●● ●●●● ●
●
●
●
●●●
●
●●
●●
●
●
●
●
●
●
●
●●●
●
●●
207.0 207.5 208.0 208.50
4
8
Disease locus = CR1 (rs6656401)
QTL coloc = Monocyte psi
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
CR1
●● ●● ●
●●
●
●●● ●● ● ●●●
●
●● ● ●●● ● ●● ●
●
● ●●●●
●
●
●
●●
●
●
●● ●
●●
●●
●●
● ●
● ●●● ●
●
●●●● ●●● ●●●●
●●
● ●● ●
●
● ●●● ●●
●
●
● ●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
● ●
●
●
●
●
●
●●
●
●●
●●
●●
●
●
●
●
●
●●
●
●●
●
●
● ●
●
●
● ●● ● ●
●
●
●
● ●● ●● ●
● ●● ●● ●●
●
●● ●●
●
●
●
●● ●
●
0 2 4 6 80
5
mono psi ENSG00000203710.6.11_207715526 AD
QTL −log10PG
W
AS
 −
log
10
P
●●
●
●
●●
●
●●●●●●●
●●
●
●
●●
●
●
●
●●●●●
●●●
●
●●●●●
●
●
●
●●
●
●●
●
●●●
●
●
●●
●
●●●
●
●●
●
●
●
●●
●
●●●●●●●
●●●●●●●●●●●●
●
●●●●
●●●●●●●●●●
●●●●
●
●
●
●●●
●
●
●●●
●
●●
●
●●
●
●
●
●
●●
●●●●
●
●●
●●
●●
●●
●
●
●
●
●
●●●●●●●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●●●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●●
●●
●
●●●●●
●●●●
●
●●
●●●
●
●●
●
●●
●
●
●
●
●●●
●
●●
●●
●
●
●●
●●●●●●●●●
●●●●●●●
●
●
●●●
●●●●
●
●●●●
●●●●●●●
●
●
●
●●●
●●
●●●●●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●●●●●
● 0
5
10
●●
●
●●●
●●
●
●
●
●
●●
●
●●●●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●●
●●
●
●●
●
●
●
●●
●
●●
●
●
●
●●
●●
●●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●●
●●
●●●
●●●●●●
●
●
●
●
●●●
●
●
●●●●
●●
●
●● ●●
●
●
●●
●
●
●●●
●
●
●
●
●●
●●●
●
●●
●
●●●
●●
●
●
●
●
●●
●●
●●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●●●
●●●●
●●
●
●
●
●
●
●●
●
●●●●
● ●●
●
●
●
●
●●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
207.0 207.5 208.0 208.50
4
Disease locus = CR1 (rs6656401)
QTL coloc = Monocyte psi
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
CR1
●●●●●
●●
●
●●●● ● ● ●●
●
●
● ●● ●● ●● ●●● ●●
●
●●
●
●
●
●●●
●
●
●
● ●●
●●
●●
●
●●● ●
●
●
●
●
●
●●
●●
●
●● ●● ●●●
●
●●●
●
● ●●
●● ●
●●● ●●● ●●
●●
●
●
●●
● ● ●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ● ●
●
●
●
●
● ●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
●●●● ●
●
●
●
●
●●
●
●
●●● ●
●●●
●● ● ●●●●
●● ●●● ●● ●●
●
●●
● ● ●0 2 4 60
5
mono psi ENSG00000203710.6.11_207734083 AD
QTL −log10PG
W
AS
 −
log
10
P
●
●●●●●●●●●
●
●
●●
●
●
●
●●●●●
●●●
●
●●●●●●
●●
●●
●
●●
●
●●●
●
●
●●
●
●●●
●
●●
●
●
●
●●
●
●●●●●●●●
●
●●●●●●●●●
●
●●●●
●●●●
●
●●●●
●●●●●●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●●
●●
●●●
●●●
●
●
●
●
●
●●●●●●●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●●●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●●●●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●●
●●
●
●●●●●
●●●●
●
●●
●●●
●
●●
●
●●
●
●
●
●
●●●●
●
●
●●●
●
●●
●●●●●●●●●●
●
●●●●●●
●●●●●
●●
●●
●
●●●
●
●●●●
●
●
●●●●
●
●
●
●
●●●●●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●●●●●
●●● 0
5
10
● ●●
●● ●● ●
●
● ●●●●
●
●
●
●●
●●●
● ●●●●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●●●
●
●●●●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●●●●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●●●●●
●●
●●
●●●●
●
●
●●●●
●●●
●
●
●●●●
●●●●●●
●
●●●
●
●●
●
●
●●
207.0 207.5 208.0 208.50
4
8
Disease locus = CR1 (rs6656401)
QTL coloc = Monocyte psi
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
CR1
●
●
●
●●●●●●●●
● ●
● ●
●
●●
●
● ●
● ●
●●● ●● ●
●
●
●
● ●● ●
●●
● ●●●
●
●
●
●●
●●
●● ● ●
●
● ●●
●
●
●
●
●●
●●
●● ●●●
●
●
● ●●
●● ●
● ●●● ● ●●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●
● ●
●
●
●
●●
●
●
●
●
●● ● ●●● ●
●●
●●
●
●
●
●
●●● ●
●
●
●● ●● ●
●●
●●
●●
● ●
●
●
● ●●
●
● ●●● ●●
●
●
●●● ●
●
●
●●0 2 4 6 8 100
5
mono psi ENSG00000203710.6.27_207726197 AD
QTL −log10PG
W
AS
 −
log
10
P
●●
●
●
●●
●
●●●●●●●
●●
●
●
●●●
●●●●●●●●
●●●
●
●●●●●●
●●
●●
●
●●
●
●●●
●
●
●●
●
●●●
●
●●
●
●
●
●●
●
●●●●●●●●
●
●●●●●●●●●
●
●●●●
●●●●
●
●●●●●
●●●●●●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●●
●●
●●●
●●●
●
●
●
●
●
●●●●●●●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●●●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●●
●●
●
●●●●●
●●●●
●
●●
●●●
●
●●
●
●●
●
●
●
●
●●●●
●
●
●●●
●
●●
●●●●●●●
●
●●
●
●●●●●●
●
●
●●●
●●●●
●
●●●●
●●●●●●
●●●●
●●
●
●●●●●●●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●●● 0
5
10
●●●
●
●●
●
●
●●●
●
●●●●●●
●●●
●
●
●●●
●
●●
● ●●
●
●
● ●
●
●
●
●●●
●●
●
●●
●●●●●
●
●●
●
●
●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●
●●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●●
●
●●●●
●
●
●
●●
●
●
●●
●●●
●
●●
●
●●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●
●●
●●
●●●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●●●
●
●
●●●●
●●
●
●
●
●●
●●
●
●
●●
●●
●●●
●
●
●●●
●
●
●
●
●
●
●
●●
207.0 207.5 208.0 208.50
4
8
Disease locus = CR1 (rs6656401)
QTL coloc = Neutrophil psi
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
CR1
● ●●● ●
●●
●
●● ●● ● ●● ●●
●
●
●
●
●
●● ●● ●●●
● ● ●
●●
●●
●
●
●
●
●●
● ●●●
●
● ●
●
●
● ●
●
●
●●
●●
●●●●
● ●
●
●
●
●
● ●● ●
● ●● ●● ●● ●
●● ●
●
●
●
●●
●●
●●
●
●
●
● ●●●
●●● ●●
●
●● ●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
● ●
● ●
●
●
●
●● ●●
●
●
●
●
●
●
● ●
●
●
●
●●●● ●●
● ●
●● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●● ● ●●
●
● ●●● ●●
●●
●
●
● ●●
●
●●● ● ●●
● ●
●
●● ●●
●
●
0 2 4 6 8 100
5
neut psi ENSG00000203710.6.11_207715526 AD
QTL −log10PG
W
AS
 −
log
10
P
●
●●●●●●●●●
●
●
●●
●
●
●
●●●●●
●●●
●
●●●●●●
●●
●●
●
●●
●
●●●
●
●
●●
●
●●●
●
●●
●
●
●
●●
●
●●●●●●●●
●
●●●●●●●●●
●
●●●●
●●●●
●
●●●●
●●●●●●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●●
●●
●●●
●●●
●
●
●
●
●
●●●●●●●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●●●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●●●●
●
●
●●
●
●●
●
●
●
●●●
●
●
●
●●
●●●
●●
●
●●●●●
●●●●
●
●●
●●●
●
●●
●
●●
●
●
●
●
●●●●
●
●
●●●
●
●●
●●●●●●●●
●
●●
●
●●●●●●
●●●●●
●●
●●
●
●●●
●
●●●●
●
●
●●●●
●
●
●
●
●●●●●●●●
●
●
●
●
●
●
●●
●
●●
●
●
●●●●●
●●● 0
5
10
●●●●
●●
●●
●
●
●●●●●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●
●
●
●
●
●●
●
●●
●●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●●
●
● ●●●●
●●
●
●
●
●●
●●●
●●● ●● ●● ●
●●●
●
●●●
●
●
●●●●
●●●●●●●●
●
207.0 207.5 208.0 208.50
5
15
Disease locus = CR1 (rs6656401)
QTL coloc = Neutrophil psi
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
CR1
●
●
●
●●
●●●●● ●●
● ●●
●
●
●
●● ●
●
●
●●
●●●
●
●●
●●
●
●●● ●●● ●●
● ●●● ● ●
●●●
●
●
●
●
●●
●
●●●
●
●
● ●
●
●
●● ●
●●
●
● ●●●
●●
● ●
● ●●● ● ●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●●
●●
●
●
●●
●
●● ●●
●
●
●
●
●
●
●● ●●●● ●
●
●
●
●
●
●
●
●●
●
●
●
●●
● ●
●
●
●
●
●●
●
●
●
●● ●●●
●●
●
● ●
0 5 10 150
5
neut psi ENSG00000203710.6.27_207726197 AD
QTL −log10PG
W
AS
 −
log
10
P
R) Alzheimer’s disease CR1 locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 264 
●
●●
●
●
●
●●
●
●
●
●
●●
●●●
●●●●●●
●
●●
●
●
●
●●●●●
●
●●●●●
●●●●●●●●
●
●
●
●●●●
●
●●
●
●●
●
●
●
●●●●●●
●
●
●
●
●●●
●
●
●●●
●●
●
●●
●
●●●
●●●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●●
●●●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●●
●
●
●
●●●●●●
●
●
●
●●●●●●
●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●●●●●
●●
●
●
●●●●●●●
●●
●●
●
●●
●
●
●●●●
●●●
●●●
●●●●●
●●●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●●
●
●●●
●
●●
●●●●
●●●●
●
●
●
●●●
●
●
●
●●
●●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●●
●●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●●●
●●
●
●●
●●
●●●
●
●●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●●
●
21.0 21.5 22.0 22.50
.0
1.
5
3.
0
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Monocyte gene
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
UBE2L3
●
● ●
●
●
●
●
●●
●
●
●●
●
●●
●
●
●●
●
●●
●● ● ●
●●
●●
●● ●
● ●●●
● ●
●
●
● ● ● ●
●●●●
●●
●
●●●
●
●
●
●
●●
●
●●●
●●●
●
●
●
●● ●●●●
●
●●
● ●
●
●
●
●
●
●
●●●
●● ●
●●
●
● ●● ● ● ●● ●
●
●
● ●
●
●
●
●●
● ● ● ● ●
●
●
●●
●
●
●
● ● ●
●●
●
●
●
● ●
●
●●
●
●● ●●●
●
● ●
●● ●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●● ● ●●
●
●
●
●
●
●
●
●
●
● ●
●
● ●●
●
●
● ● ●●
●
●
●
●
● ●●● ●
●
●● ●
●
●●●
●
●●●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●● ●
●
● ●●●
●
●●
● ● ●●● ●
●●
● ●●
●
●
●
●
●
●
● ●● ● ●
●
●●
●
●●
●
●● ●● ● ●
●●● ● ●●●
●●
●
●
●
●● ●
●
●●●
●
● ● ●
●
●
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.50
4
8
12
mono gene ENSG00000185651.10 SLE
QTL −log10P
GW
AS
 −
log
10
P
●●
●
●
●
●●
●●
●
●●●
●
●
●
●●
●●●
●
●
●
●●●●
●
●●●●●
●●●●●●●●
●
●
●
●●●●
●
●●
●
●●●
●
●●
●
●●●●●●
●
●
●
●
●●
●
●
●●●
●●
●
●●
●
●●●
●●●
●●●
●
●●●●
●
●
●●
●
●
●
●
●
●●
●●●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●●●●
●
●
●
●●●●●●
●●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●●●●●
●
●
●
●●●●●●
●●
●●
●
●●
●
●●●●●
●●●
●●●
●●●●●
●●●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●●
●
●●●
●
●
●●●●●●●
●
●
●●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●●●●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●●
●●
●●
●●●
●
●
●
●
●●
●
●
●
●●●
●●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
21.0 21.5 22.0 22.5
0
1
2
3
4
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Monocyte K4ME1
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
K4ME1
●●
●●
●
●
●●●
●
●●
●
●
● ●
●
●
● ●●
●
●
●
●●
●●●●
● ● ●
●●●●
● ●●
●●
●
●
●
● ●
●
●● ●●● ●●●
●
●●
●
●●●●
●
●●
● ● ●
● ●●
●
●●● ●● ●
●●
●
●
● ●● ●● ●●
● ●
●● ● ●●●
●
● ● ●●
● ●●
●
● ●
● ●
●●● ●
●
●●● ●●
●
●●●
●
●● ●
●
●
●
●
●
●
● ●●
●
● ●
●
●
● ●
●
●
●●
●
●
●
●
●
●●
●●
●
●●
●
●
●
●
●
●
●
●●● ●
●
●
●
● ●
●● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●●
●● ● ●●
●
●
●
●
●
●
●
●
●
●
●
●●
●● ●●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●●
●●
●
●●●
●
● ●●
● ●
●
●●
●
●
●
●
●
●●●
●
●
● ●
●●●
● ●
●
●● ●
●
●
●● ●●●
●●● ●● ●●●
●
●●●
● ●
●
●●
●
●
● ●
0 1 2 3 40
4
8
12
mono K4ME1 22:21917050:22033004 SLE
QTL −log10P
GW
AS
 −
log
10
P
●
●●
●
●
●
●●
●
●
●
●
●●
●●●
●●●●●●
●
●●
●
●
●
●●●●●
●
●●●●●
●●●●●●●●
●
●
●
●●●●
●
●●
●
●●
●
●
●
●●●●●●
●
●
●
●
●●●
●
●
●●●
●●
●
●●
●
●●●
●●●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●●
●●●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●●
●
●
●
●●●●●●
●
●●
●
●●●●●●
●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●●●●●
●●
●
●
●●●●●●●
●●
●●
●
●●
●
●
●●●●
●●●
●●●
●●●●●
●●●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
● ●●● ●● ●●● ●●● ●
●
● ● ●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●
●●●● ●
●
● ●
●●●●
●
● ● ●●●●●
●●
●
●
●●●●●●● ●
21.0 21.5 22.0 22.5
0
10
20
30
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Neutrophil gene
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
UBE2L3
●
●●
●●●
●
●●● ●
●● ●
●●●●
●●
●
●
●
●
●
●●
●●
● ●
●
● ●●
●
●
●
●●
●
●
●
●
●
●
●
●●●
●
● ●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
● ●
● ● ●●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●●
●
●
●
●
●
● ●●
●
●● ●
●
●
●
●
●
●
●●●
●● ● ●
●
●
●
●●●●
0 5 10 15 20 25 300
4
8
12
neut gene ENSG00000185651.10 SLE
QTL −log10P
GW
AS
 −
log
10
P
●
●
●
●●
●
●
●
●
●
●●
●●
●
●●●●
●
●●
●
●
●
●●●●
●
●●
●
●●●●●
●●●●●●●●
●
●
●
●●●●
●
●●
●
●●●
●
●●
●
●●●●●●
●
●●●●
●●
●●
●●
●
●●
●
●●●
●●●
●
●
●
●●●●
●
●
●●
●
●
●
●
●
●●
●●●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●
●●●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●●●●
●
●
●
●●●●●●
●●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●●●●●
●●
●
●
●
●●●●●●
●●
●●
●
●●
●
●●●●●
●●●
●●●
●●●●●
●●●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
●●●●●
●
●
●●●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●●●
●
●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●●●
●
●●●●●●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●●●●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●●●
●●
●
●●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●●●
●
●●●●
●
●
●
●
●● ●
21.0 21.5 22.0 22.5
0
2
4
6
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Neutrophil K27AC
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
K27AC
●
●●
●
●●●
●
●●
●
● ●●
●
●●●
● ●
●● ●●●
●●●
●
●● ●●● ●
●●
●
● ● ●●
●
●
●●●●● ●● ●● ●
●
● ●
●● ●● ● ●●● ●
●
●● ●
●●
●
●
●● ●●
●
●●
●
●●● ●● ●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●● ●
●
●
●
●
●
●
●●
●
●
●
● ● ●
●●● ●
●
● ● ●
● ●
●
● ●
● ●
●
●
●●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
● ●●●
●
●
●
●
●
●
●
●
●
●
● ● ●
● ●●
●
●
●
●
●
●
●
● ●
●
●
●●
●
●●
●
●●
●
● ●
● ●●●●
●
●
●
● ●●●●
● ● ●
●
●●
● ●●● ●●
● ●
●
●
●
●●
● ● ● ●●
●●● ●
● ●●
●
0 1 2 3 4 5 60
4
8
12
neut K27AC 22:21920490:21930954 SLE
QTL −log10P
GW
AS
 −
log
10
P
●●
●●
●●●
●
●
●
●●
●●●
●
●
●
●●●
●
●
●
●●●●●
●●●●●●●●
●
●●
●
●●●●
●
●
●
●●●
●
●●
●
●●●●●●
●
●●●●
●
●
●●●
●●
●
●●
●
●●●
●●●
●
●
●
●●●●
●
●
●●
●
●●
●
●
●●●
●
●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●
●●●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●●●●
●
●●●●●●●●
●●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●●●●●
●●
●
●
●
●●●●●●
●●
●●
●
●●
●
●●●●●
●●●
●
●●
●●●●●
●●●
●●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
●●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
●●
●●
●
●
●●●●●●●●●●
●
●●●●
●
●
●
●●
●●
●
●●●
●●●●●●●●●●●● ● ● ●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●
●
●
●●●●●● ●
●
●●● ●
●●●
●●●●● ●●●●
●
●●●
●●●●●●●●●
21.0 21.5 22.0 22.5
0
10
20
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Neutrophil K27AC
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
K27AC
●●
●●●
●●
●● ●
●●
●●
● ●
●●●●
●
●
●
●●●
●
●
● ●
●
●● ●
●●● ●● ●● ●
●
●
●
●●
●●
●●
●
●
●
● ●
●●●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●●●
0 5 10 15 20 250
4
8
12
neut K27AC 22:21938482:21985305 SLE
QTL −log10P
GW
AS
 −
log
10
P
●●
●
●
●
●●
●●
●
●●●
●
●
●
●●
●●●
●
●
●
●●●●
●
●●●●●
●●●●●●●●
●
●
●
●●●●
●
●●
●
●●●
●
●●
●
●●●●●●
●
●●●●
●●
●●
●●
●
●●
●
●●●
●●●
●
●
●
●●●●
●
●
●●
●
●
●
●
●
●●
●●●●
●
●
●
●●●
●●●●
●●●
●
●●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●●●●●
●
●
●
●●●●●●
●●●●●●●
●●●●●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●●●●●
●
●
●
●
●
●
●●●●●
●
●
●●
●
●●
●●●
●●●●
●●●
●●●
●●●●●
●●●
●●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●●
●●
●●
●●
●●●●●
●
●●
●
●
● ● 0
4
8
12
●●
● ●● ●●● ●● ●●● ●
●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●●●●●●
●
●
●●● ●● ●●
● ●
● ● ● ●
●
●●● ●
●● ●
21.0 21.5 22.0 22.5
0
10
20
30
Disease locus = UBE2L3 (rs3747093)
QTL coloc = Neutrophil K4ME1
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
SLE
K4ME1
●●
●
●●
●
●●
●●
●● ●
●●
●●●● ●
●
●
●
●
●●●
● ● ●●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●
●
● ●
● ●●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●●
● ●●
●
●
●
●
●
●
●
●
●
●
●● ●
● ●●
●
●
●
●
●
●
●
●●
●●
●
●●●
●
● ●●
●
●
●●●
●
0 5 10 15 20 25 300
4
8
12
neut K4ME1 22:21917050:22033004 SLE
QTL −log10P
GW
AS
 −
log
10
P
 
 
S) Systemic lupus erythematosus UBE2L3 locus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 265 
●
●●
●
●●●
●
●
●
●●
●●●●
●
●●
●
●●
●
●●●
●
●
●
●●●●●●●●
●●●●●
●
●●●●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●●
●●
●
●●
●
●
●
●
●●
●
●
●●●●●
●
●●
●
●
●
●
●
●
●●●●
●●
●●
●
●●
●
●●
●
●●
●
●●●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●●●●●●●●●●
●
●●●
●
●●
●
●
●
●●●●●●●●●●●●●●
●
●●●●
●
●●●
●●●
●
●●
●
●
●●●●
●
●
●
●●
●
●●
●●●●●
●●●●●●●●●●●
●●
●●
●
●
●
●●●●●●
●●
●●
●●
●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
0
4
8
●
●●●●● ●
● ●●●●●●●●●
● ●
●
●
●●●●
●●●
●
●
●
●●
●●●●
●
●●● ●●●●●
●
●
●
●
●
●●
●●
●●
●
●
●●
●
●
●
●
●●●
●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●●●● ●●●●●●●●
●
●●
●●●
●
●●●●●
●
●
●
●●●
●
●
●●●
●
●●●●●
●●●●●
●
●●●●●
●●●●●●●●●●
●
●●●●
●●●
●
● ●
●
59.0 59.5 60.0 60.5 61.00
4
8
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte gene
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
MS4A6A
●●
●● ●
●
● ●●●
●
●
●● ● ●
●
●●
●
●
●
●● ●●
●
●
●
●●
● ●●●● ● ●●●
●
●●
●
●●
●
●
●●
● ●●
●
●
●●● ●
●
●
●
●
● ●●
●
●
●
●
●
●
● ●● ●●●
●●
●
●●
●● ●● ● ●●●
● ●●
●
●
●
●●●
● ●●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●● ●
● ●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●●●
● ●
●
●●
●
●
●
●●
●
●
●
● ●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●●● ●●●
●
0 2 4 6 8 100
6
12
mono gene ENSG00000110077.10 AD
QTL −log10PG
W
AS
 −
log
10
P
●
●
●●●
●
●
●
●●●●●●●●
●●●●●
●
●●●●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●●
●●
●
●●
●
●
●
●
●●
●
●
●●●●●
●
●●
●
●
●
●
●
●
●●●●
●●
●●
●●
●●
●●
●
●●●●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●●●●●●●●●●
●
●●●
●
●●
●
●
●
●●●●●●●●●●●●●●
●
●●●
●
●●●●●●
●
●●
●
●
●●●●
●
●●●●
●
●
●
●●●
●●●
●●●●●●●●●●●
●●
●●●
●●●●●●●●
●●
●●●
●●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●
●● ●●●● 0
4
8
● ●●●
●
●●●
●●●●●●●
●●●●●●●●●●●●●
●
●
●
●
●
●
●●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●●●●●●
●
●●●
●
●●●●●●● ●
●
●
●●
●●
●●●
●
●
●●
●●
●●●
●
● ●●●
●
●●● ● ●●●●
59.0 59.5 60.0 60.5 61.00
5
15
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte gene
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
MS4A4A
●● ●
●
●
●
●● ●●●●● ●
●
●
●
●● ●●
●
●● ●
●
●
●
●●●
●
●
●
●
●●●
●
●
●● ●●
●
● ●
●● ●
●● ●●
● ●●
●● ●●●●
● ●●
●
●
●● ●
● ●●
●
●
● ●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●● ● ●●● ●●●● ●● ●● ●●●
●
●
●
●
●
0 5 10 150
6
12
mono gene ENSG00000110079.12 AD
QTL −log10PG
W
AS
 −
log
10
P
●●●
●
●
●
●●
●●●●
●
●●
●
●●
●
●
●
●●
●
●
●
●●●●●●●●
●●●●●
●
●●●●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●●●●
●
●●●●●●●●
●
●
●
●
●●●●
●●
●●
●
●●
●
●●
●
●●
●
●●●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●●●●●●●●●●
●
●●●
●
●●
●
●
●
●●●●●●●●●●●●●●
●
●●●●
●
●●●
●●●
●
●●
●●
●●
●
●
●
●
●●
●
●●
●●●●●
●●●●●●●●●●●
●●
●●
●
●
●
●●●●●●
●●
●●
●●
●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●
●● 0
4
8
●
●
●●●●●
●●
●
●●●●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●●●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●
●●●●●
●●
●
●
●
●●●
●
●●●
●
●●●●
●
●●●●
●
●●
●●●
●●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●●
●
●●●●●●●●●●●●
●
●
●
●
●
●●●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●●
●
●●●●
●
●
●
●
●
●
●
●
●●
59.0 59.5 60.0 60.5 61.00
2
4
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte gene
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
MS4A4E
●● ●●
●
●●
●
●
●
●
●
●
●
●● ●●
●
●●●● ● ● ●● ●● ●●●
●
●●
●
●● ● ●●● ●●
●● ●● ● ●
● ●●●
●
●●
●●
●
●
●
●●● ●
●●
●
●●
●
●
● ●
●●
●
●
●●
●
●●
● ●
●
●
●
●●●
●
●
●
●●
●
●
●
● ● ●●●● ●●●
●
●
●● ●
● ●
● ●
●
● ●
● ●●
●
●●
●● ●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●● ●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●● ●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
● ●● ●
●
● ●●●●●● ●
●
●● ●
● ● ●
●● ●
●
●
● ●
● ●● ●● ●●
●
●
●
●0 1 2 3 4 50
6
12
mono gene ENSG00000214787.4 AD
QTL −log10PG
W
AS
 −
log
10
P
●●●
●
●●
●
●●
●
●●●
●●●
●●●
●
●
●
●●
●
●
●
●●●●
●●●●●●●●●●
●
●●●●●
●●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●●
●●
●●
●
●●
●
●●
●
●●
●
●●●●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●●●●●●●●
●
●●●
●
●●
●
●
●
●●●●●●●●●●●●●●
●
●●●●
●
●●●
●●●
●
●●
●
●
●●●●
●
●
●
●●
●
●●
●●●●●
●●●●●●●●●●●
●●●
●●●●
●●●●●●
●●
●●●
●●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●
●● 0
4
8
●●●●●●●● ●●
●
●
●
●
●
●
●●●●●●● ●●●●●●●●
●
●●●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●●●●●
●●●
●
●
●
●
●●●
●●●●●●
●
●●
●
●●
●
●
●
●●
●●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●●
59.0 59.5 60.0 60.5 61.00
2
4
6
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte K27AC
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
K27AC
●●● ●
●
●●●
●
●
●
●●● ●
●
●● ●● ●● ●●●●
●
●
●
● ●
●
● ●
●● ● ●●
●●●
●
●
● ●
●●
●
●
●●●
●●
●●
●
●
● ●
●●●
●
●
●
●
●● ●● ● ●
●
● ●● ● ●
●●
●●
●● ●●●
●
●●
●●●
●
●
●
●●●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●●
●●
●
●
●
●●
●
●
●
● ●● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●● ●●
●
●
●
●●● ●●
●
●
● ●● ●● ●
●
● ●●●●● ●●
●
●● ●
● ●● ● ●●
●● ● ●
●●
●
● ●
●● ●
●
●● ● ●● ●● ●
● ●●●● ●
●●
● ●●
●●
●
0 1 2 3 4 5 60
6
12
mono K27AC 11:59958990:59966366 AD
QTL −log10PG
W
AS
 −
log
10
P
●●
●
●●
●
●
●
●●
●
●
●
●●●●
●●●●●
●●●●●
●
●●●●●
●●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●●
●●
●●
●
●●
●
●●
●
●●
●
●●●●
●●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●●
●●●●●
●●●●●
●
●●●●●●
●
●
●
●
●
●●●●●●●●●●●●●●●●
●
●●●●
●
●●●
●●●
●
●●
●●
●●
●
●
●
●
●●
●
●●
●●●●●
●●●●●●●●●●●
●●●
●●●●
●●●●●●
●●
●●●●●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●
●● ● 0
4
8
●
●
●●●●●●
●
●
●
●●●●●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●● ●
●●
●
●●●●●
●
●●
●●
●
●
●
●
●
●
●
●
●●●●
●●
●
●●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●●●●
●
●●●●
●●●●
●
●●●●
●●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●
●●
●
●●
●
●●●
●
●●●
●
●
●●●●
●
●●●
●
●
●
●●●●
●●
●●
●●
●●●
●●●
59.0 59.5 60.0 60.5 61.00
2
4
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte K27AC
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
K27AC
● ●●●●
●●
● ●●●
●●
●●
●
●
●
●●●
● ● ●●●● ●● ● ●
●
●●
●
●
●
●
●
●
●
●●
● ●●
●
●●
● ●
● ●
●●
●● ●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●●
●
●● ● ●
●
● ●
●●● ●
●
●
●
●
●
●
●●
●
●
● ●
●●● ●
●●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
● ●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●● ●● ●
●
●
●●
●●●
●
●
●
● ●●● ●
●
●● ●●● ● ●● ●● ●● ●●●● ●●● ● ●●
●
● ●●● ●
●
●
●
●●
● ●
●● ●
●
●
● ● ●●
●
●
●
●
0 1 2 3 4 50
6
12
mono K27AC 11:60029596:60032280 AD
QTL −log10PG
W
AS
 −
log
10
P
●
●
●
●
●●
●
●
●
●●●●
●●●●●●●●●●
●
●●●●●
●●●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●●●
●
●●
●
●●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●●
●●
●●
●
●●
●
●●
●
●●
●
●●●●
●●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●●●●●●●●
●
●●●
●
●●
●
●
●
●●●●●●●●●●●●●●●
●
●●●●
●
●●●
●●●
●
●●
●●
●●
●
●
●
●
●●
●
●●
●●●●●
●●●●●●●●●●●
●●●
●●●●
●●●●●●
●●
●●●●●●●●●●
●
●
●
●●
●
●
●
●●●●●
●
●
●● ●●● 0
4
8
●
●
●●
●●
●●
●
●
●
●●●
●
●
●●
●
●●●●●●
●●●●●●●●●●
●●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●●
●
●●●●●
●●
●●
●
●
●
●
●
●
●●
●
●●●
●●●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●●
●
●
●
●
●●●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●●●
●●●
●●
●
●●●
●
●●●●
●
●●
●
●
●
●
●
●●●
●
●
●●
●
●●
●●
●
●
●
●
●
●
●●
●
●●●●
●
●
●
●
●●●
●
●●
●
●●●●
●
●
●
●
●
●
●●
●●●
●
●
●
●
●●
●
●
●
●●●
●●●
●
●
●
●
●
●●
●
●
●●●●●●●
●
●●●●
●●●●●
● ●
59.0 59.5 60.0 60.5 61.00
2
4
Disease locus = MS4A6A (rs983392)
QTL coloc = Monocyte K27AC
Genomic location (Mb)
−l
og
10
(P
)
GW
AS
 −
log
10
(P
)
AD
K27AC
●●●● ●
●
●●
●
●● ●
● ●
●● ● ●●
●●●● ●●●● ●●
●
●● ●●
●
● ●● ● ● ●
●
●●●
●
●
● ●●
●
●
●
●● ●
●
●
●
●●
● ●
●
●●
●
●
●
●
●
●
●●
●
●●
●●
●
● ●●
●
●
● ●●● ●● ●
●
●●●
●●●●
● ●
● ● ●
● ●●
●
●
●
●
●● ●
● ●●
●
●
● ●
● ●
● ●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
● ●
●
●●●
●
●
●
●●
●
●
●
●
●● ●●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●●
●
●
●
●●●
● ●
●●
●
●
●
●
●
●●● ● ● ●●
●
●● ●● ● ● ●●
●
● ● ●● ● ●● ●
●
●
● ●● ●
● ●● ●●●
●
●●● ●● ●●
●●
0 1 2 3 4 50
6
12
mono K27AC 11:60046766:60053631 AD
QTL −log10PG
W
AS
 −
log
10
P
T) Alzheimer’s disease MS4A6A locus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 266 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 267 
  
 268 
Chapter 2 Supplementary Tables 
 
 
 
 
 
 
Feature SNP (EA/OA) (EAF) Beta SE 
TNFRSF10A 
(rs13255394) 
Univariate -0.266 (0.017) 9.725 x 10-35 
Conditional 
(RP11-114O23.3 expression) 
-0.075 (0.028) 8.638 x 10-03 
Conditional 
(RP11-114O23.3 expression + H3K27ac 
signal) 
-0.045 (0.031) 1.355 x 10-01 
RP11-
114O23.3 
(rs13255394) 
Univariate -0.880 (0.040) 5.433 x 10-54 
Conditional (TNFRSF10A expression) -0.576 (0.052) 2.312 x 10-22 
Conditional 
(TNFRSF10A expression + H3K27ac 
signal) 
-0.565 (0.061) 2.325 x 10-16 
 
 
 
 
 
Supplementary Table 2.1: Conditional causality analysis in the TNFRSF10A locus 
using Blueprint phase 1 genetic data Association results (beta, SE, and p value) from a simple 
linear regression model. The univariate approach tests for association of the respective gene 
expression with the genotype of rs13255394 (lead monocyte SNP). Conditional analysis then tests for 
association of the gene with genotype whilst conditioning on the expression of the alternative gene. 
The reduction in p value is greatest when testing for association between the SNP and TNFRSF10A 
expression whilst conditioning on RP11-114O23.3 expression, which suggests the RNA may be 
causal for variation in expression of TNFRSF10A. The further approach conditions on the gene 
expression and H3K27ac level.  
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Disease SNP Study SNP LD Locus Feature SNP Cell Mark Feature.ID 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M G ENSG00000185899.1 
AD rs11771145 rs11771145 NA EPHA1 rs112524998 M G ENSG00000229153.1 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M G ENSG00000221855.1 
AD rs11771145 rs11771145 NA EPHA1 rs10265814 M K27 7:143173365:143179545 
AD rs11771145 rs11771145 NA EPHA1 rs10237465 M K27 7:143118095:143120257 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M K27 7:143067879:143115356 
AD rs11771145 rs11771145 NA EPHA1 rs12540656 M K27 7:143115439:143117746 
AD rs11771145 rs11771145 NA EPHA1 rs10265814 M K27 7:143158610:143161683 
AD rs11771145 rs11771145 NA EPHA1 rs10237465 M K27 7:143122978:143124643 
AD rs11771145 rs11771145 NA EPHA1 rs112524998 M K27 7:143133149:143136359 
AD rs11771145 rs11771145 NA EPHA1 rs112524998 M K27 7:143154161:143157641 
AD rs11771145 rs11771145 NA EPHA1 rs10265814 M K27 7:143200449:143202615 
AD rs11771145 rs11771145 NA EPHA1 rs10265814 M K27 7:143180293:143187266 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M K27 7:143195718:143199833 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M K4 7:143052447:143144656 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 M K4 7:143147624:143164247 
AD rs11771145 rs11771145 NA EPHA1 rs6966814 N G ENSG00000229153.1 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 N G ENSG00000185899.1 
AD rs11771145 rs11771145 NA EPHA1 rs6966814 N G ENSG00000234066.1 
AD rs11771145 rs11771145 NA EPHA1 rs11771145 N G ENSG00000221855.1 
AD rs11771145 rs11771145 NA EPHA1 rs10265814 N K4 7:143052447:143144656 
AD rs11771145 rs11771145 NA EPHA1 rs112524998 T S 7:143104980:143112160:1:3:1, 7:143104984:143112160:1:1:1, 
7:143111539:143112160:1:1:0 
AD rs6656401 rs6656401 NA CR1 rs7515905 M S 1:207685000:207715526:1:1:1, 1:207713412:207715526:1:1:1 
AD rs6656401 rs6656401 NA CR1 rs7515905 M S 1:207726197:207731882:1:1:1, 1:207726197:207748939:1:1:1 
AD rs6656401 rs6656401 NA CR1 rs7515905 M S 1:207685000:207734083:1:1:1, 1:207713412:207734083:1:1:1, 
1:207731969:207734083:1:1:1 
AD rs6656401 rs6656401 NA CR1 rs7515905 N S 1:207726197:207731882:1:1:1, 1:207726197:207748939:1:1:1 
AD rs6656401 rs6656401 NA CR1 rs7515905 N S 1:207685000:207715526:1:1:1, 1:207713412:207715526:1:1:1 
AD rs983392 rs983392 NA MS4A6A rs611418 M G ENSG00000110079.12 
AD rs983392 rs983392 NA MS4A6A rs611418 M G ENSG00000110077.10 
AD rs983392 rs983392 NA MS4A6A rs617135 M G ENSG00000214787.4 
AD rs983392 rs983392 NA MS4A6A rs4938931 M K27 11:60029596:60032280 
AD rs983392 rs983392 NA MS4A6A rs2081545 M K27 11:59958990:59966366 
AD rs983392 rs983392 NA MS4A6A rs1562990 M K27 11:60072491:60079697 
AD rs983392 rs983392 NA MS4A6A rs1582763 M K27 11:60046766:60053631 
AD rs983392 rs983392 NA MS4A6A rs580064 M K4 11:59969674:60062296 
AD rs983392 rs983392 NA MS4A6A rs4938931 M K4 11:60097581:60108825 
AD rs983392 rs983392 NA MS4A6A rs617135 M K4 11:59594047:59638261 
 270 
AD rs983392 rs983392 NA MS4A6A rs4939311 M S 11:59943085:59949053:2:2:1, 11:59945790:59949053:2:2:1, 
11:59947439:59949053:2:2:1 
AD rs983392 rs983392 NA MS4A6A rs7107627 N K27 11:60018228:60023007 
AD rs983392 rs983392 NA MS4A6A rs7933202 N K27 11:59958990:59966366 
AD rs983392 rs983392 NA MS4A6A rs1019671 N K27 11:59932786:59958180 
AD rs983392 rs983392 NA MS4A6A rs1441586 N K4 11:59867337:59870007 
AMD rs10033900 rs10033900 NA CFI rs3181191 T G ENSG00000248785.1 
AMD rs11080055 rs11080055 NA VTN rs2027993 M G ENSG00000244045.5 
AMD rs11080055 rs11080055 NA VTN rs11080055 N G ENSG00000004139.9 
AMD rs11080055 rs11080055 NA VTN rs241777 N G ENSG00000244045.5 
AMD rs11080055 rs11080055 NA VTN rs241777 T K27 17:27592619:27623928 
AMD rs1142 rs1142 NA SRPK2 rs12534381 M G ENSG00000135250.12 
AMD rs1142 rs1142 NA SRPK2 rs10263499 M K27 7:104849291:104858777 
AMD rs1142 rs1142 NA SRPK2 rs55671517 M K27 7:104840590:104849222 
AMD rs1142 rs1142 NA SRPK2 rs2299304 M K27 7:104578443:104588833 
AMD rs1142 rs1142 NA SRPK2 rs2385558 M K4 7:104817678:105045953 
AMD rs1142 rs1142 NA SRPK2 rs1204061 N G ENSG00000135250.12 
AMD rs1142 rs1142 NA SRPK2 rs2074753 N K27 7:104982791:105001752 
AMD rs1142 rs1142 NA SRPK2 rs3823752 N K27 7:104828844:104835525 
AMD rs140647181 rs140647181 NA COL8A1 rs6791887 M G ENSG00000036054.8 
AMD rs140647181 rs140647181 NA COL8A1 rs7611566 N S 3:100029387:100034942:1:1:1, 3:100030722:100034942:1:1:1 
AMD rs140647181 rs140647181 NA COL8A1 rs6794668 T K27 3:99927877:99930243 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 M G ENSG00000135437.5 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 M G ENSG00000258311.1 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 N G ENSG00000258311.1 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 N S 12:56113008:56113282:1:1:1, 12:56113008:56115472:1:1:1 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 T G ENSG00000135437.5 
AMD rs3138141 rs3138141 NA RDH5 rs3138142 T G ENSG00000258311.1 
AMD rs5817082 rs5817082 NA CETP rs7205804 M G ENSG00000087237.6 
AMD rs5817082 rs5817082 NA CETP rs1532625 M K27 16:56996497:57122386 
AMD rs5817082 rs5817082 NA CETP rs7205804 M K4 16:56989796:57234898 
AMD rs6565597 rs6565597 NA NPLOC4 rs112612275 M K27 17:79585940:79590489 
AMD rs6565597 rs6565597 NA NPLOC4 rs35816741 M K4 17:79594768:79608902 
AMD rs6565597 rs6565597 NA NPLOC4 rs67050149 M S 17:79526443:79532530:2:2:1, 17:79531006:79532530:2:2:1 
AMD rs6565597 rs6565597 NA NPLOC4 rs112612275 N K27 17:79585940:79590489 
AMD rs6565597 rs6565597 NA NPLOC4 rs11655377 T K27 17:79596351:79605193 
AMD rs6565597 rs6565597 NA NPLOC4 rs11150803 T K27 17:79619627:79621546 
AMD rs6565597 rs6565597 NA NPLOC4 rs35816741 T K27 17:79622135:79624634 
AMD rs6565597 rs6565597 NA NPLOC4 rs11150803 T K27 17:79578768:79583302 
AMD rs6565597 rs6565597 NA NPLOC4 rs35816741 T K27 17:80244653:80295172 
AMD rs6565597 rs6565597 NA NPLOC4 rs9912071 T K4 17:79594768:79608902 
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AMD rs6565597 rs6565597 NA NPLOC4 rs8070929 T S 17:79526443:79532530:2:2:1, 17:79531006:79532530:2:2:1 
AMD rs6565597 rs6565597 NA NPLOC4 rs8070929 T S 17:79526443:79530946:2:2:1, 17:79526443:79532530:2:2:1 
AMD rs6565597 rs6565597 NA NPLOC4 rs8070929 T S 17:79526443:79527746:2:2:1, 17:79526443:79530946:2:2:1, 
17:79526443:79532530:2:2:1 
AMD rs67538026 rs67538026 NA CNN2 rs10419072 M G ENSG00000064666.9 
AMD rs67538026 rs67538026 NA CNN2 rs62131196 M K27 19:1024681:1033920 
AMD rs67538026 rs67538026 NA CNN2 rs10417845 N G ENSG00000261526.1 
AMD rs67538026 rs67538026 NA CNN2 rs62131196 T G ENSG00000064687.8 
AMD rs67538026 rs67538026 NA CNN2 rs62131196 T K27 19:1024681:1033920 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M G ENSG00000121716.12 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M G ENSG00000066923.12 
AMD rs7803454 rs7803454 NA PILRB/A rs7803454 M G ENSG00000146834.8 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M K4 7:99906073:99912427 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 M K4 7:99801401:99888538 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99954456:99955842:0:0:1, 7:99954507:99955842:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1, 
7:99943592:99947421:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99954456:99955842:0:0:1, 7:99954507:99955842:1:1:1, 
7:99954562:99955842:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99933844:99935801:1:1:1, 7:99933961:99935801:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99943592:99947339:1:1:1, 7:99943592:99947421:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 M S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs67471932 N G ENSG00000233389.2 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N G ENSG00000066923.12 
AMD rs7803454 rs7803454 NA PILRB/A rs7787825 N G ENSG00000146834.8 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N K4 7:99906073:99912427 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N K4 7:99801401:99888538 
AMD rs7803454 rs7803454 NA PILRB/A rs67471932 N K4 7:99912739:99917535 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N S 7:99954456:99955842:0:0:1, 7:99954507:99955842:1:1:1, 
7:99954562:99955842:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N S 7:99933844:99935801:1:1:1, 7:99933961:99935801:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 N S 7:99954456:99955842:0:0:1, 7:99954507:99955842:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs11769886 N S 7:99943592:99947339:1:1:1, 7:99943592:99947421:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs11769886 N S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1, 
7:99943592:99947421:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs11769886 N S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T G ENSG00000085514.10 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T G ENSG00000078487.13 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 T G ENSG00000241357.1 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 T G ENSG00000121716.12 
AMD rs7803454 rs7803454 NA PILRB/A rs7787825 T G ENSG00000146834.8 
 272 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T S 7:99951107:99951517:1:1:1, 7:99951107:99952765:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 T S 7:99933844:99935801:1:1:1, 7:99933961:99935801:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 T S 7:99947511:99949785:1:1:0, 7:99949034:99949785:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs113387325 T S 7:99947511:99948874:1:1:1, 7:99947511:99949785:1:1:0 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T S 7:99943592:99947339:1:1:1, 7:99943592:99947421:1:1:1 
AMD rs7803454 rs7803454 NA PILRB/A rs111312383 T S 7:99943592:99947339:1:1:1, 7:99943592:99947353:1:1:1, 
7:99943592:99947421:1:1:1 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M G ENSG00000246582.2 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M G ENSG00000147457.9 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M G ENSG00000104689.5 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M K27 8:23048166:23092260 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M K27 8:23092704:23132254 
AMD rs79037040 rs79037040 NA TNFRSF
10A 
rs13255394 M K4 8:22998146:23133613 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs148513392 M G ENSG00000163596.12 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs78488377 M G ENSG00000144426.14 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs140201293 M G ENSG00000138380.12 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs16839813 M K4 2:204391511:204403180 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs4675290 N K27 2:204364327:204367436 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs72934535 N K27 2:203772046:203778875 
CAD chr2:203828796
:I 
chr2:203828796:I NA WDR12 rs72932553 T G ENSG00000236047.1 
CAD rs11191416 rs11191416 NA NT5C2 rs79780963 M S 10:104934740:104940941:2:2:1, 10:104934740:104940987:2:2:0 
CAD rs11191416 rs11191416 NA NT5C2 rs111374294 N G ENSG00000237827.1 
CAD rs11191416 rs11191416 NA NT5C2 rs111374294 N G ENSG00000076685.14 
CAD rs11191416 rs11191416 NA NT5C2 rs3740390 T K27 10:104811999:104815290 
CAD rs11191416 rs11191416 NA NT5C2 rs79780963 T S 10:104934740:104936242:2:2:0, 10:104934740:104937274:2:2:0, 
10:104934740:104940941:2:2:1, 10:104934740:104940987:2:2:0, 
10:104934740:104952992:2:2:1 
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CAD rs11191416 rs11191416 NA NT5C2 rs79780963 T S 10:104934740:104940941:2:2:1, 10:104934740:104940987:2:2:0, 
10:104934740:104952992:2:2:1 
CAD rs1412444 rs1412444 NA LIPA rs1412444 M G ENSG00000107798.12 
CAD rs1412444 rs1412444 NA LIPA rs1320496 M K27 10:90993615:91006217 
CAD rs1412444 rs1412444 NA LIPA rs1412444 M K27 10:90976768:90986051 
CAD rs1412444 rs1412444 NA LIPA rs1412444 M K27 10:91010098:91013357 
CAD rs1412444 rs1412444 NA LIPA rs1320496 M K27 10:91013477:91017078 
CAD rs1412444 rs1412444 NA LIPA rs1332326 M K4 10:91050031:91073249 
CAD rs1412444 rs1412444 NA LIPA rs1332326 M K4 10:91306722:91311404 
CAD rs1412444 rs1412444 NA LIPA rs1412444 M K4 10:91131855:91136597 
CAD rs1412444 rs1412444 NA LIPA rs1320496 M K4 10:90987967:91024823 
CAD rs1412444 rs1412444 NA LIPA rs1320496 M K4 10:91042400:91044298 
CAD rs1412444 rs1412444 NA LIPA rs1332326 M K4 10:90962723:90987091 
CAD rs1412444 rs1412444 NA LIPA rs1412444 M K4 10:91027656:91032000 
CAD rs1412444 rs1412444 NA LIPA rs1332328 N K27 10:90993615:91006217 
CAD rs1412444 rs1412444 NA LIPA rs1412444 N K4 10:90987967:91024823 
CAD rs1412444 rs1412444 NA LIPA rs1332327 T G ENSG00000107798.12 
CAD rs1412444 rs1412444 NA LIPA rs1320496 T K27 10:90248309:90252291 
CAD rs17087335 rs17087335 NA REST rs12645070 M G ENSG00000084093.11 
CAD rs17087335 rs17087335 NA REST rs12645070 M K27 4:57771837:57788561 
CAD rs17087335 rs17087335 NA REST rs12645070 M K27 4:57823529:57826313 
CAD rs17087335 rs17087335 NA REST rs12645070 M K4 4:57770788:57806908 
CAD rs17087335 rs17087335 NA REST rs12645070 M K4 4:57820927:57828891 
CAD rs17087335 rs17087335 NA REST rs12645070 N K27 4:57823529:57826313 
CAD rs17087335 rs17087335 NA REST rs6554401 N K4 4:57820927:57828891 
CAD rs6689306 rs6689306 NA IL6R rs7549250 N K27 1:154372031:154419908 
CAD rs6689306 rs6689306 NA IL6R rs7549338 N K4 1:153669232:153673360 
CAD rs6689306 rs6689306 NA IL6R rs11265611 N K4 1:154342399:154479953 
CAD rs6689306 rs6689306 NA IL6R rs4845625 T S 1:154422457:154437609:1:1:1, 1:154427058:154437609:1:1:1 
CAD rs6689306 rs6689306 NA IL6R rs4845625 T S 1:154422457:154426963:1:1:1, 1:154422457:154437609:1:1:1 
CAD rs6689306 rs6689306 NA IL6R rs4845625 T S 1:154422457:154426548:1:1:0, 1:154422457:154426963:1:1:1, 
1:154422457:154437609:1:1:1 
CAD rs67180937 rs67180937 NA MIA3 rs35700460 T K4 1:222943024:222949002 
CAD rs67180937 rs67180937 NA MIA3 rs35700460 T S 1:222828136:222831263:1:1:0, 1:222828136:222832063:1:1:1 
CAD rs7528419 rs7528419 NA SORT1 rs12740374 M G ENSG00000134222.11 
CAD rs7528419 rs7528419 NA SORT1 rs660240 M K27 1:109812607:109818851 
CAD rs7528419 rs7528419 NA SORT1 rs12740374 M K4 1:109779241:109861456 
CAD rs7528419 rs7528419 NA SORT1 rs12740374 N G ENSG00000134222.11 
CAD rs7528419 rs7528419 NA SORT1 rs660240 N K27 1:109812607:109818851 
CAD rs7528419 rs7528419 NA SORT1 rs660240 N K4 1:109779241:109861456 
CAD rs7528419 rs7528419 NA SORT1 rs660240 T K27 1:109109862:109115257 
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CAD rs7568458 rs7568458 NA GGCX rs12714145 M G ENSG00000115486.6 
CAD rs7568458 rs7568458 NA GGCX rs1078004 N G ENSG00000115486.6 
CAD rs7568458 rs7568458 NA GGCX rs56819945 N K27 2:85760296:85771243 
CAD rs7568458 rs7568458 NA GGCX rs10176176 N K4 2:85523177:85561159 
CAD rs7568458 rs7568458 NA GGCX rs11891260 T G ENSG00000115486.6 
CAD rs7568458 rs7568458 NA GGCX rs1561198 T G ENSG00000118640.6 
CAD rs9970807 rs9970807 NA PPAP2B rs56186267 M G ENSG00000162407.8 
CAD rs9970807 rs9970807 NA PPAP2B rs56186267 M K27 1:56969801:56978117 
CAD rs9970807 rs9970807 NA PPAP2B rs6588634 N K27 1:56931078:56933449 
FEV1 rs7218675 rs7218675 NA TSEN54 rs35643020 M G ENSG00000182173.8 
FEV1 rs78420228 rs78420228 NA CDC123 rs12241367 M K27 10:12310277:12315701 
FEV1 rs78420228 rs78420228 NA CDC123 rs61848342 M K27 10:12374604:12376790 
FEV1 rs78420228 rs78420228 NA CDC123 rs11599700 M K4 10:12273289:12320006 
FEV1 rs78420228 rs78420228 NA CDC123 rs10795944 N G ENSG00000228302.2 
FEV1 rs7842022 rs78420228 NA CDC123 rs12241367 N K4 10:12273289:12320006 
SLE rs1143679 rs34572943 0.94 ITGAM rs34082782 M G ENSG00000140688.12 
SLE rs1143679 rs34572943 0.94 ITGAM rs34550882 N G ENSG00000261385.1 
SLE rs1143679 rs34572943 0.94 ITGAM rs34550882 N G ENSG00000260219.1 
SLE rs1143679 rs34572943 0.94 ITGAM rs9673398 N G ENSG00000169896.11 
SLE rs1143679 rs34572943 0.94 ITGAM rs9673404 T K4 16:31355247:31421179 
SLE rs13136219 rs10028805 0.98 BANK1 rs7683892 M G ENSG00000153064.7 
SLE rs13136219 rs10028805 0.98 BANK1 rs34029191 M K4 4:102739046:102740746 
SLE rs13136219 rs10028805 0.98 BANK1 rs4270588 M K4 4:103358563:103361314 
SLE rs13136219 rs10028805 0.98 BANK1 rs7683892 M K4 4:102721764:102725667 
SLE rs13136219 rs10028805 0.98 BANK1 rs7683892 N K27 4:102711289:102714021 
SLE rs13136219 rs10028805 0.98 BANK1 rs7683892 N K4 4:102752891:102758975 
SLE rs2736332 rs2736340 0.9 BLK rs13257831 M K4 8:11336396:11344630 
SLE rs2736332 rs2736340 0.9 BLK rs12680762 M K4 8:11272557:11278140 
SLE rs2736332 rs2736340 0.9 BLK rs922483 T G ENSG00000136573.7 
SLE rs2736332 rs2736340 0.9 BLK rs2736345 T K27 8:11353734:11357736 
SLE rs2736332 rs2736340 0.9 BLK rs922483 T K27 8:11348864:11353299 
SLE rs2736332 rs2736340 0.9 BLK rs922483 T K4 8:11345910:11367069 
SLE rs35251378 rs2304256 0.95 TYK2 rs11085725 N G ENSG00000105397.9 
SLE rs35251378 rs2304256 0.95 TYK2 rs280497 T G ENSG00000105397.9 
SLE rs3747093 rs7444 0.88 UBE2L3 rs5749485 M G ENSG00000185651.10 
SLE rs3747093 rs7444 0.88 UBE2L3 rs2070512 M K4 22:21917050:22033004 
SLE rs3747093 rs7444 0.88 UBE2L3 rs2298429 N G ENSG00000185651.10 
SLE rs3747093 rs7444 0.88 UBE2L3 rs11089620 N K27 22:21920490:21930954 
SLE rs3747093 rs7444 0.88 UBE2L3 rs140488 N K27 22:21938482:21985305 
SLE rs3747093 rs7444 0.88 UBE2L3 rs140488 N K4 22:21917050:22033004 
SLE rs3747093 rs7444 0.88 UBE2L3 rs5754102 T K4 22:22399916:22404237 
 275 
SLE rs58688157 rs12802200 0.48 IRF7 rs7120313 M G ENSG00000070047.6 
SLE rs58688157 rs12802200 0.48 IRF7 rs2246614 M G ENSG00000161328.10 
SLE rs58688157 rs12802200 0.48 IRF7 rs11246177 M G ENSG00000185507.14 
SLE rs58688157 rs12802200 0.48 IRF7 rs936472 M G ENSG00000185522.4 
SLE rs58688157 rs12802200 0.48 IRF7 rs936472 M K27 11:600961:621989 
SLE rs58688157 rs12802200 0.48 IRF7 rs386614207 M K4 11:601613:633623 
SLE rs58688157 rs12802200 0.48 IRF7 rs2246614 N K27 11:600961:621989 
SLE rs58688157 rs12802200 0.48 IRF7 rs11246217 N S 11:614038:614173:2:2:1, 11:614038:614475:2:2:1 
SLE rs58688157 rs12802200 0.48 IRF7 rs12290989 N S 11:614038:614475:2:2:1, 11:614400:614475:2:2:1 
SLE rs58688157 rs12802200 0.48 IRF7 rs4963128 T G ENSG00000185507.14 
SLE rs58688157 rs12802200 0.48 IRF7 rs12419618 T K27 11:600961:621989 
SLE rs58688157 rs12802200 0.48 IRF7 rs12803048 T K4 11:601613:633623 
SLE rs6671847 rs1801274 0.89 FCGR2A rs4657041 M S 1:161512990:161595934:2:2:0, 1:161594430:161595934:2:2:1 
SLE rs6671847 rs1801274 0.89 FCGR2A rs12129787 N S 1:161487928:161489591:1:1:0, 1:161488906:161489591:1:1:0, 
1:161489451:161489591:1:1:1 
 
Supplementary Table 2.2: Summary of all features colocalised with disease loci that colocalised with at least one gene or splicing QTL  
All disease loci that colocalised with at least one gene or splicing QTL is summarised here. Loci colocalised with only histone features are not listed. The Disease 
SNP columns describes the SNP assigned from the GWAS summary statistics (Materials and Methods). The Study SNP is the disease lead SNP listed in the study, 
and the LD is the 1000G LD between the Study SNP and Disease SNP if these differ. Differences may occur if the summary statistics available were a subset of a 
full study meta-analysis. The Study SNP was used to assign the locus, designated in the study. The Feature SNP is the molecular feature lead SNP. Cell is the cell-
type of the corresponding feature (M = monocyte, N = neutrophil, T = T cell). Mark describes the feature type (G = Gene, S = splicing/PSI, K4 = H3K4me1, K27ac, 
H3K27ac). The feature ID describes the Ensembl gene ID or the histone signal peak defined as chr:start:end. The splicing ID describes the splicing junctions defined 
by Chen et al (2016a). 
 
BLUEPRINT summary statistics for lead QTLs can be found here: http://blueprint-dev.bioinfo.cnio.es/WP10/ 
Lead study SNP summaries can be found here: AMD PMID: 26691988, AD PMID: 24162737, CAD PMID: 26343387, FEV1 PMID: 26423011, SLE PMID: 26502338 
Freely downloadable Summary statistics: Alzheimer’s Disease, Lambert et al (2013): http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php 
Coronary artery disease, Nikpay et al. (2015): http://www.cardiogramplusc4d.org/data-downloads/ Systemic lupus erythematosus, Bentham et al. (2015): 
https://www.immunobase.org/downloads/protected_data/GWAS_Data/ 
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Position
Hepes
Buffer1
Buffer3
Percoll
Zymosan
Age
Gender
Season
Respiratory burst Zymosan
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
Diff.RFU.1.to.60
RFU.60
Position
Hepes
Buffer1
Buffer3
Percoll
PAF_fMLP
Age
Gender
Season
Respiratory burst PAF + fMLP
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
RFU.6
Position
Hepes
Buffer1
Buffer3
Percoll
STZ
Age
Gender
Season
Respiratory burst STZ
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
Mean.Slope.10.15
Time.to.RFU.40000
RFU.15
RFU.10
Position
Hepes
Buffer1
Buffer3
Percoll
PMA
Age
Gender
Season
Respiratory burst PMA
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
Mean.Slope.10.15
Time.to.RFU.40000
RFU.15
RFU.10
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Position
Hepes
Buffer1
Buffer3
Percoll
DQBSA
fMLP
Age
Gender
Season
Degranulation fMLP
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
Mean.Slope.20.40
RFU.20
Position
Hepes
Buffer1
Buffer3
Percoll
DQBSA
fMLP
CytoB
Age
Gender
Season
Degranulation CytoB + fMLP
Variance explained
0.0 0.1 0.2 0.3 0.4 0.5 0.6
Max.Slope
Mean.Slope.20.40
RFU.20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.1: Contribution of known sources of co-variation to 
respiratory burst and degranulation neutrophil responses  
Barplots show R2 values from fitting linear models of each trait with each covariate independently. 
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Supplementary Figure 3.2: Predicted power of the neutrophil function study  
A power calculation was performed for a study of 135 individuals (approximately equal to this function 
cohort) and for increasing sample sizes up to 500 individuals. Variants will be likely detected by the 
study if the variant falls above the line which describes the relationship between beta (effect size in 
standard deviation of the trait value) and minor allele frequency. This study is powered to detect 
common variants for moderate effect size or low frequency variants with higher effect sizes of beta 
greater than 2. The power for the suggestive p value threshold of 1 x 10-07 for N = 135 is also shown. 
The corresponding frequency of the genome-wide significant locus (rs116811177/rs115109232) 
identified in this study is marked. The beta for the association for both SNPs from this study was 2.92, 
which is close to the predicted power of this study to detect SNPs of this low-frequency. The pwr 
package was used in this power calculation (Champely, 2012).  
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Supplementary Figure 4.1: Receptor MFI values stratified by experimental processing 
batch  
Normalised GCSFR and PLAUR MFI stratified by experimental processing batch with outliers 
removed from both datasets. ANOVA testing with inverse normalised trait values found this covariate 
to be significant for PLAUR MFI only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4.2: Covariate effects on MFI values for PLAUR receptor 
Normalised MFI values for the PLAUR receptor, excluding outliers, are shown stratified by date, sex 
and time from bleed to labelling, which were all found to be significant covariates using ANOVA. The p 
value for each covariate from the ANOVA testing is listed in the corresponding plots.  
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Supplementary Figure 4.3: Relative abundance of CSF3R transcripts in T cells and 
monocytes stratified by rs3917924 genotypes  
This abundance by genotype plot shows all 18 CSF3R transcripts (Gencode v15) for T cells (top 
panel) and monocytes (bottom panel). rs3917924 is common GCSFR surface expression index SNP). 
The receptor-encoding transcript (green) is most abundantly expressed in monocytes but not highly 
expressed in T cells. 
  
 281 
AA AG GG
20
40
60
80
p=0.655, beta=0.047
Tr
an
sc
rip
t F
PK
M
CSF3R−204
ENST00000418048.2
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
AA AG GG
20
25
30
35
p=0.059, beta=0.197
Tr
an
sc
rip
t F
PK
M
CSF3R−020
ENST00000526980.1
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
AA AG GG
30
35
40
45
50
55
p=0.065, beta=−0.193
Tr
an
sc
rip
t F
PK
M
CSF3R−008
ENST00000489551.1
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
AA AG GG
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
p=9.148e−05, beta=0.399
Tr
an
sc
rip
t F
PK
M
CSF3R−019
ENST00000533491.1
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4.4: CSF3R transcript expression level in monocytes  
The three most abundant transcripts (left to right) including the short truncated transcript, CSF3R-019 
(far right) are shown with the transcript expression level (FPKM) in monocytes stratified by the 
genotype of rs3917924. The p value and beta are shown after using a linear regression to test 
association of transcript level with genotype. Although the expression level of CSF-020 is significant 
(beta = 0.483, SE = 0.151, p value 0.002), the effect does not look additive. CSF3R-019 transcript 
expression is significantly associated with rs3917924 genotype (beta = 0.48, SE = 0.147, p value = 
0.001) but the effect is much smaller than observed with neutrophils (Figure 4.12). The transcript 
expression levels of all four transcripts are lower than in neutrophils.  
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SNP Proteins 
bound 
Motifs altered  Histone  CEBPB/PU1  ChromHMM HL60 TF Differentiated 
HL60 
rs3917912  AP-2_disc2, ELF1_disc2, 
Ets_known3 
 
K27ac (1:36928496: 
36957321) 
K4me1 (1: 36778894: 
36993055) 
PU1 (1: 36947299: 
36949245) 
Active TSS high 
H3K4me3+K27Ac 
(1: 36947600: 
36948600) 
P300 (1: 
36947664: 
36948535) 
CEBPE (1: 
36947667: 
36949236), 
H3K4me1, 
H3K4me3, 
H3K27ac 
H3K27ac DMSO, 
H3K4me3 ATRA 
(1:36946936: 
36948821), 
H3K27ac ATRA, 
H3K4me1 
DMSO, 
H3K4me3 ATRA 
rs3917914   K27ac (1:36928496: 
36957321) 
K4me1 (1: 36778894: 
36993055) 
PU1 (1: 36947299: 
36949245) 
Active TSS high 
H3K4me3+K27Ac 
(1: 36947600: 
36948600) 
P300 (1: 
36947664: 
36948535) 
CEBPE (1: 
36947667: 
36949236), 
H3K4me1, 
H3K4me3, 
H3K27ac 
H3K27ac DMSO, 
H3K4me3 ATRA 
(1:36946936: 
36948821), 
H3K27ac ATRA, 
H3K4me1 
DMSO, 
H3K4me3 ATRA 
rs3917924 CEBPB, 
JUND, P300, 
TBP, BAF170 
(Hela) 
BCL_disc5, NRSF_disc3 
 
K27ac (1:36928496: 
36957321) 
K4me1 (1: 36778894: 
36993055) 
PU1 (1: 36944990: 
36945853) 
CEBPB (1: 
36944999: 
36945946) 
Active TSS High 
H3K4me3 (E10) (1: 
36945600: 
36945800) 
CEBPE (1: 
36944824: 
36946074), 
H3K4me1, 
H3K4me3 
H3K4me1 ATRA, 
H3K4me1 DMSO 
rs3917932  AP-1_disc1, ATF3_disc1, 
ATF3_known1, 
ATF3_known10, 
ATF3_known9, ATF4, ATF6, 
E2F_disc1, HEY1_disc1, 
LXR_2, Maf_disc2, 
Mxi1_known1, Myc_disc1, 
SIRT6_disc1, 
SREBP_known4, T3R, 
TATA_disc2 
K27ac (1:36928496: 
36957321) 
K4me1 (1: 36778894: 
36993055) 
 Active Enh (K27ac, 
K4ME1,E9) (1: 
36943800: 
36944000)  
 
H3K4me1  
 
Supplementary Table 4.1: Intersection of CSF3R significant variants with epigenomic and molecular data  
Common and rare lead SNPs for GCSFR MFI and neutrophil count are listed and annotations/ First those using HaploReg v4.1 including predicted disrupted motifs 
(Keradpour and Kellis, 2014). Column four onwards are epigenome-SNP overlaps (bedtools intersect). The data used was for primary neutrophils from the 
BLUEPRINT consortium (Chen et al, 2016, Carrillo-de-Santa-Pau et al., 2017) as well as data from Stephen Watt (manuscript in preparation). The histone peaks 
used for intersection were those as tested for QTL in the blueprint consortium using a 1Mb window. The final two columns list epigenome-SNP overlaps of ChIP-seq 
data generated in the neutrophil model cell line, HL60 and the differentiated more-mature HL60 model (ATRA and DMSO) (Chapter 2).  
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SNP EA/OA PU1 1Mb QTL Exon   Splicing Junction  Allele-specific eQTL 
(WASP-ASE) 
rs3917924 G/A 1:36924227:36924948, 1.518 x 
10-06, -0.6867 (peak falls 3’ 
outside of CSF3R gene) 
ENSG00000119535.13.46, 1.091 x 
10-37, 1.104 
ENSG00000119535.13.41, 4.353 x10-
04, 0.3637 
1:36945118:36945587:2:2:1 4.487 x 10-58, 1.245 
1:36945682:36947078:2:2:1 6.407 x 10-55, 1.231 
1:36943279:36945033:2:2:1 2.056 x 10-09, 0.600 
1:36941275:36943205:2:2:0 5.667 x 10-06, 0.463 
ENSG00000119535.13 
5.587 x 10-33, 0.103 
rs3917931 C/T 1:36924227:36924948, 1.518 x 
10-06, -0.6867 
ENSG00000119535.13.46, 1.483 x 
10-38, 1.122 
ENSG00000119535.13.41, 2.871 x 
10-04, 0.378 
1:36945118:36945587:2:2:1 1.687 x 10-59, 1.264 
1:36945682:36947078:2:2:1 9.940 x 10-56, 1.247 
1:36943279:36945033:2:2:1 7.018 x 10-10, 0.622 
1:36941275:36943205:2:2:0 4.664 x 10-06, 0.471 
ENSG00000119535.13 
7.191 x 10-32, 0.100 
rs3917925 G/A 1:36924227:36924948, 1.518 x 
10-06, -0.6867 
ENSG00000119535.13.46, 1.483 x 
10-38, 1.122 
ENSG00000119535.13.41, 2.871 x 
10-04, 0.378 
1:36945118:36945587:2:2:1 1.687 x 10-59, 1.264 
1:36945682:36947078:2:2:1 9.940 x 10-56, 1.247 
1:36943279:36945033:2:2:1 7.018 x 10-10, 0.622 
1:36941275:36943205:2:2:0 4.664 x 10-06, 0.471 
ENSG00000119535.13 
7.191 x 10-32, 0.100 
rs6667127 C/T 1:36924227:36924948, 1.690 x 
10-05, -0.6704 
ENSG00000119535.13.46, 3.067 x 
10-22, 0.969 
1:36945118:36945587:2:2:1 1.407 x 10-32, 1.119 
1:36945682:36947078:2:2:1 2.881 x 10-30, 1.092 
1:36943279:36945033:2:2:1 4.997 x 10-06, 0.500 
1:36941275:36943205:2:2:0 1.349 x 10-04, 0.420 
ENSG00000119535.13 
1.095 x 10-22, 0.090 
rs955115 C/A 1:36924227:36924948, 5.247 x 
10-05, -0.6151 
ENSG00000119535.13.46,  7.116 x 
10-08, 0.5853 
1:36945682:36947078:2:2:1 1.519 x 10-10, 0.683 
1:36945118:36945587:2:2:1 6.471 x 10-09, 0.623 
1:36935442:36937033:2:2:1 1.899 x 10-04, 0.415 
1:36943279:36945033:2:2:1 7.702 x 10-04, 0.374 
ENSG00000119535.13  
3.852 x 10-09, 0.068 
rs3917933 G/A 1:36924227:36924948, 1.518 x 
10-06, -0.6867 
ENSG00000119535.13.46, 1.483 x 
10-38, 1.122 
ENSG00000119535.13.41, 2.871 x 
10-04, 0.378 
1:36945118:36945587:2:2:1 1.687 x 10-59, 1.264 
1:36945682:36947078:2:2:1 9.940 x 10-56, 1.247 
1:36943279:36945033:2:2:1 7.018 x 10-10, 0.622 
1:36941275:36943205:2:2:0 4.664 x 10-06, 0.471 
ENSG00000119535.13 
7.191 x 10-32, 0.100 
 
 
Supplementary Table 4.2: Summary of significant QTL associations within the GCSFR locus that were tested in the BLUEPRINT consortium 
Significant QTL associations with the common SNPs from the BLUEPRINT consortium (Chen et al. 2016). Features with a qvalue of 5% or less are listed. For 
comparison, the uncorrected raw p value of association is listed for each feature. The phenotype for PU1 is the binding of this transcription factor assayed using 
ChIP-seq in primary neutrophils in a subset of the same individuals as the main Blueprint consortium (Stephen Watt, manuscript in preparation). 1Mb refers to the 
window size around the feature for the QTLs tested. Exon and splicing junction QTLs were identified using RNA-seq data and processed in the same way as gene 
expression QTLs from Chen et al. (2016), but the reads for exon QTLs are summed over each individual exon in a gene and over each splicing junction for the latter 
QTLs. These were not published as part of the Chen et al. (2016) paper. Allele-specific eQTLs were published as part of the main study and analysed using the 
WASP software. 
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